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Abstract 
In the tumour microenvironment pericellular proteolytic activity affects cells by cleavage 
of extracellular matrix proteins, activation of cell-surface receptors such as the protease 
activated receptors (PAR), and processing of mitogenic growth factors such as 
hepatocyte growth factor (HGF). As proteolysis is irreversible in physiological settings, 
protease activity is tightly regulated by a number of factors including localization, 
zymogen activation and protease inhibitors. However, overexpression of proteases in 
the dysregulated prostate cancer microenvironment has the potential to facilitate disease 
progression. 
The secreted serine proteases kallikrein-related peptidase (KLK)14 and KLK4 as well as  
the type II transmembrane serine proteases (TTSPs) hepsin and transmembrane 
protease serine 2 (TMPRSS2) have been implicated in the progression of prostate cancer 
as all four are upregulated this malignancy. For instance, increased KLK14 expression 
has been correlated with aggressive, late stage prostate cancer and decreased 
progression-free survival. KLK4 also has increased expression; however, this is seen in 
early stages of prostate cancer, with diminished KLK4 levels in late stages. Hepsin has 
also been implicated as expression increase through all prostate cancer stages to bone 
metastasis. Further, in a non-metastasising mouse model, hepsin overexpression has 
been implicated in invasion/extravasion and metastasis of primary prostate tumour cells 
through disorganisation of the basement membrane. TMPRSS2 also has increased 
expression in localized prostate cancer. Further, TMPRSS2 has dysregulated cellular 
localization in prostate cancer, moving from the apical cellular localization of normal 
epithelial prostate cells to the entire cell surface with intracellular accumulation in 
prostate cancer cells. Critically, KLK14, KLK4 and TMPRSS2 induce intracellular 
signalling pathways via proteolytic activation of PARs, and modulation of PAR-
mediated signalling has been associated with cells acquiring a more cancerous 
phenotype.  
While hepsin and TMPRSS2 auto-activate, the endogenous activators of KLK14 and 
KLK4 are unknown. It was recently determined that matrix metalloproteinase MMP3 
activates KLK4 in vitro and so may be an endogenous activator. Moreover, it is prostate 
expressed and has also been implication in the progression of several cancer types 
including prostate. In turn, MMP3 is activated by auto-activating TTSP family member 
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matriptase, thereby potentially forming an activation cascade from matriptase to MMP3 
to KLK4. As auto-activating proteases, hepsin and TMPRSS2 also have the potential to 
function in proteolytic activation cascades, activating either the KLKs or MMP3. In 
turn, the activated KLKs may induce PAR-mediated intracellular signalling or activate 
HGF, the MET receptor ligand. 
The goal of this study was to examine pericellular proteolytic activity. In particular, it 
focussed on proteolytic interactions of KLK14 and KLK4 with hepsin and TMPRSS2. 
To a lesser extent, interactions of hepsin and TMPRSS2 with MMPs, MMP3 and MMP9 
were also examined. This study also examined HGF activation by KLK14 and KLK4, 
and inhibition of KLK14 by hepatocyte growth factor activator inhibitor-1 (HAI-1). 
Further, activation of PAR family members PAR1, PAR2 and PAR4 by KLK14, hepsin 
and matriptase, and PAR2 by KLK4, was examined. 
For the first part of this study recombinant pro-KLK14 was generated in insect cells 
and characterized. It was determined that while pro-KLK14 from this system is N-
glycosylated, the protease produced by Cos-7 cells lack this modification. This indicates 
the potential for cell-type differential N-glycosylation of KLK14. Active recombinant 
KLK14 was also shown to activate pro-HGF, while KLK4 primarily degrades it. 
Examination of KLK14 inhibition by HAI-1A and HAI-1B isoforms indicated that this 
inhibitor is a KLK14 substrate rather than inhibitor as both isoforms were degraded by 
KLK14. In comparison, hepsin and HAI-1A formed the stable complexes characteristic 
of inhibition. 
The second part of this study examined the interactions between KLK4 and KLK14, 
the hepsin and TMPRSS2, and to a lesser extent matriptase, MMP3 and MMP9. The 
data from these studies suggest complex pericellular interactions between these 
proteases and can be summarized as follows:  
 KLK4 and, to a lesser extent, KLK14 are proteolysed by hepsin and TMPRSS2, 
and the shortened forms of these KLKs were mainly detected in association 
with the cell 
 Proteolysis of KLK4 by hepsin and TMPRSS2 does not appear to lead to 
activation; however, it is not known if cell-associated forms of KLK14 are 
activated by these TTSPs 
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 KLK4 cleaves the stem region of hepsin and TMPRSS2; however, these cleaved 
forms remain cell membrane-bound through disulphide links in the stem 
 While KLK4 and KLK14 co-immunoprecipitate with hepsin and TMPRSS2, 
KLK14 and active KLK4 are located on the cell surface independently of these 
TTSPs 
 MMP3 and MMP9 are activated by hepsin and TMPRSS2 (and matriptase) 
 MMP3 and MMP9 co-immunoprecipitate with hepsin and TMPRSS2. 
The third and final part of the study focussed on PAR1, PAR2 and PAR4 activation by 
KLK14, matriptase and hepsin, as well as inhibition of KLK4 activation of PAR2 using 
the KLK4-specific inhibitor SFTI-FCQR. PAR2 activation by KLK4 was investigated 
further using human primary kidney proximal tubule cells (PTC), which have previously 
been described as co-expressing PAR2 and KLK4. It was determined that while KLK14 
activated PAR1, PAR2 and PAR4, and matriptase activated PAR2-mediated signalling, 
in the form of intracellular Ca2+ mobilization, there was negligible activation of PAR1, 
PAR2 or PAR4 by hepsin. Further, KLK4 activation of PAR2 could be abrogated by 
the KLK4-specific inhibitor SFTI-FCQR. Interestingly, further examination of KLK4 
activation of PAR2 showed that while it activates PAR2 in a number of cell types, it 
elicited minimal PAR2 activation and Ca2+ mobilization in human kidney PTCs. This 
data suggests cell-type biased agonism of PAR2 by KLK4 potentially initiating 
alternative intracellular signalling pathways, or alternatively, a KLK4 competitive 
substrate on the surface of these cells.  
In this final section LNCaP cells overexpressing hepsin or active site mutated hepsin 
were also generated as a tool to examine the participation of hepsin with other serine 
proteases in proteolytic cascades resulting in PAR activation. However, overexpression 
of hepsin in these cells resulted in minimal plasma membrane localization in contrast to 
catalytically inactive hepsin which readily localized to the plasma membrane. 
Importantly, this is the first report of KLK14 activation of pro-HGF. Further, this is the 
first time KLK14 degradation of HAI-1, and formation of hepsin-HAI-1 complexes, 
have been reported. It is also the first time cell-surface localization of KLK4 and 
KLK14 has been demonstrated. In addition, this is the first time active KLK4 has been 
isolated from the cell surface.  
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The data in this study suggest that KLK14 may have a role in regulation of MET 
receptor/HGF signalling axis through HGF activation and degradation of key protease 
inhibitors, HAI-1A and HAI-1B. Further, the data set up the premise for a proteolytic 
cascade at the plasma membrane involving TMPRSS2 and hepsin activation of MMP3 
and MMP9, with MMP3 then activating KLK4. Finally, the cell surface localization of 
KLK14 and KLK4 may facilitate activation of PARs, degradation of HAI-1 isoforms 
and pericellular activation of HGF. Based on the results of this study a number of 
exciting and interesting avenues have been proposed to further explore the role of 
KLK14, and these other prostate-expressed proteases, in modulation of the pericellular 
environment. 
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1.1 Prostate cancer 
Prostate cancer has the highest rate of incidence of any cancer in Australian men, 
excluding non-melanoma skin cancers, and is the second highest cause of cancer-related 
death after lung cancer (AIHW&AACR, 2012). A feature of prostate cancer that 
complicates prediction of patient prognosis and treatment is the high levels of 
heterogeneity, in patient and between patient, in tumour pathology and clinical 
presentation (Mackinnon et al., 2009; Boyd et al., 2012). Further to this, the molecular 
mechanisms underlying the development and progression of prostate cancer remain 
poorly understood (Boyd et al., 2012).  
The prostate is an exocrine gland that surrounds the urethra just below the bladder. It is 
comprised of secretory epithelia containing luminal, basal and neuroendocrine cells, 
encased by a supportive, fibrous stroma containing smooth muscle cells as well as blood 
vessels (Aumuller, 1989; Jequier, 2008) (Figure 1.1). The prostate epithelium is separated 
from the stroma by a basement membrane (or basal lamina) (Aumuller, 1989). The 
prostate generates a portion of the seminal fluid produced by the male reproductive 
tract, secreted apically by the luminal epithelial cells (Aumuller, 1989; Jequier, 2008). The 
prostatic fluid includes high concentrations of citrate and zinc (Zn2+) ions from stores 
accumulated by the prostate epithelium (Kavanagh, 1985; Costello and Franklin, 1998). 
Prostatic fluid also contains many proteases, several of which are involved in dissolution 
of the seminal clot and sperm motility (Aumuller, 1989; Veveris-Lowe et al., 2007; 
Emami et al., 2009).  
A crucial aspect of prostate cancer is the progressive disruption of normal glandular 
architecture through loss of the basal cell layer, ductal lumen architecture and epithelial 
cell polarity, and disordering of the basement membrane (Abate-Shen and Shen, 2000; 
Vasioukhin, 2004; Geiger and Peeper, 2009) (Figure 1.1). It is thought that loss of 
secretory cell polarity may allow indiscriminate secretion of proteases normally secreted 
into the luminal space (Djakiew et al., 1992; Webber et al., 1995; Kulasingam and 
Diamandis, 2008; Pinzani et al., 2008). This in turn facilities further disruption to 
prostate architecture through numerous mechanisms including degradation of the 
extracellular matrix (ECM) and basement membrane components, activation of stromal 
proteases, and other off-target activity (Djakiew et al., 1992; Webber et al., 1995). 
Ultimately, the breakdown of tissue architecture may become a self-perpetuating cycle 
mediated by spatially dysregulated proteolytic activity. Importantly, due to the 
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breakdown of normal tissue architecture and overexpression of particular proteases, 
there is significant opportunity for proteases to interact in new or altered proteolytic 
pathways. Therefore, identification of interacting partners is essential to understand the 
roles of proteases in this pathology. 
 
Figure 1.1 Dissemination of prostate lumen proteases into the stroma in prostate cancer 
1.2 Proteases 
Proteases are enzymes that hydrolyse peptide bonds (Rawlings and Salvesen, 2013). 
Based on mechanistic, sequence and structural similarities and evolutionary relationship 
they are classified into distinct classes, with further grouping into clans and families 
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(Rawlings and Salvesen, 2013). The classes of aspartic, cysteine, serine, threonine and 
metallo- proteases have all been found in mammals (Lopez-Otin and Bond, 2008). They 
have numerous roles in cellular process regulation through proteolytic processing of 
bioactive molecules. These include processes such as growth, differentiation, apoptosis, 
migration, angiogenesis and immune surveillance (Egeblad and Werb, 2002; Lopez-Otin 
and Bond, 2008). Aberrant protease expression and activity has also been implicated in 
several disease states including neurodegenerative, inflammatory and vascular disease, 
and cancer (Egeblad and Werb, 2002; Lopez-Otin and Bond, 2008).  
Gene expression studies as well as in vitro and in vivo assays, have implicated many 
members of the serine and metallo- protease classes in progression or suppression of 
multiple cancer types (Lopez-Otin and Matrisian, 2007; Affara et al., 2009). For 
instance, chymotrypsin- and trypsin-like serine proteases and matrix metalloproteinases 
(MMPs) have been associated with cancers including breast, ovarian, colorectal, lung 
and prostate (as reviewed in (Egeblad and Werb, 2002; Rickles et al., 2003; Borgono and 
Diamandis, 2004; Deryugina and Quigley, 2006; Li and Cozzi, 2007; Lopez-Otin and 
Matrisian, 2007; List, 2009; Deryugina and Quigley, 2010; Antalis et al., 2011)).  
Proteases do not function in isolation, rather as part of dynamic interconnected 
networks of proteases, substrates, inhibitors, receptors, cofactors and cleavage products 
(Lopez-Otin and Bond, 2008). In normal tissue, proteases are tightly regulated by 
several spatial and temporal mechanisms such as gene expression and translation 
regulation, protein targeting, endogenous inhibitors and protease degradation (Lopez-
Otin and Bond, 2008). As another regulatory mechanism, many proteases are generated 
as inactive precursors or zymogens. For instance, all trypsin-like serine proteases and 
MMPs are generated as inactive pre-pro-enzymes (Rawlings and Barrett, 2013b, 2013a). 
The amino (N)-terminal pre- region can confer the signal for secretion and is removed 
in the process, or, the N-terminal may contain a transmembrane region for cell-surface 
localization of the protease. Then before the pro-enzyme (zymogen) can catalyse 
proteolysis, the pro- region requires cleavage by limited proteolysis (Rawlings and 
Barrett, 2013b, 2013a).  
As many proteases are generated as inactive zymogens, several families of proteases 
participate in highly regulated intracellular and extracellular activation cascades, often 
initiated by external stimuli (Amour et al., 2004). Protease cascades have been well 
characterized in a number of essential physiological processes including the complement 
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(Duncan et al., 2008; Forneris et al., 2012), plasminogen activation (Castellino and 
Ploplis, 2005; Deryugina and Quigley, 2012), blood coagulation (Spronk et al., 2003) and 
digestive cascades (Zheng et al., 2009). 
There are considered to be three general phases to proteolytic cascades (Figure 1.2) 
(Amour et al., 2004). In the initiation phase, the proteases are in an inactive zymogen 
state. The initiating protease self-activates (autoactivates) in response to stimuli and then 
activates down-stream proteases in a propagation phase. The propagator protease 
activates executioner proteases in the execution phase but also activates more initiating 
proteases in a positive-feedback mechanism. This results in amplification of the cascade 
and downstream proteolytic activity with very little initial activation (Amour et al., 2004). 
The cascades are governed by specificity of the activating proteases for the zymogens as 
well as negative-feedback through deactivating proteolysis.  
 
Figure 1.2 Schematic representation of a proteolytic cascade 
 
1.3 Serine proteases 
There are over 80 families of serine proteases. The trypsin-like, as well as chymotrypsin-
like and elastase-like, serine proteases are in the S1 family of serine proteases (Rawlings 
and Barrett, 2013b). For the remainder of this chapter, trypsin-like and, to lesser extent, 
chymotrypsin-like proteases will be the focus of discussion about serine proteases. In 
their active site they possess a catalytic triad of histidine (His)57, aspartic acid (Asp)102 
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and serine (Ser)195 (chymotrypsin numbering) located at the interface of a fold in the 
protein known as the chymotrypsin fold (Perona and Craik, 1995, 1997; Page and Di 
Cera, 2008).  
Nomenclature developed by Schechter and Berger (Schechter and Berger, 1967) 
provides a common terminology describing substrate cleavage and substrate/protease 
interactions. The substrate cleavage point is between residues P1-P1’, with residues on 
either side numbered outwards P2, P3...Pn to the N-terminus and P2’, P3’…Pn to the 
carboxyl (C-)terminus (Figure 1.3). Correspondingly, there are subsites in the protease 
that bind the substrate residues. These are numbered Sn...S3, S2, S1, S1’, S2’, S3’…Sn’ 
(Schechter and Berger, 1967).  
 
Figure 1.3 Schematic representation of protease-substrate subsite interactions 
Using this terminology, serine protease substrate specificity is governed by P1/S1 
complementarity. The S1 residue of the protease is six amino acids N-terminal to the 
catalytic Ser residue, and it resides in a pocket that is highly complementary to the P1 
residue of the substrate (Perona and Craik, 1997; Page and Di Cera, 2008). Trypsin-like 
serine proteases cleave on the C-terminal side of positively charged residues, arginine 
(Arg) or lysine (Lys). Correspondingly, the S1 pocket is deep, to accommodate the P1 
side-chain, and has a negatively charged S1 residue at the base, Asp189 (Perona and 
Craik, 1997; Page and Di Cera, 2008). Chymotrypsin-like protease substrates have large 
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hydrophobic P1 residues. Correspondingly, the S1 pocket is deep and has an S1 residue 
without a negative charge (Perona and Craik, 1997; Page and Di Cera, 2008).  
Other aspects of substrate/protease interactions influencing specificity include, residues 
that line the sides of the S1 pocket,  complementarity at subsites other that S1, and 
interactions with surface loops on the protease (Brillard-Bourdet et al., 1995; Perona and 
Craik, 1997; Page and Di Cera, 2008). In addition, binding of a substrate residue at a 
particular protease subsite can negatively or positively regulate binding of residues at 
other subsites, a property known as subsite cooperatively (Ng et al., 2009). Together 
these factors regulate which substrates are hydrolysed by a protease, and the efficiency 
of the process. 
While in zymogen form, the S1 site and active site of the serine protease are deformed 
which means they have very low activity. Once the pro- region is cleaved, the nascent 
N-terminal residue (P1’), a hydrophobic residue such as isoleucine (Ile) or valine (Val), 
forms a salt bridge with the conserved Asp residue located immediately prior to the 
catalytic Ser. This induces a conformation change that opens up the active site and S1 
pocket (Hedstrom, 2002; Rawlings and Barrett, 2013b). When the active serine protease 
binds a substrate, five enzyme-substrate hydrogen bond points, at positions P1 and P3, 
position the scissile peptide bond in the active site for nucleophilic attack by catalytic 
Ser195 (Perona and Craik, 1997). Briefly, nucleophilic Ser operates together with His 
and Asp in a charge relay system to catalyse hydrolysis (proteolysis) of the scissile 
peptide bond between P1 and P1’ of the substrate (Banacky and Linder, 1981; Page and 
Di Cera, 2008). When the bond is cleaved, the C-terminus part of the substrate is 
released as an amine. The N-terminus portion remains bound to the protease as a 
covalent (acyl-enzyme) intermediate. The sequence then repeats as water attacks and 
binds the acyl-enzyme. As a result the N-terminus of the substrate is released and the 
protease active site is regenerated (Perona and Craik, 1995; Hedstrom, 2002). 
 
1.4 Kallikrein-related peptidases (KLKs) 
The KLKs are secreted serine proteases comprising 15 highly homologous family 
members encoded by genes (KLK) clustered on chromosome 19q13.3-13.4 (Clements et 
al., 2001), and include tissue kallikrein, designated KLK1, and 14 kallikrein-related 
peptidases designated KLK2 to KLK15 (Lundwall et al., 2006) (Figure 1.4). 
8 
 
 
Figure 1.4 Sequence alignment and structure of kallikrein-related peptidases 
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The KLKs have widespread tissue expression (Harvey et al., 2000; Shaw and Diamandis, 
2007), with immunohistochemistry studies showing that they are largely expressed by 
glandular epithelial cells and are secreted (Petraki et al., 2006). They also cleave or 
degrade several ECM proteins and growth factors, as well as activate a number of 
proteases (Lawrence et al., 2010). For these reasons KLKs have been associated with a 
wide range of normal physiological functions as well as pathological processes.  
Importantly, deregulated KLK expression has been noted in several cancers, most 
notably, reproductive organ cancers (Borgono and Diamandis, 2004; Schmitt et al., 
2013). Moreover, a singular feature of KLKs is the co-ordinated gene expression 
regulation and de-regulation of groups of KLKs by steroid hormones in hormone-
related cancers such as breast, ovarian, prostate and testicular (Lawrence et al., 2010).  
The KLKs are synthesized as pre-pro-enzymes, with the 16-34 amino acid signal 
peptide pre- region cleaved prior to zymogen secretion (Lundwall and Brattsand, 2008; 
Clements et al., 2013). The KLK zymogens range from 228 to 264 residues with 
molecular masses of 24-29 kDa which increase to 30-40 kDa with glycosylation 
(Lundwall and Brattsand, 2008). Specific N-glycosylation sites have been identified in 
vitro for KLK1 (Kellermann et al., 1988), KLK5 (Debela et al., 2007a) and KLK12 
(Picariello et al., 2008), while the remainder have been identified in silico.  
The cleavage site for removal of the pro- region from the zymogen is evenly split across 
the KLKs as either an Arg or a Lys P1 residue, except for KLK4, which has a glutamine 
(Gln) P1 (Yousef and Diamandis, 2001) (Figure 1.4). All the KLKs, except KLK3, 
KLK7, KLK9 and KLK15, have an Asp S1 residue (Yousef and Diamandis, 
2001)(Figure 1.4) and in vitro analyses confirmed that most of the Asp S1 KLKs have 
trypsin-like substrate specificity with a preference for Arg at P1 (Lundwall and 
Brattsand, 2008; Goettig et al., 2010). Similarly, the cysteine residues are highly 
conserved in the KLKs with all having 12, except for KLK1-KLK3 and KLK13 which 
have 10 cysteine residues (Yousef and Diamandis, 2001) (Figure 1.4). Crystal structure 
analyses have confirmed that in  KLK4-KLK7 the 12 cysteine residues form 6 
disulphide bridges (Gomis-Ruth et al., 2002; Debela et al., 2006a; Debela et al., 2007a; 
Debela et al., 2007b) and in KLK1 and KLK3 the 10 residues form 5 
bridges(Laxmikanthan et al., 2005; Menez et al., 2008).The KLKs also have a conserved 
“kallikrein loop” prior to the catalytic Asp, consisting of eleven or fewer amino acids, 
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and it has been speculated that the loop influences substrate specificity for the KLKs 
(Clements et al., 2001).  
To identify potential KLK substrates and design specific inhibitors, the substrate 
preferences beyond P1, extended substrate specificity, has been examined for a number 
of KLKs using methods such as phage display, systematic positional scanning 
approaches or peptide libraries (Brillard-Bourdet et al., 1995; Felber et al., 2005; Debela 
et al., 2006b; Borgono et al., 2007a; Debela et al., 2008; Li et al., 2008; Swedberg et al., 
2009; Goettig et al., 2010). In vitro studies have also identified potential mechanisms of 
KLK inhibition including a variety of serine protease inhibitors, Zn2+ and pH (Goettig 
et al., 2010). For instance, KLK4 and KLK14 are inhibited by several serpins (Luo and 
Jiang, 2006; Obiezu et al., 2006; Stefansson et al., 2006; Borgono et al., 2007c). KLK14 
is also inhibited by the Kazal-type inhibitors SPINK5 and SPINK6 (Borgono et al., 
2007b; Deraison et al., 2007; Meyer-Hoffert et al., 2010; Fortugno et al., 2011).  
Furthermore, work done in our laboratory exploited the Bowman-Birk serine protease 
inhibitor sunflower trypsin inhibitor (SFTI) (Luckett et al., 1999) to develop a highly 
selective, potent KLK4 inhibitor (SFTI-FCQR) for potential therapeutic use (Swedberg 
et al., 2009). 
Another mode of KLK regulation is deactivating proteolysis, enacted by other 
proteases, or autolysis in the case of KLK14 and several other KLKs (Goettig et al., 
2010). Indeed, active KLK14 efficiently autolyses, with several Arg residue cleavage 
points identified in the body of the protein (Borgono et al., 2007c).  
 
1.4.1 KLK4 
The protein sequence of KLK4 was first determined from isolates from enamel of 
developing pig teeth (Simmer et al., 1998a). Human KLK4 coding sequence was 
subsequently identified by several groups (Simmer et al., 1998b; DuPont et al., 1999; 
Nelson et al., 1999; Stephenson et al., 1999; Yousef et al., 1999).  Human KLK4 mRNA 
and protein is expressed in tissues including kidney, liver, pituitary and cervix (Shaw and 
Diamandis, 2007). The protein is also normally expressed by prostatic epithelial cells, is 
secreted into the prostate gland lumen, and has been detected in seminal fluid and urine 
(Obiezu et al., 2002; Dong et al., 2005; Obiezu et al., 2005; Veveris-Lowe et al., 2005; 
Shaw and Diamandis, 2007; Veveris-Lowe et al., 2007). It has been detected in the 
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cytoplasm of cells from normal and cancerous prostatic tissue (Day et al., 2002; Obiezu 
et al., 2002; Veveris-Lowe et al., 2005) as well as the nuclei of LNCaP cells, and normal 
epithelial and malignant prostate cells (Dong et al., 2005; Klokk et al., 2007). Moreover, 
there are several reports of increased KLK4 mRNA expression in prostate cancer 
(Obiezu et al., 2002; Xi et al., 2004; Avgeris et al., 2012). However, there are conflicting 
reports on the expression of KLK4 at the protein level when compared to benign or 
normal prostate. For instance, work done by Veveris-Lowe and colleagues (2005) and by 
Klokk and colleagues (2007) have shown increased KLK4 expression in prostate cancer. 
In contrast, Obiezu and colleagues (2002; 2005) reported lower expression or no 
difference to KLK4 in prostate cancer. Most recently, Seiz and colleagues (2010) 
reported increased KLK4 in early stages of prostate cancer followed by decreased levels 
in later stages.  
While KLK4 is expressed in the prostate, its role in this tissue is unclear. Recent studies 
of KLK4 (-/-) mice (Simmer et al., 2009; Smith et al., 2011), and analysis of KLK4  
mutations in humans with the hereditary tooth disorder, amelogenesis imperfecta (Hart 
et al., 2004), it has been shown that KLK4 is crucial to the development and 
mineralization of tooth enamel. This role is likely achieved through degradation of ECM 
proteins amelogenin and enamelin (Ryu et al., 2002; Yamakoshi et al., 2006). However, 
no other alteration to phenotype was detected in the KLK4 (-/-) mice (Simmer et al., 
2009; Smith et al., 2011). 
KLK4 is a 254 amino acid pre-pro-protease with one consensus N-glycosylation 
sequence (Marshall, 1967; Neuberger and Marshall, 1968) at Asn169-Val-Ser (Nelson et 
al., 1999). It also has an atypical N-glycosylation sequence (Bause and Legler, 1981) at 
Asn239-Leu-Cys.  Moreover, the increased MW of recombinant KLK4 over the 
calculated MW of 28 kilodaltons (kDa) (Nelson et al., 1999) has been attributed to N-
glycosylation (Day et al., 2002; Dong et al., 2005; Obiezu et al., 2006; Ramsay, 2008); 
however, the sites that are N-glycosylated have not been confirmed. It has also been 
demonstrated in vitro to be a trypsin-like protease with a preference for Arg P1 residues 
in substrates (Takayama et al., 2001b; Matsumura et al., 2005; Debela et al., 2006a; 
Debela et al., 2006b; Obiezu et al., 2006; Borgono et al., 2007a; Swedberg et al., 2009).  
As KLK4 is unique in the KLK family with a Gln(30) P1 residue for zymogen 
activation (Nelson et al., 1999; Yousef and Diamandis, 2001), it has been proposed that 
the endogenous KLK4 activator is not a trypsin-like serine protease. Indeed, KLK inter-
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activation studies have shown that none of the KLKs activate KLK4 in vitro (Yoon et 
al., 2007; Yoon et al., 2008; Beaufort et al., 2010). Nor is it activated by serine proteases 
plasmin, urokinase-type plasminogen activator (uPA), tissue plasminogen activator 
(tPA), thrombin, factor Xa (FXa) or plasma kallikrein (Yoon et al., 2009). So far, only 
cysteine exopeptidase cathepsin C, and MMP3 and MMP20 have been shown to activate 
KLK4 in vitro (Tye et al., 2009; Beaufort et al., 2010; Yamakoshi et al., 2013; Yoon et al., 
2013). However, as yet, the KLK4 in vivo activator has not been identified. Certainly, 
MMP20 is a possible in vivo KLK4 activator as they are co-expressed in developing 
enamel (Lu et al., 2008). However, while KLK4 has low level protein expression across 
multiple tissues (Obiezu et al., 2005; Shaw and Diamandis, 2007), MMP20 has very 
restricted expression, so far detected only in teeth and some oral carcinomas (Fukae et 
al., 1998; Takata et al., 2000; Vaananen et al., 2004). In contrast, MMP3 has fairly 
widespread expression in connective tissues (Nagase, 1998), and cathepsin C is 
ubiquitously expressed (Rawlings and Salvesen, 2013), and therefore they may be 
candidates for activation of KLK4 in other tissues. 
 
1.4.2 KLK14 
KLK14 was one of the last genes to be identified in the KLK locus. It was identified and 
initially characterized by Yousef and colleagues (2001) and by our laboratory (Hooper et 
al., 2001a). KLK14 has widespread, low level protein expression across many tissues 
(Shaw and Diamandis, 2007). The prostate is one site of higher level expression. It has 
been detected in normal prostate epithelial cells, and secreted into seminal fluid 
(Borgono et al., 2003; Petraki et al., 2006; Borgono et al., 2007c; Shaw and Diamandis, 
2007; Rabien et al., 2008). Importantly, in prostate cancer KLK14 expression is 
increased at both the mRNA and protein level, with a correlation between increased 
expression level and disease progression (Yousef et al., 2003b; Borgono et al., 2007c; 
Rabien et al., 2008). 
KLK14 is a 267 amino acid pre-pro-protease with a Lys(40) P1 residue for zymogen 
activation (Hooper et al., 2001a; Yousef et al., 2001). While KLK14 has a consensus N-
glycosylation sequence at Asn184-Ile-Ser and an atypical N-glycosylation sequence, 
Asn252-Leu-Cys, glycosylation of recombinant or endogenous KLK14 has not been 
reported (Borgono et al., 2003; Borgono et al., 2007c). Also like KLK4, KLK14 has a 
strong preference for an Arg P1 residue in substrates (Brattsand et al., 2005; Felber et 
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al., 2005; Oikonomopoulou et al., 2006a; Borgono et al., 2007a; Borgono et al., 2007c; 
Rajapakse and Takahashi, 2007; Stefansson et al., 2008; de Veer et al., 2011). However, 
low level chymotrypsin-like activity has also been reported for KLK14 (Brattsand et al., 
2005; Felber et al., 2005).  
The KLK14 zymogen is not able to autoactivate (Brattsand et al., 2005; Borgono et al., 
2007c). However, despite having a strong Arg P1 substrate preference, active KLK14 
has a low level ability to activate zymogen KLK14 in vitro (Yoon et al., 2007). Similarly, 
while most of the KLK family members also have a preference for Arg P1 residues 
(Ramsay et al., 2008b), a few have been identified as in vitro KLK14 activators of varying 
efficiency. These include KLK5 (Brattsand et al., 2005), KLK11 (Yoon et al., 2007) and 
KLK15 (Yoon et al., 2009) as well as potentially KLK4 and KLK12 (Yoon et al., 2007). 
Outside of the KLK family only the transmembrane serine protease enteropeptidase 
(Brattsand et al., 2005) and secreted serine protease plasmin (Yoon et al., 2008) have 
been identified as KLK14 activators.  
Interestingly, due to overlapping tissue/gland localization the KLK14 activators 
identified in vitro may be physiologically relevant. For instance, the epidermis is a site of 
high levels of KLK14 expression, in particular the epithelial cells of eccrine sweat glands 
where KLK14 is secreted into sweat (Borgono et al., 2003; Komatsu et al., 2005; 
Komatsu et al., 2006; Stefansson et al., 2006; Borgono et al., 2007c; Shaw and 
Diamandis, 2007). The epidermis is also a site of KLK5, KLK11 and enteropeptidase 
expression (Brattsand and Egelrud, 1999; Ekholm et al., 2000; Komatsu et al., 2005; 
Komatsu et al., 2006; Shaw and Diamandis, 2007; Nakanishi et al., 2010). Plasma-
derived plasmin is also located in the skin as it has a tightly regulated role in ECM 
degradation and MMP activation in dermal/epidermal wound healing (Toriseva and 
Kahari, 2009). Similarly in the prostate, KLK14, KLK5 and KLK11 are co-expressed 
and secreted into the seminal plasma (Luo et al., 2006; Michael et al., 2006; Shaw and 
Diamandis, 2007).  Moreover, plasmin is also a seminal fluid protein (Lwaleed et al., 
2004; Stief, 2007).  
 
1.4.3 KLKs in proteolytic cascades 
KLK substrate specificity, pro-peptide cleavage sites, as well as the coordinated 
expression of the KLK genes, has led to speculation about tissue-specific KLK 
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activation cascades. This has been borne out by studies showing in vitro KLK cross-
activation and deactivation (Yoon et al., 2007; Emami and Diamandis, 2008; Yoon et al., 
2009; Beaufort et al., 2010). In addition, a number of KLKs autoactivate, and in so 
doing potentially serve as cascade initiators (Pampalakis and Sotiropoulou, 2007).  
In a physiological context, KLK14 along with KLK5, KLK7 and KLK8 have been 
associated with proteolytic cascades culminating in epidermal desquamation through 
degradation of corneodesmosome proteins (Lundstrom and Egelrud, 1991; Egelrud, 
1993; Brattsand and Egelrud, 1999; Caubet et al., 2004; Brattsand et al., 2005; Borgono 
et al., 2007b; Kishibe et al., 2007; Ishikawa et al., 2008; Eissa et al., 2011). In this 
scenario, KLK14 is activated by autoactivating KLK5 which also activates KLK7 and 
KLK8 (Brattsand et al., 2005; Eissa et al., 2011). Furthermore, cascade amplification 
may occur through KLK14 activating KLK5 (Brattsand et al., 2005).  
Similarly, KLK4 and KLK14 may be involved in proteolytic cascades essential to sperm 
motility. While seminal fluid liquefaction through degradation of seminogelins and 
fibronectin is largely mediated by KLK3 (Sotiropoulou et al., 2009; Lawrence et al., 
2010), the KLK3 zymogen does not autoactivate (Denmeade et al., 2001; Yoon et al., 
2007). In vitro studies of prostate-expressed proteases have shown that it is activated by 
KLK4 and KLK14 as well as KLK2, KLK5, and KLK15 (Kumar et al., 1997; Lovgren 
et al., 1997; Takayama et al., 1997; Vaisanen et al., 1999; Malm et al., 2000; Takayama et 
al., 2001a; Takayama et al., 2001b; Michael et al., 2006; Emami et al., 2008; Emami and 
Diamandis, 2008; Emami et al., 2009). The cascades are potentially initiated by the 
autoactivating KLK2, KLK5, KLK6, KLK11 and KLK13 (Mikolajczyk et al., 1998; 
Lovgren et al., 1999; Denmeade et al., 2001; Magklara et al., 2003; Sotiropoulou et al., 
2003; Brattsand et al., 2005; Yoon et al., 2007). When all prostate-expressed KLKs are 
considered, the inter-activation web is fairly complex (Figure 1.5). For example, KLK5 
activates KLK2 (Michael et al., 2006) and, as mentioned earlier, it also activates KLK7, 
and KLK5 and KLK14 activate each other (Brattsand et al., 2005). Furthermore, KLK2 
and KLK14 (Yoon et al., 2007; Emami and Diamandis, 2008) activate KLK1; KLK11 is 
activated by KLK4, KLK5 (Beaufort et al., 2010) and KLK14 (Yoon et al., 2007); and 
KLK14 is activated by KLK11 (Yoon et al., 2007) and KLK15 (Yoon et al., 2009).  
KLK4 and KLK14 also potentially participate in cascades with other proteases. For 
instance, KLK4, KLK14 and other KLKs may participate in the plasminogen activation 
16 
 
system. In this cascade uPA and tPA require proteolytic activation and they in turn 
activate plasminogen to plasmin which is involved in degradation of ECM components, 
Figure 1.5 Inter-activation web of prostate-expressed kallikrein-related peptidases 
activation of growth factors, cytokines, and MMPs (Deryugina and Quigley, 2012), as 
well as cleavage of cell-surface signal transduction protein Cub domain-containing 
protein 1 (CDCP1) (Brown et al., 2004; Casar et al., 2012a; Casar et al., 2012b). The 
plasminogen system is regulated by plasminogen activator inhibitors (PAI)-1 and PAI-2, 
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as well as by cell-surface receptors that bind uPA and plasminogen to the cell surface 
(Deryugina and Quigley, 2012). KLK4 may positively regulate the plasminogen system 
through activation uPA (Takayama et al., 2001b). On the other hand, KLK4 may 
negatively regulate the plasminogen system through fragmentation of the urokinase 
plasminogen activator receptor (uPAR) (Beaufort et al., 2006). In addition, KLK14 may 
also negatively regulate the system through degradation of plasminogen to generate anti-
angiogenic angiostatin and angiostatin-like fragments (Borgono et al., 2007c). In so 
doing, the KLK14 may reduce ECM turnover as well as reducing angiogenic capability 
of the cells. 
Interestingly, it was also shown that KLK14 proteolysed complement C3 in vitro to 
generate complement C3a, and also induced complement C3a receptor-mediated cell 
signalling in vivo (Oikonomopoulou et al., 2013). The C3a receptor is expressed by many 
cell types including cells of myeloid origin as well as epithelial and smooth muscle cells 
(Klos et al., 2009). Moreover, C3a-induced signalling has been associated with a range of 
cellular effects that facilitate cancer progression including inflammation, increased 
activity of mitogenic pathways, up regulation of cytokines, anti-apoptotic effects, 
angiogenesis and migration (Rutkowski et al., 2010). This represents a novel pathway for 
KLK14 interaction in the complement cascade and may have particular relevance to the 
inflammatory aspects of prostate cancer development. 
 
1.4.4 KLKs in prostate cancer 
As disruption of normal prostate architecture, in particular the loss of epithelial cell 
polarity, alters the secretory characteristics of the epithelial cells (Djakiew et al., 1992; 
Webber et al., 1995; Pinzani et al., 2008), this results in increased release of KLK3 (also 
known as prostate-specific antigen or PSA) into the surrounding tissue and the blood, 
instead of the luminal space (Webber et al., 1995; Ishida et al., 2003; Lilja et al., 2008; 
Pinzani et al., 2008). So, despite an overall decrease in KLK3 expression at the mRNA 
and protein levels in prostate cancer (Qiu et al., 1990; Magklara et al., 2000; Herrala et 
al., 2001), increased serum PSA is the basis for clinical diagnostic tests of prostatic 
disease (Kuriyama et al., 1981; Wang et al., 1981; Lilja et al., 2008).  
Indeed, a similar scenario is likely for other prostate expressed KLKs. For example, in 
prostate cancer patients, serum KLK14 (Borgono et al., 2007c) is elevated compared to 
18 
 
normal. Another example is that the level of KLK4 in sera of healthy subjects or 
prostate cancer patients is not significant (Obiezu et al., 2002; Obiezu et al., 2005), 
however, serum antibodies to KLK4 have been detected in prostate cancer patients 
(Day et al., 2002) possibly indicating increased access to the immune system afforded by 
prostate architecture disorganization. 
Moreover, spatial dysregulation of KLKs combined with the dysregulated expression of 
several KLKs in prostate cancer, has the potential to alter KLK interactions with 
proteins in the prostate environment. As a consequence, the dysregulated proteases may 
initiate or participate in proteolytic cascades normally compartmentalized by tissue 
architecture. Furthermore, pre-malignant prostate cells have significantly reduced ability 
to accumulate Zn2+ (Costello et al., 2004). Therefore, as many KLKs including KLK4 
and KLK14 are inhibited by Zn2+ in vitro (Debela et al., 2006a; Borgono et al., 2007c), 
regulation of KLK activity may be compromised in prostate cancer due to the reduced 
concentration of Zn2+ in the tissue. 
Importantly for prostate cancer, stable overexpression of KLK4 leads to increased in 
vitro migration of PC-3 cells, and this was associated with the loss of E-cadherin and  
epithelial to mesenchymal transition (EMT) (Veveris-Lowe et al., 2005). EMT is a trait 
of cancer progression marked by loss of cell polarity, down regulation of cell-cell 
adhesive proteins, such as E-cadherin, and, occasionally, morphological changes to a 
spindle shape cell (Thiery, 2002; Christofori, 2006). The mechanism by which KLK4 
effects this functional change is not yet known.  
As well as inducing increased migratory ability, overexpression of KLK4 also results in 
increased LNCaP cell proliferation (Klokk et al., 2007). Consistent with this, 
knockdown of KLK4 inhibited cell growth (Klokk et al., 2007). Recent work by Jin and 
colleagues (2013) showed that the KLK4 contribution to increased proliferation may be 
due to alteration of two proliferative pathways – phosphatidylinositol 3-kinase 
(PI3K)/protein kinase B/mammalian target of rapamycin (mTOR) and androgen 
receptor (AR) signalling. Further work by this group showed knockdown of KLK4 in 
LNCaP cells inhibited in vitro and in vivo growth, as well as reducing anchorage 
independent growth, inducing apoptosis and increasing cell susceptibility to apoptosis-
inducing agents (Jin et al., 2013).  
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Of the KLK proteolytic targets identified in vitro, several have potential to contribute to 
prostate cancer progression. For example, KLK14 cleaves insulin-like growth factor 
binding proteins (IGFBP) thus potentially increasing the availability of insulin-like 
growth factor (IGF) and thereby contributing to increased cell proliferation (Borgono et 
al., 2007c). In addition, KLK14 cleaves cell-cell adhesion protein desmogelin (Borgono 
et al., 2007b) and degrades ECM proteins like the collagens, laminin, fibronectin and 
vitronectin (Borgono et al., 2007c; Rajapakse and Takahashi, 2007). KLK4 also cleaves 
without degrading sex hormone-binding globulin (SHBG), a protein involved in the 
stabilization and delivery of steroid hormones such as androgens to target tissues 
including the prostate (Sanchez et al., 2012). However, as SHBG retains function after 
KLK4 cleavage, the relevance of this to cell homeostasis is as yet unknown (Sanchez et 
al., 2012). In contrast, KLK14 degrades unbound SHBG, thereby potentially 
participating in negative regulation of  androgen delivery through decreasing the 
availability of SHBG (Sanchez et al., 2012). 
The in vivo function of KLK4 and KLK14 in normal prostate and seminal fluid is 
speculative, as is the role of dysregulated KLKs in prostate cancer progression. 
However, taken together, there is potential enhancement in the invasive capability of 
tumour cells through increased KLK protease activity, breakdown of tissue structure 
and release of cells. 
 
1.5 Type II transmembrane serine proteases (TTSPs) 
Similar to the KLKs, the TTSPs are a large family of serine proteases with 17 human 
TTSPs identified (Bugge et al., 2009). They are synthesized as single chain pre-pro-
enzymes characterized by an N-terminal signal peptide that is not removed but is 
retained as a short intracellular domain and transmembrane anchor domain. They also 
have a highly homologous extracellular serine protease domain at the C-terminal. In 
between the transmembrane domain and the serine protease domain, TTSPs have an 
extracellular stem region of varying lengths (Hooper et al., 2001b) (Figure 1.6).  
TTSP activation by proteolysis generates a heterodimer as the serine protease domain 
remains tethered to the stem region by an intramolecular disulphide bond conserved in 
other two-chain proteases such as plasminogen and plasma kallikrein (Lin et al., 1999c; 
Hooper et al., 2001b). In addition, the TTSP hepsin has a further eight conserved 
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cysteine residues in the serine protease domain that form four intra-domain disulphide 
bonds confirmed by crystal structure analysis (Somoza et al., 2003). Similarly, six 
conserved cysteine residues in the matriptase serine protease domain form three intra-
domain disulphide bonds (Friedrich et al., 2002). Transmembrane protease serine 2 
(TMPRSS2) is also predicted to have three intra-domain disulphide bonds; however, this 
has not been confirmed experimentally. There is also one unpaired cysteine residue in 
the serine protease domain of TMPRSS2. It is semi-conserved in several other serine 
proteases including hepsin as one of a pair of cysteine residues found forming a fourth 
disulphide bond (Paoloni-Giacobino et al., 1997; Jacquinet et al., 2001). However, the 
second cysteine of the pair is not conserved in TMPRSS2 (Paoloni-Giacobino et al., 
1997; Jacquinet et al., 2001). Hepsin also has one unpaired cysteine residue in its serine 
protease domain, however, it is not conserved in other serine proteases (Leytus et al., 
1988; Kurachi et al., 1994). The significance of these unpaired cysteines is unknown. 
However, Kurachi and colleagues (Kurachi et al., 1994) suggest that in the case of 
hepsin, the unpaired cysteine may assist with protein or ligand interactions.  
TTSP stem regions contain up to 11 modular structural domains that are also potentially 
involved in protein or ligand interactions (Antalis et al., 2011). Hepsin and TMPRSS2 
have a single scavenger receptor cysteine-rich (SRCR) domain, while TMPRSS2 has an 
additional low density lipoprotein receptor class A (LDLA) domain (Szabo and Bugge, 
2008) (Figure 1.6). In contrast, matriptase has multiple domains in the stem (Szabo and 
Bugge, 2008) (Figure 1.6). Studies have shown that these domains may be involved in 
cellular localization, as well as matriptase activation and inhibition (Oberst et al., 2003b; 
List et al., 2006a; Kojima et al., 2009). Furthermore, crystal structure analysis of hepsin 
has shown the stem region may have a role in orienting the serine protease domain on 
the cell surface (Somoza et al., 2003).  
Localization to the cell surface suggests these proteases have an important role in 
modulating the pericellular environment. However, several TTSPs such as 
enteropeptidase, matriptase, hepsin and TMPRSS2 do not require membrane anchoring 
for in vitro activity (Bugge et al., 2009). Indeed, in vivo shed forms have been found for 
enteropeptidase (Louvard et al., 1973; Fonseca and Light, 1983), TMPRSS2 (Afar et al., 
2001; Lucas et al., 2008) and matriptase (Lin et al., 1999b; Benaud et al., 2001; Jin et al., 
2005; Wang et al., 2009) which suggests some may have roles in addition to in the 
immediate pericellular environment. 
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Figure 1.6 Domain structures of hepsin, TMPRSS2 and matriptase 
 
 
1.5.1 Hepsin 
The gene encoding hepsin was first cloned from human liver cDNA libraries (Leytus et 
al., 1988), and it encodes a 417 residue protein (Leytus et al., 1988; Tsuji et al., 1991) 
(Figure 1.6). Peptide substrate assays using recombinant extracellular region (soluble) 
hepsin have shown it has a strong preference for Arg P1 residues (Herter et al., 2005). 
The P1 activation residue for hepsin zymogen is also an Arg (Leytus et al., 1988). 
Furthermore, hepsin is regarded as capable of autoactivation (Bugge et al., 2009), as 
demonstrated for mouse hepsin (Vu et al., 1997) and proposed for human hepsin by 
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Qiu and colleagues (2007). Certainly, mutation of active site residues prevents 
autoactivation of mouse hepsin (Vu et al., 1997). 
Hepsin is highly expressed at the mRNA and protein level in the liver, with lower level 
expression in most tissues including prostate (Leytus et al., 1988; Tsuji et al., 1991; Li et 
al., 2005). Interestingly, hepsin has been associated with hearing and inner ear 
development, as deletion of hepsin in mice leads to profound hearing loss (Guipponi et 
al., 2007; Guipponi et al., 2008).  
Importantly, hepsin mRNA and protein are highly overexpressed in primary prostate 
carcinoma compared to benign prostatic tissue (Dhanasekaran et al., 2001; Luo et al., 
2001; Magee et al., 2001; Stamey et al., 2001; Welsh et al., 2001; Ernst et al., 2002; Chen 
et al., 2003; Stephan et al., 2004; Halvorsen et al., 2005; Landers et al., 2005; Riddick et 
al., 2005; Xuan et al., 2006; Kube et al., 2007; Goel et al., 2011), and is considered a 
significant biomarker for diagnosis and prognosis of prostate cancer (Dhanasekaran et 
al., 2001; Stephan et al., 2004; Landers et al., 2005). Hepsin protein expression has been 
shown to increase as early as the transition from normal epithelium to prostatic 
intraepithelial neoplasia (PIN) (Dhanasekaran et al., 2001) with continued increase as 
prostate cancer progresses to high grade carcinoma (Dhanasekaran et al., 2001; Xuan et 
al., 2006; Goel et al., 2011). As prostate cancer metastasizes, higher hepsin protein 
expression has been found in bone metastasis than lymph node or liver metastasis 
(Morrissey et al., 2008). Another study found the hepsin protein expression increase 
continues from low grade carcinoma through to bone metastasis (Xuan et al., 2006). 
However, in two studies, a decrease in hepsin mRNA and/or protein has been found in 
hormone refractory metastatic prostate cancer, when compared to primary prostate 
cancer (Dhanasekaran et al., 2001; Fromont et al., 2005). 
 
1.5.2 TMPRSS2 
TMPRSS2 cDNA was first cloned in the development of a transcription map of 
chromosome 21 (Paoloni-Giacobino et al., 1997). The TMPRSS2 gene was mapped to 
chromosome 21q22.3 (Paoloni-Giacobino et al., 1997; Hattori et al., 2000; Jacquinet et 
al., 2001) and described as encoding a protein of 492 residues (Paoloni-Giacobino et al., 
1997) (Figure 1.6). Since the cloning of TMPRSS2, several studies have focussed on the 
role of the 5’-untranslated region of TMPRSS2 in gene fusions with members of the 
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erythroblast transformation specific (ETS) transcription factor family genes (Tomlins et 
al., 2005).  However, fusion of TMPRSS2 with ETS genes is unlikely to result in 
proteolytic function as the product does not encode the TMPRSS2 serine protease 
domain (Kumar-Sinha et al., 2008). For this reason, TMPRSS2 fusion with ETS will not 
be discussed further. Few studies have been made of the structure or serine protease 
activities of the TMPRSS2 protein. As a result many of the features have been inferred 
from sequence and domain structure conservation between TMPRSS2 and other TTSPs 
and serine proteases. 
TMPRSS2 cleaves after arginine residues in synthetic substrate assays (Wilson et al., 
2005; Bottcher-Friebertshauser et al., 2010; Meyer et al., 2013). The TMPRSS2 zymogen 
activation also occurs at an Arg P1 (Afar et al., 2001). In this same study it was shown 
that mutation of the active site serine to an alanine residue prevented activation and also 
prevented cleavage of TMPRSS2 at other sites, demonstrating TMPRSS2 autoactivation 
and self-cleavage (Afar et al., 2001). 
The prostate has the highest TMPRSS2 mRNA and protein expression levels with lower 
levels in several other tissues (Lin et al., 1999a; Afar et al., 2001; Jacquinet et al., 2001; 
Vaarala et al., 2001b; Donaldson et al., 2002; Lucas et al., 2008; Bertram et al., 2012). 
Immunohistochemistry studies have shown TMPRSS2 protein is localized to epithelial 
cells (Afar et al., 2001; Lucas et al., 2008; Chen et al., 2010b). In the prostate the protein 
is localized to the apical plasma membrane of the luminal cells (Afar et al., 2001; Lucas 
et al., 2008; Chen et al., 2010b). As mentioned earlier, TMPRSS2 is shed into the 
prostate luminal space and has been detected in seminal fluid (Afar et al., 2001; Lucas et 
al., 2008). It has also been detected as a component of prostasomes (Utleg et al., 2003; 
Chen et al., 2010b) along with a number of other proteases including KLK3, and 
protease inhibitors including hepatocyte growth factor activator inhibitor (HAI)-1 
(Utleg et al., 2003; Poliakov et al., 2009). These organelle-like membrane vesicles are 
secreted from the prostate luminal cells into seminal fluid and are thought to facilitate 
sperm function (Kravets et al., 2000). Therefore, TMPRSS2 may play a key role in the 
cascade of KLKs in the prostate microenvironment. 
Importantly, TMPRSS2 mRNA and protein expression is increased in prostate cancer 
(Lin et al., 1999a; Afar et al., 2001; Vaarala et al., 2001a; Vaarala et al., 2001b; Lucas et 
al., 2008; Chen et al., 2010b). Moreover, cellular localization of TMPRSS2 is 
dysregulated, moving from the apical to the entire plasma membrane surface and 
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increased intracellular accumulation as the acinar macrostructure is lost during prostate 
cancer progression (Lucas et al., 2008; Chen et al., 2010b). A significant aspect of 
TMPRSS2 is that similar to members of the KLK family, expression is androgen-
regulated in prostate cancer-derived cell lines expressing androgen receptor (Lin et al., 
1999a; Afar et al., 2001; Jacquinet et al., 2001). Furthermore, TMPRSS2 expression is 
down-regulated in bone metastasis-derived androgen-independent prostate cancer 
xenograft tissue (Afar et al., 2001).  
Interestingly, the physiological role of TMPRSS2 remains undetermined from 
TMPRSS2 (-/-) mice studies as the mice were viable and fertile and exhibited no 
detectable abnormalities (Kim et al., 2006). Moreover, there were no differences in 
prostate secretions, development of prostate cancer or regeneration of the prostate 
epithelium after castration in the TMPRSS2 (-/-) mice. This lack of phenotype suggests 
either functional redundancy involving one or more serine proteases or that TMPRSS2 
has a function in circumstances of disease or stress (Kim et al., 2006). 
 
1.5.3 Matriptase 
Matriptase was first identified from the media of cultured breast cancer cells as a gelatin-
degrading protease (Shi et al., 1993). Matriptase is an 855 residue protein encoded by a 
gene located on chromosome 11q24-25 (Lin et al., 1999c; Takeuchi et al., 1999) (Figure 
1.6). It has a preference for Arg P1 residues in substrates (Takeuchi et al., 2000; Bhatt et 
al., 2007), and a two-step process involving cleavage in the sea urchin sperm protein, 
enterokinase, agrin (SEA) domain followed by cleavage at the conserved activation site 
is required for matriptase activation. Matriptase autoactivates, however, the mechanisms 
of the process are complex involving domains in the stem region, N-glycosylation 
(Oberst et al., 2003b; Inouye et al., 2013), homodimer formation (Xu et al., 2011) and 
cell-surface localization (Benaud et al., 2002), and can also be induced in LNCaP cells by 
androgen treatment (Kiyomiya et al., 2006). Furthermore, activated matriptase cell-
surface localization depends on specific interactions with its cognate inhibitor HAI-1 
(Oberst et al., 2003b; Oberst et al., 2005). 
Matriptase mRNA and protein are widely expressed in epithelial cells of most tissues 
(Takeuchi et al., 1999; Oberst et al., 2003a; List et al., 2006b; Netzel-Arnett et al., 2006; 
Szabo et al., 2007). Studies in matriptase-null mice have identified it as crucial for 
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terminal epidermal differentiation, epidermal barrier formation and hair follicle 
development (List et al., 2002; List et al., 2003; List et al., 2009). Moreover, tissue-
dependent effects of matriptase deficiency have been determined demonstrating its role 
in loss of secretory and epidermal barrier function, and, in some tissues, loss of 
anatomical integrity (List et al., 2007; List et al., 2009; Buzza et al., 2010).  
In vitro studies have shown this protease is expressed in the basolateral surface of 
prostate epithelial cells and when activated, translocates to the apical surface in complex 
with HAI-1 (Wang et al., 2009). Significantly, there is increased matriptase expression in 
prostate cancer with a positive correlation to increased tumour grade (Riddick et al., 
2005; Saleem et al., 2006). However, while matriptase expression increases in localized 
prostate cancer compared to benign tissue, it decreases in metastatic disease (Warren et 
al., 2009). 
  
1.5.4 TTSPs in proteolytic cascades 
Similarly to the KLK family, studies have addressed the potential for other proteolytic 
cascades featuring TTSPs. Indeed, as matriptase (Takeuchi et al., 2000; Oberst et al., 
2003b; Desilets et al., 2008),  hepsin (Qiu et al., 2007) and TMPRSS2 (Afar et al., 2001) 
autoactivate they have the  potential to function as cascade initiators.  
Matriptase is one of the most comprehensively studied TTSPs. It has been implicated in 
proteolytic cascades in the skin through activation of the serine protease prostasin 
(Netzel-Arnett et al., 2006). As determined from the phenotypes of matriptase- and 
prostasin-deficient mice, matriptase-activated prostasin is required for epidermal 
differentiation and epithelial barrier function (List et al., 2002; List et al., 2003; Leyvraz 
et al., 2005; List et al., 2009).  
Hepsin also activates transmembrane serine protease prostasin (Chen et al., 2010a), as a 
result providing an avenue for participation in the matriptase/prostasin cascade and 
epithelial barrier function (List et al., 2002; Leyvraz et al., 2005). Indeed, recent 
subcellular localization studies showing hepsin localized to desmosomal junctions in 
ovarian cancer cell lines (Miao et al., 2008) and primary mouse mammary epithelial cells 
(Partanen et al., 2012) also suggest a possible role in epithelial integrity. Co-localization 
studies have also implicated matriptase in cascades with prostasin or hepsin in 
embryonic development (Camerer et al., 2010). Prostasin and hepsin activate matriptase 
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(Camerer et al., 2010), though the mechanism by which prostasin achieves this is 
indirect, in the manner of a co-factor (Buzza et al., 2013). However, while a number of 
tissues and organs in matriptase- and prostasin-null mice have similarities in epithelial 
defects (List et al., 2002; List et al., 2003; Leyvraz et al., 2005; List et al., 2009), no 
epithelial phenotypic changes were detected in hepsin-null mice (Wu et al., 1998; Yu et 
al., 2000; Guipponi et al., 2007). 
 
1.5.5 TTSPs in prostate cancer 
In vitro and in vivo studies have been used to examine the roles of TTSPs in prostate and 
other cancers. For instance, matriptase is considered an oncogenic protein as increases 
in expression have been associated with progression of several cancers of epithelial 
origin including prostate cancer (List et al., 2005; Saleem et al., 2006; List, 2009). In 
accord, in vivo inhibition of matriptase reduced the growth of androgen-independent 
prostate cancer xenografts in mice (Galkin et al., 2004). Furthermore, in vitro matriptase 
inhibition or expression knockdown, by using siRNA or hammerhead ribozyme 
transgenes, reduced invasion of PC-3 and prostate cancer brain metastasis-derived 
DU145 cells (Forbs et al., 2005; Sanders et al., 2006). It has also been found that 
reduction in matriptase inhibitor HAI-1 led to increased motility and invasion of PC-3 
and DU145 cells in vitro (Sanders et al., 2007). Similarly, decreased HAI-2 in a prostate 
cancer xenograft model led to increased matriptase activation and increased tumour cell 
migration invasion and metastasis (Tsai et al., 2013).  
Other in vitro and in vivo overexpression models have also demonstrated possible 
influences of hepsin on progression of prostate cancer (Klezovitch et al., 2004; Moran et 
al., 2006; Xuan et al., 2006; Yemelyanov et al., 2007; Tripathi et al., 2008; Li et al., 2009; 
Ganesan et al., 2011; Wittig-Blaich et al., 2011). For instance, a study has shown that 
blocking hepsin activity using hepsin-neutralising antibodies inhibited in vitro Matrigel 
invasion of DU145 cells and ovarian cancer CAOV-3 cells while not altering cell growth 
(Xuan et al., 2006). Furthermore, in an in vivo study using hepsin-overexpressing ovarian 
cancer SKOV-3 cells, blocking hepsin activity by mutating the catalytic residues of 
hepsin reduced the size of subcutaneous tumours grown in mice (Miao et al., 2008). 
One of the tools developed for studying hepsin in prostate cancer is a hepsin-
overexpressing LNCaP cell line, designated LNCaP-34. Generated by Moran and 
colleagues (2006), these cells have been used to demonstrate the in vitro ability of cell-
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surface hepsin to activate uPA (Moran et al., 2006) and macrophage-stimulating protein 
(Ganesan et al., 2011), and degrade laminin-332 (Tripathi et al., 2008). The LNCaP-34 
cells, implanted into mouse prostate to model prostate cancer, were also used to 
demonstrate the increased growth rate, invasive and metastatic potential of the hepsin-
overexpressing cells (Li et al., 2009).  
Interestingly, studies have also demonstrated a growth suppressive effect of hepsin 
overexpression in vitro.  For instance, overexpression of hepsin in metastatic prostate 
cancer-derived PC-3, LNCaP and DU145 cells reduced cell growth, invasion and colony 
formation in soft agar assays (Srikantan et al., 2002). As such, it was proposed that the 
hepsin down-regulation observed in hormone-refractory prostate cancer may contribute 
to the growth and invasive capability of the metastatic cells (Fromont et al., 2005). 
Certainly studies in cell lines derived from ovarian and endometrial cancers have also 
shown hepsin overexpression reduced cell growth and anchorage-independent growth, 
increased apoptosis, in vitro, and decreased in vivo tumourigenicity (Nakamura et al., 
2006; Nakamura et al., 2008). Furthermore, in a study by Klezovitch and colleagues 
(2004) using mice with SV40 large T antigen in the prostate epithelium, a mouse model 
of non-metastasizing prostate cancer, while hepsin overexpression caused disruption to 
the basement membrane and metastasis of prostate tumour cells to lung, liver and bone 
in the prostate epithelium, it had no observed impact on tumour cell proliferation 
(Klezovitch et al., 2004). 
The study by Klezovitch and colleagues (2004) highlighted an interesting aspect of 
hepsin overexpression as they observed a weakening of epithelial-stromal adhesion in 
the prostate. Changes to epithelial integrity were also observed in a study by Partanen 
and colleagues (2012) of mouse mammary epithelium, tumourigenesis promoted by a 
loss of expression of the tumour suppressor liver kinase B1 (LkB1) combined with 
overexpression of the oncogene c-Myc resulted in loss of epithelial integrity marked by 
loss of cell polarity, desmosomal junction and basement membrane deterioration. 
Hepsin was identified as a key factor in the structural alterations as it was no longer seen 
to be confined to desmosomal complexes. Moreover, silencing hepsin restored 
basement membrane integrity in this tumourigenesis model. Interestingly, this model 
demonstrated the delocalization of hepsin from the desmosomal junctions at the cell 
surface to the cytosol in response to either LkB1 loss and c-Myc expression, or the 
deterioration of cell-cell junctions induced by calcium depletion.  This study is 
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complemented by a study in which an overexpression of hepsin and c-Myc in a prostate 
cancer mouse model demonstrated rapid progression of prostate cancer (Nandana et al., 
2010). Interestingly, unlike the hepsin overexpressing prostate cancer mouse model 
studied by Klezovitch and colleagues (2004), in the hepsin/c-Myc model, the cancer did 
not progress to metastasis, further highlighting the vagaries of hepsin (Nandana et al., 
2010). 
Taken together, these studies suggest that the serine protease activity exerted by hepsin 
is one mechanism by which hepsin contributes to prostate cancer progression. 
Furthermore, hepsin may have a complex role in maintenance of epithelial integrity. 
Deregulation of hepsin may contribute to prostate cancer progression through 
disruption of the basement membrane and altered interactions with proteins involved in 
cell-to-cell contact and cell-to-substratum adhesion (Vasioukhin, 2004).  
 
1.6 Hepatocyte growth factor 
Activated HGF (also known as scatter factor) (Figure 1.7) is the ligand of a tyrosine 
kinase receptor, hepatocyte growth factor receptor (HGFR) (also known as the MET 
receptor) (Bottaro et al., 1991). Primarily produced by stromal cells, HGF induces 
epithelial cell proliferation, motility and morphogenesis through activation of HGFR 
(Nakamura and Mizuno, 2010). Irregular receptor signalling due to HGFR and HGF 
overexpression has an established role in tumourigenesis (Trusolino et al., 2010; 
Gherardi et al., 2012) and, in particular, has been associated with the progression of 
prostate cancer (Humphrey et al., 1995; Nakashiro et al., 2000; Knudsen et al., 2002; 
Nakashiro et al., 2003; Knudsen and Edlund, 2004; Hashem and Essam, 2005; Yasuda 
et al., 2009).  
HGF has a domain structure similar to the serine protease plasminogen (Figure 1.7) 
(Miyazawa et al., 1989; Nakamura et al., 1989; Donate et al., 1994), however, the serine 
protease domain of HGF is catalytically inactive (Lokker et al., 1992). Activation of the 
HGF single chain precursor (pro-HGF) to produce a heterodimer linked by a disulphide 
bond occurs by proteolysis at an arginine residue immediately prior to the serine 
protease homology domain (Gak et al., 1992; Naka et al., 1992; Naldini et al., 1992). 
Several serine proteases with a preference for Arg P1 residues activate HGF including 
the serum protease hepatocyte growth factor activator (HGFA) (Shimomura et al., 1995; 
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Itoh et al., 2004), and the transmembrane proteases matriptase (Lee et al., 2000; Owen 
et al., 2010) and hepsin (Herter et al., 2005; Kirchhofer et al., 2005; Owen et al., 2010). 
In contrast, two prostate-expressed members of the KLK family, KLK4 and KLK5, 
both with Arg P1 specificity, degrade rather than activate HGF (Mukai et al., 2008). In 
this same study it was determined that these KLKs activate HGFA, thereby potentially 
positively regulating the HGF-HGFR signalling cascade. However, a role for KLK14 in 
HGF activation and the HGF-HGFR signalling cascade has not been reported. 
 
Figure 1.7 Domain structures of HGF, HAI-1A and HAI-1B 
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1.7 Hepatocyte growth factor activator inhibitor-1 
A crucial aspect of HGF activation and induced HGFR signalling, is regulation of the 
activating proteases by inhibitors (Gherardi et al., 2012). HAI-1 is a Kunitz-type, type-1 
transmembrane serine protease inhibitor with two isoforms, HAI-1A and splice variant 
HAI-1B (Shimomura et al., 1997; Kirchhofer et al., 2003). HAI-1 is an endogenous 
inhibitor of HGF activators HGFA and matriptase (Shimomura et al., 1997; Lin et al., 
1999b; Benaud et al., 2001; Wang et al., 2009). Moreover, a role for HAI-1 in tight 
regulation of matriptase pericellular activity has been proposed (Oberst et al., 2003b; 
Oberst et al., 2005; Fan et al., 2007; Lee et al., 2007; Szabo et al., 2007; Tseng et al., 
2010; Friis et al., 2011). It has also been shown to inhibit other HGF activators in vitro 
including hepsin (Herter et al., 2005; Kirchhofer et al., 2005). 
The HAI-1 isoforms are expressed on the surface of epithelial cells with high expression 
of mRNA and protein in tissues such as prostate, kidney, intestine and placenta 
(Kataoka et al., 1999; Itoh et al., 2000; Tanaka et al., 2009; Wang et al., 2009). While one 
study determined that compared to normal prostate tissue HAI-1 protein expression 
decreased in prostate cancer with increasing cancer grade (Saleem et al., 2006), several 
other studies have demonstrated contrary results. For instance, Knudsen and colleagues 
(2005) found that HAI-1 increased in localized and metastasized prostate cancer 
compared to normal tissue. Similarly, in another study HAI-1 was found to increase in 
all proliferative prostate diseases, from benign prostatic hyperplasia (BPH) to aggressive 
and metastatic prostate cancer, with no distinction between diseased tissue type (Warren 
et al., 2009). Recently, Yasuda and colleagues (2013) also found that HAI-1 had higher 
expression in prostate tissue from patients with prostate cancer compared to patients 
with benign disease. However, they also found that HAI-1 decreased in patients with 
castration-resistant prostate cancer compared to those with untreated metastasized 
prostate cancer. HAI-1 has also been detected in the serum from patients with prostate 
cancer and found to be significantly elevated compared to patients with BPH 
(Nagakawa et al., 2006). This study also showed that serum HAI-1 was higher in 
patients with metastasized and hormone-resistant prostate cancer compared to those 
with localized disease.  
The HAI-1 isoforms are very similar (Figure 1.7), consisting of a region at the N-
terminus with eight cysteines called the MANEC domain (Guo et al., 2004), a Kunitz 
domain (KD1), a LDLR domain, a second Kunitz domain (KD2), a transmembrane 
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region, and a cytoplasmic domain (Shimomura et al., 1997). However, HAI-1B has an 
extra 16 amino acid insert between KD1 and LDLR of unknown significance 
(Kirchhofer et al., 2003).   
HAI-1 inhibitory activity likely occurs via standard mechanism inhibition (Laskowski 
and Qasim, 2000; Krowarsch et al., 2003), mediated by the Kunitz domains (Shimomura 
et al., 1997). These domains in effect act like substrates, binding to a protease active site 
through a P1 residue in a substrate-like binding loop on the surface of the domain 
(Laskowski and Qasim, 2000; Krowarsch et al., 2003). It binds the serine protease in a 
very stable, but also reversible complex, resembling a Michaelis complex. Dissociation 
of the complex can either result in release of the protease and intact inhibitor or can 
result in release of protease and inhibitor hydrolysed at the reactive site. The inhibitor 
hydrolysed at the active site is still able to form the same complex with the protease as 
the intact inhibitor. As the protease-inhibitor complex formed is very stable, the 
progression to dissociation is very slow, which results in the inhibition of the protease 
by holding it in complex for extended periods (Laskowski and Qasim, 2000; Krowarsch 
et al., 2003). 
 A recent study, using LNCaP cells overexpressing hepsin implanted into mouse 
prostate to model prostate cancer, found that a truncated form of HAI-1 containing 
KD1 inhibits hepsin-mediated tumour growth and invasion (Li et al., 2009). Mukai and 
colleagues (2008) also showed that this same form of truncated HAI inhibits KLK4. 
However, the inhibition of KLK14 by HAI-1 has not been reported. 
 
1.8 Matrix metalloproteinases (MMPs) 
Metalloproteinases are proteases that contain a Zn2+ ion in the active site (Bode et al., 
1993). They are grouped into several clans and families of which the MMPs are a part 
(Rawlings et al., 2012). There are 23 MMPs found in humans (Quesada et al., 2009) and 
the structure, function and activation of these have been well reviewed recently by 
several authors (Nagase et al., 2006; Ra and Parks, 2007; Gomis-Ruth, 2009; Tallant et 
al., 2010; Klein and Bischoff, 2011).  
In MMPs, the Zn2+ ion in the catalytic domain is coordinated by three histidine residues 
in a conserved zinc binding motif, HEXXHXXGXXH, followed by a strictly conserved 
methionine-containing turn. Based on studies of other members of the 
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metalloproteinase superfamily, catalysis of a peptide substrate probably follows a 
mechanism in which the glutamate reside in the catalytic motif, as a general base, 
polarizes a zinc bound water molecule to provide a nucleophile that attacks the carbonyl 
group of the substrate scissile bond (Ra and Parks, 2007; Tallant et al., 2010). In general 
MMPs cleave substrates before a P1’ residue with a hydrophobic side chain, such as Ile, 
Leu, Phe, Met and Tyr (Murphy and Nagase, 2008). Substrate specificity is governed by 
several factors including the shape of the MMP S1’ pocket which accommodates the P1’ 
residue, and other substrate contact points (Murphy and Nagase, 2008).  
Similar to the serine proteases, the MMPs are produced as a zymogen with a signal 
peptide sequence targeting them to secretory vesicles from which they are secreted or 
anchored to the cell surface (Ra and Parks, 2007). In addition, all the MMPs, except 
MMP23, contain a cysteine switch motif, PRCGXPD, in the pro-region of the zymogen. 
The thiol of the cysteine residue in the motif interacts with the catalytic site Zn2+ to 
keep the MMP inactive (Ra and Parks, 2007). This thiol-Zn2+ interaction can be broken 
by alkylating agents, heavy metal ions and reducing agents, rendering the zymogen MMP 
active. However, it is generally considered that zymogen MMPs are activated by 
proteolytic cleavage to remove the pro-region, similar to other zymogen proteases (Ra 
and Parks, 2007). 
All the MMPs, except MMP7, MMP23 and MMP26, also have a flexible proline-rich 
hinge region after the catalytic domain which connects to a C-terminal hemopexin-like 
domain (Ra and Parks, 2007). This domain functions particularly in substrate 
recognition, for example, it is essential for the cleavage of triple helical collagen chains 
(Murphy and Nagase, 2008). The hemopexin domains of proMMP2 and proMMP9 also 
bind tissue inhibitors of metalloproteinases (TIMPs) forming complexes that, in some 
instances, are known to inhibit other MMPs (Murphy and Nagase, 2008). Figure 1.8 
shows schematic diagrams of the domain structures of MMP3 and MMP9. 
 
1.8.1 MMP3 
MMP3 is found in the stroma of tumours, expressed by fibroblasts and endothelial cells 
(Deryugina and Quigley, 2010) and is induced by inflammatory cytokines and a number 
of growth factors (Nagase, 2013). However, the role of MMP3 in cancer is uncertain 
with early studies pointing to pro-carcinogenic effects of MMP3 in breast cancer 
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(Sternlicht et al., 1999; Sternlicht et al., 2000) while more recent studies have suggested a 
protective role in some cancers such as squamous cell carcinoma (McCawley et al., 
2004). The role of MMP3 in prostate cancer has not yet been determined. However, 
there are higher levels of MMP3 in the serum of prostate cancer patients with 
metastases (Jung et al., 1997) and it has been detected in the ECM surrounding 
neoplastically transformed cells in prostate cancer (Bodey et al., 2001). Furthermore, in a 
prostate cancer mouse model, MMP3 mRNA expression was 6-fold higher in the 
stromal cells of invasive prostate cancer compared to prostate intraepithelial neoplasms 
(Bacac et al., 2006). Together these results suggest a role for MMP3 in tumour 
progression.  
Figure 1.8 Domain structures of the metalloproteinases MMP3 and MMP9 
 
MMP3 cleaves a variety of ECM and non-matrix proteins, generating several bioactive 
molecules including anti-angiogenic factors endostatin and tumstatin (Ferreras et al., 
2000; Noe et al., 2001; Hamano et al., 2003; Heljasvaara et al., 2005). It shows a strong 
preference for hydrophobic P1’ residues with no particular preference for the P1 
(Nagase, 2013). For this reason, it has the potential to activate a wide range of serine 
proteases possessing a hydrophobic P1’ (Hedstrom, 2002; Rawlings and Barrett, 2013b). 
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Indeed, as mentioned earlier, MMP3 activates KLK4 (Beaufort et al., 2010; Yoon et al., 
2013). Moreover, MMP3 activates other MMPs including MMP9 (Ogata et al., 1992; 
Nagase, 2013). In turn, MMP3 can be activated by trypsin-2 (Moilanen et al., 2003), 
plasmin (Nagase et al., 1990) and matriptase (Jin et al., 2006), thereby potentially 
participating in activation cascades with a range of serine proteases. 
 
1.8.2 MMP9 
MMP9 is a gelatinase capable of degrading ECM proteins as well as releasing pro-
angiogenic vascular endothelial growth factor (VEGF) and anti-angiogenic factors such 
as tumstatin (Egeblad and Werb, 2002; Deryugina and Quigley, 2006; Klein and 
Bischoff, 2011). Similar to MMP3, it is expressed by stromal cells such as fibroblasts, 
inflammatory and endothelial cells (Egeblad and Werb, 2002). MMP9 has also been well 
documented in diverse malignant processes. Certainly, a number of studies have 
implicated MMP9 in pro-/anti-angiogenesis, invasion, metastasis and regulation of 
inflammatory cells in cancer (Egeblad and Werb, 2002; Deryugina and Quigley, 2006; 
Klein and Bischoff, 2011). Moreover, upregulation of MMP9 expression is well 
correlated with diagnosis or prognosis in several cancer types including prostate cancer 
(Stearns and Wang, 1993; Escaff et al., 2011a; Klein and Bischoff, 2011). 
Immunohistochemical analysis has shown that MMP9 has very low expression in 
normal or benign prostate tissue and it remained confined to the epithelial cells and was 
not detected in the stroma to any significant degree (Stearns and Wang, 1993; Escaff et 
al., 2010, 2011b). However, in prostate cancer MMP9 expression increased in epithelial 
cells with increasing grade and was also detected in stromal cells (Stearns and Wang, 
1993; Escaff et al., 2010, 2011b). Furthermore, similar to MMP3, MMP9 plasma 
concentrations were higher in patients with metastasis (Morgia et al., 2005). 
Several studies have shown a clear link between MMP9 and degradation of bone matrix 
(Edlund et al., 2004) as well as it being a key protease in prostate cancer development 
(Deryugina and Quigley, 2006; Littlepage et al., 2010). In vitro studies have also 
demonstrated that MMP9 overexpression promoted the invasive capability of LNCaP 
cells (Aalinkeel et al., 2011). Moreover, MMP9 expression knockdown reduced DU145 
in vitro cell proliferation and in vivo tumour growth, invasion and angiogenesis (London 
et al., 2003). However, in a prostate cancer mouse model MMP9 knockdown had no 
effect on tumour growth or survival, though it was associated with decreased blood 
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vessel size (Littlepage et al., 2010). Similarly, MMP9 positively affected angiogenesis in a 
prostate cancer bone metastasis mouse model (Bruni-Cardoso et al., 2010). 
In addition to in vitro activation by MMP3, MMP9 is activated by several serine proteases 
including KLK1 (Tschesche et al., 1989; Desrivieres et al., 1993; Menashi et al., 1994), 
trypsin (Okada et al., 1992), trypsin-2 (Sorsa et al., 1997) and plasmin (Mazzieri et al., 
1997). While MMP9 has a preference for small P1 residues and hydrophobic, aliphatic 
P1’ residues, it is unlikely to activate trypsin-like serine proteases with Arg/Lys P1 
residues (Eisen et al., 2013). So, MMP9 is more likely to be activated by, than activate, 
serine proteases in a proteolytic cascade. This possibly relegates MMP9 to the role of 
executor at the end of a cascade. This is consistent with the substrates identified as 
favoured by MMP9 which include mostly ECM proteins, as well as processing of a few 
growth factors and cytokines, a serine protease inhibitor, and plasmin into angiostatin 
(Eisen et al., 2013). 
 
1.9 Protease-activated receptors (PARs) 
The four PAR family members, designated PAR1-PAR4, are members of the GPCR 
superfamily (Macfarlane et al., 2001) of transmembrane proteins that transduce 
extracellular stimuli into intracellular signals. While the general mechanism of GPCR 
activation is by interaction or binding with soluble ligands (Metaye et al., 2005), the 
PARs are a unique group in which specific proteolytic cleavage of the PAR extracellular 
N-terminal creates a new N-terminal which functions as a tethered ligand (Vu et al., 
1991a; Macfarlane et al., 2001) (Table 1.1). However, PAR1, PAR2 and PAR4 can also 
be activated in vitro by short peptides, known as agonist peptides (AP), which mimic the 
tethered ligand sequence (Ramachandran et al., 2012b 1443). PAR signalling is thought 
to occur when a protease-exposed tethered ligand or AP binds intramolecularly to 
conserved regions of the PAR including the second extracellular loop (Vu et al., 1991a; 
Lerner et al., 1996; Adams et al., 2011). 
The range of cellular effects resulting from PAR activation is extensive. They include 
inflammation, immune response, differentiation, proliferation, migration, angiogenesis, 
apoptosis evasion and metastasis (Steinhoff et al., 2005; Adams et al., 2011; Kaufmann 
and Hollenberg, 2012), and they are all functional capabilities acquired by cancer cells 
(Hanahan and Weinberg, 2011). Importantly for this project, increased mRNA and 
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protein expression of PAR1, PAR2 and PAR4, but not PAR3, have been detected in 
prostate adenocarcinoma compared to normal prostate tissue (Tantivejkul et al., 2005; 
Kaushal et al., 2006; Black et al., 2007). Moreover, PARs are activated by proteases from 
well-established proteolytic cascades such as the coagulation, plasminogen activation 
and digestive enzyme cascades (Ossovskaya and Bunnett, 2004; Adams et al., 2011). 
Likewise, PARs may be activated by other proteolytic cascades or as a result of aberrant 
cascades in a tumour microenvironment. 
 
1.9.1 PARs structure and activation 
The structural features for each of the four PARs are detailed in Figure 1.9. The general 
features of this receptor family include: length of between 374 and 425 amino acids; an 
extracellular N-terminal, seven-transmembrane domains, a conserved second 
extracellular loop, and an intracellular C-terminal (Macfarlane et al., 2001; Luttrell, 
2008). The PAR1 and PAR3 N-termini also contain thrombin-binding hirudin-like 
domains (Macfarlane et al., 2001).  
PAR1 was the first of the PARs identified and characterized as the thrombin receptor 
(Vu et al., 1991a; Vu et al., 1991b) and it is the most extensively studied of the PAR 
family. Identification of PAR1 was followed by identification of PAR2 as a trypsin- and 
tryptase-activated receptor (Nystedt et al., 1994; Nystedt et al., 1995a; Nystedt et al., 
1995b), and PAR3 (Ishihara et al., 1997) and PAR4 (Kahn et al., 1998; Xu et al., 1998) as 
thrombin-activated receptors. 
A number of other serine proteases were found capable of PAR activation including 
members of the KLK and TTSP families including KLK4, KLK14, TMPRSS2 and 
matriptase (Ramsay et al., 2008b; Adams et al., 2011). Proteases from other classes are 
also capable of PAR activation including PAR1 activation by MMP1 (Boire et al., 2005), 
MMP2 (Malaquin et al., 2013) and MMP13 (Jaffre et al., 2012), and PAR2 and PAR4 
activation by cysteine protease cathepsin S (Reddy et al., 2010).  
In addition to using proteases to cleave the PAR tethered ligand in in vitro studies, APs 
have proved to be useful tools for investigating PAR activation. However, the AP 
modelled directly on the six residue sequence of the PAR1 tethered ligand, SFLLRN-
NH2 (also known as TRAP), also activates PAR2 (Nystedt et al., 1995b; Blackhart et al., 
1996; Lerner et al., 1996).  So a PAR1-specific AP was developed in which the S is 
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substituted for T in the first position of SFLLRN-NH2, this modification abrogated the 
ability of the peptide to cross-activate PAR2 while retaining PAR1 activation ability 
(Hollenberg et al., 1997). Furthermore, the final residue, N, was found to have little 
effect on the potency of the activating peptide as so was eliminated to yield the agonist 
peptide TFLLR-NH2 (Hollenberg et al., 1997). 
 
Figure 1.9 PAR structural features 
 
In analysis of PAR APs, Hollenberg and colleagues (1997) also demonstrated that a 
PAR2-activating peptide modelled on the sequence of mouse PAR2, SLIGRL-NH2 has 
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higher potency in human PAR2 activation than the human sequence SLIGKV-NH2. 
Similarly, structure-activity analysis revealed that the low potency PAR4 AP based on 
the tethered ligand, GYPGFK-NH2, was 10 times more potent if modified to 
AYPGFK-NH2 (Faruqi et al., 2000). On the other hand, PAR3 is not activated by its 
thrombin-revealed tethered ligand sequence (Ishihara et al., 1997) and so far a PAR3 AP 
has not been developed. Indeed, peptide sequences modelled on the PAR3 tethered 
ligand activate PAR1 and PAR2 but not PAR3 (Hansen et al., 2004; Kaufmann et al., 
2005).  As there is no PAR3 AP or conclusive method to activate PAR3 singly, it was 
not included in this PhD project. 
 
1.9.2 PAR signal transduction 
Similar to other GPCRs, it is likely that ligand binding causes conformational changes in 
the PAR. It then functions as a guanine nucleotide exchange factor (GEF) facilitating 
the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on 
the Gα subunit of heterotrimeric G proteins that associate with GPCRs (Figure 1.10) 
(Oldham and Hamm, 2008; Soh et al., 2010). The PARs associate with a number of 
different heterotrimeric G protein subtypes including, G12/13, Gq/11 and Gi/o (Russo et al., 
2009b; McCoy et al., 2010).  The GTP-bound Gα subunit of the heterotrimeric G 
protein is able to dissociate from tight-binding with the Gβγ heterodimer subunit 
(Oldham and Hamm, 2008). GTP-Gα and Gβγ then independently activate effector 
proteins, such as ionic channels, phospholipase Cβ (PLCβ), Rho GEFs, and PI3K, 
depending on the G protein subtype activated (Oldham and Hamm, 2008; Russo et al., 
2009b). The effector proteins in turn modulate cellular levels of second messenger 
molecules such as diacylglycerol (DAG), inositol 1,4,5-trisphosphate (IP3) and Ca
2+, as 
well as regulating down-stream effector pathways such as the mitogen-activated protein 
kinase (MAPK) and RhoA pathways (Metaye et al., 2005; Luttrell, 2008; Soh et al., 
2010). Ultimately, the second messenger levels and down-stream effector pathways 
modify cellular metabolism and biological responses (Metaye et al., 2005; Soh et al., 
2010).  
In addition to the heterotrimeric G proteins,  PARs recruit other interacting proteins to 
regulate receptor signalling, ligand specificity, cell-surface localization, endocytosis and 
recycling or degradation (Soh et al., 2010). This includes termination of PAR1 and 
PAR2 signalling by phosphorylation of PAR C-terminal regions, thereby, desensitizing  
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Figure 1.10 Protease-activated receptor (PAR) signalling 
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the receptor (Ishii et al., 1994; Bohm et al., 1996a; Tiruppathi et al., 2000; Ricks and 
Trejo, 2009). PAR1 and PAR2 receptor desensitization and G protein-independent 
signalling are also mediated by β-arrestins (DeFea et al., 2000; Paing et al., 2002; Chen et 
al., 2004; Defea, 2008; Soh and Trejo, 2011), as is the internalization by endocytosis of 
PAR2 (Dery et al., 1999; DeFea et al., 2000). Furthermore, while β-arrestins also 
promote PAR4 G protein-independent signalling (Li et al., 2011), the mechanisms of 
PAR3 and PAR4 desensitization and internalization are largely unknown 
(Ramachandran et al., 2012b).  
Proteolytic activation of PARs is irreversible therefore receptor desensitization and 
internalization are crucial aspects of PAR regulation to prevent continuous signal 
transduction by activated PAR (Ossovskaya and Bunnett, 2004). For instance, PAR1 
signalling via Gq is active for a finite period in which it initiates production of a specific 
quantity of second messenger (Ca2+) before signal termination (Ishii et al., 1993). 
Following desensitization, renewed PAR1 and PAR2 signalling requires mobilization of 
intracellular stores or synthesis of new receptors (Hein et al., 1994; Bohm et al., 1996a; 
Roosterman et al., 2003; Paing et al., 2006; Luo et al., 2007), a process known as 
resensitization. The mechanism of PAR3 and PAR4 resensitization is unknown. 
However, recent work has shown that heterodimerization with PAR2 facilitates PAR4 
translocation from the endoplasmic reticulum (ER) to the plasma membrane and also 
PAR4 signalling (Cunningham et al., 2012).  
 
1.9.3 PAR disarming proteases and biased agonism 
Proteases can also disarm PARs through cleavage at sites to remove the N-terminal 
tethered ligand sequence (Hollenberg and Compton, 2002; Ramachandran et al., 2012b). 
This disarming event may prevent PAR activation by other proteases, but not by AP 
(Hollenberg and Compton, 2002). For instance, neutrophil elastase, cathepsin G and 
proteinase 3 have distinct PAR1 N-terminal cleavage sites that disarm PAR1 preventing 
subsequent activation by thrombin (Renesto et al., 1997). Similarly, PAR2 is disarmed by 
N-terminal cleavage downstream of the tethered ligand by neutrophil elastase, cathepsin 
G and proteinase 3, preventing subsequent trypsin activation (Dulon et al., 2003; 
Ramachandran et al., 2011).  
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Interestingly, however, Ramachandran and colleagues (2011) demonstrated that while 
neutrophil elastase treatment of rat kidney-derived cell line KNRK transfected with 
human PAR2 (KNRK-PAR2) did not exhibit a Gq-mediated intracellular calcium 
signalling response (Ca2+ mobilization), neutrophil elastase elicited PAR2 signalling via 
the extracellular signal-regulated kinase (ERK)1/2 MAPK signalling pathway. This 
induction of distinct signalling pathways by different GPCR agonists/antagonists is the 
result of association with multiple signalling effectors and is known as functional 
selectivity or biased agonism (Kenakin, 2007; Urban et al., 2007; Kenakin, 2011). 
Another example of biased agonism in PARs is that AP-induced PAR1 signalling 
favours Gαq over Gα12/13-mediated pathways while the opposite was observed for PAR1 
thrombin-activation (McLaughlin et al., 2005). As reviewed by Russo and colleagues 
(2009b), plasma membrane localization of PAR1 and PAR2 also facilitates biased 
agonism through recruitment of different signalling effectors. These observations of 
biased agonism increase the complexity of PAR-induced signalling and necessitate 
examination of what constitutes a PAR-activating or -inactivating protease. 
 
1.9.4 PARs in prostate cancer 
Prostate expression of PARs at the mRNA and protein level has been assessed in a 
number of studies comparing normal prostate with BPH and prostate cancer. 
Immunohistochemical analysis of tissue microarrays of prostate biopsies demonstrated 
that PAR1 expression was significantly increased in prostate cancer compared to normal 
and BPH prostatic tissue (Tantivejkul et al., 2005). Similarly, Kausal and colleagues 
(2006) demonstrated PAR1 protein expression in advanced prostate cancer was 2.75-
fold higher than in early-stage prostate cancer. This group also showed that PAR1 
expression was predominantly localized to the vascular endothelial cells in the prostate 
tumour. Significantly, PAR1 expression was also correlated with advanced disease.   
In an examination of all four PARs, Black and colleagues (2007) determined PAR1 
expression was mostly negative in normal prostate tissue, while, PAR2 was detected 
occasionally. In contrast, PAR4 was detected in over 50% of normal tissue. However, in 
prostate cancer PAR1, PAR2 and PAR4 all demonstrated increased expression levels. 
PAR3 levels on the other hand were consistently low in all normal and diseased prostate 
tissue. Interestingly, PAR1, PAR2 and PAR4 were detected mostly in the epithelial cells. 
However, increased PAR1 expression was also detected in periglandular stroma of 
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higher grade cancer compared to lower grades and was associated with prostate cancer 
recurrence.  
A further study by this group determined that over 80% of primary prostate cancer 
tissues expressed PAR1 in the peritumoural stroma (Zhang et al., 2009). PAR1 was 
localized predominantly to stromal myofibroblast cells while PAR2 was predominantly 
localized to the primary tumour cells and, to a lesser extent, the smooth muscle cells of 
the stroma. Similarly, in a study of BPH, this group also detected increased PAR1 
stromal expression in BPH compared to normal prostate stroma (Wang et al., 2008). 
Mannowetz and colleagues (2010) also demonstrated the differential localization of 
PAR2 in normal, prostate cancer and BPH tissues. In normal tissue PAR2 was located 
in the apical membrane of epithelial cells. However, in prostate cancer tissue PAR2 was 
located on both the apical and basal membrane as well as a small amount in the stroma.  
On the other hand, in BPH, PAR2 was absent from the epithelial cells and localized to 
the stroma.  
Examination of bone metastasis also demonstrated PAR1 expression in the bone 
reactive stroma, in endothelial and fibroblast cells predominantly, and in the carcinoma 
cells to a lesser extent while PAR2 remained primarily expressed by the carcinoma cells 
(Zhang et al., 2009). However, both PAR1 and PAR2 were expressed by osteoclasts and 
osteoblasts in the bone reactive stroma. An earlier study comparing cells derived from 
prostate cancer bone metastasis with soft tissue metastasis-derived cells identified 
increased PAR1 gene expression as relevant to prostate cancer metastasis to bone (Chay 
et al., 2002). Interestingly, in a study by our laboratory, it was also shown that in 
addition to elevated PAR2 and KLK4 co-expression in primary prostate cancer, there 
was elevated co-expression of these proteins in prostate cancer bone metastases 
(Ramsay et al., 2008a).  
In vitro studies have indicated PAR activation has a range of cellular effects in prostate 
cancer-derived cells. For instance, in DU145 and LNCaP cells, thrombin induces 
concentration-dependent effects on cell cycle and proliferation (Zain et al., 2000; Liu et 
al., 2003). Low levels of thrombin induced cell proliferation of DU145 and LNCaP cells, 
however, higher concentrations of thrombin resulted in cell cycle arrest and apoptosis 
for the DU145 cells (Zain et al., 2000) and initial growth stimulation followed by growth 
inhibition for the LNCaP cells (Liu et al., 2003), indicating concentration- and cell-type-
dependent biased agonism of PAR1 by thrombin. In addition, Greenberg and colleagues 
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(2003) demonstrated the role of PARs in morphology, adhesion and migration as 
thrombin and trypsin, as well as PAR1 and PAR2 APs, induced RhoA activation in 
LNCaP cells. Thrombin and trypsin also induced morphological changes in the LNCaP 
cells through cytoskeletal rearrangement and formation of stress fibres and focal 
adhesions. Recent work in the same laboratory has shown that in addition to RhoA, 
migration signalling proteins Rac1 and Cdc42 were recruited and migration was induced 
in LNCaP cells by thrombin and trypsin activation of PAR1 and PAR2, respectively 
(Black et al., 2007).  
 
1.9.5 PARs, KLKs and TTSPs 
As mentioned before, KLK4, KLK14, TMPRSS2 and matriptase activate PAR family 
members. For instance, PAR1, PAR2 and PAR4 are activated by KLK14 
(Oikonomopoulou et al., 2006b; Stefansson et al., 2008; Gratio et al., 2011; Chung et al., 
2012). However, KLK14 also disarms and desensitizes PAR1 to activation by other 
proteases in a concentration-dependent manner (Oikonomopoulou et al., 2006a). 
Furthermore, in HT-29 colon cancer-derived cells and platelets, KLK14 preferentially 
activates PAR2 and PAR4, respectively, over PAR1 (Oikonomopoulou et al., 2006a; 
Gratio et al., 2011; Chung et al., 2012). PAR2 activation by KLK14 in HT29 cells results 
in intracellular signalling via ERK1/2 as well as cell proliferation. As KLK14 expression 
is up-regulated in colon adenocarcinoma compared to normal colon cells, it is possible 
that KLK14 acts in an autocrine/paracrine fashion to effect cell signalling and growth 
of colon cancer cells (Gratio et al., 2011; Chung et al., 2012).  Similarly, Stefansson and 
colleagues (2008) showed that while KLK14 expression is usually restricted to epithelial 
cells of sweat glands in normal skin, in inflammatory skin conditions such as atopic 
dermatitis and rosacea, KLK14 is also highly expressed in the upper squamous and 
granular layers of the epidermis and is co-localized with PAR2. This suggests PAR2-
mediated inflammatory responses in the skin (Steinhoff et al., 2005) may involve 
KLK14 (Stefansson et al., 2008). It is possible that KLK14 participates in similar 
inflammatory or proliferative processes in the prostate. 
Studies in this laboratory demonstrated KLK4 activates PAR1 and PAR2, but not PAR4 
(Ramsay et al., 2008a). Moreover, KLK4 activated PAR2-induced intracellular signalling 
via ERK1/2 in PC-3 cells (Ramsay et al., 2008a). KLK4 activation of PAR1 and PAR2 
was also demonstrated in DU145 cells by Mize and colleagues (2008) who also showed 
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KLK4-induced proliferation via PAR activation. On the other hand, Gratio and 
colleagues (2010) showed that in colon cancer-derived cell lines, KLK4 activated PAR1 
but not PAR2. Together these results suggest there may be cell line/type-specific KLK4 
activation of PAR2. 
The paracrine effects of stromal PAR activation were also examined by Wang and 
colleagues (2010). In this study PAR1 AP or thrombin treatment induced ERK1/2 
signalling and mitogenic cytokine interleukin (IL)-6 release from WPMY-1 prostate 
stromal myofibroblast cells. Subsequent treatment of LNCaP cells with the conditioned 
media from the AP-treated WPMY-1 cells induced LNCaP cell proliferation and 
ERK1/2 signalling. KLK3 and KLK4 expression were also induced in the LNCaP cells 
via the IL-6 pathway. Furthermore, KLK4 activated PAR1 on WPMY-1 cells inducing 
ERK1/2 signalling and up-regulation of IL-6. This suggests prostate epithelium/stromal 
cell interaction via a double-paracrine mechanism involving KLK4 (Wang et al., 2010). 
PAR1 siRNA mitigated the thrombin- and KLK4-induced IL-6 upregulation by 80% 
and 60%, respectively. From this the authors concluded the lower reduction in KLK4-
induced IL-6 may be due to the ability of KLK4 to activate both PAR1 and PAR2 
(Wang et al., 2010). 
TMPRSS2 also activates PAR2 in LNCaP cells, inducing intracellular Ca2+ mobilization 
(Wilson et al., 2005). It is unknown whether it also activates PAR4, however, PAR1 
activation was deemed unlikely as pre-treatment of the LNCaP cells with PAR1 AP 
failed to abrogate TMPRSS2-induced Ca2+ mobilization. Similarly matriptase is a potent 
PAR2 activator, but it does not activate PAR1 or PAR4 (Takeuchi et al., 2000; Seitz et 
al., 2007; Camerer et al., 2010). PAR2 activation by matriptase has also been shown to 
induce release of cytokines IL-6 and IL-8 by human umbilical vein endothelial 
(HUVEC) cells, implicating matriptase in inflammatory, mitogenic and pro-angiogenic 
processes (Seitz et al., 2007).  
In contrast, Camerer and colleagues (2010) demonstrated that hepsin does not activate 
PAR1 or PAR2. However, in this study they demonstrated a possible proteolytic 
cascade in keratinocyte-derived HaCaT cells in which hepsin activated matriptase which 
subsequently activated PAR2. Furthermore, this cascade was blocked by a matriptase-
activity blocking antibody. 
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1.10 Study aims 
1.10.1 Rationale 
The role of KLK14 in both normal and cancerous prostate is likely to involve 
participation in proteolytic cascades. In the normal prostate, this role may be highly 
regulated to prevent inappropriate activation/degradation cascades. However, in the 
cancerous prostate, up-regulation of KLK14 protein expression in combination with 
dysregulation of other proteases and/or inhibitors and the breakdown of tissue 
architecture may result in a significant role for KLK14 in the progression of prostate 
cancer. 
KLK14, HGF and HAI-1 are all prostate-expressed, with KLK14 and HGF over 
expressed in prostate cancer. HGF-induced HGFR signalling has been implicated in 
prostate cancer progression. Furthermore, HGFR signalling is reliant on proteolytic 
processing of HGF. In turn, several HGF activating proteases such as hepsin and 
matriptase are regulated by HAI-1 inhibition.  
KLK14 is also co-expressed with KLK4, hepsin, TMPRSS2 and matriptase in the 
prostate epithelium and overexpressed in prostate cancer. Similarly, MMP3 and MMP9 
are overexpressed in prostate cancer, in the stromal and epithelial cells, respectively. 
PAR1, PAR2, and PAR4 are also overexpressed in prostate cancer stromal and/or 
epithelial cells. By virtue of this, these proteins have been implicated in the progression 
of prostate cancer.  
While hepsin, matriptase and TMPRSS2 autoactivate, proteolytic cleavage by alternative 
proteases is required for KLK4, KLK14, MMP3 and MMP9 activation. It has already 
been determined that matriptase activates MMP3, MMP3 activates KLK4, and KLK4 
activates PAR1 and PAR2. It has also been determined that hepsin activates matriptase 
which in turn activates PAR2. Further identification of interacting partners for these 
proteases overexpressed in prostate cancer is essential to understand their roles in this 
pathology. 
 
1.10.2 Hypothesis 
Based upon the above summary the hypotheses of this PhD project are: 
 KLK14 activates pro-HGF and is inhibited by HAI-1 isoforms 
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 KLK4 and/or KLK14 may proteolyse hepsin and/or TMPRSS2, or vice versa, 
in the prostate or prostate cancer. 
 Hepsin and TMPRSS2 activate MMP3 and MMP9 
 The proteolytic cascade of serine proteases and MMPs regulates PAR signalling. 
 
1.10.3 Objectives 
Aim 1 To generate and enzymatically characterize recombinant KLK14 and to 
examine its activation of HGF and inhibition by HAI-1. [Chapter 3] 
Aim 2 To analyse KLK14 in an enzymatic cascade involving the prostate 
cancer-associated serine proteases KLK4, hepsin and TMPRSS2. [Chapter 4] 
Aim 3 To analyse an enzymatic cascade involving hepsin, TMPRSS2, 
matriptase, MMP3 and MMP9. [Chapter 4] 
Aim 4 To examine whether these enzymatic cascades facilitate activation of the 
protease activated receptors PAR1, PAR2 and PAR4. [Chapter 5] 
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Chapter 2 Materials and Methods 
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2.1 Materials 
Table 2.1 General materials 
MATERIAL SUPPLIER 
Amicon® Ultra-15 Ultracel-10 Millipore Ltd, Kilsyth, Vic, Australia 
BioTrace™ polyvinylidene fluoride (PVDF) Pall Australia, Cheltenham, Vic, Australia 
Cell Scraper, 25cm (1.7cm blade) Sarstedt, Mawson Lakes, SA, Australia 
Cell Strainer, 70 µm BD Biosciences, San Jose, Ca, USA 
Corning® bottle-top vacuum filter system 
cellulose acetate membrane, pore size 
0.22 μm, membrane area 33.2 cm2, filter 
capacity 500 mL 
Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Dialysis Tubing Cellulose Membrane Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Glass Econo-Column® Bio-Rad Laboratories Pty, Ltd, 
Gladesville, NSW, Australia 
NucleoCassettes™ ChemoMetec A/S, Allerød, Denmark 
Nitrocellulose Pall Australia, Cheltenham, Vic, Australia 
Pierce Spin Columns - Snap Cap Pierce, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
Poly-Prep® Column Bio-Rad Laboratories Pty, Ltd, 
Gladesville, NSW, Australia 
Slide-A-Lyzer™ Dialysis Cassettes 10K 
molecular weight cut-off (MWCO) 3 mL, 
10 mL 
Pierce, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
Vivaflow 200 10,000 MWCO 
polyethersulfone (PES) 
Sartorius Stedim Australia Pty Ltd, 
Dandenong South, Vic, Australia 
X-ray film Imaging Solutions Pty, Underwood, 
Australia 
 
Table 2.2 Chemicals and reagents 
Common chemicals and reagents for solution preparation were obtained from either 
Sigma-Aldrich Pty Ltd or Ajax FineChem Pty Ltd (now Thermo Fisher Scientific). 
Specialized reagents and suppliers are listed below. All reagents were analytical grade or 
highest purity possible. 
REAGENTS SUPPLIER 
4-methylumbelliferone (4-MU) Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
4-methylumbelliferyl 4-
guanidinobenzoate (MUGB)  
Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
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REAGENTS SUPPLIER 
5-bromo-4-chloro-indolyl-β-D-
galactopyranoside (X-gal) 
Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
7-amino-4-methylcoumarin (AMC) Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
40% Acrylamide/Bis Solution, 29:1 Bio-Rad Laboratories Pty, Ltd, 
Gladesville, NSW, Australia 
Ammonium persulfate (APS) Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Ampicillin Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
Beta-mercaptoethanol (βME) Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Biotinylated Glu-Gly-Arg-
chloromethylketone (Biotin-EGR-CMK) 
Haematologic Technologies, Inc., Essex 
Junction, VT, USA 
Biotinylated Phe-Pro-Arg-
chloromethylketone (Biotin-FPR-CMK) 
Haematologic Technologies, Inc., Essex 
Junction, VT, USA 
Boc-Gln-Ala-Arg-7-amido-4-
methylcoumarin hydrochloride  
(QAR-AMC) 
Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Cellfectin® Reagent Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
cOmplete™, Mini, EDTA-free Protease 
Inhibitor Cocktail Tablets 
Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
Coomassie Brilliant Blue R250 (Fluka) Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
deoxyadenosine-triphosphate (dATP) Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
Dimethyl sulphoxide (DMSO) anhydrous 
≥99.9% 
Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Deoxyribonucleic acid (DNA) Molecular 
Weight Marker VII 
Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
DNA Molecular Weight Marker XIV (100 
base pair ladder) 
Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
Deoxyribonucleotide-triphosphate 
(dNTPs) 
Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
Ethidium bromide Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
EZ-Link™ Sulfo-NHS-SS-Biotin Pierce, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
Fura-2 acetoxymethyl ester (AM) Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Gelatin from porcine skin Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
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REAGENTS SUPPLIER 
Hepsin (recombinant - generated minus 
the transmembrane and intracellular 
regions) 
Dr D. Kirchhofer, Genentech, Inc., 
South San Francisco, CA, USA 
(Kirchhofer et al., 2005) 
Hepatocyte growth factor activator 
inhibitor-1 isoform 1 (HAI-1B) 
(recombinant - generated minus the 
transmembrane and intracellular regions) 
Dr D. Kirchhofer, Genentech, Inc., 
South San Francisco, CA, USA 
(Kirchhofer et al., 2003) 
Hepatocyte growth factor activator 
inhibitor-1 isoform 2 (HAI-1A) 
(recombinant - generated minus the 
transmembrane and intracellular regions) 
Dr D. Kirchhofer, Genentech, Inc., 
South San Francisco, CA, USA  
 Isopropyl-β-D-thiogalactophyranoside 
(IPTG) 
Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Lipofectamine™ 2000  Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Lipofectamine™ LTX Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Matriptase (recombinant - generated 
minus the transmembrane and 
intracellular regions) 
Dr D. Kirchhofer, Genentech, Inc., 
South San Francisco, CA, USA 
(Kirchhofer et al., 2003) 
N,N,N′,N′-tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Nickel-nitrilotriacetic acid (Ni-NTA) 
Superflow Resin 
QIAGEN Pty Ltd, Doncaster, Vic, 
Australia 
NucleoCounter® Reagent A ChemoMetec A/S, Allerød, Denmark 
NucleoCounter® Reagent B ChemoMetec A/S, Allerød, Denmark 
PageRuler™ Prestained Protein Ladder 
#0671 
Fermentas, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
Phosphoramidon Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Pluronic® F-127 Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Precision Plus Protein™ Dual Color 
Standards 
Bio-Rad Laboratories Pty, Ltd, 
Gladesville, NSW, Australia 
Prestained sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-
PAGE) Standards, low range 
Bio-Rad Laboratories Pty, Ltd, 
Gladesville, NSW, Australia 
Pro-hepatocyte growth factor (pro-HGF) Dr D. Kirchhofer, Genentech, Inc., 
South San Francisco, CA, USA 
(Kirchhofer et al., 2005) 
Probenecid Fairlie Research Group, Chemistry and 
Human Therapeutics, Institute for 
Molecular Bioscience, University of 
Queensland, St Lucia, Qld, Australia 
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REAGENTS SUPPLIER 
Protease-activated receptor 1 agonist 
peptide (PAR1AP) 
 H-Thr-Phe-Leu-Leu-Arg-NH2 (TFLLR) 
Auspep Pty Ltd, Tullamarine, Vic, 
Australia 
Protease-activated receptor 2 agonist 
peptide (PAR2AP) 
 H-Ser-Leu-Ile-Gly-Lys-Val-NH2 (SLIGKV) 
Auspep Pty Ltd, Tullamarine, Vic, 
Australia 
Protease-activated receptor 2 agonist 
peptide (PAR2AP) 
 H-Ser-Leu-Ile-Gly-Arg-Leu-NH2 (SLIGRL) 
Auspep Pty Ltd, Tullamarine, Vic, 
Australia 
Protease-activated receptor 4 agonist 
peptide (PAR4AP) 
 H-Ala-Tyr-Pro-Gly-Lys-Phe-NH2 (AYPGKF) 
Auspep Pty Ltd, Tullamarine, Vic, 
Australia 
Protein A Agarose Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
Protein G Agarose Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
Ribonuclease A (RNase A) (20 mg/mL) Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Skim milk powder Fonterra Foodservices, Hendra, Qld, 
Australia 
Slide-A-Lyzer™ Concentrating Solution Pierce, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
Sodium dodecyl sulphate (SDS) Amresco LLC, Solon, OH, USA 
Streptavidin Agarose Resin Pierce, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
Streptavidin, Alexa Fluor® 680 conjugate Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
SuperSignal™ West Femto 
Chemiluminescent Substrate 
Pierce, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
SYBR® Safe DNA Gel Stain Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Thermolysin Calbiochem, San Diego, CA, USA 
Thioglycolic acid > 98% Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Triton X-100 Amresco LLC, Solon, OH, USA 
Trypan blue solution , 0.4% Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Trypsin Worthington Biochemical, Lakewood, 
NJ, USA 
Tween® 20 Amresco LLC, Solon, OH, USA 
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Table 2.3 DNA vectors  
VECTOR SUPPLIER 
pcDNA™3.1/hygro©(+) Invitrogen, Life Technologies Australia Pty Ltd, 
Mulgrave, Vic, Australia 
pIB/V5-His Invitrogen, Life Technologies Australia Pty Ltd, 
Mulgrave, Vic, Australia 
pEFIRES-P Dr Steve Hobbs, Institute of Cancer Research, Sutton, 
UK (Hobbs et al., 1998) 
pReceiver-M02 GeneCopoeia, Rockville, MD, USA 
 
Table 2.4 DNA expression constructs 
EXPRESSION CONSTRUCT SOURCE 
pIB-KLK14-V5-His Dr N. Bennett 
pcDNA3.1-KLK4-V5-His Dr N. Bennett 
pcDNA3.1-KLK4SA-V5-His Dr N. Bennett 
pcDNA3.1-Hepsin-Flag Assoc. Prof. J. Hooper 
pcDNA3.1-Hepsin-Myc Assoc. Prof. J. Hooper 
pcDNA3-TMPRSS2-Myc Assoc. Prof. J. Hooper 
pcDNA3.1-Matriptase Assoc. Prof. C-Y. Lin, Greenborne Cancer Centre, 
Baltimore, MD, USA (Lin et al., 1999b) 
pEZ-M02-MMP3 GeneCopoeia, Rockville, MD, USA 
pEZ-M02-MMP9 GeneCopoeia, Rockville, MD, USA 
pBluescript-
Enteropeptidase* 
Dr J. Evan Sadler, School of Medicine, Washington 
University, St Louis, MO, USA (Kitamoto et al., 1995) 
* pBluescript is a phagemid cloning vector 
 
Table 2.5 Restriction endonuclease 
Enzymes were supplied with appropriate buffer concentrates. 
RESTRICTION 
ENDONUCLEASE 
SUPPLIER 
BamHI Fermentas, Thermo Fisher Scientific, Scoresby, Vic, Australia 
DpnI Roche Diagnostics Australia Pty Ltd, Castle Hill, NSW, Australia 
EcoRI Fermentas, Thermo Fisher Scientific, Scoresby, Vic, Australia 
KpnI Roche Diagnostics Australia Pty Ltd, Castle Hill, NSW, Australia 
NotI Fermentas, Thermo Fisher Scientific, Scoresby, Vic, Australia 
XhoI Fermentas, Thermo Fisher Scientific, Scoresby, Vic, Australia 
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Table 2.6 Other DNA manipulation enzymes 
Enzymes were supplied with appropriate buffer concentrates. 
OTHER ENZYMES SUPPLIER 
Platinum® Pfx DNA 
Polymerase 
Invitrogen, Life Technologies Australia Pty Ltd, 
Mulgrave, Vic, Australia 
Shrimp Alkaline Phosphatase 
(SAP) 
Fermentas, Thermo Fisher Scientific, Scoresby, 
Vic, Australia 
T4 DNA Ligase Promega Australia, Alexandria, NSW, Australia 
Taq DNA Polymerase Roche Diagnostics Australia Pty Ltd, Castle Hill, 
NSW, Australia 
 
Table 2.7 Primers 
All oligonucleotide primers for DNA amplification, modification and sequencing were 
purchased from Proligo, now Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia. 
PRIMER 
NAME 
SEQUENCE 5’ to 3’ USE  
K14-F7 GGACTCTTGTCAGGGTGACGC
TGGGGGACCCCTGG 
KLK14 site-directed mutation 
(KLK14 S220→A) (underline), 
forward 
K14-R5 CCAGGGGTCCCCCAGCGTCAC
CCTGACAAGAGTCC 
KLK14 site-directed mutation 
(KLK14 S220→A) (underline), 
reverse 
K14-F10 ggatccTGCTGTGTCTTCATGTC
CC 
KLK14 with BamHI site (lower 
case), forward 
K14-R7 ctcgagTTAAGCGTAATCTGGA
ACATCGTATGGGTATTTGTCC
CGCATCGTTTCC 
KLK14 with HA tag (bold), stop 
codon and XhoI site (lower 
case), reverse 
K14-R9 ctcgagTTACAGGTCCTCCTCCG
AGATAAGCTTCTGCTCTTTGTC
CCGCATCGTTTCC 
KLK14 with Myc tag (bold), stop 
codon and XhoI site (lower 
case), reverse 
Hep-F S-A GCCTGCCAGGGCGACGCCGGT
GGTCCCTTTGTG 
Hepsin site-directed mutation 
(hepsin S353→A) (underline), 
forward 
Hep-R S-A CACAAAGGGACCACCGGCGTC
GCCCTGGCAGGC 
Hepsin site-directed mutation 
(hepsin S353→A ) (underline), 
reverse 
tmprss2-F S-A GCCAGGGTGACGCTGGAGGG
CCTCTGG 
Tmprss2 site-directed mutation 
(TMPRSS2 S478→A) (underline), 
forward 
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PRIMER 
NAME 
SEQUENCE 5’ to 3’ USE  
tmprss2-R S-A CCAGAGGCCCTCCAGCGTCAC
CCTGGC  
Tmprss2 site-directed mutation 
(TMPRSS2 S478→A) (underline), 
reverse 
K14-F2 CTGGGCAAGCACAACCTGAG forward KLK14 internal 
sequencing 
K14-R3 CAAGACACGAGGCCCTGGAG reverse KLK14 internal 
sequencing 
M13F-mod GCCAGGGTTTTCCCAGTCACG pGEM forward sequencing  
primer 
pGEM-rev GACCATGATTACGCCAAGC pGEM reverse sequencing 
primer  
T7 TAATACGACTCACTATAGGG pcDNA3 series  forward 
sequencing primer  
BGH-rev TAGAAGGCACAGTCGAGG pcDNA3 series reverse 
sequencing primer  
pIB-F (OplE2 
forward) 
CGCAACGATCTGGTAAACAC pIB forward sequencing primer  
pIB-R CTCAATGGTGATGGTGATGAT
GACC 
pIB reverse sequencing primer  
pEFIRES-for ACTCCCAGTTCAATTACAGC pEFIRES forward sequencing 
primer  
pEFIRES-rev ATAGACAAACGCACACCG pEFIRES reverse sequencing 
primer  
 
Table 2.8 Escherichia coli (E. coli) strains 
BACTERIAL STRAIN NAME SUPPLIER 
JM109 Competent Cells, High Efficiency 
(>108 cfu/µg of pUC19 DNA) 
Promega Australia, Alexandria, NSW, 
Australia 
JM109 Competent Cells (>108 cfu/µg of 
pUC19 DNA) 
Stratagene, Agilent Technologies, 
Inc., Life Sciences and Chemical 
Analysis Group, Santa Clara, CA, USA 
XL10-Gold Ultracompetent cells (5 ×109 
cfu/µg of pUC19 DNA) 
Stratagene, Agilent Technologies, 
Inc., Life Sciences and Chemical 
Analysis Group, Santa Clara, CA, USA 
XL10-Gold cells Stratagene, Agilent Technologies, 
Inc., Life Sciences and Chemical 
Analysis Group, Santa Clara, CA, USA 
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Table 2.9 Bacterial culture media 
CULTURE MEDIUM 
NAME 
COMPOSITION 
Luria-Bertani (LB) broth 1% (w/v) tryptone,  0.5% (w/v) yeast extract , 1% (w/v) 
NaCl, autoclaved 
Luria-Bertani (LB) agar 1% (w/v) tryptone,  0.5% (w/v) yeast extract , 1% (w/v) 
NaCl, 1.5% (w/v) bactoagar, autoclaved 
When required for antibiotic selection, ampicillin (100 µg/mL) (Table 2.2) was added to 
LB broth and to melted, cooled (≤ 55°C) LB agar prior to pouring plates. 
 
Table 2.10 Cell culture lines 
CELL LINE ORIGIN SOURCE 
22Rv1 Homo sapiens, prostate 
carcinoma 
American Type Culture Collection, 
Manassas, VA, USA 
Cos-7 Chlorocebus aethiops, 
kidney fibroblast 
American Type Culture Collection, 
Manassas, VA, USA 
DU145 Homo sapiens, prostate 
carcinoma, brain 
metastasis  
American Type Culture Collection, 
Manassas, VA, USA 
HeLa Homo sapiens, cervical 
carcinoma 
American Type Culture Collection, 
Manassas, VA, USA 
Kidney proximal 
tubule cells 
(PTC) 
Homo sapiens, primary 
kidney proximal tubule 
cells 
Dr David Vesey, Princess Alexandra 
Hospital, Woolloongabba, Qld, 
Australia 
LNCaP Homo sapiens, prostate  
carcinoma, lymph node 
metastasis  
American Type Culture Collection, 
Manassas, VA, USA 
PAR1-LMF Mus musculus, PAR1-/- 
lung myofibroblasts 
reconstituted with 
human PAR1 
Johnson & Johnson Pharmaceutical 
Research and Development, Spring 
House, PA, USA (Darrow et al., 
1996; Andrade-Gordon et al., 1999) 
PAR2-LMF Mus musculus, PAR1-/- 
lung myofibroblasts 
reconstituted with 
human PAR2 
Johnson & Johnson Pharmaceutical 
Research and Development, Spring 
House, PA, USA (Darrow et al., 
1996; Andrade-Gordon et al., 1999) 
PAR4-LMF Mus musculus, PAR1- 
lung myofibroblasts 
reconstituted with 
human PAR4 
Johnson & Johnson Pharmaceutical 
Research and Development, Spring 
House, PA, USA (Darrow et al., 
1996; Andrade-Gordon et al., 1999) 
PC-3 Homo sapiens, prostate 
adenocarcinoma, bone 
metastasis 
American Type Culture Collection, 
Manassas, VA, USA 
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CELL LINE ORIGIN SOURCE 
RWPE-1 Homo sapiens, prostate 
normal 
American Type Culture Collection, 
Manassas, VA, USA 
RWPE-2 Homo sapiens, prostate 
normal  
American Type Culture Collection, 
Manassas, VA, USA 
Sf9 (SFM 
Adapted) 
Spodoptera frugiperda, 
ovary 
Gibco®, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
 
Table 2.11 Cell culture media and supplements 
MEDIUM SUPPLIER 
Blasticidin InvivoGen, San Diego, CA, USA; 
Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
DMEM (Dulbecco's Modified Eagle 
Medium), High Glucose – L-Glutamine 
Gibco®, Life Technologies Australia Pty 
Ltd, Mulgrave, Vic, Australia 
DMEM-F-12 Thermo Fisher Scientific, Scoresby, 
Vic, Australia 
Fetal Bovine Serum (FBS) Gibco®, Life Technologies Australia Pty 
Ltd, Mulgrave, Vic, Australia 
G418 InvivoGen, San Diego, CA, USA; 
Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Hygromycin B Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Keratinocyte-SFM (Serum-Free Medium) 
with Epidermal Growth Factor 1-53 (EGF 
1-53) and Bovine Pituitary Extract (BPE) 
Gibco®, Life Technologies Australia Pty 
Ltd, Mulgrave, Vic, Australia 
Opti-MEM®I Reduced Serum Medium Gibco®, Life Technologies Australia Pty 
Ltd, Mulgrave, Vic, Australia 
Penicillin and Streptomycin Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
Puromycin InvivoGen, San Diego, CA, USA 
RPMI-1640 - L-Glutamine Gibco®, Life Technologies Australia Pty 
Ltd, Mulgrave, Vic, Australia 
Sf-900 II SFM (Serum-Free Medium) Gibco®, Life Technologies Australia Pty 
Ltd, Mulgrave, Vic, Australia 
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Table 2.12 Primary antibodies 
All antibodies were reconstituted and stored according to manufacturer’s 
recommendations. 
PRIMARY ANTIBODIES DILUTIONS USED SUPPLIER 
Anti-Enterokinase LC 
antibody (sc-51283) 
1:1000 (WB) Santa Cruz Biotechnology, Inc. 
Dallas, TX, USA 
Anti-Flag® M2 (F1804) 
Mouse  
1:1000 (FCM) Sigma-Aldrich Pty Ltd, Castle Hill, 
NSW, Australia 
Anti-Flag® (F7425) 
Rabbit 
1:3000-5000 (WB), 
8 ng/μg lysate (IP) 
Sigma-Aldrich Pty Ltd, Castle Hill, 
NSW, Australia 
Anti-GAPDH Mouse 1:5000-10,000 
(WB) 
Chemicon (now Millipore Ltd, 
Kilsyth, Vic, Australia) 
Anti-GAPDH (G9545) 
Rabbit 
1:10,000 (WB) Sigma-Aldrich Pty Ltd, Castle Hill, 
NSW, Australia 
Anti-HA (H6908) Rabbit 1:1250-2500 (WB) Sigma-Aldrich Pty Ltd, Castle Hill, 
NSW, Australia 
Anti-Hepsin A15 
Mouse 
1:1000-5000 (WB) Dr Q. Wu, Cleveland Clinic, 
Cleveland, OH, USA (Xuan et al., 
2006) 
Anti-Kallikrein 14 
(ab28841) Rabbit 
1:1000 (WB) Abcam, Cambridge, MA, 
USA(Brattsand et al., 2005) 
Anti-Kallikrein 4 mid 
Rabbit 
1:1000 Hormone Dependent Cancer 
Program, IHBI, Kelvin Grove, Qld, 
Australia (Harvey et al., 2003) 
Anti-Kallikrein 4 C-term 
Rabbit 
1:1000 Hormone Dependent Cancer 
Program,  IHBI, Kelvin Grove, Qld, 
Australia (Harvey et al., 2003) 
Anti-Matriptase M69 
Mouse 
1:1000 Assoc. Prof. C-Y. Lin, Greenborne 
Cancer Centre, Baltimore, MD, 
USA (Lin et al., 1999b; Benaud et 
al., 2001)  
Anti-MMP3 antibody 
(ab18898) Goat 
1:500 (WB), 1:200 
(IP) 
Abcam, Cambridge, MA, USA 
Anti-MMP9 antibody - 
Whole molecule 
(ab38898) Rabbit 
1:5000 (WB), 
1:1000 (IP) 
Abcam, Cambridge, MA, USA 
Anti-Myc-Tag (9B11) 
Mouse mAb 
1:5000 (WB), 
1:1000 (IP) 
Cell Signaling Technology Inc., 
Danvers, MA, USA 
Anti-V5 (R96025) 
Mouse 
1:5000-10,000 
(WB), 1:1000 (IP) 
Invitrogen , Life Technologies 
Australia Pty Ltd, Mulgrave, Vic, 
Australia 
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Table 2.13 Secondary antibodies 
SECONDARY ANTIBODIES DILUTIONS USED SUPPLIER 
Alexa Fluor® 488 goat anti-
mouse IgG 
1:750 (FCM) Invitrogen, Life Technologies 
Australia Pty Ltd, Mulgrave, 
Vic, Australia 
Alexa Fluor® 680 goat anti-
rabbit IgG 
1:10,000 (WB) Invitrogen, Life Technologies 
Australia Pty Ltd, Mulgrave, 
Vic, Australia 
Anti-Goat  IgG (H&L) 
(Donkey) Antibody 
IRDye®700-Conjugated 
1:10,000 (WB) Rockland Immunochemicals 
Inc., Gilbertsville, PA, USA 
Anti-Goat  IgG (H&L) 
(Donkey) Antibody 
IRDye®800CW-Conjugated 
1:10,000 (WB) Rockland Immunochemicals 
Inc., Gilbertsville, PA, USA 
Anti-Mouse IgG (H&L) 
(Donkey) Antibody 
IRDye®800-Conjugated 
1:10,000 (WB) Rockland Immunochemicals 
Inc., Gilbertsville, PA, USA 
Anti-Mouse  IgG (H&L) 
(Donkey) Antibody 
IRDye®800CW-Conjugated 
1:10,000 (WB) Rockland Immunochemicals 
Inc., Gilbertsville, PA, USA 
Anti-Rabbit IgG (H&L) 
(Donkey) Antibody 
IRDye®700CW-Conjugated 
1:10,000 (WB) Rockland Immunochemicals 
Inc., Gilbertsville, PA, USA 
Anti-Rabbit IgG (H&L) 
(Donkey) Antibody 
IRDye®800CW-Conjugated 
1:10,000 (WB) Rockland Immunochemicals 
Inc., Gilbertsville, PA, USA 
Anti-Rabbit IgG (H&L) 
(Donkey) Antibody 
IRDye®800-Conjugated 
1:10,000 (WB) Rockland Immunochemicals 
Inc., Gilbertsville, PA, USA 
Goat Anti-Mouse IgG (H&L) 
horseradish peroxidase (HRP) 
1:2000-4000 
(WB) 
Pierce, Thermo Fisher 
Scientific, Scoresby, Vic, 
Australia 
Goat Anti-Rabbit IgG (H&L) 
HRP  
1:2000-4000 
(WB) 
Pierce, Thermo Fisher 
Scientific, Scoresby, Vic, 
Australia 
Anti-Mouse IgG +A+M (Goat) 1:4000 (ELISA) Zymed, Life Technologies 
Australia Pty Ltd, Mulgrave, 
Vic, Australia 
 
 
 
59 
 
Table 2.14 Isotype antibodies 
ISOTYPE ANTIBODY 
CONTROLS 
 SUPPLIER 
Mouse IgG 2a  Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia 
Rabbit IgG  Invitrogen , Life Technologies Australia Pty Ltd, 
Mulgrave, Vic, Australia 
Abbreviations: FCM, Flow cytometry; IP, immunoprecipitation; WB, Western blot. 
 
Table 2.15 Commercial kits 
KIT SUPPLIER 
BCA™ Protein Assay Kit Pierce, Thermo Fisher Scientific, 
Scoresby, Vic, Australia 
High Pure™ PCR Product Purification Kit Roche Diagnostics Australia Pty Ltd, 
Castle Hill, NSW, Australia 
pGEM®-T Easy Vector System I Kit Promega Australia, Alexandria, NSW, 
Australia 
PNGase F De-N-glycosylation kit New England BioLabs Inc., Ipswich, MA, 
USA 
PureLink® HiPure Plasmid Midiprep Kit Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
PureLink™ Quick Plasmid Miniprep Kit Invitrogen, Life Technologies Australia 
Pty Ltd, Mulgrave, Vic, Australia 
QIAGEN Plasmid Maxi Kit QIAGEN Pty Ltd, Doncaster, Vic, 
Australia 
QIAprep Miniprep Kit QIAGEN Pty Ltd, Doncaster, Vic, 
Australia 
 
Table 2.16 Buffers and solutions 
BUFFER OR SOLUTION NAME COMPOSITION or SUPPLIER 
Binding Buffer 28 mM NaH2PO4, 72 mM Na2HPO4, 0.15 M 
NaCl, pH 7.2 
Ca2+ Flux Assay (CaFA) Buffer  1.26 mM CaCl2, 5.37 mM KCl, 0.44 mM KH2PO4, 
8.12 mM MgSO4, 136.9 mM NaCl, 0.336 mM 
Na2HPO4, 4.17 mM NaHCO3, 5.55 mM D-
glucose, 20 mM HEPES, pH 7.4, filtered, 2.5 
mM probenecid added immediately prior to 
use (from a stock solution of 0.5 M probenecid 
suspended in 1N NaOH)  
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BUFFER OR SOLUTION NAME COMPOSITION or SUPPLIER 
CAPS Buffer N-cyclohexyl-3-aminopropanesulfonic acid 
(CAPS), 10 mM, adjusted to pH 11.0 with NaOH 
Coomassie Blue R250 Stain  0.25% (w/v) Coomassie Brilliant Blue R250 
(Fluka),  45% (v/v) methanol, 10% (v/v) acetic 
acid 
Coomassie Destain 45%  (v/v) methanol, 10% (v/v) acetic acid 
DNA Loading Buffer, 6×  
(diluted to 1× in use) 
0.25% Bromophenol blue, 30% (v/v) glycerol 
HEPES Buffer Solution Gibco®, Life Technologies Australia Pty Ltd, 
Mulgrave, Vic, Australia 
KLK14 Buffer 5 mM NaH2PO4, 95 mM Na2HPO4, 0.01% (v/v) 
Tween®20, pH 8.0 
Lysis Buffer 10 mM Tris pH 8.0, 150 mM NaCl, 1% (v/v) 
Triton X-100, 5 mM EDTA.  
MUGB Assay Buffer 50mM Tris, 50mM NaCl, pH8.8, 0.01% (v/v) 
Tween®20 
Ni-NTA Dialysis Buffer 50 mM NaH2PO4, 500 mM NaCl, pH 8.0 
Ni-NTA Elution Buffer 250 
 
250 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0 
Ni-NTA PE Buffer 300 300 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0 
Ni-NTA Wash Buffer 10 10 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0 
Ni-NTA Wash Buffer 30 30 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0 
Odyssey® Blocking Buffer LI-COR Biosciences, Lincoln, NE, USA 
Phosphate-buffered saline 
(PBS) 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.47 mM KH2PO4, pH 7.4 
Phosphate-buffered saline 
(Dulbecco A) –(DPBS) 
Oxoid, Thermo Fisher Scientific, Scoresby, Vic, 
Australia 
Phosphate-buffered saline plus 
Tween®20 (PBS-T) 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.47 mM KH2PO4, pH 7.4, 0.1% (v/v) Tween®20 
SDS-PAGE Loading Buffer, 6× 
(diluted to 1× in use) 
0.35 M Tris pH 6.8, 30% (v/v) glycerol, 12% 
(w/v) SDS, 0.012% (w/v) Bromophenol Blue 
plus 10% (v/v) beta-mercaptoethanol for 
reducing conditions 
SDS-PAGE, Resolving Gel 12% 12% (v/v) Acrylamide/Bis (29:1), 0.37 M Tris pH 
8.8, 0.1% (w/v) SDS, 0.05% (w/v) APS, 0.05% 
(v/v) TEMED 
SDS-PAGE, Resolving Gel 10% 10% (v/v) Acrylamide/Bis (29:1), 0.37 M Tris pH 
8.8, 0.1% (w/v) SDS, 0.05% (w/v) APS, 0.05% 
(v/v) TEMED 
SDS-PAGE, Stacking Gel 4% 4% (v/v) Acrylamide/Bis (29:1), 0.125 M Tris pH 
6.8, 0.1% (w/v) SDS, 0.05% (w/v) APS, 0.1% 
(v/v) TEMED 
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BUFFER OR SOLUTION NAME COMPOSITION or SUPPLIER 
Skim milk blocking buffer 50 mM Tris, 150 mM NaCl, pH 7.4, 5% (w/v) 
skim milk powder 
Tris-acetate-EDTA (TAE) 40 mM Tris, 20 mM acetic acid, pH 8.0, 1 mM 
EDTA 
Tris-buffered saline plus 
Tween®20 (TBS-T) 
50 mM Tris, 150 mM NaCl, pH 7.4, 0.1% (v/v) 
Tween®20 
Tris-Glycine Running Buffer 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS 
Tris-Glycine Transfer Buffer 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, 
20% (v/v) methanol 
Tris-NaCl Buffer 50 mM Tris, 50 mM NaCl, pH 7.4 
Versene 0.53 mM EDTA in DPBS, autoclaved 
Zymography Developing Buffer 50 mM Tris, 5 mM CaCl2, 1 μM ZnCl2, pH 7.4 
Zymography Renaturation 
Buffer 
50 mM Tris, 5 mM CaCl2, 1 μM ZnCl2, pH 7.4, 
2.5% Triton X-100 
Zymography Stain 0.5% (w/v) Coomassie Brilliant Blue R250 
(Fluka),  30% (v/v) ethanol, 10% (v/v) acetic 
acid 
Zymography Destain 30% (v/v) ethanol, 10% (v/v) acetic acid 
 
2.2 Computer software 
Chromatograms from DNA sequencing were viewed using DNASTAR® SeqMan®.  
MARS Data Analysis Software (BMG LABTECH, Mornington, Vic., Australia), 
GraphPad Prism 5, Microsoft® Excel 2003 and Microsoft® Excel 2010 were used for 
data analysis for BCA, enzyme activity, kinetic and Ca2+ flux assays. 
LI-COR Odyssey® 2.0 and 3.0 (LI-COR, Lincoln, NE, USA ) and Microsoft® 
PowerPoint 2010 were used for image analysis. 
Flow cytometry data were analysed and manipulated using Flowing Software (Terho, 
2010) (http://www.flowingsoftware.com). 
 
2.3 Web resources 
Australian National Genomic Information Service (ANGIS) BioManager (Cattley and 
Arthur, 2007) (http://www.angis.org.au/) (now closed) for DNA sequence 
manipulation. 
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Center for Biological Sequence Analysis (CBS) Prediction Servers 
(http://www.cbs.dtu.dk/services/) to access signal peptide prediction program SignalP-
4.0 Server (Petersen et al., 2011), N-linked glycosylation prediction program NetNGlyc-
1.0 Server (Gupta et al., 2004) and NetSurfP-1.0, protein surface accessibility and 
secondary structure prediction program. 
The European Bioinformatics Institute (EMBL-EBI) (http://www.ebi.ac.uk/) to access 
ClustalW(Larkin et al., 2007) and ClustalO(Sievers et al., 2011) for multiple sequence 
alignment. 
ExPASy Bioinformatics Resource Portal (http://expasy.org/) to access SWISS-
MODEL and DeepView PDB Viewer (Guex and Peitsch, 1997; Schwede et al., 2003; 
Arnold et al., 2006). 
GeneCards human gene database (http://www.genecards.org/).  
National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/guide/) to access PubMed, nucleotide, protein sequence 
databases and also Basic Local Alignment Search Tool (BLAST). 
New England BioLabs (NEB) NEBcutter V2.0 (http://tools.neb.com/NEBcutter2/) to 
locate restriction endonuclease sites in DNA sequences. 
The Sequence Manipulation Suite (http://www.bioinformatics.org/sms/index.html) for 
access to open reading frame finder and DNA → protein translation programs. 
Stockholm Bioinformatics Centre (http://phobius.sbc.su.se/) to access signal peptide 
prediction program Phobius (Kall et al., 2004). 
UniProt (http://www.uniprot.org/) for sequence and function information. 
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2.4 Methods 
2.4.1 Characterization of the KLK14 amino acid sequence 
The complete KLK14 amino acid sequence (NCBI Reference Sequence NP_071329.2) 
was examined using online protein prediction tools.  
The KLK14 signal peptide was examined using SignalP-4.0 Server (Petersen et al., 
2011), hosted by the Centre for Biological Sequence Analysis (CBS) 
(http://www.cbs.dtu.dk/services/), and Phobius (Kall et al., 2004), hosted by the 
Stockholm Bioinformatics Centre (http://phobius.sbc.su.se/). Predictions about 
KLK14 N-glycosylation as well as secondary structure and surface solvent accessibility 
were explored using  NetNGlyc-1.0 Server (Gupta and Brunak, 2002; Gupta et al., 2004) 
and NetSurfP-1.0 (Petersen et al., 2009) (CBS). SWISS-MODEL hosted by ExPASy 
(http://expasy.org/) and DeepView-4.1 Swiss PDB-Viewer (Guex and Peitsch, 1997; 
Schwede et al., 2003; Arnold et al., 2006) were used to generate and analyse a KLK14 
homology model using the crystal structure of KLK5 (Protein Data Bank (PDB) 
identification (ID) 2PSX) (Debela et al., 2007a) as a template. KLK14 and KLK5 
protein sequence alignment was performed using ClustalO (Sievers et al., 2011). 
 
2.4.2 General molecular biology techniques 
The general techniques outlined in this section were used in the generation, 
manipulation and isolation of DNA expression constructs. 
 
2.4.2.1 Plasmid DNA isolation  
To extract and purify high quality plasmid DNA from bacterial cultures for sequencing, 
gene cloning and transfection, one of four kits was used depending on the quantity of 
DNA required. The QIAprep Miniprep Kit and the PureLink™ Quick Plasmid 
Miniprep Kit (Table 2.15) were used for isolation of <30 µg DNA. The 
PureLink®HiPure Plasmid Midiprep Kit and the QIAGEN Plasmid Maxi Kit (Table 
2.15) were used for isolation of quantities of up to 350 and 500 µg DNA, respectively. 
The manufacturer’s instructions were followed for the growth and preparation of the 
bacterial cultures and purification of the plasmid DNA. 
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DNA concentration and purity was assessed using a Pharmacia GeneQuantII 
RNA/DNA Spectrophotometer (now GE Healthcare Australia Pty Ltd, Rydalmere, 
NSW, Australia) or a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, 
Scoresby, Vic, Australia). An absorbance at 260 nm (A260) of 1 represents 50 µg/mL 
DNA and an A260/A280 ratio of ≥1.8 was regarded as a pure sample.  
 
2.4.2.2 DNA sequencing 
An 8 µL sequencing mix was prepared containing ~600 ng of plasmid DNA and 6.4 
pmol of a primer. The primers (Table 2.7) were either vector specific or internal 
sequencing specific. DNA sequencing was performed using ABI BigDye Terminator 
sequencing by the Australian Genomic Research Facility (AGRF), St Lucia, Qld, 
Australia. 
 
2.4.2.3 Agarose gel electrophoresis 
DNA was separated and analysed on gels of 0.8-2.0% (w/v) agarose in Tris-acetate-
EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid, pH 8.0, 1 mM EDTA, Table 
2.16). Ethidium bromide (0.1 µg/mL) (Table 2.2) or SYBR® Safe DNA Gel Stain (0.1 
µL/mL) (Table 2.2) was added to the gel solution prior to casting. Samples were diluted 
5:1 in 6× DNA loading buffer (for final concentration 0.25% Bromophenol blue, 30% 
(v/v) glycerol, Table 2.16) prior to loading into gel wells. DNA Molecular Weight 
Markers VII or XIV (Table 2.2) were also loaded onto the gel for DNA size 
comparison. Electrophoresis was conducted in TAE buffer at 100-120V for up to 1 
hour (h), depending on fragment size. For ethidium bromide cast gels, DNA was 
visualized and photographed using ultraviolet (UV) illumination (Syngene UV System, 
Geneworks, Adelaide, SA, Australia). For SYBR® Safe cast gels, a Safe Imager™ 2.0 
Blue-Light Transilluminator (Invitrogen, Life Technologies Australia Pty Ltd, Mulgrave, 
Vic, Australia) was used for DNA visualization and images were captured using a 
Fujifilm FLA-5000 laser scanner (Fuji Photo Film Co., Stafford, Qld, Australia). 
65 
 
2.4.2.4 Polymerase chain reaction (PCR) protocols 
A PTC-200 Peltier thermal cycler DNA Engine (Bresatec, Adelaide, SA, Australia) or a 
Bio-Rad C1000™ Thermal Cycler (Bio-Rad Laboratories Pty, Ltd, Gladesville, NSW, 
Australia) were used for PCR reactions and also linear amplifications. 
PCR reactions for overlap extension polymerase chain reaction (OE-PCR) routinely 
consisted of a 25 or 50 μL reaction volume with 0.5 ng/µL template DNA, 200-300 nM 
of primers (Table 2.7), 0.3 mM of deoxyribonucleotide triphosphates (dNTPs) (Table 
2.2), 1 mM MgSO4 and 1-1.25 units (U) of Platinum® Pfx DNA polymerase (Table 2.6). 
The cycling conditions consisted of an initial denaturation at 94-95°C for 2-3 minutes 
followed by 30-32 cycles of three steps: denaturation at 94-95°C for 15-30 seconds, 
annealing at 53°C for 30 seconds and extension at 68°C for 1 minute per kilobase (kb) 
of the amplicon. To isolate PCR products, the reaction products were electrophoresed 
on agarose gel. Bands were visualized, and then bands of appropriate size were excised 
in gel slices and purified using the High Pure™ PCR Product Purification Kit (Table 
2.15). 
 
2.4.2.5 Site-directed mutagenesis 
For site-directed mutagenesis, linear amplification reactions of whole plasmid consisted 
of a 25 μL reaction with 1 ng/µL template DNA, 440-600 nM of mutagenic primers 
(Table 2.7), 0.4 mM of dNTPs, 1.5 mM MgSO4 and 2.5 U of Platinum® Pfx DNA 
polymerase. The thermal cycling conditions consisted of an initial denaturation at 95°C 
for 30 seconds followed by 18 cycles of three steps: denaturation at 95°C for 30 
seconds, annealing at 55°C for 1 minute and extension at 68°C for 1 minute per 
kilobase (kb) of the plasmid. Following amplification, the template DNA was eliminated 
by selective digestion of methylated DNA using the enzyme DpnI (5 U) (Table 2.5) for 
1 hour at 37 °C. The digestion reaction product was then used directly for 
transformation of competent Escherichia coli (E. coli) cells (Section 2.4.2.8). 
 
2.4.2.6 Ligation of DNA 
Ligation of DNA into expression vectors or pGEM™T-Easy (Table 2.15) typically 
consisted of a 10 µL reaction containing T4 DNA ligase buffer, 3 U of T4 DNA ligase 
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(Table 2.6), 50 ng vector DNA and insert DNA added to achieve a 3:1 insert:vector 
molar ratio. After incubation overnight at 4°C, ligation reactions (1-10 μL) were used 
directly for transformation of competent E.coli cells (Section 2.4.2.8). 
As Platinum® Pfx has extensive 3’ to 5’ exonuclease activity it does not leave 3’ poly A-
overhangs. Therefore, before ligation into the pGEM™T-Easy vector, insert DNA 
generated by PCR was always subjected to an A-tailing reaction. The A-tailing reaction 
typically consisted of a 10 µL mixture containing 6 µL of the PCR product, 2 mM 
deoxyadenosine triphosphate (dATP) (Table 2.2), 1 U Taq DNA polymerase (Table 2.6) 
and PCR buffer with MgCl2 (1.5 mM). The mixtures were incubated at 90°C for 10 
minutes then 70°C for 30 minutes. The A-tailed product was used directly in 
pGEM™T-Easy ligation reactions. 
 
2.4.2.7 Restriction digest of DNA 
Routinely, purified DNA (0.5-9 µg) was digested with restriction endonuclease/s (1-10 
U) of choice (Table 2.5) in an appropriate buffer for 1.5-2 hours at 37°C. The digestion 
reaction products were electrophoresed on agarose gel and the bands visualized. To 
isolate DNA fragments for ligation reactions, bands were excised in gel slices and 
purified using the High Pure™ PCR Product Purification Kit. 
When preparing vector DNA for cloning using a single restriction endonuclease, shrimp 
alkaline phosphatase (SAP) (1 U) (Table 2.6) was included in the digestion reaction to 
prevent vector re-circularization. The SAP was then deactivated by heating at 65°C for 
15 minutes. DNA clean-up for SAP-treated vector digests was performed by adding 900 
µL of 95% (v/v) ethanol and 0.16 M sodium acetate (pH 4.7) and incubating overnight 
at -80°C. The sample was then centrifuged at 18,000 relative centrifugal force (RCF or g) 
for 30 minutes at 4°C. Supernatant was aspirated and the pellet was washed in ice-cold 
75% (v/v) ethanol. After centrifugation at 18,000 g for 30 minutes the supernatant was 
aspirated and the pellet was allowed to air dry for 5 minutes before resuspension in 10 
µL of 10 mM Tris, pH 8.5.  
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2.4.2.8 Preparation and transformation of competent E.coli cells  
All E. coli strains used for transformation with plasmid DNA in this study were 
chemically-induced competent cells. For transformation of commercial preparations of 
competent cells JM109 and XL10-Gold Ultracompetent (Table 2.8), the manufacturer’s 
instructions were followed except that in all instances LB broth was used as the post-
recovery incubation medium.  
XL10-Gold competent cells were also prepared in-house using a calcium chloride 
method (Sambrook et al., 1989) described as follows. A single colony of XL10-Gold 
(Table 2.8) picked from a Luria Bertani (LB) agar plate (Table 2.9) was used to inoculate 
2 mL LB broth (Table 2.9). After overnight incubation with shaking at 37°C, the culture 
was used to inoculate 200 mL LB broth and was further incubated until log phase 
growth was reached, as indicated by an optical density (OD) at 600 nm of 0.4-0.5. After 
transfer to sterile falcon tubes, the culture was placed on ice for 20 min. All further 
manipulations were performed on ice or at 4°C. Cells were pelleted by centrifugation at 
4,000 g for 10 minutes. The cells were then resuspended in 24 mL of ice-cold 100 mM 
CaCl2 (autoclaved) then incubated for 40 minutes. Cells were pelleted by centrifugation 
at 4,000 g for 10 minutes and resuspended in ice-cold 100 mM CaCl2, 14% (v/v) glycerol 
(autoclaved). Cells were aliquoted at 100 µL per 2 mL sterile tube and frozen in liquid 
nitrogen before transfer to -80°C until required. 
For transformation of in-house preparations of XL10-Gold competent cells, cells (100 
µL) thawed on ice were then incubated on ice with DNA (~1 ng of plasmid DNA or 1-
10 µL of a ligation mixture, or 10-25 μL of site-directed mutagenesis mixture) for 30 
minutes. Cells were then heat shocked in a water bath at 42°C for 45 seconds and then 
allowed to recover on ice for 15 minutes. LB broth (900 µL) was then added to the tube 
and cells were incubated for 1 hour at 37°C.  
After incubation, for all transformations, cells were pelleted by centrifugation at 4,000 g 
for 10 minutes and then resuspended in warmed LB broth (100-200 µL). As all plasmids 
used in this study contained genes to confer ampicillin resistance, cells (50-200 µL) were 
then plated onto warmed LB-ampicillin (100 µg/mL) agar plates (Table 2.9). Plates were 
then incubated overnight at 37°C. For all pGEM®-T Easy transformations, plates were 
impregnated with 100 µL of 100 mM isopropyl-β-D-thio-galactoside (IPTG) (Table 2.2) 
and 20 µL of 50 mg/mL 5-bromo-4-chloro-indolyl-β-D-galactopyranoside (X-gal) 
(Table 2.2) before use. 
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2.4.2.9 Screening transformed clones 
Individual E.coli colonies selected from overnight culture plates of transformed cells 
were propagated in LB-ampicillin (100 µg/mL) broth (5 mL), overnight, shaking at 
37°C. For transformants with pGEM®-T Easy vector, colony selection was assisted by 
the pGEM®-T Easy cloning site located within the coding region of a β-galactosidase 
enzyme. This allowed for screening by insertional inactivation and blue-white colony 
selection on LB-ampicillin plus IPTG and X-gal agar plates. For transformation with 
other vectors, colonies were selected at random.  
After overnight culture, plasmid DNA was isolated using a miniprep kit and the DNA 
yield determined (Section 2.4.2.1). For all transformants resulting from ligation reactions 
the purified plasmid DNA was subjected to diagnostic restriction digestion using 
restriction endonuclease EcoRI or KpnI (Section 2.4.2.7) and agarose gel 
electrophoresis (Section 2.4.2.3) to confirm the presence of the insert in the vector. 
When a single restriction endonuclease was used for preparing the vector and insert 
DNA for ligation, an alkaline lysis protocol to extract plasmid DNA was performed to 
economically screen multiple clones before proceeding to isolation of high quality 
plasmid DNA using a commercial miniprep kit.  
For the alkaline lysis protocol a 200 µL sample of overnight culture of transformed 
bacteria was combined with 200 µL 0.2 M NaOH, 1% (w/v) SDS and the tube was 
inverted 4-5 times. To neutralize the solution, 200 µL 3 M potassium acetate, pH 4.7 
was added and the tube was inverted again 4-5 times. After centrifugation at 18,000 g for 
5 minutes, the supernatant was removed to a new tube and the DNA was precipitated 
by adding 500 µL 100% isopropanol and inverting the tube 4-5 times. The sample was 
then centrifuged for 5 minutes at 18,000 g. After discarding the supernatant, the pellet 
was centrifuged again, as above, and the remaining isopropanol was removed. A 
diagnostic restriction digest of the isolated DNA was then performed by resuspending 
the pellet in a digestion mix comprising restriction endonuclease/s (0.5 U/ µL) plus 
Ribonuclease A (RNase A) (200 ng/µL) (Table 2.2) in a total volume of 10 µL. After 1.5 
hours incubation at 37°C, agarose gel electrophoresis was performed. Those 
transformants found to have plasmid DNA fragments of the expected size were selected 
for plasmid DNA isolation by miniprep kit. 
In all instances DNA sequencing (Section 2.4.2.2) was performed on purified plasmid 
DNA to check for the desired sequence. Transformed E. coli clones containing plasmid 
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with the correct sequence were prepared for long term storage by combining 800 µL 
overnight culture with 200 µL autoclaved 80% (v/v) glycerol and then stored at -80°C. 
 
2.4.3 Generation of expression constructs 
2.4.3.1 Construct for expression in insect cells 
To generate a construct for the expression of KLK14 in insect cells, full-length KLK14 
(NCBI Reference Sequence NM_022046.4) coding sequence was amplified from the 
construct pGEM®-T Easy KLK-L6 (KLK14) using primers (forward) 5’GAC 
ggatccTGCTGTGTCTTCATGTCCCT3’ and (reverse) 5’CGctcgagACTTTGTCCCGC 
ATCGTTTCC3’ to engineer BamHI and XhoI restriction sites (lower case, respectively) 
at either end of the coding sequence of KLK14. Following amplification and gel 
purification, the product was ligated into the shuttle vector pGEM®-T Easy, 
transformed into E. coli, propagated and isolated. Clones were screened for correct 
sequence by sequencing using vector-specific primers, M13F-mod and pGEM-rev. 
KLK14 was then excised from the shuttle vector using  BamHI and XhoI  and ligated 
into BamHI/XhoI digested insect expression vector pIB/V5-His, in frame with the V5-
His tag and stop codon. Following transformation into JM109 E. coli, pIB-KLK14-V5-
His was propagated and isolated. Clones were then selected based on screening by 
restriction digest followed by sequencing using vector-specific primers, pIB-F and pIB-
R, and internal sequencing primers, K14-F2 and K14-R3. (Sub-cloning was performed 
by Dr Nigel Bennett, Table 2.4). 
 
2.4.3.2 Constructs for expression in mammalian cells 
Table 2.17 contains a summary of the constructs generated including the primers and 
templates used for each construct. Three main methods of construct generation were 
used: OE-PCR to generate new DNA restriction sites and/or protein C-terminal 
epitope tags; site-directed mutagenesis to generate constructs with specific mutations in 
the coding sequence of the protein; and excision and ligation to shuttle coding sequence 
from one vector to another.  
For the expression of KLK14 in mammalian cells, DNA sequence encoding full-length 
KLK14 (NCBI Reference Sequence NM_022046.4) was amplified by OE-PCR using 
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the pIB-KLK14-V5-His construct (Table 2.4) as a template. The primers used, K14-
F10, K14-R7 and K14-R9 (primer sequences, Table 2.7), were designed to engineer 
KLK14 coding sequence with either a HA (K14-R7) or Myc (K14-R9) C-terminus 
epitope tag and a stop codon as well as BamHI and XhoI restriction sites at either end. 
Following amplification and gel purification, the products were ligated into the shuttle 
vector pGEM®-T Easy, transformed into JM109 E. coli, propagated and isolated. 
Clones were screened for correct sequence by sequencing using vector-specific primers, 
M13F-mod and pGEM-rev. Sequence encoding KLK14-HA and KLK14-Myc were 
then excised from the shuttle vector using BamHI and XhoI (Table 2.5) and ligated into 
BamHI/XhoI digested mammalian expression vector pcDNA™3.1/hygro©(+) (Table 
2.3). Following transformation into JM109 E. coli, pcDNA3.1-KLK14-HA and 
pcDNA3.1-KLK14-Myc clones were propagated and isolated. Clones with correct 
sequence were then selected based on screening by restriction digestion followed by 
sequencing using vector specific primers, T7 and BGH-rev, and internal sequencing 
primers, K14-F2 and K14-R3.  
Site-directed mutagenesis was used to generate constructs containing a mutation in the 
coding sequence of KLK14, Hepsin and TMPRSS2 to alter the coded protease active 
site serine residue to an alanine residue, S220→A, S353→A and S478→A, respectively.  The 
templates used encoded KLK14-HA, KLK14-Myc, Hepsin-Flag, Hepsin-Myc and 
TMPRSS2-Myc, all with C-terminus epitope tags (Table 2.17). Following whole plasmid 
amplification using mutagenic primers (primer sequences, Table 2.7), the template DNA 
was digested with DpnI and the reaction mix was used to transform XL10-Gold E. coli. 
Clones were propagated, isolated and screened by sequencing using vector specific 
primers, T7 and BGH-rev. Clones with the correct mutation and sequence integrity 
were selected.  
For stable expression of hepsin-Flag and hepsinSA-Flag in the PAR2-LMF cell line, 
pEFIRES-P (Hobbs et al., 1998), a bicistronic vector encoding puromycin resistance, 
was used in the generation of the constructs. DNA sequence encoding hepsin-Flag and 
hepsinSA-Flag were excised using the restriction endonuclease NotI (Table 2.5) from 
the pcDNA3.1 construct and ligated into the NotI digested pEFIRES-P vector (Table 
2.3). Following transformation of E. coli XL10-Gold and propagation, the pEFIRES-P-
Hepsin-Flag and pEFIRES-P-HepsinSA-Flag (pEF-Hepsin-Flag and pEF-HepsinSA-
Flag) clones were screened using restriction digest analysis of alkaline lysis preparations. 
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Constructs found to have the insert in the correct orientation were then isolated and 
screened by sequencing using vector-specific primers.  
For the expression of enteropeptidase in mammalian cells DNA sequence encoding full-
length enteropeptidase was excised using the HindIII and XbaI from the pBluescript-
enteropeptidase phagemid construct (Kitamoto et al., 1995)and then ligated into the 
HindIII/XbaI digested pcDNA™3.1/hygro©(+). Following transformation of E. coli 
XL10-Gold and propagation, the pcDNA3.1-enteropeptidase clones were screened 
using restriction digest analysis of alkaline lysis preparations followed by sequencing 
using vector specific primers, T7 and BGH-rev. 
 
Table 2.17 Summary of mammalian expression constructs generated. 
Method 
Construct generated 
Primers† 
Forward       Reverse 
Template 
OE-PCR 
      
pcDNA3.1-KLK14-HA K14-F10 K14-R7 pIB-KLK14-V5-His 
pcDNA3.1-KLK14-Myc K14-F10 K14-R9 pIB-KLK14-V5-His 
Site-directed mutagenesis 
      
pcDNA3.1-KLK14SA-HA K14-F7 K14-R5 pcDNA3.1-KLK14-HA 
pcDNA3.1-KLK14SA-Myc K14-F7 K14-R5 pcDNA3.1-KLK14-Myc 
pcDNA3.1-HepsinSA-Flag Hep-F S-A Hep-R S-A pcDNA3.1-Hepsin-Flag 
pcDNA3.1-HepsinSA-Myc Hep-F S-A Hep-R S-A pcDNA.3.1-Hepsin-Myc 
pcDNA3-TMPRSS2SA-Myc tmprss2-F 
S-A 
tmprss2-R 
S-A 
pcDNA3-TMPRSS2-Myc 
Other 
      
pEF-Hepsin-Flag N/A* N/A* pcDNA3.1-Hepsin-Flag 
pEF-HepsinSA-Flag N/A* N/A* pcDNA3.1-HepsinSA-Flag 
pcDNA3.1-Enteropeptidase N/A* N/A* pBluescript-Enteropeptidase 
†, see Table 2.7 for primer sequences; OE-PCR, overlap extension polymerase chain 
reaction; *N/A - not applicable, sub-cloning was performed without in vitro PCR 
amplification of target DNA. 
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2.4.4 General cell culture 
2.4.4.1 Insect cell culture 
Sf9 (SFM Adapted) insect cells (from now on referred to as Sf9) were kept at 28°C in a 
non-humidified ambient air-regulated incubator. The cells were cultured in Sf-900 II 
SFM (Table 2.11) supplemented with penicillin (50 U/mL) and streptomycin (50 
µg/mL) (Table 2.11). For adherent cell culture, the medium was replaced every 3-4 days 
and cells were grown until a confluent monolayer was formed. To passage the cells the 
culture medium was then discarded and replaced with fresh medium and cells were 
dislodged by sharply rapping the culture flask. Detached cells were re-seeded at 10-20% 
confluence in pre-warmed medium.  
For cryopreservation, pre-confluent cells were resuspended in a medium consisting of 
50% conditioned culture medium and 50% fresh medium with dimethyl sulphoxide 
(DMSO) (Table 2.2) added to a final concentration of 7.5% (v/v).  Aliquoted into 
cryovials, the cells were frozen at a rate of -1°C/minute to -80°C in an isopropanol 
cryovessel and were then transferred to liquid nitrogen for long-term storage. To 
resuscitate, the cells were thawed rapidly in a 37°C water bath. The entire aliquot of cells 
was transferred to a culture flask containing pre-warmed medium. After allowing cells to 
attach, the medium was replaced with fresh culture medium. 
When grown as a suspension for the purpose of recombinant protein production, cells 
in conical flasks were placed on an orbital shaker platform rotating at ~150 revolutions 
per minute (rpm). Medium volume for suspension culture did not exceed 35% of flask 
total volume. Cells were seeded at 2-3 × 105 cells/mL and conditioned medium 
harvested when cell density reached 1-2 × 107 cells/mL. 
One of two methods was used to determine cell numbers. The first method, used 
predominantly, used NucleoCassettes™ (Table 2.1) containing immobilized propidium 
iodide and a NucleoCounter®N-100™ (ChemoMetec A/S, Allerød, Denmark) to 
detect the fluorescent signals of DNA intercalation by PI. Cell suspensions were lysed 
with Reagent A100 (Table 2.2) and stabilized with Reagent B (Table 2.2) then drawn up 
into NucleoCassettes™ to determine total cell count. A non-viable cell count, based on 
PI exclusion from viable cells, was determined using a non-lysed cell suspension. The 
second method to determine cell numbers used cell suspensions mixed with 0.4% 
trypan blue solution (Table 2.2). Based on trypan blue exclusion from viable cells, viable 
(white) cells were manually counted using a haemocytometer and a microscope. 
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2.4.4.2 Mammalian cell culture 
All cells were kept in a humidified incubator at 37°C, under 5% CO2. Cos-7, HeLa and 
PAR-LMF cells (Table 2.10) were cultured in DMEM (Table 2.11). Culture medium of 
PAR-LMF cells was supplemented with 200 µg/mL hygromycin B (Table 2.11). 22Rv1, 
DU145, LNCaP and PC-3 cells (Table 2.10) were cultured in RPMI-1640-L-Glutamine 
(Table 2.11). Kidney tubule cells (Table 2.10) were cultured in serum-free, hormonally 
defined culture medium, supplied by D. Vesey, consisting of DMEM-F-12 (Thermo 
Fisher Scientific, Scoresby, Vic, Australia) supplemented with 10 ng/ml epidermal 
growth factor, 5 g/ml insulin, 5 g/ml transferrin, 50 nM hydrocortisone, 50 µM 
prostaglandin E1, 50 nM selenium, and 5 pM triiodothyronine (all from Sigma-Aldrich 
Pty Ltd, Castle Hill, NSW, Australia). RWPE-1 and RWPE-2 cells (Table 2.10) were 
grown in Keratinocyte serum-free medium (SFM) supplemented with 5 ng/mL 
epidermal growth factor 1-53 (EGF 1-53) and 50 µg/mL bovine pituitary extract (BPE) 
(Table 2.11). The culture medium for all cell lines, except for RWPE-1, RPWE-2 and 
kidney proximal tubule cells (PTC), was supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Table 2.11) unless otherwise specified. The culture medium was replaced 
every 2-4 days. 
To passage cell monolayers, after discarding culture medium, cells were washed with 
phosphate-buffered saline (Dulbecco A) (DPBS) (Table 2.16) then incubated in 1-2 mL 
Versene (0.53 mM EDTA in DPBS, autoclaved, Table 2.16) at 37°C until cells detached. 
PAR-LMF and NILF cells were seeded at 10-20% and passaged at 60-70% confluence. 
All other cell lines were seeded at 10-20% and passaged at >80% confluence. 
Cryopreservation, resuscitation and cell number determination methods used for 
mammalian cells are as described in Section 2.4.4.1, Insect Cell Culture, with the 
exception that mammalian cell cryopreservation medium consisted of fresh culture 
medium plus 10% (v/v) DMSO. 
 
2.4.5 General protein techniques 
2.4.5.1 Protein quantification 
Protein concentrations were assayed by bicinchoninic acid protein assay using a BCA™ 
Protein Assay kit (Table 2.15) according to the manufacturer’s instructions. A standard 
curve of bovine serum albumin (BSA) ranging from 0-1.5 mg/mL was generated. Ten 
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µL replicates of each standard, unknown sample and blank (diluent) were pipetted into a 
microplate. Two hundred µL BCA™ Working Reagent was added to each well, mixed 
gently by rocking, covered and incubated at 37°C for 30 minutes. After cooling the plate 
to room temperature, the absorbance at 560 nm was read using either a Benchmark™ 
Plus (Bio-Rad Laboratories Pty, Ltd, Gladesville, NSW, Australia) or POLARstar 
Omega fluorescence polarization (BMG LABTECH, Mornington, Vic., Australia) 
microplate reader. A standard curve was generated and unknown protein concentrations 
calculated using linear regression using either Microsoft® Excel 2003 or MARS Data 
Analysis software (BMG LABTECH, Mornington, Vic., Australia). 
 
2.4.5.2 Conditioned medium and whole-cell lysate preparation  
Conditioned medium was collected and centrifuged at 370 g for 5 minutes to remove 
whole cells. Supernatant was then collected and centrifuged at 16,000 g for 5 minutes. 
Supernatant was collected and pellets discarded. 
Whole-cell lysate was prepared by removing the medium from cell monolayers, then 
washing the monolayer with DPBS. Ice-cold Lysis Buffer (10 mM Tris pH 8.0, 150 mM 
NaCl, 1% (v/v) Triton X-100, 5 mM EDTA, Table 2.16) was prepared with 1× 
cOmplete™ EDTA-free Protease Inhibitor Cocktail (Table 2.2) and added to the cells 
(100 µL/well for a 6-well plate, 1 mL/flask for a T-75 flask, 2 mL/flask for a T-175 
flask). Cells were incubated by rocking on ice for 15 minutes and then detached using a 
cell scraper and lysed cells were then collected into a microcentrifuge tube. Lysed cells 
were passed through a syringe with 26 gauge needle 5-6 times, vortexed briefly, placed 
on ice for 10 minutes and then vortexed again. After centrifuging the cells at 16,000 g 
for 10 minutes at 4°C, the supernatant was collected and the protein concentration was 
determined using the BCA assay (Section 2.4.5.1). 
 
2.4.5.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Routinely proteins were separated by SDS-PAGE conducted using hand-cast gels 
comprised of 4% acrylamide stacking gel with a 10% or 12% acrylamide resolving gel 
(Table 2.16). For routine sample preparation, proteins (20-40 μg lysate or 5-40 μL 
medium) were combined with 6× SDS-PAGE Loading Buffer (0.35 M Tris pH 6.8, 
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30% (v/v) glycerol, 12% (w/v) SDS, 0.012% (w/v) Bromophenol Blue, ± 10% (v/v) 
beta-mercaptoethanol (βME), Table 2.16) to dilute the loading buffer to 1× in the 
sample. Addition or omission of 10% βME allows for samples to be separated by SDS-
PAGE under reducing or non-reducing conditions, respectively. Incubation in loading 
buffer was carried out at either room temperature for a minimum of 20 minutes or at 
100°C for 5 minutes. Samples were then loaded into the gel well alongside a pre-stained 
molecular weight marker, one of Precision Plus Protein™ Dual Color Standards, 
Prestained SDS-PAGE Standards low range or PageRuler™ Prestained Protein Ladder 
#0671 (Table 2.2). Samples were then electrophoresed at 90-110 V in Tris-Glycine 
Running Buffer (25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, Table 2.16) on a Mini-
Protean® 3 apparatus (Bio-Rad Laboratories Pty, Ltd, Gladesville, NSW, Australia).  
 
2.4.5.4 Electrophoretic transfer of protein from SDS-PAGE gel to 
membrane  
Proteins separated by SDS-PAGE were transferred onto either nitrocellulose (Table 2.1) 
or BioTrace™ polyvinylidene fluoride (PVDF) (Table 2.1) membrane using a Mini 
Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad Laboratories Pty, Ltd, Gladesville, 
NSW, Australia) with Tris-Glycine Transfer Buffer (25 mM Tris, 192 mM glycine, 0.1% 
(w/v) SDS, 20% (v/v) methanol, Table 2.16). Prior to assembly of the apparatus for 
transfer, the gel was equilibrated for 15 minutes in Tris-Glycine Transfer Buffer and the 
filter paper, fibre pads and nitrocellulose membrane were soaked in the same. If PVDF 
was used, the membrane was pre-wet in 100% methanol before equilibration in Transfer 
Buffer. Proteins were then transferred to the membrane at 100-110 V for 1-1.5 hours or 
25 V overnight.  
 
2.4.5.5 Western blot analysis 
To prevent non-specific antibody binding, Western blot analysis consisted first of 
blocking the nitrocellulose membrane for 10-15 minutes using primarily Odyssey® 
Blocking Buffer (Table 2.16) or, less often, skim milk blocking buffer (50 mM Tris, 150 
mM NaCl, pH 7.4, 5% (w/v) skim milk powder, Table 2.16). After blocking, the 
membranes were then incubated in primary antibody diluted in blocking buffer for a 
minimum of 1 hour at room temperature or, alternatively, at 4°C overnight.  
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Membranes were then washed 3 times for 5 minutes each in either tris-buffered saline 
plus Tween®20 (TBS-T) (50 mM Tris, 150 mM NaCl, pH 7.4, 0.1% (v/v) Tween®20, 
Table 2.16) or phosphate-buffered saline plus Tween®20 (PBS-T) (137 mM NaCl, 2.7 
mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4, 0.1% (v/v) Tween®20, Table 
2.16). A species-appropriate secondary antibody diluted in blocking buffer was then 
applied to the membranes and was incubated in the dark for 45-60 minutes at room 
temperature. Membranes were then washed as above. Routinely the secondary 
antibodies used were fluorescent dye conjugates with excitation at 680, 700 or 800 nm 
to allow detection using a LI-COR Odyssey® Infrared Imaging System (LI-COR, 
Lincoln, NE, USA). On rare occasions, a species-appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibody was used in place of fluorescent dye conjugates. 
In this case, chemiluminescent detection was carried out using SuperSignal™ West 
Femto Chemiluminescent Substrate (Table 2.2) according to the manufacturer’s 
instructions and then exposing the membranes to X-ray film (Table 2.1). The film was 
then developed using an AGFA CP 1000 automated X-ray film processor (Agfa-
Gevaert Ltd, Scorsby, Australia).  See Table 2.12 and Table 2.13 for complete lists of 
primary and secondary antibodies as well as dilutions routinely used. 
 
2.4.5.6 Protein staining  
To stain proteins in SDS-PAGE gels, the proteins were fixed in the gels by soaking in 
the Coomassie Destain (45%  (v/v) methanol, 10% (v/v) acetic acid, Table 2.16) for 30 
minutes and then were stained using Coomassie Blue R250 stain (0.25% (w/v) 
Coomassie Brilliant Blue R250, 45% (v/v) methanol, 10% (v/v) acetic acid, Table 2.16) 
with gentle rocking overnight at room temperature. Gels were destained by washing the 
gels first with Milli-Q® water, then with multiple changes of Coomassie Destain with 
gentle rotation until there was sufficient contrast between the protein bands and the 
background. 
To stain proteins transferred onto nitrocellulose or PVDF membranes, the membranes 
were first washed in Milli-Q® water, 3 times for 5 minutes each and then stained with 
fresh Coomassie Blue R250 stain for 5 minutes. Membranes were destained by washing 
first with Milli-Q® water, then with multiple changes of Coomassie Destain with gentle 
rotation until there was sufficient contrast between the protein bands and the 
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background. For N-terminal sequencing samples Coomassie Blue R250 stain and 
Coomassie Destain were prepared without acetic acid. 
 
2.4.5.7 Active-site titration of serine proteases using 4-methylumbelliferyl 4-
guanidinobenzoate (MUGB)  
To determine the quantity of active protease to use in assays, active-site titration was 
performed immediately prior to use of  preparations of recombinant KLK14 and 
KLK4, as well as spontaneously active recombinant hepsin and matriptase (supplied by 
Dr D. Kirchhofer, Genentech (Kirchhofer et al., 2005)), and natural bovine trypsin 
(Table 2.2).  Active-site titration was performed using suicide pseudo-substrate MUGB 
to determine the number of active sites available in activated or spontaneously active 
protease preparations and was performed as follows. Serine protease (300 nM) was 
incubated with MUGB (1 µM) (Table 2.2) in MUGB Assay Buffer (50mM Tris, 50mM 
NaCl, pH8.8, 0.01% (v/v) Tween®20, Table 2.16) for 10 minutes at 37°C. 
Stoichiometric 1:1 release of fluorescent 4-methylumbelliferone (4-MU) from the 
MUGB for every active protease molecule was measured over a further 10 minutes at 
37°C using a POLARstar Optima or Omega fluorescent plate reader (BMG 
LABTECH, Mornington, Vic., Australia) by excitation at 355 nm and reading emission 
at 460 nm.  Concentration of active protease was calculated using the relative 
fluorescence against a standard curve generated from known concentrations of 4-MU 
(0-1 µM) (Table 2.2).  
 
2.4.6 Generation of recombinant KLK14 and KLK4 in Sf9 cells and 
purification from conditioned medium 
2.4.6.1 Generation and purification of recombinant KLK14 
The expression construct used here, pIB-KLK14-V5-His, was generated by Dr N. 
Bennett, a former student in the School of Biomedical Sciences, QUT. 
Sf9 cells were seeded to approximately 60% confluency in a well of a six well plate and 
allowed to attach for 15 minutes in Sf-900 II SFM without antibiotics then the medium 
was removed. Cellfectin® Reagent (Table 2.2) (6 µL) and pIB-KLK14-V5-His (2 µg) 
were diluted in Sf-900 II SFM and added to the cells. The cells plus transfection mix (1 
mL) were incubated at 27°C on a rocker for 3 hours whereupon extra medium (1 mL) 
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was added and incubation without rocking continued for a further 2 days. Selection 
pressure for stable transfection was applied using Blasticidin (50 µg/mL) (Table 2.11) in 
Sf-900 II SFM with medium changes and/or passaging every 2-3 days. Expression of 
pro-KLK14-V5-His was confirmed using Western blot analysis of conditioned medium 
probed with mouse anti-V5 antibody and with rabbit anti-kallikrein 14 antibody 
ab28841. At 3 weeks post-transfection, Blasticidin maintenance concentration for the 
stable transfectants was established at 10 µg/mL.  
For recombinant protein production cells stably expressing KLK14-V5-His were 
cultured as described in Section 2.4.4.1. As the pIB-KLK14-V5-His construct contains 
the endogenous coding sequence for the KLK14 secretion signal peptide, conditioned 
medium was harvested for recombinant KLK14 purification. This was done by pelleting 
the Sf9-KLK14-V5-His cells with centrifugation at 370 g for 5 minutes and then 
decanting the medium. After harvest all manipulations of the conditioned medium and 
downstream products were performed at 4°C or on ice, unless otherwise stated. The 
conditioned medium was then centrifuged at 20,000 g for 15 minutes or filtered using a 
bottle-top vacuum filter set (Corning) to remove small particulate matter. The 
conditioned medium was then prepared for recombinant protein purification by one of 
three different methods using concentration and dialysis or dialysis alone. The dialysis 
tubing cellulose membrane (Table 2.1) was prepared for use by boiling for 10 minutes in 
100 mM Na2CO3, 10 mM EDTA then boiling for a further 10 minutes in reverse 
osmosis-purified (RO) water followed by extensive rinsing in RO water. All dialysis was 
performed on a magnetic stirrer with at least two changes of buffer. 
The three different methods for preparation of the conditioned medium were:  
1/ Concentration using ammonium sulphate precipitation at 4°C; ammonium sulphate 
was added slowly with continuous stirring to 50% saturation (262 g/L) and allowed to 
equilibrate overnight. Equilibrated conditioned medium was centrifuged at 20,300 g for 
15 minutes and supernatant was decanted and discarded. The pellet was resuspended in 
nickel-nitrilotriacetic acid (Ni-NTA) Dialysis Buffer (Table 2.16) and dialysed into same 
overnight. 
2/ Concentration by diafiltration; a VivaFlow 200 diafiltration cassette with a 10,000 
MWCO polyethersulfone (PES)  membrane (Table 2.1) connected to a peristaltic pump 
(Masterflex L/S economy, John Morris Scientific, Murarrie, Qld, Australia) was used to 
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concentrate conditioned medium by a factor of 10 to 20. The concentrated medium was 
then dialysed against Ni-NTA Dialysis Buffer (50 mM NaH2PO4, 500 mM NaCl, pH 
8.0, Table 2.16) overnight. 
3/ Unconcentrated conditioned medium was dialysed against Ni-NTA Dialysis Buffer 
overnight. 
For efficiency, the first method was favoured. However, recombinant KLK14 purified 
by all three methods was used in later assays and all methods generated similar end 
results. 
Following dialysis, 1 mL Ni-NTA Superflow resin (Table 2.2) slurry per 1 L of original 
conditioned medium volume, was washed 3 times in Ni-NTA Dialysis Buffer, loaded 
onto a column (1 × 10 cm glass Econo-column® or Poly-Prep® column, Table 2.1) 
and the dialysed medium was applied by gravity flow. After 3 washes of 10 column 
volumes of each of Ni-NTA Wash Buffer 10 (10 mM imidazole, 50 mM NaH2PO4, 300 
mM NaCl, pH 8.0, Table 2.16) and Ni-NTA Wash Buffer 30 (30 mM imidazole, 50 mM 
NaH2PO4, 300 mM NaCl, pH 8.0, Table 2.16), pro-KLK14-V5-His was eluted from the 
Ni-NTA resin by competition affinity using Ni-NTA Elution Buffer 250 (250 mM 
imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 8.0, Table 2.16) 10 fraction series of 1 
column volume each. Post-elution, a final wash of the resin with 1 × 5 column volumes 
of Ni-NTA PE Buffer 300 (300 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 
8.0, Table 2.16) was used to remove remaining proteins. 
Aliquots of 30 µL conditioned medium, concentrated conditioned medium and flow 
through from the Ni-NTA resin as well as wash fractions and elution fractions were 
subjected to reducing SDS-PAGE. Known quantities of BSA were also run on each gel 
to allow for quantification of pro-KLK14-V5-His in each elution. Gels were stained 
with Coomassie Blue R-250 stain and elutions showing a high level of purity were 
pooled, further concentrated using Slide-A-Lyzer™ 10K dialysis cassettes (Table 2.1) 
and Slide-A-Lyzer™ Concentrating Solution (Table 2.2) and then dialysed in the 
cassettes against two changes of KLK14 Buffer (5 mM NaH2PO4, 95 mM Na2HPO4, 
0.01% (v/v) Tween®20, pH 8.0, Table 2.16) (Borgono et al., 2007b). After dialysis, the 
protein concentration was determined using the BCA assay. Aliquots of purified pro-
KLK14-V5-His were stored at -80°C.  
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2.4.6.2 Generation and purification of recombinant KLK4 
Initial batches of pro-KLK4-V5-His were purified from the conditioned medium of 
stably expressing Sf9 cells as described in Ramsay (2008) by Ms Melanie Carroll (née 
Hunt) and Mr Carson Stephens. Later batches of pro-KLK4-V5-His were produced 
using the procedures for the cell culture and purification for pro-KLK14-V5-His 
described in Section 2.4.6.1, with the exception that final dialysis of pro-KLK4-V5-His 
was into phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.47 mM KH2PO4, pH 7.4, Table 2.16) not KLK14 Buffer. Aliquots of 
purified pro-KLK4-V5-His were stored at -80°C.  
 
2.4.7 N-glycosylation status of KLK14 
Recombinant pro-KLK14-V5-His and pro-KLK4-V5-His (100 ng) from stable Sf9 cells 
as well as medium (40 μL) harvested from Cos-7 cells transiently transfected with 
pcDNA3.1-KLK14-Myc (Table 2.17) or pcDNA3.1-KLK4-V5-His (generated by Dr N. 
Bennett, Table 2.4) were heated for 5 minutes at 100°C in 0.5× SDS-PAGE Loading 
Buffer plus βME. Samples were cooled and 250 U peptide-N4-(N-acetyl-beta-
glucosaminyl)asparagine amidase (PNGase F) and 1% Nonidet P-40 (Table 2.15) were 
added and samples were incubated overnight at 37°C in buffer containing 50 mM 
sodium phosphate pH 7.5. After incubation, 6× SDS-PAGE Loading Buffer was added 
to 1× final concentration and samples were subjected to SDS-PAGE and Western blot 
analysis. Blots were probed using mouse anti-Myc and mouse anti-V5 antibodies. 
 
2.4.8 Activation of recombinant KLK14 and KLK4 with thermolysin 
First, the optimal incubation time and ratio of KLK14 zymogen to thermolysin for 
KLK14 activation was determined by incubating pro-KLK14-V5-His with thermolysin 
(Table 2.2) at ratios of 10:0, 10:0.125, 10:0.25, 10:1, 10: 2 µg/mL (molar ratios: 13.8:0, 
13.8:0.125,  13.8:0.25, 13.8:1, 13.8:2) for 1, 1.5 and 2 hours at 37°C in KLK14 Buffer. 
After terminating thermolysin activity with phosphoramidon (33 μM) (Table 2.2), 
activated KLK14 was then subjected to active-site titration with MUGB and the 
proportion of active KLK14 calculated as detailed in Section 2.4.5.7. 
81 
 
Subsequently, immediately prior to use in assays pro-KLK14-V5-His was incubated with 
thermolysin at 37°C for 1.5 hours at a ratio of 10 µg/mL KLK14 to 1 µg/mL 
thermolysin (13.8:1 molar ratio) in KLK14 Buffer. Further thermolysin activity was 
inhibited using phosphoramidon (33 μM) or EDTA (50 mM) followed by MUGB 
active-site titration of activated KLK14. 
Likewise, pro-KLK4-V5-His was incubated with thermolysin at 37°C for 1 hour at a 
molar ratio of 80:1 (pro-KLK4:thermolysin) in PBS, pH 7.4 (Ramsay et al., 2008a). 
Further thermolysin activity was inhibited using phosphoramidon (10 μM) followed by 
MUGB active-site titration of activated KLK4. 
 
2.4.9 N-terminal sequencing of zymogen KLK14 and thermolysin 
activated KLK14 
For each sequencing submission, 10 µg (~330 picomoles) of pro-KLK14-V5-His was 
activated as above in Section 2.4.8. Activated KLK14 (10 µg) and pro-KLK14-V5-His 
(1.5 µg, ~50 picomoles) were subjected to reducing SDS-PAGE. Prior to loading the 
sample the gel was pre-run for 15 minutes at 100 V with 139 µL/L of > 98% 
thioglycolic acid (Table 2.2) included in the running buffer of the inner well of the 
electrophoresis tank to prevent oxidative changes to the protein during electrophoresis. 
Proteins separated by SDS-PAGE were then transferred exclusively onto PVDF 
membrane using 10 mM CAPS Buffer, pH 11 (Table 2.16), instead of Tris-Glycine 
Transfer Buffer, to avoid the presence of primary amines which can cause high 
background readings. Prior to assembly of the transfer apparatus, the gel was washed in 
Milli-Q® (Millipore Ltd, Kilsyth, Vic, Australia) purified ultrapure water for 15 minutes 
before equilibration in CAPS Buffer. Filter paper, fibre pads and methanol soaked 
PVDF membrane were all soaked in CAPS Buffer. Proteins were transferred at 25 V 
overnight and then the blot was stained with Coomassie Blue R-250 staining solution 
with or without acetic acid. Bands of 30 kDa for the pro- and 25 kDa for the active 
KLK14 were excised and sent for Edman degradation N-terminal sequencing to the 
University of Queensland (UQ), School of Chemistry and Molecular Biosciences 
(SCMB) sequencing facility, or to the Australian Proteome Analysis Facility (APAF Ltd). 
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2.4.10 Kinetic measurements of thermolysin activated KLK14 
To determine the activity of KLK14 toward the tri-peptide substrate Boc-Gln-Ala-Arg-
7-amido-4-methylcoumarin hydrochloride (QAR-AMC) (Table 2.2), active KLK14 (12 
nM), KLK4 (12 nM) and trypsin (0.4 nM) (concentration determined by MUGB active-
site titration assay) were incubated with substrate at concentrations of 1, 0.5, 0.1, 0.05, 
0.01, 0.005, 0.001 and 0 mM in KLK14 Buffer.  Fluorescence of released 7-amido-4-
methylcoumarin hydrochloride (AMC) (Table 2.2) was measured over 20 minutes at 
37°C using a POLARstar Omega fluorescent plate reader by excitation at 380 nm and 
reading emission at 460 nm. Concentration of released AMC was calculated using the 
relative fluorescence against a standard curve generated from known concentrations of 
AMC. The Michaelis-Menten enzyme kinetics model was used to calculate the kcat/KM 
constants using non-linear regression and GraphPad Prism 5 software. 
 
2.4.11 KLK14 activation of pro-HGF 
To examine whether KLK14 activates recombinant pro-HGF (supplied by Dr 
D.Kirchhofer, Genentech (Kirchhofer et al., 2005)), active recombinant KLK14 with 
concentrations ranging 0 nM to 100 nM was incubated with recombinant pro-HGF (1 
μM) in KLK14 Buffer for 4 hours at 37°C. As negative and positive controls, 
respectively, active recombinant KLK4 and active recombinant hepsin, that was 
generated minus the transmembrane and intracellular regions (Kirchhofer et al., 2005), 
were also incubated with pro-HGF under the same conditions. The reactions, stopped 
with 6× SDS-PAGE Loading Buffer plus βME added to 1× final concentration, were 
subjected to SDS-PAGE then electrophoretic transfer onto nitrocellulose membrane. 
Blots were then stained with Coomassie Blue R250. 
 
2.4.12 Examination of KLK14 inhibition by HAI-1A and 1B 
To assess HAI-1 inhibition of KLK14 hydrolysis of QAR-AMC, recombinant HAI-1A 
and HAI-1B generated minus the transmembrane and intracellular regions (supplied by 
Dr D. Kirchhofer, Genentech) (Kirchhofer et al., 2003; Fan et al., 2005) at 
concentrations of 0 to 50 nM were incubated with 5 nM active KLK14 in KLK14 
Buffer for 30 minutes at 37°C. Substrate QAR-AMC (200 µM)  was added and then the 
fluorescence of released AMC was measured over 20 minutes at 37°C using a 
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POLARstar Omega fluorescent plate reader by excitation at 380 nm and reading 
emission at 460 nm. Concentration of released AMC was calculated using the relative 
fluorescence against a standard curve generated from known concentrations of AMC. 
Rate of hydrolysis of QAR-AMC by uninhibited KLK14 was set as 100 per cent activity, 
the hydrolysis rate of HAI-1A- and HAI-1B-inhibited KLK14 as a per cent thereof. 
 
2.4.13 KLK14 interaction with HAI-1A and 1B  
To assess whether active KLK14 forms stable complexes with HAI-1A and 1B, three 
assay sets were performed. The interaction of HAI-1A and 1B with hepsin was assessed 
concurrently: 
1) Active KLK14 (1 µM) was incubated with either HAI-1A or 1B, concentrations 
ranging from 0 µM to 10 µM, for 30 minutes at 37°C. Included were 10 µM HAI-
1A or 1B only and 10 µM HAI-1A or 1B plus 50 mM EDTA inhibited thermolysin 
control incubations.  
2) Active KLK14 and hepsin with final concentration of 1 µM were each incubated 
with HAI-1A and 1B, concentrations ranging from 0 µM to 1 µM, for 30 minutes at 
37°C. Included were 1 µM HAI-1A and 1B only incubations. 
3) Active KLK14 and hepsin with final concentrations ranging from 0 µM to 1 µM 
were each incubated with HAI-1A (1 μM) for 30 minutes at 37°C. Included were 
KLK14 (1 µM) and hepsin (1 μM) only incubations. 
Reactions, stopped with 6× SDS-PAGE Loading Buffer plus βME added to 1× final 
concentration, were then subjected to SDS-PAGE, proteins were transferred onto 
PVDF membrane and the blots were stained using Coomassie Blue R-250. 
 
2.4.14 Transient transfection of Cos-7 cells 
A series of transient transfections and co-transfections into Cos-7 cells were performed 
as follows. Cells were transfected with DNA expression or vector constructs using 
Lipofectamine™ 2000 or Lipofectamine™ LTX (Table 2.2) according to the 
manufacturer’s instructions. Table 2.18 lists the expression constructs used as well as the 
protein encoded by each. Briefly, the DNA and Lipofectamine™ were prepared in 
Opti-MEM®I Reduced Serum Medium (Table 2.11) with a ratio of 
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DNA:Lipofectamine™ (µg:µL) of 1:2. The transfection mixture was applied to sub-
confluent cells seeded in complete medium in the absence of antibiotics and cells were 
cultured for 24 hours post-transfection. For co-expression experiments, when co-
expressing two or more proteins, equal quantities (μg) of expression construct DNA 
were co-transfected into the Cos-7 cells. For the single protein controls in the co-
expression experiments, the expression construct was co-transfected with an equal 
quantity (μg) of a vector with a backbone matching the expression construct. The total 
quantity of DNA used for co-transfection in 6-well plates, 10 cm culture dishes or T-75 
flasks, was 4, 16 or 40 μg, respectively. 
To analyse the proteolytic interactions between co-expressed proteases, SDS-PAGE of 
the whole-cell lysate (20 μg) and conditioned medium (40 μL) from transfected Cos-7 
cells was performed followed by Western blot analysis using epitope tag-specific or 
protein-specific primary antibodies (Table 2.18) and species-appropriate secondary 
antibodies were used for detection (Table 2.13). Table 2.19 contains a summary of the 
protein co-expression combinations. 
 
2.4.15 Recombinant hepsin incubation with recombinant pro-KLK14 and 
pro-KLK4 
Recombinant pro-KLK14-V5-His and pro-KLK4-V5-His (3 μM) were each incubated 
with recombinant hepsin (active) with concentrations ranging from 0 to 3 μM. As a 
control pro-KLK14-V5-His and pro-KLK4-V5-His (3 μM) were also incubated with 
thermolysin at molar ratios of 1:0.08 and 1:0.008. Incubations were carried out in a Tris-
NaCl buffer (50 mM Tris, 50 mM NaCl, pH 7.4) for 1 hour at 37°C. The reactions, 
stopped with 6× SDS-PAGE Loading Buffer plus 10% βME added to 1× final 
concentration, were subjected to SDS-PAGE and Western blot analysis using anti-V5, 
anti-Kallikrein 14 ab28841 and anti-KLK4 mid and C-term (combined) (Hormone 
Dependent Cancer Program, IHBI, Kelvin Grove, Qld, Australia (Harvey et al., 2003)) 
antibodies. 
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Table 2.18 Summary of expression constructs, protein product and primary 
antibodies used for Western blot analysis. 
Construct Product Primary antibodies† 
pcDNA3.1-Enteropeptidase Enteropeptidase Anti-Enterokinase LC antibody 
(sc-51283) 
pcDNA3.1-KLK14-HA KLK14-HA Anti-HA (H6908) Rabbit* or 
anti-Kallikrein 14 (ab28841) 
Rabbit pcDNA3.1-KLK14SA-HA KLK14SA-HA 
pcDNA3.1-KLK14-Myc KLK14-Myc Anti-Myc-Tag (9B11) Mouse 
mAb* or anti-Kallikrein 14 
(ab28841) Rabbit pcDNA3.1-KLK14SA-Myc KLK14SA-Myc 
pcDNA3.1-KLK4-V5-His KLK4-V5 Anti-V5 (R96025) Mouse*, 
anti-Kallikrein  4 mid Rabbit or  
anti-Kallikrein  4 C-term Rabbit pcDNA3.1-KLK4SA-V5-His KLK4SA-V5 
pcDNA3.1-Hepsin-Flag Hepsin-Flag 
Anti-Flag® (F7425) Rabbit* or 
anti-Hepsin A15 Mouse 
pcDNA3.1-HepsinSA-Flag HepsinSA-Flag 
pcDNA-3.1-Hepsin-Myc Hepsin-Myc Anti-Myc-Tag (9B11) Mouse 
mAb* or anti-Hepsin A15 
Mouse pcDNA3.1-HepsinSA-Myc Hepsin-SA-Myc 
pcDNA3-TMPRSS2-Myc TMPRSS2-Myc 
Anti-Myc-Tag (9B11) Mouse 
mAb 
pcDNA3-TMPRSS2SA-Myc TMPRSS2SA-Myc 
pcDNA3.1-Matriptase Matriptase Anti-Matriptase M69 Mouse 
pEZ-M02-MMP3 MMP3 Anti-MMP3 antibody 
(ab18898) Goat 
pEZ-M02-MMP9 MMP9 Anti-MMP9 antibody 
(ab38898) Rabbit 
† Antibody supplier and dilutions in Table 2.12; * most frequently used antibody. 
  
86 
 
Table 2.19 Summary of proteins co-expressed in Cos-7 cells for proteolysis and 
immunoprecipitation analysis. 
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+, Co-transfections; IP, Immunoprecipitations; Biotin, cell-surface biotinylation; ABP, 
activity based probe; *, ABP of conditioned media only. 
 
2.4.16 Immunoprecipitation of proteases expressed in transiently 
transfected Cos-7 cells 
Cos-7 cells were transiently co-transfected in 10 cm culture dishes as outlined in Section 
2.4.14. The co-transfection combinations performed for immunoprecipitation studies 
are detailed in Table 2.19. Cells were washed twice with ice-cold DPBS and then 400 µL 
of Lysis Buffer with Protease Inhibitor Cocktail was added.  Whole-cell lysate was 
prepared and then protein concentration determined by BCA assay. Protein A Agarose 
and/or Protein G Agarose (Table 2.2) was equilibrated in Lysis Buffer and then whole-
cell lysate was pre-cleared by adding 10 µL Protein A and/or G Agarose to 200-300 µg 
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of whole-cell lysate and incubating for 1 hour at 4°C on a rolling platform. The agarose 
beads were pelleted by centrifugation at 3000 g for 2 minutes and the pre-cleared 
supernatant recovered. Appropriate antibodies (Table 2.18) or isotype immunoglobulin 
G (IgG)s (control) (2-5 µg) (Table 2.14) were added to the supernatant and incubated 
overnight at 4°C on a rotating wheel. Fresh aliquots of Protein A and/or G Agarose (10 
µL) were added and incubated for 4 hours at 4°C with gentle agitation. The unbound 
(flow through) protein fraction was then collected by centrifugation of the agarose in 
Pierce Spin Columns (Table 2.1) for 2 minutes at 3000 g. The agarose was then washed 
three times with 20 column volumes of Lysis Buffer, centrifuging for 1 minute at 3000 g 
after each wash. The bound (immunoprecipitated) fraction was then eluted by adding 40 
µL of 3× SDS-PAGE Loading Buffer plus βME, incubating at 100°C for 10 minutes 
then centrifuging at 3000 g for 2 minutes to collect eluate. The immunoprecipitated, 
column flow through as well as the input whole-cell lysate fractions were then subjected 
to SDS-PAGE and Western blot analysis. Primary antibodies used in the Western blot 
analysis were directed at detecting proteins that co-immunoprecipitated with the target 
protein (Table 2.2). 
 
2.4.17 Cell-surface biotinylation of transiently transfected Cos-7 cells 
Cos-7 cells in 10 cm culture dishes were transiently co-transfected as outlined in Section 
2.4.14. The co-transfection combinations performed are detailed in Table 2.19. In order 
to isolate cell surface localized proteins cell-surface biotinylation and streptavidin 
agarose pull-down was performed, outlined as follows. Cell monolayers were washed 
twice with ice-cold DPBS then plasma membrane proteins were biotin-labelled by 
incubation with 1.22 mg/mL EZ-Link™ Sulfo-NHS-SS-Biotin (Table 2.2) for 10 
minutes on ice with gentle rocking. Cells were then washed 3 times with ice-cold DPBS 
and then 0.5-1 mL Lysis Buffer plus Protease Inhibitor Cocktail was added per 10 cm 
culture dish or T-75 culture flask and whole-cell lysate was prepared. From this a sample 
of whole-cell lysate (50-100 µL) was taken for later analysis.  To pull down the 
biotinylated proteins in the remaining whole-cell lysate, Streptavidin Agarose Resin 
(streptavidin agarose) (Table 2.2) 50% slurry (20 µL), equilibrated in Binding Buffer (28 
mM NaH2PO4, 72 mM Na2HPO4, 0.15 M NaCl, pH 7.2, Table 2.16), was added and the 
mixture incubated on ice for 1 hour rocking gently. The unbound (cytoplasmic) protein 
fraction was then collected by centrifugation in Pierce Spin Columns for 2 minutes at 
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1000 g. The resin was then washed three times with 10 column volumes of Lysis Buffer, 
centrifuging for 1 minute at 1000 g after each wash. The bound (plasma membrane) 
fraction was then eluted by adding 40 µL of 3× SDS-PAGE Loading Buffer plus βME, 
incubating at 100°C for 10 minutes then centrifuging at 1000 g for 2 minutes to collect 
eluate. The cytoplasmic, plasma membrane and whole-cell lysate fractions were then 
subjected to SDS-PAGE and Western blot analysis using primary antibodies listed in 
Table 2.2. 
 
2.4.18 Activity-based probe (ABP) labelling of proteases expressed in 
transiently transfected Cos-7 cells  
In order to isolate active serine proteases, biotin tagged ABPs were used in conjunction 
with streptavidin agarose pull-down, described as follows. Cos-7 cells in T-75 flasks 
were transiently co-transfected (Section 2.4.14). . The co-transfection combinations 
performed are detailed in Table 2.3. For ABP of conditioned medium, the medium was 
collected and then concentrated and buffer exchanged into 50 mM Tris pH 7.4 using an 
Amicon® Ultra-15 Ultracel-10 spin column (Table 2.1) spun at 3,200 g. The protein 
concentration was then assayed by BCA assay and then to an equivalent of 40 µg of 
protein, ABP, biotinylated Glu-Gly-Arg-chloromethylketone (biotin-EGR-CMK) or 
biotinylated Phe-Pro-Arg-chloromethylketone (biotin-FPR-CMK) (Table 2.2) was added 
to a final concentration of 50 µM. The mixture was incubated alongside an untreated 
control for 1.5 hours at 37°C.   
For ABP of whole cells, after removing the conditioned medium, the cell monolayer 
was first washed with DPBS then cells were detached with Versene as described in 
Section 2.4.4.2. The cells were then washed twice in DPBS with centrifugation for 5 
minutes at 370 g after each wash to remove buffer. The cells were then resuspended in 
DPBS (300 µL) and divided equally into three microcentrifuge tubes. One hundred µL 
of ABP, to a final concentration of 50 µM, or 100 µL DPBS (untreated control) was 
added to each tube and allowed to incubate with gentle rotation for 1.5 hours at 37°C. 
After incubation, cells were washed twice with ice-cold DPBS, as above, and then 100 
µL of ice-cold Lysis Buffer with Protease Inhibitor Cocktail was added to the cell pellet. 
Whole-cell lysate was then prepared and a sample (5 µL) was taken from each 
preparation for quantification by BCA assay.  
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Streptavidin agarose was used to pull down the proteins attached to the biotinylated 
ABP in the conditioned medium and the whole-cell lysate. The streptavidin agarose was 
prepared by equilibrating with Binding Buffer and then a 50% slurry of streptavidin 
agarose (2 µL per µg of ABP) was added to the ABP-treated and also the untreated 
controls. After incubation for 10 minutes rocking gently at room temperature, the 
unbound protein fraction was then collected by centrifuging the samples in Pierce Spin 
Columns for 2 minutes at 1000 g. The resin was then washed twice with 20 column 
volumes of Binding Buffer, centrifuging for 1 minute at 1000 g after each wash. The 
bound fraction was then eluted by adding 8-10 column volumes of SDS-PAGE Loading 
Buffer plus βME, incubating at 100°C for 10 minutes then centrifuging at 1000 g for 2 
minutes to collect eluate. The eluted fractions, as well as the input conditioned medium 
and whole-cell lysate, were then subjected to SDS-PAGE and Western blot analysis 
using primary antibodies listed in Table 2.2. In addition, the blots were probed with 
Streptavidin, Alexa Fluor® 680 conjugate (Table 2.2) to detect all proteases pulled down 
by the ABPs. 
 
2.4.19 Gelatin zymography of conditioned media from transiently 
transfected cells 
Conditioned media were collected from Cos-7 cells transiently transfected for 24 hours 
with constructs encoding either wild-type hepsin or TMPRSS2 and either MMP3 or 
MMP9. After concentrating the media ×10, gelatin zymography was carried out under 
non-reducing conditions (without βME) using hand-cast SDS-PAGE gels comprising 
4% acrylamide stacking gel and 10% acrylamide resolving gel including 1 mg/mL gelatin 
from porcine skin (Table 2.2) in the resolving gel. Following electrophoresis the 
proteins were renaturated by incubating the gels in Zymography Renaturation Buffer 
(50 mM Tris, 5 mM CaCl2, 1 μM ZnCl2, pH 7.4, 2.5% Triton X-100, Table 2.16) for 1 
hour at room temperature on an orbital shaker platform. The gels were then washed 
briefly in Milli-Q® water followed by incubation rotating overnight at 37°C in 
Zymography Developing Buffer (50 mM Tris, 5 mM CaCl2, 1 μM ZnCl2, pH 7.4, Table 
2.16). The gels were then stained using Zymography Stain (0.5% (w/v) Coomassie 
Brilliant Blue R250 (Fluka),  30% (v/v) ethanol, 10% (v/v) acetic acid, Table 2.16) for 
60 minutes followed by de-staining with Zymography Destain (30% (v/v) ethanol, 10% 
(v/v) acetic acid, Table 2.16). When clear bands appeared in the gels the de-staining was 
stopped using 2% acetic acid followed by rehydration of the gel overnight in the same. 
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2.4.20 Recombinant hepsin and matriptase and bovine trypsin incubation 
with MMP3 and MMP9 from transiently transfected Cos-7 cells 
Conditioned medium from Cos-7 cells transiently transfected for 24 hours with 
constructs encoding either MMP3 or MMP9 was incubated at 37°C for 1 or 14 hours  
with recombinant hepsin (50 nM), recombinant matriptase (50 nM) or bovine trypsin 
(10 nM). The reactions, stopped with Protease Inhibitor Cocktail and 6× SDS-PAGE 
loading buffer ± βME added to 1× final concentration, were subjected to SDS-PAGE 
under reducing and non-reducing conditions (data not shown) and Western blot analysis 
using anti-MMP3 and anti-MMP9 antibodies. 
 
2.4.21 Intracellular Ca2+flux assays to examine serine protease-initiated 
PAR activation  
For Ca2+ flux assays cells grown to 80% confluence were washed with DPBS, then 
detached using Versene and collected. The cells were washed twice with Ca2+ Flux Assay 
(CaFA) Buffer (Table 2.16) without probenecid and centrifuged at 370 g for 5 minutes 
after each wash to remove Versene. The cells were then loaded with the ratiometric 
calcium indicator Fura-2 acetoxymethyl ester (Fura-2 AM) by resuspending (4× 106 
cells/mL) in CaFA Buffer with probenecid plus Fura-2 AM (6 µM) (Table 2.2) and 
0.021% (w/v) Pluronic® F127 (Table 2.2).  After incubation for 1 hour in the dark at 
37°C, cells were pelleted by centrifugation at 370 g for 5 minutes, load buffer was 
aspirated and cells resuspended (2 × 106 cells/mL) in CaFA Buffer. For fluorescence 
measurements, 100 µL cell suspension replicates were pipetted into black 96-well 
microplates and maintained at 37°C. All agonists, either active serine proteases or 
agonist peptides (AP), PAR1AP, PAR2AP and PAR4AP (Table 2.2), were diluted in 
CaFA Buffer and brought to 37°C immediately before use. A continuous measurement 
of free intracellular Ca2+ ion concentration ([Ca2+i]) was established by exciting Fura-2 at 
alternating 340 and 380 nm, and the emission at 510 nm was measured using a 
POLARstar Optima or Omega fluorescent plate reader. After recording a baseline 
[Ca2+i] for 30 seconds, agonist or buffer was applied to the Fura-2 loaded cells and 
changes in [Ca2+i] were measured for 180 seconds. A consecutive agonist treatment 
could then be applied, if required, and changes in [Ca2+i] measured for a further 210 
seconds. The data are presented as the change in ratio of emission 510 nm(340/380 nm), 
proportional to free [Ca2+i]., and are representative of experiments performed in 
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triplicate and repeated on 3 independent occasions unless limited by the availability of 
serine proteases. 
 
2.4.21.1 Examination of PAR activation by KLK14, hepsin, matriptase and 
trypsin using intracellular Ca2+flux assays 
PAR1-, PAR2- and PAR4-lung myofibroblast (LMF) cells (Table 2.10) were used to 
assess serine protease-initiated changes in [Ca2+i]. These cell lines are derived from lung 
myofibroblasts immortalized from PAR1 -/- mice (Darrow et al., 1996). These cells, 
also lacking functional endogenous mouse PAR2 and PAR4, have been transfected to 
stably express human PAR1, PAR2 or PAR4 (Andrade-Gordon et al., 1999). Expressing 
only one each of PARs, the cells, designated PAR1-LMF, PAR2-LMF and PAR4-LMF, 
are useful in vitro tools for examining PAR activation as Ca2+ flux response is elicited 
from each line by the respective PAR AP.  
To assess the ability of the serine proteases to completely activate each PAR, 
consecutive treatments of a serine protease followed by a PAR AP were made as 
described in Section 2.4.21. The cells were first treated with one of the following active 
serine proteases, KLK14 (150 nM), hepsin (50 nM), matriptase (10 nM for PAR1- and 
PAR2-LMF; 50 nM for PAR4-LMF), or bovine trypsin (10 nM for PAR1- and PAR2-
LMF; 50 nM for PAR4-LMF).  One of the following APs was then applied: PAR1AP 
(TFLLR) (50 μM), PAR2AP (SLIGRL) (50 µM) and PAR4AP (AYPGKF) (500 µM; 150 
μM for KLK14), to PAR1-, PAR2- and PAR4-LMF cells, respectively.  
HAI-1B inhibition of hepsin and matriptase activation of PAR2 was also assessed. 
Hepsin (50 nM) and matriptase (10 nM) were pre-incubated with 1 μM HAI-1B. Then 
application of HAI-1B/hepsin and HAI-1B/matriptase to the PAR2-LMF cells was 
followed by application of PAR2AP (SLIGRL) (50 μM). 
Dose response of PAR-LMF cells to hepsin, trypsin and matriptase (for PAR2-LMF 
only) was also ascertained by Ca2+ flux assay. The hepsin concentration range assayed 
for all PAR-LMF cells was 1 to 100 nM. The trypsin concentration range assayed for 
PAR1-LMF was 0.1 to 100 nM; for PAR2-LMF, 0.05 to 5 nM; and for PAR4-LMF, 1 to 
100 nM. The matriptase concentration range for the PAR2-LMF cells was 0.06 to 30 
nM. The concentration to stimulate half-maximal response (EC50) was calculated from a 
nonlinear regression curve using GraphPad Prism 5. Data is presented as the mean 
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value, +/- SEM, of experiments performed in triplicate. Due to limited availability of 
the recombinant proteases, only the trypsin experiments were conducted three times. 
 
2.4.21.2 Inhibition of KLK4 induced activation of PAR2 using the inhibitor 
peptide SFTI-FCQR 
Inhibition of KLK4 activation of PAR2 by KLK4-specific inhibitor SFTI-FCQR 
(Swedberg et al., 2009) was assessed by Ca2+ flux assay. PAR2-LMF cells were 
challenged with buffer only, PAR2AP (SLIGKV) (50 μM), trypsin (10 nM), trypsin (10 
nM) pre-incubated with 1 μM SFTI-FCQ, and KLK4 (200 nM). To assess the status of 
PAR2 after agonist treatment, PAR2-LMF cells were also challenged with consecutive 
treatments of KLK4 (200 nM) pre-incubated with 1 μM SFTI-FCQR followed by either 
PAR2AP (SLIGKV) (50 μM) or trypsin (10 nM). 
 
2.4.21.3 Examination of activation of PAR2 in primary kidney proximal 
tubule cells (PTC) 
Cultures of human primary kidney PTC (passage number 2-3, provided by Dr D. Vesey, 
Princess Alexandra Hospital, Brisbane) were assessed by Ca2+ flux assay for activation of 
PAR2 by KLK4. The kidney PTC were passaged no more than once in our laboratory 
before they were challenged with buffer only, trypsin (10 nM), or KLK4 (300 nM, 600 
nM and 1.2 μM). To examine the activity of KLK4 post-Ca2+ flux assay, the assay mix 
was collected from the wells of the microplate. Half the assay mix was centrifuged at 
370 g for 5 minutes to pellet the kidney PTC, and the supernatant was collected. The 
cell-free supernatant and the cell-containing assay mix were both subjected to MUGB 
active-site titration to determine KLK4 activity. 
To assess how much of the Ca2+ flux initiated by trypsin and KLK4 was mediated via 
PAR2, the cells were also challenged with consecutive treatments of PAR2AP 
(SLIGKV) (100 μM) to desensitize the PAR2 response, followed by either trypsin (10 
nM) or KLK4 (300 μM).  
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2.4.22 Generation and characterization of prostate cancer LNCaP and 
PAR2-LMF cells stably expressing the cell-surface serine protease 
hepsin 
2.4.22.1 Generation of LNCaP and PAR2-LMF cells stably expressing hepsin 
or catalytically inactive hepsin 
Prostate cancer LNCaP cells were stably transfected with constructs encoding full-
length hepsin or active-site mutated hepsinSA, with a carboxyl-terminus Flag epitope tag 
(designated hepsin-Flag and hepsinSA-Flag) as follows. The cells were transfected using 
Lipofectamine™ LTX (4 μL) with 2 μg of pcDNA3.1-Hepsin-Flag, pcDNA3.1-
HepsinSA-Flag (Table 2.4 and Table 2.17) or pcDNA3.1 vector. The 
DNA/Lipofectamine™ mixture was prepared in Opti-MEM®I Reduced Serum 
Medium and applied to cells seeded in 6-well plates at ~70% confluency in culture 
medium, RPMI-1640-L-Glutamine containing 10% FBS (v/v). At 48 hours post-
transfection the transfection medium was replaced with culture medium. For stable 
transfection of the LNCaP cells selection pressure was applied using G418 (500 μg/mL) 
(Table 2.11) in the culture medium. For maintenance of the stable cell lines, the medium 
was changed and/or cells passaged every 2 to 3 days. G418 concentration was set at 350 
μg/mL 2 weeks post-transfection. 
PAR2-LMF cells were also transfected with constructs encoding hepsin-Flag and 
hepsinSA-Flag by the method as follows. The cells were seeded in a 6-well plate to 
~60% confluency in DMEM containing 10% FBS (v/v) and then transfected using 
Lipofectamine™ LTX (5 μL) with 4 μg of pEF-Hepsin-Flag, pEF-HepsinSA-Flag 
(Table 2.17) or pEFIRES-p vector prepared in Opti-MEM®I Reduced Serum Medium. 
At 48 hours post-transfection the transfection medium was replaced with culture 
medium, DMEM containing 10% FBS (v/v), 200 μg/mL hygromycin B. The culture 
medium contained hygromycin for the maintenance of the PAR2 transfection (Andrade-
Gordon et al., 1999). For stable transfection, selection pressure was applied using 
puromycin (5 μg/mL) (Table 2.11) in the culture medium. The medium was changed 
and/or cells passaged every 2 to 3 days.  
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2.4.22.2 Fluorescence-Activated Cell Sorting (FACS) and screening by flow 
cytometry of stably transfected LNCaP-hepsin and LNCaP-
hepsinSA cells  
To obtain homogeneous populations of LNCaP cells expressing high levels of hepsin-
Flag or active-site mutated hepsinSA-Flag, FACS using an anti-Flag antibody was used 
to isolate single cells with high plasma membrane expression of hepsin-Flag or 
hepsinSA-Flag a minimum of two weeks post-transfection and antibiotic selection.   
To prepare cells for FACS, conditioned medium was collected from cell monolayers, 
centrifuged to remove cells at 500 g for 5 minutes, filtered with a sterile 0.2 µM filter and 
reserved for later use. The cell monolayers were washed with DPBS and detached with 
Versene and cells were then collected in DPBS with 2% (v/v) FBS (DPBS-FBS).  Cells 
were pelleted by centrifugation at 500 g for 5 minutes and then resuspended at 1 × 107 
cells/mL in DPBS-FBS plus mouse anti-Flag M2 primary antibody (Table 2.12) diluted 
1/1000. After incubation at room temperature for 20 minutes, cells were washed in 
DPBS-FBS and centrifuged to pellet cells. Pelleted cells were then resuspended to 8 × 
106 cells/mL in Alexa Fluor® 488 goat anti-mouse IgG secondary antibody (Table 2.13) 
diluted 1/750 in DPBS-FBS and then incubated at room temperature for 20 min. After 
being washed in DPBS-FBS, cells were pelleted and then resuspended to at 8 × 106 
cells/mL in DPBS-FBS. Before FACS, cells were filtered using a Cell Strainer (70 μm) 
(Table 2.1) and then cells were sorted using a DAKO MoFlo High Speed FACS 
(Beckman Coulter, Gladesville, NSW, Australia). Operation of the FACS machine was 
performed by Dr. Ibtissam Abdul-Jabbar of the Diamantina Institute, University of 
Queensland, Brisbane.  
For monoclonal populations, cells were sorted one cell/well in 96-well plates. For 
triclonal populations, cells were sorted three cells/well in 96-well plates. For polyclonal 
populations, 8,000 – 20,000 cells were sorted into medium (3 mL) which was then split 
across two or three wells of a 24-well plate. In the first round of FACS, cells were sorted 
into 96-well plates or 5 mL tubes pre-aliquoted with cell-conditioned RMPI-1640, 10% 
(v/v) FBS and 350 µg/mL G418. In subsequent rounds of FACS, the make-up of the 
medium was modified to include 50% cell-conditioned medium plus 50% fresh medium 
with FBS supplemented to 20% (v/v) and G418 (350 μg/mL). 
Cell-surface expression of hepsin-Flag and hepsinSA-Flag in the stably transfected cell 
lines was screened by flow cytometry using an anti-Flag antibody. Cell monolayers were 
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washed with DPBS, detached with Versene and cells were then collected in DPBS-FBS. 
Cells were pelleted by centrifugation at 500 g for 5 minutes and then resuspended at 0.75 
× 107 cells/mL in DPBS-FBS containing mouse anti-Flag M2 primary antibody diluted 
1/1000. After incubation at room temperature for 20 minutes, cells were washed in 
DPBS-FBS, then centrifuged to pellet. Pelleted cells were then resuspended at 0.75 × 
107 cells/mL in Alexa Fluor® 488 goat anti-mouse IgG secondary antibody diluted 
1/750 in DPBS-FBS and incubated at room temperature for 20 min. After washing in 
DPBS, cells were pelleted then resuspended at 0.75 × 106 cells/350 µL in DPBS. Cell 
surface hepsin-Flag and hepsinSA-Flag were then assessed using an FC500 flow 
cytometer (Beckman Coulter, Gladesville, NSW, Australia). 
 
2.4.22.3 Examination of LNCaP-hepsin and LNCaP-hepsinSA expression by 
Western blot analysis 
To compare relative expression of hepsin and hepsinSA, whole-cell lysates were 
prepared from several LNCaP-hepsin-Flag and LNCaP-hepsinSA-Flag monoclonal and 
triclonal populations as well as vector transfected and untransfected LNCaP cells. The 
whole-cell lysates were subjected to reducing Western blot analysis. The blots were 
probed using the following antibodies: rabbit anti-Flag, mouse anti-hepsin A15 (Dr 
Q.Wu, Cleveland Clinic) and mouse anti-GAPDH (Table 2.12). 
To examine endogenous expression of hepsin in prostate cancer cell lines, whole cell 
lysates were prepared from LNCaP 22Rv1, DU145, PC-3 and RWPE2 cells. Whole cell 
lysate from Cos-7 cells transiently transfected with a construct encoding hepsin-Flag was 
used as a positive control. The lysates were subjected to Western blot analysis using 
mouse anti-hepsin A15 antibody. 
 
2.4.22.4 Examination of LNCaP-hepsin and LNCaP-hepsinSA expression by 
Western blot analysis of cell-surface biotinylated fractions 
To examine relative cell surface expression of hepsin and hepsinSA, cell surface 
biotinylation was performed (as described in Section 2.4.17) for one each of the 
LNCaP-hepsin-Flag and LNCaP-hepsinSA-Flag clones as well as LNCaP-vector and 
untransfected LNCaP cells. The biotinylated plasma membrane, unbiotinylated 
cytoplasmic flow-through, and whole-cell lysate fractions were subjected to reducing 
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SDS-PGE followed by Western blot analysis. The blots were probed using the following 
antibodies: rabbit anti-Flag, mouse anti-hepsin A15 and mouse anti-GAPDH. 
 
2.4.22.5 Examination of zymogen KLK14 and KLK4 interactions with cell 
surface hepsin and hepsinSA 
To examine whether KLK14 and KLK4 interact with cell surface expressed hepsin, 
LNCaP-hepsin-Flag and LNCaP-hepsinSA-Flag cells at 90% confluence in 6-well plates 
were washed twice with PBS and then incubated with RMPI-1640-L-Glutamine 
(without FBS) containing 80 μM recombinant pro-KLK14-V5-His or pro-KLK4-V5-
His. The cells were then incubated for 1, 5 or 18 hours at 37°C, under 5% CO2. After 
incubation, the conditioned media and whole-cell lysate were prepared and then 
subjected to reducing and non-reducing Western blot analysis using mouse anti-V5 and 
rabbit anti-Flag antibodies (Table 2.12). 
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Chapter 3 Generation and characterization of 
recombinant KLK14 
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3.1 Introduction 
KLK14 is a secreted serine protease with unresolved physiological roles (Hooper et al., 
2001a; Yousef et al., 2001). It has widespread tissue expression with higher levels in 
skin, breast and prostate (Borgono et al., 2003; Brattsand et al., 2005; Komatsu et al., 
2006; Stefansson et al., 2006; Borgono et al., 2007c), and suggested roles in seminal clot 
liquefaction (Emami and Diamandis, 2008), epidermal desquamation (Brattsand et al., 
2005; Stefansson et al., 2006; Borgono et al., 2007b; Deraison et al., 2007; Komatsu et 
al., 2007a; Komatsu et al., 2007b; Emami and Diamandis, 2008) and also PAR 
activation/inactivation (Oikonomopoulou et al., 2006a; Stefansson et al., 2008). 
Furthermore, increased KLK14 expression in prostate cancer has been correlated with 
disease progression. 
In recent years several groups have generated recombinant KLK14 for characterization 
using expression systems including insect cell Drosophila Schneider 2 cells (Brattsand et 
al., 2005), yeast expression in Pichia pastoris (Borgono et al., 2003; Brattsand et al., 2005), 
and mammalian cell expression in HEK293 (Borgono et al., 2007c) and Cos-7 
(Rajapakse and Takahashi, 2007) cells. Of these, Borogono and colleagues (2007a) 
reported that KLK14 generated in Pichia pastoris was not N-glycosylated. In addition, 
they speculated that based on MW KLK14 generated in HEK293 cells was also not N-
glycosylated (Borgono et al., 2003). The N-glycosylation status of KLK14 has not been 
reported for any other expression system. Nonetheless, N-glycosylation is a significant 
post-translational modification that can have a wide range of effects on function, 
activity, localization and stability of a protein (Skropeta, 2009).  
In contrast to N-glycosylation, the enzymatic properties of recombinant KLK14 
generated in various expression systems have been well described. Approaches have 
included hydrolytic activity of recombinant KLK14 against synthetic tripeptide 
substrates (Brattsand et al., 2005; Borgono et al., 2007c; Rajapakse and Takahashi, 2007), 
phage display (Felber et al., 2005), and combinatorial and sparse matrix libraries 
(Borgono et al., 2007a; de Veer et al., 2011). From these it has been determined that 
KLK14 has a preference in substrates for Arg P1 residues over Lys>Tyr residues 
(Brattsand et al., 2005; Felber et al., 2005; Oikonomopoulou et al., 2006a; Borgono et 
al., 2007a; Borgono et al., 2007c; Rajapakse and Takahashi, 2007; Stefansson et al., 2008; 
de Veer et al., 2011).  
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Using in vitro approaches a number of KLK14 substrates have also been determined 
(Lawrence et al., 2010), as have inhibitors including several serpins, and Kazal-type 
inhibitors SPINK5 and SPINK6 (Goettig et al., 2010).  However, to date there has been 
no report of the growth, motility and morphogenic factor HGF (Bottaro et al., 1991; 
Nakamura and Mizuno, 2010) as a substrate for KLK14. Furthermore, KLK14 
interactions with isoforms of the Kunitz-type inhibitor HAI-1 have not been defined. 
HGF is expressed in the prostate (Humphrey et al., 1995; Gmyrek et al., 2001), with 
increased expression, along with its cognate receptor HGFR, in prostate cancer 
(Kurimoto et al., 1998; Zhu and Humphrey, 2000). Moreover, there is increased 
activated HGF in the serum of patients with untreated prostate cancer compared to 
those with benign disease (Hashem and Essam, 2005; Yasuda et al., 2009). In contrast, 
HAI-1 has been associated with prostate cancer progression through decreased 
expression (Kataoka et al., 1999; Wang et al., 2009; Warren et al., 2009). 
As KLK14 has a preference for Arg P1 residues, it is a potential HGF activator as 
activation of HGF single chain precursor (pro-HGF) occurs by limited proteolysis after 
residue Arg494 to produce a heterodimer linked by a disulphide bond (Gak et al., 1992; 
Naka et al., 1992; Naldini et al., 1992) (Figure 3.1). In so doing, KLK14 potentially joins 
a list of HGF-activating proteases including the serum protease HGFA (Shimomura et 
al., 1995; Itoh et al., 2004), and the transmembrane proteases matriptase (Lee et al., 
2000; Owen et al., 2010), hepsin (Herter et al., 2005; Kirchhofer et al., 2005; Owen et al., 
2010) and TMPRSS13 (Hashimoto et al., 2010). 
 
Figure 3.1 Pro-region cleavage site of HGF 
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Protease inhibitors are a crucial aspect of regulation of HGF activation (Gherardi et al., 
2012). Indeed, HAI-1 is an endogenous inhibitor of HGFA and matriptase (Shimomura 
et al., 1997; Lin et al., 1999b; Benaud et al., 2001; Wang et al., 2009) and a role of tight 
regulation of matriptase pericellular activity has been proposed (Oberst et al., 2003b; 
Oberst et al., 2005; Fan et al., 2007; Lee et al., 2007; Szabo et al., 2007; Tseng et al., 
2010; Friis et al., 2011). HAI-1A and 1B isoforms are very similar, however, HAI-1B has 
an extra 16 amino acid insert between KD1 and LDLR domain of unknown significance 
(Kirchhofer et al., 2003). The inhibitory activity of the HAI-1 isoforms is mediated by 
Kunitz domains KD1 and KD2 (Denda et al., 2002; Kirchhofer et al., 2003; Fan et al., 
2005; Kirchhofer et al., 2005; Kojima et al., 2008). These domains have an Arg and a 
Lys P1 residue, respectively, in a substrate-like binding loop on the surface of the 
domain (Denda et al., 2002; Kirchhofer et al., 2003) (Figure 3.2). As KLK14 has a 
preference for Arg P1 residues, KLK14 is a possible target for HAI-1 inhibition.  
 
 
Figure 3.2 P1 residues of HAI-1A and HAI-1B. 
The aim of this chapter was to generate recombinant human KLK14 for use in in vitro 
assays in this and subsequent chapters. A number of expression systems are used for 
recombinant protein production including bacterial, yeast, insect and mammalian, each 
with advantages and disadvantages (Brondyk, 2009). The Sf9 insect cell expression 
system was chosen for its cost effective high capacity for secreted protein production as 
well as the ability to provide post-translational modifications including N-glycosylation 
(Altmann et al., 1999; Brondyk, 2009). This chapter describes the characterization of N-
glycosylation status and enzymatic activity of the generated KLK14. It also describes the 
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examination of HGF as a potential KLK14 substrate and HAI-1 isoforms HAI-1A and 
1B as inhibitors. Examination of recombinant KLK4 and hepsin activity were included 
in this study for comparison. Furthermore, in this chapter, the KLK14 protein 
sequence, including post-translational modification predictions, is reviewed. To further 
explore KLK14, a KLK14 structure homology model was also developed in this 
chapter.  
 
3.2 Results 
3.2.1 Characterization and review of the KLK14 amino acid sequence 
The KLK14 gene includes DNA sequence that encodes a protein of 267 amino acids. 
The complete KLK14 translated sequence is shown in Figure 3.3A and it is annotated 
with some pertinent features. KLK14 is comprised of an N-terminal signal peptide 
followed by a short, 6 residue, pro- sequence and then the catalytic domain spanning 
227 residues (Hooper et al., 2001a; Yousef et al., 2001). KLK14 is directed to the 
secretory pathway by the signal peptide whereupon it is secreted into the extracellular 
space as a zymogen. To activate KLK14, the pro- region is removed by limited 
proteolysis between the Lys40 and Ile41 (Hooper et al., 2001a; Yousef et al., 2001).  
The DNA sequence has three potential ATG translation start codons (Hooper et al., 
2001a) that translate as residues Met1, Met17 and Met31 (see schema in Figure 3.3B). It 
has been considered that KLK14 translation begins from the second start codon 
(Met17) to yield a 251 amino acid product (Hooper et al., 2001a; Yousef et al., 2001). In 
this model, KLK14 has a signal peptide sequence of 18 amino acids which falls 
comfortably within the average range for eukaryotic signal peptides of 23 +/- 6 amino 
acids (Hiss and Schneider, 2009). However, longer (and shorter) signal peptides are 
possible (Hiss and Schneider, 2009). So, to analyse which of the three start codons yields 
a likely signal peptide, the signal peptide prediction software SignalP 4.0 Server 
(Petersen et al., 2011) and Phobius (Kall et al., 2004) were used to evaluate the KLK14 
amino acid sequence starting at each of the three Met residues. SignalP 4.0 and Phobius 
predicted that the protein encoded by translation from the Met31 codon lacks a signal 
peptide and would be located intracellularly, however, to date there have been no 
reports of KLK14 localized intracellularly. In contrast, both analysis programs predicted 
that peptides beginning at either Met1 or Met17, and terminating at serine (Ser) 34, were  
102 
 
Figure 3.3 Features of the KLK14 protein 
 
signal peptides targeting the zymogen for secretion. Met1 and Met17 yield signal 
peptides of 34 and 18 residues, respectively. Indeed, several groups have used the 
truncated coding sequence of KLK14, beginning at the second start codon (Met17), to 
produce secreted recombinant KLK14 in mammalian and insect cell cultures (Brattsand 
et al., 2005; Borgono et al., 2007c; Rajapakse and Takahashi, 2007). However, as 
sequences beginning with both Met1 and Met17 produce recognized signal peptides, in 
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this project, the entire coding sequence beginning at the first ATG start codon (Met1) 
was used for all sub-cloning and subsequent protein expression of KLK14. 
Hooper and colleagues (2001a) and Yousef and colleagues (2001) performed sequence 
alignments and comparisons of KLK14 with the other 14 members of the KLK family 
to show highly conserved regions within KLK14 that are potentially linked to 
functionality. The conserved serine protease catalytic triad residues are histidine (His) 83 
(KLK14 numbering from the first Met residue), aspartate (Asp) 127 and serine (Ser) 220 
(Figures 3.1).  
Using nomenclature established by Schechter and Berger (1967), the active site of an 
enzyme is described as semi-discrete subsites (residues), designated S3-S2-S1-S1’-S2’-S3’, 
into which the scissile bond of the substrate, P1-P1’, is inserted. There is an Asp in 
position 214 in the S1 binding pocket of KLK14 (Figure 3.3A), six residues N-terminal 
to catalytic Ser220, which generally indicates a preference for arginine (Arg) or Lys 
residues in the substrate P1 position (Perona and Craik, 1997). This gives KLK14 an 
apparent trypsin-like as opposed to chymotrypsin-like specificity. Using recombinant 
KLK14, P1 specificity of KLK14 has been determined to be a trypsin-like specificity 
with preference for Arg over Lys over tyrosine (Tyr) (Brattsand et al., 2005; Felber et al., 
2005; Oikonomopoulou et al., 2006a; Borgono et al., 2007a; Borgono et al., 2007c; 
Rajapakse and Takahashi, 2007; Stefansson et al., 2008; de Veer et al., 2011). One 
synthetic tri-peptide substrate for which KLK14 showed high catalytic efficiency 
consists of the sequence glutamine-alanine-arginine (Gln-Ala-Arg) (P3-P2-P1) with a 
fluorogenic leaving group, AMC (7-amino-4-methylcourmarin) (QAR-AMC) (Borgono 
et al., 2007c; Rajapakse and Takahashi, 2007). This substrate was used exclusively in this 
project to test the catalytic efficiency of the recombinant KLK14 produced in insect 
cells. 
There are 6 predicted disulphide bonds between cysteine (Cys) residues Cys47-Cys180, 
Cys68-Cys84, Cys152-Cys254, Cys159-Cys226, Cys191-Cys205 and Cys216-Cys241 
(Figure 3.3B) (Hooper et al., 2001a). In KLKs 4-7 the 6 disulphide bonds between these 
conserved cysteine residues have been confirmed in crystal structure analysis (Gomis-
Ruth et al., 2002; Debela et al., 2006a; Debela et al., 2007a; Debela et al., 2007b). 
Interestingly, there is only one consensus N-glycosylation motif in KLK14. Residues 
asparagine (Asn) 184-Ile-Ser (Figure 3.3A) comply with the N-glycosylation motif, 
asparagine-any amino acid-threonine/serine (Asn-Xaa-Thr/Ser) (Marshall, 1967; 
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Neuberger and Marshall, 1968). However, analysis of the KLK14 sequence with 
NetNGlyc-1.0 Server (Gupta et al., 2004) predicts no N-glycosylation on KLK14 on 
Asn184. This analysis software uses sequence context to predict N-glycosylation of Asn-
Xaa-Thr/Ser motifs. The N-glycosylation status of recombinant KLK14 produced in 
Sf9 insect cells and in transiently transfected Cos-7 (monkey kidney) cells was explored 
further in Section 3.2.3. 
 
3.2.2 Generation and purification of recombinant KLK14 
Recombinant KLK14 was required for enzymatic characterization of KLK14 and for in 
vitro assays in this chapter and subsequent chapters. For this purpose, the pIB/V5-His 
expression construct encoding full-length KLK14 with an in-frame carboxyl- (C-) 
terminus V5-HisX6 tag, pIB-KLK14-V5-His, was generated and then stably transfected 
into Sf9 insect cells.  In this system, the endogenous KLK14 signal peptide directs the 
KLK14 zymogen to the secretory pathway. Preliminary experiments determined that 
highest yields of pro-KLK14-V5-His in the conditioned medium were obtained from 
Sf9 cells grown in suspension compared with cells grown adherently (data not shown). 
Consequently, the stably transfected insect cell lines were cultured shaking in suspension 
culture flasks and the conditioned medium harvested periodically for purification of 
pro-KLK14-V5-His. 
Purification of pro-KLK14-V5-His was performed using Ni-NTA Superflow resin 
exploiting the affinity of the HisX6 tag for the immobilized nickel ions on the resin. 
Elution from the resin was achieved using competition affinity of imidazole for the 
nickel ions. The acidity of the Sf-900 II media (~pH 6) and the presence of electron 
donating groups in the media can interfere with the affinity binding of the His×6 tag to 
the Ni-NTA resin (QIAGEN, 2003).  In addition, high quantities of amino acids such as 
glycine, glutamine and histidine can compete for binding sites on the Ni-NTA resin 
(QIAGEN, 2003). Consequently, the Sf9-conditioned medium was prepared for pro-
KLK14-V5-His purification by dialysis to adjust the pH and also to remove low 
molecular weight binding competitors. 
To determine the purity of the eluted fractions, aliquots of conditioned media as well as 
the flow through from the Ni-NTA resin were run on SDS-PAGE gels with aliquots of 
the wash steps and elution fractions. Known quantities of BSA were also run on each 
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gel to allow for approximations of the quantity of pro-KLK14-V5-His in each elution. 
The images in Figure 3.4 are representative Coomassie stained gels from one batch of 
purified pro-KLK14-V5-His. The purity of pro-KLK14-V5-His was estimated to be 
~85-95%.  The expected molecular weight of endogenous pro-KLK14 is ~25.6 kDa. 
When produced from the pIB/V5-His vector, additional amino acids encoded by the 
residual nucleotides from the cloning site of the vector, as well as the V5-His tag, add to 
the molecular weight and ~27-8 kDa would be expected. However, using a recombinant 
protein molecular weight marker, Precision Plus Protein Dual Color Standard (Bio-Rad), 
for comparison, the weight of pro-KLK14-V5-His was ~29 kDa. 
 
Figure 3.4 Generation and purification of recombinant KLK14 from Sf9 cell  conditioned medium 
3.2.3 N-glycosylation status of KLK14 
It has been reported previously that recombinant KLK14 generated in yeast, Pichia 
pastoris, and mammalian cells, HEK293, is not N-glycosylated (Borgono et al., 2003; 
Borgono et al., 2007c). Furthermore, as noted in Section 3.2.1, KLK14 has a consensus 
N-glycosylation sequon, Asn184-Ile-Ser, that is predicted by the NetNGlyc-1.0 Server to 
not be N-glycosylated on the Asn. To determine if recombinant pro-KLK14-V5-His 
generated in stably transfected Sf9 insect cells holds with these predictions, purified pro-
KLK14-V5-His was treated with the amidase PNGase F which removes N-linked  
glycans. KLK14 generated in transiently transfected Cos-7 cells was also examined. 
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KLK4 was chosen as a positive control as it has previously been shown to be 
glycosylated when produced in Sf9 stable and transiently transfected HeLa (Ramsay, 
2008) and PC-3 cells (Dong et al., 2005). Moreover, the predictions made by the 
NetNGlyc-1.0 Server support the presence of an N-glycosylation on the Asn of the 
Asn169-Val-Ser sequon in KLK4 (KLK4 numbering).  
As shown in Figure 3.5, PNGase F treatment resulted in a decrease in molecular weight 
of ~2 kDa for pro-KLK14-V5-His from Sf9 cells. Consistent with results obtained 
previously (Ramsay, 2008), PNGase F treatment of pro-KLK4-V5-His from Sf9 cells 
also resulted in a ~2 kDa molecular weight decrease in the upper band of the pro-
KLK4-V5-His doublet. In contrast, PNGase F treatment had no effect on KLK14-Myc 
or KLK4-V5-His transiently expressed by monkey kidney Cos-7 cells. 
 
Figure 3.5 Recombinant KLK14 is N-glycosylated when generated in Sf9 cells 
As the result for pro-KLK14-V5-His was inconsistent with the NetNGlyc-1.0 Server 
predictions and with recombinant KLK14 produced from yeast Pichia pastoris and 
HEK293 cells (Borgono et al., 2003; Borgono et al., 2007c), two approaches were taken 
to analyse the position of the N-glycosylation consensus sequon, Asn184-Ile-Ser, 
relative to the protein structure. First, the NetSurfP-1.0 (Petersen et al., 2009) software, 
which predicts solvent accessibility and secondary structure, was applied to the KLK14 
sequence. This analysis indicated that Asn184 has probable exposure on the surface of 
the protein (data not shown) with the remaining residues of the sequon as well as the 
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residue immediately prior, Ile183, predicted to be buried beneath the surface of the 
protein structure.  
The second approach was to develop and analyse a homology model of KLK14 using 
protein homology modelling software SWISS-MODEL and DeepView-4.1 Swiss PDB 
Viewer (Guex and Peitsch, 1997; Schwede et al., 2003; Arnold et al., 2006). A template 
for the KLK14 homology model was selected from the KLK family members as they 
have a high degree of sequence similarity. While KLK14 has high overall homology to 
KLK6, KLK8 and KLK13 (45, 44 and 43% respectively), across active sites there is 
greater homology (50%) between KLK14 and KLK5 (Goettig et al., 2010; Swedberg et 
al., 2010; de Veer et al., 2011). Based on this, a homology model of KLK14 was 
generated using the crystal structure of KLK5 (PBD ID 2PSX) (Debela et al., 2007a) as 
a template.  
The generated model predicts that the potential N-glycosylation site, Asn184(-Ile-Ser), is 
located on the opposite side to the active site cleft, His83, Asp127 and Ser220 (Figure 
3.6A and B). Furthermore, the Asn184 residue is exposed on the surface, consistent 
with the NetSurfP-1.0 prediction. Alignment of the KLK14 and KLK5 sequence 
(Figure 3.6C) shows that the confirmed KLK5 N-glycosylation sequon (Debela et al., 
2007a) is located at Asn182-Ile-Ser (KLK14 numbering). This sequon also conserved 
across KLK4, KLK9, KLK11, KLK12, and KLK15 (Lundwall and Brattsand, 2008), 
and is predicted to be the N-glycosylation site of KLK4 (Ramsay, 2008). Interestingly, in 
KLK14 this position is taken by an N-glycosylation acceptor residue, Asn182. However, 
the sequon at this position (Asn182-Ile-Asn) does not conform with consensus N-
glycosylation sequons of Asn-Xaa-Ser/Thr  (Marshall, 1967; Neuberger and Marshall, 
1968). 
 
3.2.4 Activation of recombinant KLK14 with thermolysin 
It has previously been shown that the secreted zymogen pro-KLK14 does not self-
activate (Brattsand et al., 2005; Borgono et al., 2007c; Yoon et al., 2007). Therefore, 
once purified from the Sf9-conditioned medium the pro-KLK14-V5-His requires 
further processing by proteolytic removal of the pro-region to obtain active or mature 
KLK14. 
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Figure 3.6 KLK14 homology model 
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Other studies have used the protease domain of transmembrane serine protease 
enteropeptidase (Brattsand et al., 2005) or serine protease lysyl endopeptidase 
conjugated to Cyanogen Bromide-activated sepharose (CNBr-seph) (Rajapakse and 
Takahashi, 2007) to activate pro-KLK14. However, after initial experiments (data not 
shown), metalloproteinase thermolysin was chosen for pro-KLK14-V5-His activation in 
this laboratory (de Veer et al., 2011; Sanchez et al., 2012) over enteropeptidase and lysyl 
endopeptidase. This was because enteropeptidase and lysyl endopeptidase are serine 
proteases, like KLK14, therefore, overlapping substrate specificity could confound 
downstream assay results. Also, inhibition of residual enteropeptidase or lysyl 
endopeptidase activity using serine protease inhibitors would inhibit KLK14 as well. To 
overcome this, conjugating the enteropeptidase or lysyl endopeptidase to CNBr-seph to 
minimize residual activity was considered. However, conjugating lysyl endopeptidase to 
CNBr-seph proved to be an expensive and lengthy process. This was because a large 
excess of the protease was required to achieve optimal coverage of the CNBr-seph. In 
addition, the conjugation procedure had multiple extended incubations, and the storage 
temperature of the CNBr-seph was 2-8°C. As these conditions are not optimal for the 
viability of the lysyl endopeptidase it would need to be prepared anew each time KLK14 
required activation. Thermolysin on the other hand is relatively inexpensive; it could be 
used in small quantities that required little forward preparation, it retained proteolytic 
activity for long periods of time when stored appropriately; and it could be inhibited by 
the relatively inexpensive metalloproteinase inhibitors phosphoramidon (Kitagishi and 
Hiromi, 1984) or EDTA (Morihara and Tsuzuki, 1966).  
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It was necessary to determine the optimal ratio of pro-KLK14-V5-His to thermolysin to 
achieve the highest conversion to active KLK14. This was performed by quantifying at 
the molar level the conversion of pro- to active KLK14. To begin, various ratios of pro-
KLK14-V5-His to thermolysin were incubated for between 1 and 2 hours. Longer 
incubations were not used because active KLK14 auto-degrades in extended incubations 
(Borgono et al., 2007c). The concentration of active KLK14 was then determined by 
active-site titration using the suicide pseudo-substrate MUGB (Jameson et al., 1973). 
The MUGB ester is non-fluorogenic; however when an active trypsin-like serine 
protease molecule such as KLK14 hydrolyses MUGB, there is a rapid acylation step and 
release of 4-MU, which fluoresces at 460 nm when excited at 355 nm (Figure 3.7A). The 
protease effectively becomes trapped in the acylation step as an acyl-enzyme with p- 
 
Figure 3.7 Activation of recombinant KLK14 with thermolysin  
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guanidinobenzoyl as deacylation is extremely slow (Jameson et al., 1973; Urano et al., 
1988; Payne et al., 1996; Toth et al., 2006). Therefore the release of 4-MU is in a 1:1 
stoichiometric ratio to active protease and the concentration of active protease can be 
determined using a standard curve prepared using known concentrations of 4-MU.  
In Figure 3.7B, it can be seen that highest levels of conversion (17%) to active KLK14 
were achieved using a 10:1 µg/mL ratio (13.8:1 molar ratio) of pro-KLK14-V5-His to 
thermolysin, with a 1.5 hour incubation. This was the condition used for future 
activation of pro-KLK14-V5-His.  
Conversion of pro-KLK14-V5-His to active KLK14 was then examined by Coomassie 
Blue R-250 stained SDS-PAGE gel and Western blot analyses probed with anti-V5 and 
anti-KLK14 antibodies (Figure 3.8A). Conversion of pro-KLK14-V5-His (29 kDa) to 
mature KLK14 is apparent as a 4 kDa reduction in molecular weight. Mature KLK14 is 
represented by a ~25 kDa band that can be seen on the Coomassie stained gel and the 
anti-KLK14 probed Western blot in the lanes representing thermolysin treatment (+). 
The low level of conversion of pro-KLK14-V5-His to active KLK14 seen previously in 
the MUGB assay (Figure 3.7) is reflected in the Coomassie stained gel. This low level of 
conversion to mature/active KLK14 may be due to fragmentation and inactivation by 
cleavage at other points by thermolysin. The potential for thermolysin cleavage at sites 
other than the pro-site is exemplified in the anti-V5 Western blot analysis. In this it can 
be seen that treatment of pro-KLK14-V5-His with thermolysin also appears to remove 
part or all the V5-His tag as no forms of KLK14 were detected with the anti-V5 
antibody. It is also interesting to note that KLK14 untreated by thermolysin is detected 
as a doublet on the Coomassie and also the anti-KLK14 Western blot analysis. The 
lower band of the KLK14 doublet is not visible on the anti-V5 probed Western blot 
and is likely pro-KLK14 which has lost the V5-His tag during the generation or 
purification of the enzyme. Figure 3.8B illustrates the various forms of KLK14. 
 
3.2.5 N-terminal sequencing of zymogen KLK14 and thermolysin 
activated KLK14 
N-terminal sequencing was used to confirm that the activation with thermolysin 
produced the expected mature KLK14 N-terminal. For sequencing, 2 picomoles or 
more of protein per sample was required by University of Queensland (UQ), School of 
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Chemistry and Molecular Biosciences (SCMB) sequencing facility and also the 
Australian Proteome Analysis Facility (APAF). Figure 3.9 shows an image of a 
Coomassie stained  PVDF membrane blot of 10 µg (~330 picomoles) of thermolysin-
activated pro-KLK14-V5-His and 1.5 µg of pro-KLK14-V5-His (~5 picomoles) 
resolved by SDS-PAGE. Bands of approximately 29 kDa for the pro- and 25 kDa for 
the active KLK14 were excised and sent for N-terminal sequencing at the UQ SCMB 
and APAF. 
 
Figure 3.8 Coomassie and Western blot analyses of thermolysin-activated recombinant KLK14 
An initial report from the UQ SCMB sequencing facility suggested that a clear 
sequencing result could not be obtained due to either insufficient sample material or 
that the sequences were N-terminally blocked. However, due to the clear Coomassie 
staining of the bands on the PVDF membrane, the report further concluded that 
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insufficient protein was unlikely to be the cause of the sequencing failure.  Before 
making further sequencing sample submissions, the techniques used to prepare the 
samples were refined based on the premise that the protein samples were N-terminally 
blocked. Using recommendations from the UQ SCMB sequencing facility manager 
Chris Wood and also publications (Hunkapiller et al., 1983; Walsh et al., 1988; Smith, 
1997) on the subject of the N-terminal sequencing technique, refinements included 
adding thioglycolic acid to the buffer of the inner chamber of the SDS-PAGE running 
rig; pre-running the gel without sample for 15 minutes; preparing fresh Coomassie Blue 
R-250 solution for each staining; and preparing the Coomassie solution without acetic 
acid. Unfortunately, subsequent sequencing submissions to UQ SCMB and APAF 
sequencing facilities were unable to produce clear sequencing results for either the pro-
KLK14-V5-His or thermolysin-activated KLK14. There is potential for trialling 
alternative sequencing methods in future work.  
 
Figure 3.9 Samples used for N-terminal sequencing of zymogen KLK14 and activated KLK14 
 
 
3.2.6 Kinetic measurements of thermolysin activated KLK14 
The kinetic activity of thermolysin-activated KLK14 was assessed using the synthetic 
tripeptide substrate QAR-AMC as KLK14 has a high affinity for this substrate 
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(Borgono et al., 2007c; Rajapakse and Takahashi, 2007). The assay relies on hydrolysis 
of the bond between the P1 residue and the AMC leaving group of the synthetic 
substrate, QAR-AMC (Figure 3.10). From this kinetic assay, a measure of the catalytic 
efficiency, or how well KLK14 hydrolyses its substrate, was determined. For 
comparison activated KLK4 and bovine trypsin were also assayed alongside KLK14 
under the same conditions.  
 
Figure 3.10 Hydrolysis of tripeptide substrate QAR-AMC by KLK14 
The rate of hydrolysis was obtained by measuring the increase of AMC over a defined 
time period. As a single-substrate reaction, by analysing an increasing range of substrate 
concentrations applied to a fixed protease concentration, the initial rates of hydrolysis 
were used in a Michaelis-Menten kinetic model of protease–substrate reaction (Mathews 
et al., 2000). The two main parameters derived from this model were KM, which is the 
substrate concentration ([S]) at which reaction velocity is half maximal; and Vmax, the 
maximal velocity (Mathews et al., 2000). The KM is indicative of the substrate 
concentration required for maximum reaction velocity; a small KM indicates that a small 
amount of substrate is required to saturate the protease (Mathews et al., 2000). Using 
the protease concentration and Vmax, the substrate per molecule protease turnover rate, 
kcat, was derived and subsequently, the ratio kcat/ KM, as a measure of catalytic efficiency 
(Mathews et al., 2000). Direct comparison of catalytic efficiency between KLK14, 
KLK4 and trypsin cannot be made as the ratio kcat/ KM depends on the ratio [S]/ KM 
(Eisenthal et al., 2007). This means that unless the KM of the enzymes is equal the 
catalytic efficiency cannot be compared (Eisenthal et al., 2007). With this in mind, it can 
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be seen from the results presented in Table 3.1 that KLK14 has a high KM of 258 µM 
suggesting a lower affinity for the substrate than either KLK4 or trypsin. The substrate 
turnover rate, kcat, for KLK14 is higher than that of KLK4 which ultimately yields a 
higher catalytic efficiency, a kcat/ KM of 4.66 × 10
4 M-1s-1, for KLK14 under the 
conditions tested. Trypsin had the lowest KM and highest kcat and as a result, the highest 
catalytic efficiency for the substrate QAR-AMC. 
Table 3.1 Kinetic parameters for protease hydrolysis of the tri-peptide substrate 
QAR-AMC. Substrate at concentrations ranging 0.001 to 1 mM were incubated with 
KLK14, KLK4 and trypsin at 37°C. Initial rates of hydrolysis of QAR-AMC were 
determined by measuring free AMC at 1 min intervals for 20 min. A standard curve 
constructed using known concentrations of AMC was used to calculate the rate of 
release of free AMC. The Michaelis-Menten enzyme kinetics model was used to 
calculate the kcat/Km constants using non-linear regression and GraphPad Prism 5 
software. Data are averages of triplicate experiments ± SEM. 
Table 3.1 Kinetic parameters for protease hydrolysis of the tri-peptide substrate QAR-AMC 
Protease Concentration 
(nM) 
K
M
  
(µM) 
V
max
  
(µM s
-1
) 
k
cat
 
(s
-1
) 
k
cat
/K
M
  
(M
-1
s
-1
) 
KLK14 12 258± 11 0.145 12.05 4.66 × 104 
KLK4 12 124± 4 0.017 1.4 1.12 × 104 
Trypsin 0.4 38± 4 0.045 114.75 3.04 × 106 
 
3.2.7 Concentration-dependent activation of HGF by KLK14 
To examine KLK14 activation of pro-HGF, increasing concentrations of active 
recombinant KLK14 were incubated with recombinant pro-HGF. KLK4 and hepsin 
were assayed concurrently as KLK4 degrades rather than activates HGF (Mukai et al., 
2008), and hepsin is an efficient HGF activator (Herter et al., 2005; Kirchhofer et al., 
2005; Owen et al., 2010). Reaction mixtures were resolved by SDS-PAGE under 
reducing conditions then transferred onto nitrocellulose membrane and stained using 
Coomassie Blue R-250. As shown in Figure 3.11A, KLK14 converts pro-HGF to the 
two chain form in a concentration-dependent manner. Pro-HGF (1 μM) is completely 
converted to the 2 chain form at between 1 and 5 nM KLK14 (molar ratios of 1000:1 
and 200:1). However, at concentrations of KLK14 between 10 to 100 nM (molar ratios 
100:1 to 10:1), the HGF α-chain is completely degraded while the β-chain remains 
largely intact. In contrast, KLK4 demonstrates little activity toward pro-HGF (Figure  
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Figure 3.11 Activation of recombinant pro-HGF 
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3.11B) until between 10 to 100 nM KLK4, whereupon it proceeds to degrade the HGF 
α-chain. As expected, hepsin demonstrates efficient concentration-dependent 
conversion of pro-HGF to the two chain form (Figure 3.11C). At concentrations of 
hepsin as low as 0.1 nM (molar ratio of 10,000:1), there is near complete conversion of 
pro-HGF. Furthermore, at high concentrations of hepsin there is very little degradation 
of the HGF α-chain. These data show that KLK14 activates HGF in a defined 
HGF:KLK14 ‘window’ after which HGF degradation becomes evident. 
 
3.2.8 Examination of KLK14 inhibition by HAI-1A and 1B 
To examine KLK14 inhibition by HAI-1A and HAI-1B, activated recombinant KLK14 
was pre-incubated with recombinant soluble HAI-1A or 1B (HAI-1 isoforms minus the 
transmembrane region). Synthetic substrate QAR-AMC was added and measurement 
taken of the hydrolysis of the substrate relative to the hydrolysis by uninhibited 
protease. 
As shown in Figure 3.12, at equimolar concentrations of HAI-1A or 1B and KLK14 (5 
nM), there is no inhibition of KLK14. As the ratio shifts to excess HAI-1 (25, 50 nM), 
KLK14 is mildly inhibited. At 50 nM inhibitor, KLK14 activity is inhibited by 35% and 
26% for HAI-1A and 1B treatment, respectively. Due to the small amount of HAI-1 
isoforms available to use in these experiments, a full inhibition curve to determine the 
inhibitor concentration at which KLK14 was inbibited by 50% (IC50) was not 
performed. 
 
3.2.9 KLK14 interaction with HAI-1A and HAI-1B  
To further explore whether KLK14 proteolysis is impacted by HAI-1, the ability of the 
protease to form stable complexes with the inhibitor was examined. For comparison 
KLK14 and hepsin interactions with HAI-1 were also examined as HAI-1 isoforms 
have previously been reported as in vitro inhibitors of hepsin (Herter et al., 2005; 
Kirchhofer et al., 2005); however, it was not shown in these publications whether hepsin 
and HAI-1 form stable complexes. Recombinant soluble hepsin (hepsin minus the 
cytoplasmic domain and transmembrane region) was used in the following assays and 
appears at 30 kDa on Western blot analyses under reducing conditions.  
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Figure 3.12 HAI-1A and HAI-1B inhibition of KLK14 hydrolysis of tri-peptide substrate QAR-AMC 
 
First, active KLK14 was incubated with decreasing amounts of HAI-1A and 1B starting 
with HAI-1 isoforms at 10 times the molar concentration of KLK14. The samples were 
subjected to reducing SDS-PAGE then transferred onto PVDF and stained with 
Coomassie Blue R-250. HAI-1A and 1B run at approximately 55 kDa as can be seen in 
Figure 3.13. KLK14 was detected at ~25 kDa as expected for mature KLK14. An SDS 
and reducing agent-stable complex between HAI-1 isoforms and KLK14 would be 
expected at around 80 kDa with concomitant reduced signal intensity for HAI-1 
isoforms detected at 55 kDa and KLK14 at 25 kDa. Instead, the quantity of KLK14 
appears unchanged at 25 kDa and an extra band does not appear around 80 kDa.  In 
addition, HAI-1A and 1B appear to be degraded in the presence of KLK14 with the 
appearance of several lower MW bands, most notably around 40, 35, 22 and 15 kDa, 
clearly seen in lanes 3 and 4 of both membranes. In lanes 5 and 6 HAI-1 at 55 kDa is 
almost undetectable; however, several lower MW degradation bands are still visible.  
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Figure 3.13 KLK14 degrades HAI-1A and 1B 
 
Next, to compare the interactions between KLK14 and hepsin with HAI-1A and HAI-
1B, fixed concentrations of active KLK14 and hepsin were incubated with decreasing 
concentrations of HAI-1A and HAI-1B (Figure 3.14). The starting concentration of 
HAI-1 (1 μM) was less than in Figure 3.13 (10 μM). This was done to show that this 
quantity (~2.3 µg) of HAI-1 is still visible on the membrane when unchallenged by 
KLK14. Consistent with data from the results shown in Figure 3.13, KLK14 degrades 
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Figure 3.14 KLK14 degrades HAI-1A and HAI-1B while hepsin forms complexes with HAI-1A and degrades HAI-1B 
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both HAI-1 isoforms thoroughly (Figure 3.14A). In contrast, hepsin, when incubated 
with an equimolar concentration of HAI-1A shows appearance of a band in the vicinity 
of 85 kDa with the concomitant reduced signal intensity for 30 kDa hepsin (Figure 
3.14B). As the concentration of HAI-1A decreases, so does the loss of hepsin from 
the30 kDa band. There is also a small amount of possible degradation of HAI-1A by 
hepsin and possible complex formation between truncated  HAI-1A and hepsin with 
bands appearing at around 50, 40, 20, 15 kDa. Hepsin does not appear to form a 
complex with HAI-1B as there is no appearance of a band around 85 kDa and there is 
no loss of hepsin from 30 kDa. HAI-1B, however, is significantly degraded with major 
bands appearing around 40, 20, 18 and 15 kDa. 
In Figure 3.15, using a fixed concentration of HAI-1A (1 µM) and decreasing 
concentrations of KLK14 and hepsin, the dose response of HAI-1A to the proteases is  
Figure 3.15 KLK14 degrades HAI-1A in a dose dependent manner while hepsin forms complexes with HAI-1A 
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illustrated. The 55 kDa band of HAI-1A appears completely degraded at 1 μM and 0.5 
µM KLK14 (lanes 2, 3) with decreasing degradation as KLK14 concentration decreases 
(lanes 4-6).  Equimolar concentration of hepsin (lane 9) has a similar degradative effect 
on HAI-1A. However, there is also stable complex formation as there is a depletion of 
30 kDa hepsin when compared to hepsin alone (lane 8). While there are some 
degradation bands for HAI-1B at 0.5 µM hepsin (lane 10), there is clear appearance of 
the 85 kDa band and decrease in the 55 kDa HAI-1A band. As the concentration of 
hepsin decreases (lanes 11 and 12) so does the 85 kDa band. 
These results show that while HAI-1A and 1B mildly inhibit proteolytic activity of 
KLK14, they do not form the stable complexes with KLK14. KLK14 instead 
comprehensively degrades the HAI-1 isoforms. Moreover, these results are the first time 
complexes of hepsin and HAI-1A have been demonstrated.  
 
3.3 Discussion 
In this chapter the KLK14 amino acid sequence was reviewed and recombinant pro-
KLK14-V5-His was generated in insect Sf9 cells and then characterized. KLK14 
zymogen activation was achieved using thermolysin and this was followed by 
assessment of KLK14 proteolytic activity using the synthetic substrate QAR-AMC. 
Comparisons of pro-HGF activation by KLK14, KLK4 and hepsin were made. KLK14 
inhibition by HAI-1 isoforms was also examined. As was complex formation between 
KLK14 and HAI-1, and hepsin and HAI-1. It was found that: 
 KLK14 zymogen generated in Sf9 cells was a 29 kDa N-glycosylated protein.  
And as summarized in Figure 3.16: 
 KLK14 and hepsin activate pro-HGF,  while KLK4 primarily degrades it 
 KLK14 degrades HAI-1A and HAI-1B, while hepsin and HAI-1A form stable 
complexes. 
This is the first time KLK14 activation of pro-HGF has been reported. Moreover, this 
is the first time KLK14 degradation of HAI-1, and formation of hepsin-HAI-1 
complexes, have been reported. The data suggests KLK14 may have a role in regulation 
of HGF/HGFR signalling axis through activation of pro-HGF and degradation of key 
protease inhibitors, HAI-1A and HAI-1B. 
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Figure 3.16 HGF activation and HAI-1 degradation by KLK14 
 
3.3.1 KLK14 activation and sequencing 
The recombinant KLK14 zymogen generated in Sf9 cells was activated using the 
metalloproteinase thermolysin. Thermolysin was used in this manner because it has a 
preference for hydrolysis before accessible hydrophobic residues (van den Burg and 
Eijsink, 2013), and when trypsin-like serine proteases, such as KLK14, and 
chymotrypsin-like serine proteases are activated by proteolytic removal of the pro- 
region, the nascent N-terminal residue is invariably a hydrophobic residue (Page and Di 
Cera, 2008). This substrate specificity of thermolysin has been exploited extensively for 
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in vitro activation of KLK family members KLK1 (Takada et al., 1985), KLK4 (Ramsay 
et al., 2008a) and KLK7 (Ramani and Haun, 2008), and other serine proteases.  
To confirm that activation by thermolysin removed the pro-region of KLK14 at the 
Lys40↓Ile41 activation site, N-terminal sequencing by Edman degradation was used. 
This method uses labelling of the free amide group of the N-terminal residue followed 
by cleavage of the residue which is isolated and then identified by comparison with 
amino acid standards using liquid chromatography. This degradation cycle is repeated 5-
10, and up to 30 times to identify sequential N-terminal residues. However, Edman 
degradation cannot be used on proteins whose N-terminal residue has been blocked 
through post-translational modification or during sample preparation. 
As neither APAF nor UQ SCMB sequencing facility was able to obtain clear sequence it 
was concluded that zymogen and activated KLK14 forms were N-terminally blocked. 
While initially it was thought they might be blocked by acetylation of the N-terminal 
residue, subsequent literature review showed that this modification is an in vivo post-
translational modification limited to particular residues including methionine, serine, 
alanine, threonine, valine, glycine and cysteine (Krishna and Wold, 1993; Leone et al., 
2011). As the predicted N-terminal residue of zymogen KLK14 is glutamine (Figure 
3.1A) it is unlikely to be acetylated. Furthermore, KLK14 activated in vitro is separated 
from the cellular machinery required for acetylation, therefore the nascent N-terminal 
could not be acetylated in this manner.  
Similarly, most other N-terminal modifications that block Edman degradation are the 
result of in vivo processing events (Krishna and Wold, 1993; Leone et al., 2011) and 
therefore do not influence sequencing of KLK14 activated in vitro. In contrast, the N-
terminal of pro-KLK14, generated in in vivo processing and removal of the signal 
peptide, is predicted to be a glutamine. This residue may be modified by pyrroidone 
carboxylation, which is the cyclization of N-termini glutamine (Blomback, 1967) or 
glutamic acid (Twardzik and Peterkofsky, 1972; Jones, 1974; Beck et al., 2001; Chelius et 
al., 2006) residues to form pyroglutamic acid.  Modification by pyrroidone carboxylation 
has been speculated to protect these proteins from aminopeptidase degradation and can 
occur as a post-translational modification (Stott and Munro, 1972; Fischer and Spiess, 
1987) or spontaneously in response to storage or incubation conditions (Blomback, 
1967; Shih, 1985; Khandke et al., 1989). An N-terminal nitrogen attack on the side chain 
carbonyl carbon of glutamine forms 2-pyrrolidone-5-carboxylic acid or pyroglutamic 
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acid (Figure 3.17) and results in the loss of the free amide terminal required for Edman 
degradation (Abraham and Podell, 1981; Rehder et al., 2006). So while cyclization of 
glutamine is a possible explanation for the inability to sequence pro-KLK14 by Edman 
degradation, there is no comparable explanation for the failure to sequence activated 
KLK14. Furthermore, endogenous active KLK14 has been isolated from human skin, 
plantar stratum corneum, and sequenced by Edman degradation (Stefansson et al., 
2006). Certainly, there may be differences to post-translational modification between 
endogenous KLK14 and insect cell-generated recombinant KLK14, and this may 
explain the sequencing failure.  
Interestingly, Borgono and colleagues (2007c) used tandem mass spectrometry 
(MS/MS) to identify recombinant KLK14 generated in Pichia pastoris. This method is a 
viable approach to obtain N-terminal sequence data for the potentially blocked zymogen 
and activated forms of KLK14.  Briefly, sequencing proteins by MS/MS employs the 
vaporization then ionization of a sample followed by separation/selection of the ions 
based on their mass-to-charge ratio by applying electromagnetic fields. Ions are 
subjected to a second fragmentation and second mass-to-charge ratio separation, then 
detected and quantified based on ion type (Gross, 2011).  Significantly, MS/MS is not 
obstructed by N-terminal modifications. Certainly, scope exists for this to be pursued in 
the future. 
 
 
Figure 3.17 Formation of pryoglutamic acid from glutamine 
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3.3.2 Examination of the N-glycosylation status of zymogen KLK14 
The KLK14 amino acid sequence contains a consensus N-glycosylation sequon at 
Asn184-Ile-Ser, however, NetNGlyc-1.0 (Gupta et al., 2004) predicts that this site would 
not be N-glycosylated. Therefore it is interesting that the in vitro results in this study 
indicate that recombinant KLK14-V5-His zymogen produced in stably transfected 
insect Sf9 cells was N-glycosylated. In contrast, KLK14-Myc zymogen from transiently 
transfected Cos-7 cells was not. This finding in Cos-7 cells is consistent with that of 
Borgono and colleagues (2003) who determined that KLK14 was not N-glycosylated 
when generated in yeast Pichia pastoris. Additionally, in another study they speculated that 
based on the molecular weight observed by Western blot analysis KLK14 produced in 
HEK293 cells was also not glycosylated (Borgono et al., 2007c).  
The distinct pattern of N-glycosylation was also seen for KLK4 as recombinant KLK4-
V5-His zymogen was N-glycosylated when produced in stably transfected Sf9 cells and 
not when generated by transiently transfected Cos-7cells. KLK4 was chosen as a 
positive control for de-glycosylation as it has previously been shown to be N-
glycosylated when produced in stable Sf9 cells, as well as in transiently transfected HeLa 
(Ramsay, 2008) and PC-3 cells (Dong et al., 2005). Furthermore, in contrast to KLK14, 
NetNGlyc-1.0 predictions for KLK4 support the presence of N-glycosylation on 
Asn169(-Val-Ser). 
This raises two issues. First, KLK14 generated in Sf9 cells was N-glycosylated despite 
bioinformatics-based predictions. Second, there was cell-type-dependent differential N-
glycosylation for KLK14 and KLK4. Examining the first issue, it has been estimated 
that only around 60% of the consensus sequon Asn-Xaa-Thr/Ser are glycosylated 
(Apweiler et al., 1999; Ben-Dor et al., 2004; Petrescu et al., 2004). N-glycosylation is 
affected by factors including the availability of N-glycans in the endoplasmic reticulum, 
the enzyme kinetics of glycan attachment, and the sequon availability (as reviewed by 
Jones and colleagues (2005)), as well as the protein secondary structure and surface 
hydrophobicity (Petrescu et al., 2004). It is also affected by the identity of Xaa and 
residues immediately adjacent to the consensus sequon, in particular proline (Pro) 
residues as Xaa or Xaa+2 are not favoured (Gavel and von Heijne, 1990; Mellquist et 
al., 1998; Ben-Dor et al., 2004; Petrescu et al., 2004). Furthermore, sequons ending with 
Thr are more likely to be N-glycosylated that those ending with Ser (Kasturi et al., 1997; 
Ben-Dor et al., 2004; Petrescu et al., 2004). Therefore it is possible that KLK14 was 
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predicted to not be N-glycosylated by NetNGlyc-1.0 for reasons including Ser186 as the 
final residue in the sequon and Pro187 at Xaa+2 (Figure 3.1A).  
However, there are limitations to the predictive capability NetNGlyc-1.0. Briefly, as 
outlined by the authors, Gupta and colleagues (2004), based on validated glycosylation 
sites, the software predicts 86% of glycosylated sequons and 61% of nonglycosylated. 
Moreover, the default parameters for NetNGlyc-1.0 predictions do not include analysis 
of atypical N-glycosylation sites. However, as predicted by Bause and Legler (1981), 
atypical sequon Asn-Xaa-Cys is an N-glycan acceptor in proteases with examples in 
protein C (Foster and Davie, 1984; Miletich and Broze, 1990), recombinant tissue 
plasminogen activator (tPA) (Borisov et al., 2009) and also in the insect protease, 
Cowpea bruchid cathepsin B-like protein (Chi et al., 2010). Other atypical sequons 
include, Asn-Gly-Gly-Ser (Gavel and von Heijne, 1990) and Asn-Ser-Gly (Valliere-
Douglass et al., 2009) from murine and human antibodies, respectively.  
Expansion of the NetNGlyc-1.0 sequence analysis parameters to include all Asn 
residues in KLK14 results in four of seven residues predicted to be potential N-
glycosylation acceptors. In a family KLK sequence alignment (Clements et al., 2001) one 
of these residues, Asn182, is in a consensus sequon conserved across KLK4, KLK5, 
KLK9, KLK11, KLK12 and KLK15. It has also been confirmed as an N-glycosylation 
acceptor in KLK5 (Debela et al., 2007a) and a predicted acceptor in KLK4 (Ramsay, 
2008). In KLK14 however, it is the first residue of the nonconsensus sequon Asn182-
Ile-Asn. Interestingly, the second Asn of this sequon is in the previously discussed 
consensus sequon Asn184-Ile-Ser (Figure 3.1A). Furthermore, another, Asn252, is in 
the atypical sequon Asn-Xaa-Cys, this sequon is also conserved across KLK4-6 and 
KLK8 (Clements et al., 2001). Taken together, Asn184 in the consensus sequon, as well 
as one or more of the other Asn residues in atypical sequons, may act as N-glycosylation 
acceptors in KLK14. This could be examined further using site-directed mutagenesis to 
alter coding sequence for the individual Asn residues to identify the N-glycosylation 
residues. 
The second issue of cell-type differential N-glycosylation for KLK14 and KLK4 is 
interesting because as mentioned earlier, N-glycosylation has the potential to affect 
activity (Skropeta, 2009). Indeed, there are several reported examples of N-glycosylation 
affecting distinct properties of proteases. For instance, Oka and colleagues (2002) found 
that abolishing the N-glycosylation site of KLK8 by mutagenesis altered the catalytic 
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activity, reducing the KM and kcat. Ramsay (2008) also speculated that N-glycosylation 
lowered the catalytic efficiency (kcat/KM) of KLK4. Furthermore, while matriptase N-
glycosylation is required for autoactivation (Oberst et al., 2003b; Miyake et al., 2010), 
aberrant glycosylation by attachment of N-glycan structures associated with malignant 
or metastatic states results in prolonged stabilization of matriptase and has a pro-
metastatic effect (Ihara et al., 2002; Ihara et al., 2004; Ito et al., 2006). 
Differential N-glycosylation has also been reported for several proteases including tPA 
which has four typical N-glycosylation sites, two of which are generally occupied and a 
third occasionally occupied (Pohl et al., 1984). It has been found that there are cell type-
specific differences in the N-glycan moieties attached to the three sites of endogenous 
and recombinant tPA with differences in enzymatic activity between the different tPA 
glycoforms (Parekh et al., 1989a; Parekh et al., 1989b; Wittwer et al., 1989). For instance, 
occupancy of the third site hinders plasmin activation of tPA (Wittwer and Howard, 
1990). Furthermore, studies have shown variation in cell culture conditions such as 
increased manganese or iron, reduced culture temperature and decreased growth rate all 
increase occupancy of the third site (Andersen et al., 2000; Gawlitzek et al., 2009).  
Protein C is another protease that has exhibited differential N-glycosylation. It has three 
typical N-glycosylation sites, in addition to the atypical site mentioned earlier (Foster 
and Davie, 1984; Miletich and Broze, 1990).  Plasma-derived protein C  has between 
70% and 80% occupancy of the atypical site (Miletich and Broze, 1990; Gil et al., 2009), 
with lower levels of occupancy for recombinant protein C generated in HepG2 cells 
(Miletich and Broze, 1990). In addition, there is also variation in the predominant N-
glycan structures for each of the four N-glycosylation sites of recombinant protein C 
compared to plasma-derived protein C (Gil et al., 2009). Moreover, the four sites, either 
individually or collectively, affect secretion of protein C, glycosylation at the atypical site, 
catalytic efficiency, and activation by thrombin (Grinnell et al., 1991). 
As glycosylation depends on a range of conditions it is possible that KLK14 and KLK4 
zymogens may be glycosylated when expressed in the stable insect cell system but not in 
the transiently transfected mammalian Cos-7 cells. It has not been established whether 
KLK14 is glycosylated endogenously. However, as it is ubiquitously expressed in the 
human body, there is great potential for tissue-specific glycosylation which in turn may 
be a mode of modulating KLK14 activity. As shown in the KLK14 homology model in 
Figure 3.18, the N-glycosylation consensus site Asn184-Ile-Ser and the nonconsensus 
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sequons Asn182-Ile-Asn and Asn252-Leu-Cys are on the opposite side of the molecule 
to the active-site and substrate-binding pocket. N-glycosylation at one of these sites may 
alter the KLK14 active-site cleft configuration and change its catalytic efficiency. 
 
 
 
Figure 3.18 KLK14 homology model showing positions of potential N-glycosylation acceptor residues 
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3.3.3 KLK14 activity 
3.3.3.1 Catalytic efficiency of recombinant KLK14 
In this study the catalytic efficiency (kcat/KM) of KLK14 for hydrolysis of the tripeptide 
substrate QAR-AMC was 4.66 × 104 M-1s-1. In contrast, Borgono and colleagues (2007c) 
obtained a value 3-fold higher at 14.19 × 104 M-1s-1 (8516.94 mM-1min-1) for the same 
substrate and kinetic assay parameters using recombinant KLK14 generated in Pichia 
pastoris.  
The assay parameters used by Borgono and colleagues (2007c) were replicated in this 
project because of the sixteen tripeptide substrates analysed in kinetic assays, 
recombinant KLK14 had the greatest hydrolytic activity against QAR-AMC. Borgono 
and colleagues (2007c) also examined the activity of KLK14 in a Tris buffer compared 
to a phosphate buffer and found that pH 8.0 was optimal for KLK14 activity in these 
buffers. Moreover, KLK14 had 1.4-times greater activity in the phosphate buffer over 
the Tris buffer. Based on this, the tripeptide substrate QAR-AMC was used with a 
phosphate buffer at pH 8.0 to examine the hydrolytic activity of Sf9 cell-generated 
KLK14. 
As mentioned earlier, N-glycosylation status has been shown to modulate catalytic 
efficiency of several serine proteases. Indeed, for KLK4 the lower catalytic efficiency of 
Sf9 cell- (Ramsay, 2008) and Drosophila cell-generated KLK14 (Matsumura et al., 2005) 
compared to that of E. coli-generated KLK4 (Debela et al., 2006a) was attributed to the 
N-glycosylation of insect cell-generated KLK4 (Ramsay, 2008).  Similarly, as the kinetic 
parameters used by Borgono and colleagues (2007c) were replicated here in this study, 
the difference in the catalytic efficiency could be due to the N-glycosylation of Sf9 cell-
generated KLK14, as the Pichia pastoris-generated KLK14 used by Borgono and 
colleagues (2007c) was not N-glycosylated (Borgono et al., 2003). Certainly, for Sf9 cell-
generated KLK14, the impact of N-glycosylation on catalytic efficiency could be 
explored further by comparing wild-type KLK14 with KLK14 in which identified N-
glycosylation acceptor residues have been mutated. 
In another study examining KLK14 kinetic parameters, Brattsand and colleagues (2005) 
used recombinant KLK14 generated in the insect Drosophila Schneider 2 cells and 
tripeptide substrate PFR-pNA to obtained a kcat/KM of 1.2 × 10
4 M-1s-1. In contrast, 
Borgono and colleagues (2007c) obtained a 2-fold higher value of 2.5 × 104 M-1s-1 
(1520.57 mM-1min-1) for Pichia pastoris-generated KLK14 using PFR-AMC, the same 
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substrate with a different cleavable reporter. The assay conditions, including the buffer, 
were different in the two studies, and the N-glycosylation status of Drosophila Schneider 
2 cell-generated KLK14 was not reported by Brattsand and colleagues (2005). 
Therefore, it is a matter of speculation whether N-glycosylation or assay conditions 
modified the catalytic efficiency of Drosophila Schneider 2 cell-generated KLK14. 
 
3.3.3.2 Pro-HGF activation by KLK14 
This is the first study to show that KLK14 activates HGF in a dose-dependent manner. 
This study also confirms that the related protease KLK4 degrades rather than activates 
HGF, and that hepsin is a potent HGF activator. While these results show hepsin is a 
more efficient HGF activator compared to KLK14, a role for KLK14 in HGF 
activation should not be discounted. There appears to be a window where the molar 
ratio of KLK14 to HGF is optimal for HGF activation. In a physiological setting 
bimodal activity of KLK14 may have a role in regulation of HGF-dependent signalling 
with higher concentrations of KLK14 resulting in HGF degradation and lower 
concentrations resulting in activation. 
Activation of HGF relies on proteolytic cleavage between Arg494↓Val495 (Gak et al., 
1992; Naka et al., 1992; Naldini et al., 1992) and therefore, it is possible several serine 
proteases with specificity for an Arg P1 residue will activate HGF in vivo, including 
KLK14. As mentioned earlier, several in vitro HGF activators have been identified 
including HGFA (Shimomura et al., 1995; Itoh et al., 2004), matriptase (Lee et al., 2000; 
Owen et al., 2010), hepsin (Herter et al., 2005; Kirchhofer et al., 2005; Owen et al., 
2010) and TMPRSS13 (Hashimoto et al., 2010). Likewise, several HGF-degrading 
proteases have been identified including uPA, tPA (Owen et al., 2010), KLK4 and 
KLK5 (Mukai et al., 2008).  
Table 3.2 shows a summary of results from studies investigating KLK14, KLK4 and 
hepsin cleavage specificities beyond the P1 residue (Felber et al., 2005; Herter et al., 
2005; Matsumura et al., 2005; Debela et al., 2006b; Borgono et al., 2007a; Beliveau et al., 
2009; Swedberg et al., 2009; Owen et al., 2010; de Veer et al., 2011). These studies used 
a variety of techniques, including positional scanning synthetic combinatorial libraries 
(PS-SCL) (Schneider and Craik, 2009)  and non-combinatorial sparse matrix libraries 
(NC-SML) (Swedberg et al., 2009; de Veer et al., 2011), to determine P4-P1 substrate 
132 
 
Table 3.2 Substrate cleavage specificities of KLK14, KLK4 and hepsin. Peptide substrate preferences of KLK14, KLK4 and hepsin as 
determined by phage-display library (PD), positional scanning synthetic combinatorial library (PS-SCL), non-combinatorial sparse matrix library (NC-
SML), and internally quenched fluorescent peptide library (IQFP). The P4-P1 residues of HGF (KELR) are underlined. 
Table 3.2 Substrate cleavage specificities of KLK14, KLK4 and hepsin. 
Protease Method P4 P3 P2 P1 Reference 
KLK14 PD Gly Ser Asn Leu Leu Gln Gln Arg (Felber et al., 2005) 
 PS-SCL Tyr Trp Lys Ala Ser Arg  Ala Pro Asn His Ser Arg (Borgono et al., 2007a) 
 NC-SML Tyr Trp Ala Val Ser Arg (de Veer et al., 2011) 
KLK4 PS-SCL Val Ile Gln Val Ser Gln Val Leu Arg (Matsumura et al., 2005) 
 PS-SCL Ile Val Val Gln Gly Gln Val Leu Arg (Debela et al., 2006b) 
 PS-SCL Val Ile Gln Ser Ala Arg Gln Leu Arg (Borgono et al., 2007a) 
 NC-SML Phe Val Gln Arg (Swedberg et al., 2009) 
Hepsin PS-SCL Pro Lys Glu Lys Thr Leu Asp Arg (Herter et al., 2005) 
 IQFP Arg Arg Ala Leu Leu Arg Tyr Arg (Beliveau et al., 2009) 
 PS-SCL Lys Ile  Arg Gln Lys Leu Thr Arg Asn Arg (Owen et al., 2010) 
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preferences. Differences in substrate specificities for proteases examined by different 
groups, using in some cases the same method, could be due to the different host cells 
used for recombinant protease generation. As discussed earlier, post-translational 
modifications imposed by different cell types such as N-glycosylation can alter the 
catalytic specificity of proteases. Interestingly, when compared to the P4-P1 residues of 
HGF (Lys-Glu-Leu-Arg) (Gak et al., 1992; Naka et al., 1992; Naldini et al., 1992), hepsin 
is the only protease in this group that has each of these residues as a preferred residue 
(Table 3.2, underlined residues). This reflects the potent and efficient HGF activation by 
hepsin.  
Interestingly, KLK14 and KLK4 have Arg P1 and Leu P2 preferred substrate residues, 
however, KLK14 activates HGF but KLK4 does not. This highlights the phenomenon 
of subsite cooperativity (as reviewed by Ng and colleagues (2009)). Briefly, binding of a 
substrate residue to a protease subsite has a positive or negative effect on the binding of 
other residues at other sites. This extended cooperative effect plays a role in the 
substrate specificity of the protease. By the same token, the P4-P1 residues of HGF in 
addition to residues beyond this region including the P1’-P4’ residues, as well as the co-
operativity of the protease S1’-S4’ subsites and beyond, influence the proteolytic activity 
of KLK14 and KLK4. This leads to the differential effects of KLK14 and KLK4 on 
HGF activation. 
 
3.3.3.3 HAI-1 degradation by KLK14 
In vitro studies have confirmed the Kunitz-type inhibitor HAI-1A or isoform HAI-1B 
are potent inhibitors of HGFA and matriptase as well as other HGF activators such as 
hepsin and TMPRSS13 (Kirchhofer et al., 2003; Herter et al., 2005; Kirchhofer et al., 
2005; Hashimoto et al., 2010). While there are several serine proteases inhibited by the 
HAI-1 isoforms, several HGF activators such as factor XIa and factor XIIa (Shimomura 
et al., 1995; Peek et al., 2002) are not inhibited by HAI-1 isoforms (Kirchhofer et al., 
2003). This suggests certain specificity to the inhibitory activity of HAI-1. 
In this study, dose-dependent analysis indicated that the HGF-activator KLK14 was 
moderately inhibited by HAI-1A and HAI-1B. Limited access to recombinant HAI-1 
meant that the IC50 of KLK14 inhibition could not be calculated. However, the results 
showed marginally greater inhibition for HAI-1A than HAI-1B as 50 nM of these 
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inhibited 5 nM KLK14 by 35% and 26%, respectively. Fan and colleagues (2005) also 
found that prostasin was moderately inhibited by HAI-1 isoforms. However, prostasin 
(3 nM) is marginally more inhibited by HAI-1B with IC50 values of 109 nM and 66 nM 
for HAI-1A and 1B, respectively (Fan et al., 2005). For comparison, HAI-1A potently 
inhibits hepsin (1 nM) with an IC50 of 12 nM (Herter et al., 2005). In contrast, HAI-1B 
has more moderate inhibition of hepsin (0.4 nM) and matriptase (0.5 nM) with IC50 
values of 21 nM and 16 nM, respectively (Kirchhofer et al., 2003; Kirchhofer et al., 
2005). HAI-1B has also been reported to weakly inhibit plasmin and plasma kallikrein 
with IC50 values of 399 nM for plasmin (4 nM) and 686 nM for plasma kallikrein 
(concentration not reported) (Kirchhofer et al., 2003). 
As inhibition of serine proteases by HAI-1 isoforms is attributed to the P1 residues of 
the substrate-like reactive loops in KD1 and KD2 (Denda et al., 2002; Kirchhofer et al., 
2003; Fan et al., 2005; Kirchhofer et al., 2005; Kojima et al., 2008), inhibition is based 
on the protease preference for either Arg or Lys, respectively, in their substrate binding 
pocket. Reflecting their substrate preferences, matriptase, prostasin, and hepsin are only 
inhibited by KD1 of HAI-1A and/or 1B (Kirchhofer et al., 2003; Fan et al., 2005; 
Kirchhofer et al., 2005; Oberst et al., 2005; Kojima et al., 2008). Likewise, KLK14, with 
a preference for Arg P1 residues, would probably be inhibited by KD1 with negligible to 
no inhibition afforded by KD2. 
Interestingly, HAI-1 domain deletion studies for matriptase, prostasin, hepsin, plasma 
kallikrein, plasmin, TMPRSS13 and human airway trypsin-like protease (HAT), show 
the presence of KD2 attenuates HAI-1 inhibition, possibly by obstructing access to the 
reactive site of KD1 (Fan et al., 2005; Shia et al., 2005; Kojima et al., 2008; Hashimoto 
et al., 2010; Kato et al., 2011). In fact, full-length HAI-1A does not inhibit TMPRSS13 
or HAT whereas as a truncated form lacking KD2 affords strong inhibition (Hashimoto 
et al., 2010; Kato et al., 2011). KLK4 and KLK5 are also inhibited by a truncated form 
of HAI-1A featuring KD1 (Mukai et al., 2008), however, the study did not show data 
for full-length HAI-1A.  
There are some proteases that are inhibited by KD2.  For instance, using domain 
deletion studies Denda and colleagues (2002) showed that trypsin is equally inhibited by 
KD1 and KD2 of HAI-1A. This is likely due to trypsin’s preference for both Arg and 
Lys P1 residues. This group also showed that HGFA is also inhibited by KD2, though, 
to a lesser extent than KD1 (Denda et al., 2002).  
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While inhibition by HAI-1 isoforms is mediated by the Kunitz domains, the other HAI-
1 domains play roles in either obstructing or enhancing the interaction (Kojima et al., 
2008). The presence of a 16 amino acid insert in HAI-1B isoform between the two 
Kunitz domains has been speculated to create a relatively small structural change to 
HAI-1 and little change to the inhibition by KD1 (Kirchhofer et al., 2003). However, 
other than this project, the study of prostasin by Fan and colleagues (2005) is the only 
one to report direct comparison of inhibition by HAI-1A and 1B. In this study the IC50 
for prostasin (3 nM) inhibition by HAI-1A (109 nM) was higher than for HAI-1B (66 
nM), these are small changes and so far the significance is unknown. 
The moderate inhibition of KLK14 by HAI-1 isoforms was examined further using 
SDS-PAGE as it has been reported that endogenous and recombinant HAI-1 form 
stable complexes with several proteases including matriptase, TMPRSS13, prostasin and 
HAT (Lin et al., 1999b; Benaud et al., 2001; Fan et al., 2005; Wang et al., 2009; 
Hashimoto et al., 2010; Kato et al., 2011). Interestingly, KLK14 does not form stable 
complexes with either HAI-1 isoform. Instead, there is a comprehensive degradation of 
both isoforms by KLK14 resulting in several HAI-1 fragments. This would indicate 
multiple hydrolysis points along HAI-1A and 1B amenable to KLK14 proteolysis. 
Likewise, hepsin does not form stable complexes with HAI-1B. Instead there are 
multiple HAI-1B degradation bands. In contrast, hepsin and HAI-1A form stable 
complexes, but there is also some dose-dependent degradation of HAI-1A. It is possible 
the extra 16 amino acid insert in HAI-1B alters the hepsin-HAI-1 interaction resulting in 
the increased HAI-1B cleavage and abrogation of complex formation. So far, a direct 
comparison of HAI-1A and HAI-1B inhibition of hepsin in an amidolytic assay has not 
been conducted. Such a comparison would further clarify the effect of the HAI-1B 16 
amino acid insert on hepsin inhibition. 
Fragmentation of transmembrane HAI-1 has previously been reported as shed forms of 
58, 50, 48, 44, 40/39 and 25 kDa identified in conditioned media or bodily fluids such 
as milk (Shimomura et al., 1997; Lin et al., 1999b; Shimomura et al., 1999; Kataoka et al., 
2000; Benaud et al., 2001; Kiyomiya et al., 2006; Wang et al., 2009). For instance, active 
matriptase has been isolated from human milk, urine and seminal plasma in SDS-stable 
complexes with 25 and 40 kDa HAI-1 (Lin et al., 1999b; Benaud et al., 2001; Wang et 
al., 2009), the 40 kDa fragment most likely containing KD1 (Lin et al., 1999b). 
Moreover, Kojima and colleagues (2008) suggested that matriptase interaction with 
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HAI-1A does not result in the degradation of HAI-1A. Instead, shedding of HAI-1 and 
subsequent fragmentation is thought to be mediated by metalloproteinase membrane-
type-1 MMP (Domoto et al., 2012).  
Fan and colleagues (2005) also reported formation of SDS- and reducing agent-stable 
prostasin-HAI-1B complexes as well as prostasin co-immunoprecipitation with cell-
surface and shed HAI-1B from lysates and medium, respectively. Similarly, cell-surface 
HAI-1A has been co-immunoprecipitated with HAT (Kato et al., 2011). TMPRSS13 
also forms SDS- and reducing agent-stable complexes with a truncated HAI-1A 
featuring KD1 but not with full-length HAI-1A consisting of both KD1 and KD2 
(Hashimoto et al., 2010). 
While stable complex formation with serine proteases is an inhibitory tactic of the 
Kunitz-type inhibitors (Laskowski and Qasim, 2000; Krowarsch et al., 2003), the 
purpose of HAI-1 fragmentation is unknown and the potential role of KLK14 (and 
hepsin) in this activity is intriguing. It is possible that as KD1 is a more potent inhibitor 
in isolation (Fan et al., 2005; Shia et al., 2005; Kojima et al., 2008; Hashimoto et al., 
2010; Kato et al., 2011), KLK14 and hepsin may facilitate the inhibitory activity of HAI-
1 through fragmentation to release this domain. In so doing this may lead to increased 
inhibition of HGF-activating proteases. Indeed, the degradation of HAI-1B by hepsin 
generates a predominant 40 kDa band, which is possibly the liberated KD1 fragment 
(Lin et al., 1999b) (Figure 3.14B).  It is also possible that comprehensive degradation of 
HAI-1 isoforms by KLK14, or HAI-1B by hepsin modulates inhibition in the 
pericellular environment through reduction in HAI-1 availability.  
Furthermore, this finding that HAI-1 is degraded by KLK14 is consistent with the 
apparent moderate inhibition of KLK14 in the amidolytic assays. As a competitive 
substrate HAI-1A would reduce the cleavage rate of the tri-peptide substrate QAR-
AMC thereby feigning the role of KLK14 inhibitor.  
 
3.3.4 Summary 
In summary, this chapter reports the generation of KLK14 zymogen in an insect cell 
expression system, and purification and activation of the zymogen. While the catalytic 
efficiency for this Sf9 cell-generated KLK14 was lower than that generated by Borgono 
and colleagues (2007c) in a yeast cell expression system, these differences are likely 
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accounted for by the difference in glycosylation status. This is also the first report of 
KLK14 activation of HGF in a dose-dependent manner. Furthermore, this is the first 
report of Kunitz-type serine protease inhibitors HAI-1A and isoform 1B as KLK14 
substrates. Through these experiments a potential role for KLK14 in the regulation of 
HGFR signalling by two pathways has been revealed, first, directly through KLK14 
activation of HGF, and second, indirectly through degradation HAI-1, an inhibitor of a 
number of HGF-activating proteases.  
This is also the first report of hepsin forming stable complexes with HAI-1A. Moreover, 
in a surprising result, it is also the first report of hepsin degrading HAI-1B. This 
suggests that HAI-1B is a hepsin substrate as opposed to inhibitor. However, this 
conclusion requires further experimental examination. 
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Chapter 4 Proteolytic and cell-surface 
interactions of KLK14 and other 
proteases 
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4.1 Introduction 
The KLKs are generated as zymogens requiring activation by limited proteolysis 
(Borgono and Diamandis, 2004). As they have overlapping tissue distribution, KLKs are 
prime targets for intra-familial proteolytic cascade studies (Shaw and Diamandis, 2007). 
Studies of KLK proteolytic cascades have painted a complex picture of KLK inter-
activation and regulation by proteolysis as well as participation in cascades with other 
proteases (Takayama et al., 2001b; Brattsand et al., 2005; Beaufort et al., 2006; Debela et 
al., 2006b; Borgono et al., 2007c; Yoon et al., 2007; Emami et al., 2008; Emami and 
Diamandis, 2008; Mukai et al., 2008; Yoon et al., 2008; Beaufort et al., 2010). The S1 
residue of KLK4 and KLK14 (Figure 4.1) is an Asp, six residues before the catalytic Ser 
residue. These two KLKs were predicted to have trypsin-like specificity, cleaving 
substrates following an Arg or Lys residue (P1) (Nelson et al., 1999; Stephenson et al., 
1999; Hooper et al., 2001a; Yousef et al., 2001). Studies have subsequently shown that 
KLK4 and KLK14 have a preference for cleaving after Arg residues (Takayama et al., 
2001b; Brattsand et al., 2005; Felber et al., 2005; Matsumura et al., 2005; Debela et al., 
2006a; Debela et al., 2006b; Obiezu et al., 2006; Oikonomopoulou et al., 2006a; 
Borgono et al., 2007a; Borgono et al., 2007b; Borgono et al., 2007c; Stefansson et al., 
2008). Activation of KLK4 and KLK14 requires cleavage after Gln30 for KLK4 
(Nelson et al., 1999; Stephenson et al., 1999; Hooper et al., 2001a; Yousef et al., 2001) 
and after Lys40 for KLK14 (Figure 4.1).  
Results published by Yoon and colleagues (2007) showed that while KLK4 and KLK14 
may have the potential to activate several members of the KLK family, KLK4 was one 
of the few KLKs able to proteolyse KLK14 at the pro- region cleavage site, and no 
KLKs were able to activate KLK4. In addition, they demonstrated that KLK14 had 
minimal self-activation capacity. In other studies by Brattsand and colleagues (2005) and 
Borgono and colleagues (2007c) it was found that recombinant KLK14 did not self-
activate. However, Borgono and colleagues (2007c) showed that KLK14 readily auto-
degraded. Beaufort and colleagues (2010) also found that none of the KLKs they tested 
was able to activate KLK4. Furthermore, several preferentially degraded KLK4 
zymogen, including KLK4 itself. Taken together these results suggest that the proteases 
responsible for activation of KLK14 and KLK4 may not necessarily be members of the 
KLK family.  
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KLK4 and KLK14 are both highly expressed in prostate tissue and have been 
associated with progression of prostate cancer (Ramsay et al., 2008b). Other proteases 
that are similarly expressed in the prostate may have roles in activation or deactivation 
of these KLKs in this tissue. For instance, prostate-expressed transmembrane serine 
proteases hepsin and TMPRSS2 (TTSP family members) (Figure 4.1) are also associated 
with prostate cancer progression (Antalis et al., 2011). Furthermore, hepsin 
(unpublished data (Qiu et al., 2007)) and TMPRSS2 (Afar et al., 2001) autoactivate and 
so have the potential to be proteolytic cascade initiators (Bugge et al., 2009). 
Figure 4.1 Pro-region cleavage site of the serine proteases KLK14, KLK4, hepsin, TMPRSS2 and matriptase 
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Hepsin has trypsin-like specificity with a preference for cleaving substrates after an Arg 
residue (Herter et al., 2005; Beliveau et al., 2009; Owen et al., 2010), and to activate 
hepsin requires cleavage between Arg162 and Ile163 (Leytus et al., 1988; Somoza et al., 
2003). The activation site of TMPRSS2 has been identified as between Arg292 and 
Ile293 (Afar et al., 2001). However, the preferred P1 substrate of TMPRSS2 is 
unknown. It is predicted to have trypsin-like specificity with a preference for cleaving 
substrates after Arg or Lys residues (Paoloni-Giacobino et al., 1997; Wilson et al., 2005).  
There is also potential for secreted matrix metalloproteinases MMP3 and MMP9 (Figure 
4.2) to participate in proteolytic cascades with the KLKs and TTSPs. These MMPs have 
also been associated with progression of prostate and other cancers (Deryugina and 
Quigley, 2006, 2010; Fanjul-Fernandez et al., 2010; Antalis et al., 2011; Gong et al., 
2014). It has previously been determined that the autoactivating TTSP matriptase 
(Takeuchi et al., 2000; Lee et al., 2007) (Figure 4.1)  activates MMP3 (Jin et al., 2006; 
Milner et al., 2010) and further,  MMP3 activates KLK4 (Beaufort et al., 2010) and 
MMP9 (Ogata et al., 1992; Okada et al., 1992; Shapiro et al., 1995; Ramos-DeSimone et 
al., 1999; Toth et al., 2003). 
MMP3 is activated in a stepwise manner (Nagase et al., 1990). Consistent with their 
specificity, proteases including chymotrypsin, plasma kallikrein and autoactivating 
matriptase first cleave within a stretch of amino acids (Phe51-Val-Arg-Arg-Lys-Asp56) 
near the middle of the MMP3 pro-region to yield an intermediate form (Nagase et al., 
1990; Milner et al., 2010). This is followed by MMP3 self-activation by cleaving at 
His99-Phe100 to remove the remaining pro-region yielding a mature peptide (Nagase et 
al., 1990; Milner et al., 2010; Nagase, 2013) (Figure 4.2). MMP9 can also be activated in 
two steps. First, MMP3 cleaves between Glu59 and Met60 (Ogata et al., 1992), followed 
by a second cleavage at Arg106-Phe107 (Shapiro et al., 1995). However, MMP9 can also 
be activated directly by a single step cleavage between Arg106 and Phe107 by trypsin, 
KLK1 and other proteases (Desrivieres et al., 1993; Sang et al., 1995). As hepsin and 
TMPRSS2 have a preference for Arg P1 residues they may also activate these MMPs.  
The aim in this chapter was to explore the proteolytic interactions of prostate cancer-
associated secreted serine proteases KLK4 and KLK14, and transmembrane serine 
proteases hepsin and TMPRSS2. The proteolytic interactions between these proteases 
have not previously been published. Included to lesser extent in this study were secreted 
matrix metalloproteinases MMP3 and MMP9 and transmembrane serine proteases 
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Figure 4.2 Pro-region cleavage sites and stepwise activation of the matrix metalloproteinases MMP3 and MMP9 
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matriptase and enteropeptidase. Matriptase was included in this study as it is a known 
MMP3 activator. Enteropeptidase was included as it has a preference for Lys P1 
residues (Zheng et al., 2009). Furthermore,  while  enteropeptidase has previously been 
used to activate KLK14 in vitro (Brattsand et al., 2005) it has not been investigated as an 
endogenous KLK14 activator. The techniques used in this chapter to examine the 
interactions between these proteases include co-expression models and recombinant 
protein assays as well as co-immunoprecipitation studies. As hepsin and TMPRSS2 are 
transmembrane proteases cell-surface expression analysis by cell-surface biotinylation 
was also included in the study. 
 
4.2 Results 
4.2.1 Proteolytic interactions of KLK14, KLK4, hepsin, TMPRSS2 and 
enteropeptidase  
To investigate the proteolytic interactions between the secreted proteases KLK14 and 
KLK4 and the transmembrane serine proteases hepsin, TMPRSS2 and enteropeptidase, 
transient transfections and co-transfections into Cos-7 cells were conducted using 
constructs encoding each of the proteases, as well as constructs encoding active-site 
serine-to-alanine (SA) mutants of each protease. By using constructs encoding active-
site mutants of the proteases, proteolysis of/by a protease can be attributed accordingly. 
For ease of detection of the proteases by Western blot analysis, all the constructs, except 
the one encoding enteropeptidase, were engineered to encode each protease with a C-
terminal epitope tag, such as HA, Myc, Flag or V5. Purified recombinant proteases, 
when available, were also used in co-incubations to examine the proteolytic interactions 
further. Number of replicates are stated in figure legends, otherwise N=1. 
 
4.2.1.1 Co-expression or co-incubation of KLK14 with KLK4 does not result 
in proteolysis 
As mentioned in the introduction, results published by Yoon and colleagues (2007) 
showed the potential for KLK4 activation of KLK14, but not vice versa. Two 
approaches were taken to further investigate the potential for KLK14 and KLK4 cross-
activation or proteolysis. First, analysis was performed on conditioned media from cells 
co-transfected with expression constructs encoding these proteases. Second, 
conditioned media from cells transfected with only one of these expression constructs 
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were incubated for between 0 and 24 hours with the conditioned media from cells 
transfected with the other expression construct. To analyse the status of KLK14 and 
KLK4 proteolysis, conditioned media from each approach were then examined by 
Western blot analysis using anti-Myc and anti-V5 antibodies.  
These analyses revealed that KLK14 does not proteolyse KLK4 and KLK4 does not 
proteolyse KLK14 when co-expressed (Figure 4.3A) or when co-incubated (Figure 
4.3B). The same result was obtained when the co-incubation assay was conducted using 
cells transfected and grown under serum-free-media conditions (data not shown). The 
minor variations in band intensity of mutant or wild-type KLK4 or KLK14 observed in 
these analyses were not attributed to proteolysis by KLK4 or KLK14 as they were not 
observed consistently in other analyses (data not shown) or did not correlate 
consistently with wild-type KLK4 or KLK14 co-expression. Instead these variations 
were attributed to gel loading or Western blot transfer inconsistencies. 
 
4.2.1.2 Transfected hepsin self-activates in Cos-7 cells 
Several TTSPs self-activate, including TMPRSS2 (Afar et al., 2001) and matriptase 
(Takeuchi et al., 2000; Lee et al., 2007). So in this section, to confirm results by Qiu and 
colleagues (2007), the potential for hepsin to self-activate was examined. 
To determine whether hepsin will self-activate in transiently transfected Cos-7 cells, a 
construct encoding active-site mutant hepsin with a C-terminal Myc tag, hepsinSA-Myc, 
was co-transfected with constructs encoding wild-type or active-site mutant hepsin with 
a C-terminal Flag tag, hepsin-Flag or hepsinSA-Flag. As hepsin localizes to the plasma 
membrane (Tsuji et al., 1991; Kazama et al., 1995; Zacharski et al., 1998) cell lysates 
were examined by Western blot analysis using anti-Myc and anti-Flag antibodies. When 
hepsin is activated by limited proteolysis, the serine protease domain remains tethered to 
its stem region by a disulphide bond (Leytus et al., 1988; Somoza et al., 2003) (see 
Figure 4.1 for the domain structure schematic of hepsin). Therefore, when activated 
hepsin is examined under reducing conditions, the disulphide bond is reduced allowing 
the serine protease domain to run on the gel separated from the stem region. As the 
overexpressed hepsin has a C-terminal epitope tag, under reducing conditioned the anti-
Myc and anti-Flag antibodies detect unactivated full-length hepsin, the separated serine 
protease domain, as well as any other forms that have the C-terminal and epitope tag.  
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Figure 4.3 Co-expression or co-incubation of KLK14 with KLK4 does not result in proteolysis 
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As shown in Figure 4.4, hepsin-Myc, and hepsinSA-Myc, hepsin-Flag and hepsinSA-
Flag each migrate to a position indicating a MW of 45 kDa, representing unactivated 
full-length hepsin. In addition, in assays in which cells were transfected with only a 
single expression construct, both hepsin-Myc and hepsin-Flag have a 26 kDa band that 
represents the serine protease domain of activated hepsin (Figure 4.4i, lane 1; Figure 
4.4ii, lane 4 and 6). This serine protease domain band is absent from cells expressing 
active-site mutants hepsinSA-Myc or hepsinSA-Flag (Figure 4.4i, lane 2; Figure 4.4ii, 
lane 4 and 6) indicating that hepsin activation occurs via an autocatalytic mechanism. 
Consistent with this proposal, anti-Myc Western blot analysis of lysates from cells co-
transfected with hepsin-Flag and active-site mutant hepsinSA-Myc revealed the hepsin-
Myc serine protease domain migrating at 26 kDa (Figure 4.4i, lane 3). This 26 kDa band 
was not apparent from cells co-expressing catalytically inactive hepsinSA-Myc and 
active-site mutant hepsinSA-Flag (Figure 4.4ii, lane 4). These data indicate that hepsin is 
capable of undergoing autocatalytic activation. 
These analyses also indicated further hepsin activity and self-proteolysis as there are also 
30 kDa bands for hepsin-Myc and hepsin-Flag (Figure 4.4i, lane1 and Figure 4.4ii, lanes 
3 and 5) that are absent for hepsinSA-Myc and hepsinSA-Flag  (Figure 4.4i, lane 2; 
Figure 4.4ii, lane 4 and 6). However, the 30 kDa band is also generated when hepsinSA-
Myc is co-expressed with hepsin-Flag (Figure 4.4i, lane3). Therefore, this 30 kDa band is 
also a product of hepsin proteolysis. 
There are two further cleaved forms of hepsin detected by the anti-Flag and anti-Myc 
antibodies represented by 32 and 35 kDa bands. These forms are generated in part or 
completely by another protease as they are present for hepsin and hepsinSA alike. In 
addition, both hepsin and hepsin SA form SDS- and β-mercaptoethanol-stable 
complexes that can be seen at MWs above 90 kDa.  
The significance of these alternate cleavage sites is unknown. They do not result in 
shedding of hepsin as it was not detected in the conditioned media (data not shown), 
nor was it detected in cell lysates under non-reducing conditions (data not shown), 
suggesting the cleaved forms remain attached to the stem via disulphide bonds. These 
forms will be discussed further in later sections. 
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Figure 4.4 Hepsin self-activates in Cos-7 cells 
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4.2.1.3 Pericellular proteolysis of KLK14 by hepsin 
As hepsin autoactivation in transiently transfected Cos-7 cells has been established, this 
knowledge can be used as a basis to examine the proteolysis of other proteases by 
hepsin. For this purpose hepsin-Myc and hepsinSA-Myc were co-expressed with 
KLK14HA or KLK14SA-HA and conditioned media and cell lysates were examined by 
Western blot analysis. 
As shown in Figure 4.5, both KLK14 and KLK14SA migrated as 28 kDa in conditioned 
media without decrease in signal intensity indicating that they were unaffected by co-
expression with either wild-type or catalytically inactive hepsin (Figure 4.5A, Media, 
lanes 3 and 5). However, surprisingly, analysis of cell lysates showed that cell-retained 
KLK14 and KLK14SA are cleaved by hepsin to 26 and 27 kDa, respectively (Figure 
4.5A, WCL, lanes 3 and 5).  
Consistent with the data shown in Figure 4.4, anti-Myc Western blot analysis for hepsin 
indicated that this protease autoactivates as evidenced by the presence of the 26 kDa 
serine protease domain (Figure 4.5B, WCL, lanes 1, 3 and 5). In addition, it is apparent 
from the analysis in Figure 4.5B that KLK14 did not proteolyse hepsin or hepsinSA. In 
data not shown, analysis of hepsin in conditioned media confirmed previous findings 
(Tsuji et al., 1991) that hepsin is not shed from the cell surface. Moreover, co-expression 
with KLK14 did not alter this. 
 
4.2.1.4 Pericellular proteolysis of KLK14 by TMPRSS2 
To examine the proteolytic relationship of autoactivating TMPRSS2 and KLK14, 
TMPRSS2-Myc and TMPRSS2SA-Myc were co-expressed with KLK14HA or 
KLK14SA-HA and conditioned media and cell lysates were examined by Western blot 
analysis. TMPRSS2 is similar to hepsin in that when activated, the serine protease 
domain remains tethered by a disulphide bond to its stem region (Paoloni-Giacobino et 
al., 1997) (See Figure 4.1 for TMPRSS2 domain structure schematic). Therefore, when 
examined under reducing conditions, the disulphide bond is reduced and the serine 
protease domain runs separately from the stem region of TMPRSS2. Like hepsin, 
TMPRSS2 is localized on the plasma membrane (Paoloni-Giacobino et al., 1997; 
Jacquinet et al., 2001; Chen et al., 2010b). However, in contrast with hepsin, studies 
have demonstrated that endogenous TMPRSS2 expressed by LNCaP cells is shed from  
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Figure 4.5 KLK14 is proteolysed when co-expressed with hepsin 
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the cell surface into the extracellular medium when the cells are treated with androgens 
but not in the absence of androgen treatment (Afar et al., 2001; Chen et al., 2010b). 
As shown in Figure 4.6, 28 kDa KLK14 and KLK14SA are depleted from the media 
when co-expressed with TMPRSS2 (Figure 4.6A, Media, lanes 3 and 5) but not when 
co-expressed with active-site mutant TMPRSS2SA (Figure 4.6A, Media, lanes 4 and 6). 
Furthermore, examination of the cell lysate analysis (Figure 4.6A, WCL) shows that the 
28 kDa KLK14 and KLK14SA are accompanied by a 27 kDa band which has a 
marginally increased signal intensity when co-expressed with TMPRSS2 (Figure 4.6A, 
WCL, lanes 3 and 5). These data suggest that similar to hepsin, TMPRSS2 is able to 
cleave cell-retained KLK14, albeit with less efficiency. 
The analysis of TMPRSS2 expression in cell lysates in Figure 4.6B shows bands 
representing full-length TMPRSS2 at 53 kDa, and high MW complexes at >200 kDa. 
The analysis also conforms to a previous finding by Afar and colleagues (2001) that 
TMPRSS2 self-activates. This is evident from the 25 kDa band representing the serine 
protease domain of TMPRSS2 (Figure 4.6B, WCL, lanes 1, 3 and 5). The absence of this 
band for TMPRSS2SA demonstrates that integrity of the active-site is a requirement for 
TMPRSS2 activation (Figure 4.6B, WCL, lanes 2, 4 and 6). There are also cleaved forms 
of TMPRSS2 at 50, 40, 36, 35 and 30 kDa (Figure 4.6B, WCL, lanes 1, 3 and 4). With 
the exception of the 50 and 40 kDa bands, the low MW forms appear to be a result of 
self-proteolysis as they are absent for TMPRSS2SA (Figure 4.6B, lanes 2, 4 and 6). 
Interestingly, TMPRSS2SA (Figure 4.6B, WCL, lanes 2, 4 and 6) also has a band at 
around 54 kDa that is absent for TMPRSS2 (Figure 4.6B, WCL, lanes 1, 3 and 6) 
suggesting that this band was eliminated by TMPRSS2-dependent proteolysis. In data 
not shown, analysis of TMPRSS2 expression in conditioned media showed that it was 
not shed from the cell surface. Moreover, similar to the studies with KLK14 and hepsin, 
there is no indication in the analyses that KLK14 proteolysed TMPRSS2. 
 
4.2.1.5 KLK14 proteolyses GAPDH 
An unexpected finding was made during transient transfection assays to determine the 
proteolytic relationship between KLK14 and the transmembrane serine protease 
enteropeptidase. In these assays, Cos-7 cells were co-transfected with KLK14-HA and 
enteropeptidase, or the conditioned media from KLK14-HA transfected cells were 
applied to untransfected cells or cells transfected with enteropeptidase. Cell lysates were  
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Figure 4.6 KLK14 is proteolysed when co-expressed with TMPRSS2 
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then examined using anti-enteropeptidase, anti-KLK14 and anti-GAPDH antibodies. 
The anti-enteropeptidase antibody was not specific and so the data from this is not 
presented.  
However, the anti-GAPDH Western blot analyses showed that KLK14 degraded 
GAPDH, independently of co-transfection with the enteropeptidase expression 
construct. As shown in the Western blot analysis when KLK14-HA is transfected, 37 
kDa GAPDH is completely degraded (Figure 4.7A, lanes 2, 3, 6 and 7; Figure 4.7B, 
lanes 4-6). Similarly, when the conditioned media, from cells transfected with KLK-HA, 
are applied to untransfected cells, GAPDH is partially degraded into fragments ranging 
from 35 to <20 kDa (Figure 4.7B, lanes 1 and 2).  
GAPDH is a ubiquitously expressed intracellular protein and is routinely used as a 
housekeeping protein in Western blot analysis (Sirover, 2012). As GAPDH is 
intracellular, degradation by exogenously applied KLK14-HA is likely to be due to the 
accidental omission of the protease inhibitor cocktail in the cell lysis buffer when 
preparing cell lysates. It remains undetermined whether release of intracellular proteases 
during cell lysis activated KLK14, or whether KLK14 was active prior to this. However, 
the intracellular proteases do not mediate GAPDH degradation as it only occurs in Cos-
7 cells transfected with KLK14-HA or when it is exogenously applied. To be clear, this 
was an incidental finding and the degradation of GAPDH was not seen at any other 
time during the course of this project.  
However, this observation may have significance because in addition to being an 
intracellular protein in eukaryotic cells, GAPDH is also cell-surface expressed by a 
number of pathogens including bacteria such as group A streptococci (Streptococcus 
pyogenes) and several mycoplasmas, and also fungal pathogens such as Candida albicans 
(Pancholi and Chhatwal, 2003). Cell-surface expressed GAPDH is thought to act as a 
virulence factor mediating pathogen activities including adhesion to tissues, invasion, 
and immune modulation and surveillance evasion (Seidler, 2013). For instance, bacterial 
GAPDH binds host plasminogen and plasmin, and facilitates plasminogen conversion 
to plasmin. This allows the bacteria to dysregulate plasmin activity, localizing activity 
leading to disruption of tissue barriers and facilitating invasion (Seidler, 2013). 
Furthermore, GAPDH is highly conserved, with pathogenic bacterial GAPDH having 
>40% sequence identity to human GAPDH (Seidler, 2013); therefore, KLK14 may also 
degrade extracellular bacterial GAPDH. This may be relevant to host defence as KLK14  
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Figure 4.7 KLK14 proteolyses endogenous GAPDH 
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is highly expressed in the skin as well as in a number of other tissues (Borgono et al., 
2003; Komatsu et al., 2005; Borgono et al., 2007c; Shaw and Diamandis, 2007). 
Specifically, the highest expression in the skin is in the intra-epidermal and eccrine sweat 
glands (Borgono et al., 2003; Stefansson et al., 2006) and it is secreted in sweat 
(Komatsu et al., 2006). This specific, localized expression of KLK14 may decrease the 
incursion of pathogenic bacteria through the epidermal layers by way of the sweat 
glands.  
Unfortunately, this hypothesis was not pursued further as the possible significance of 
the observation that KLK14 mediates GAPDH degradation was not noted until after 
the completion of laboratory work. Moreover, it is outside of the scope of this PhD 
investigation. However, the observation merits communication as it may lead to 
therapeutic strategies for managing bacterial and fungal pathogens. 
 
4.2.1.6 Pericellular proteolysis of KLK4 by hepsin 
To examine the proteolytic relationship of hepsin and KLK4, hepsin-Flag or active-site 
mutant hepsinSA-Flag were co-expressed with KLK4-V5 or active-site mutant 
KLK4SA-V5 and conditioned medium and cell lysate were examined by Western blot 
analysis under reducing conditions.  
As shown in Figure 4.8, KLK4 and KLK4SA appear in the media at 33 kDa (Figure 
4.8A, Media). When co-expressed with hepsin, KLK4 and KLK4SA levels appear 
diminished in the conditioned media (Figure 4.8A, Media, lanes 3 and 5) – but also 
diminished when co-expressed with hepsinSA. In the cell lysate analysis, hepsin 
proteolyses KLK4 and KLK4SA, increasing the signal intensity of a band at 17 kDa 
(Figure 4.8A, WCL, lanes 3 and 5).   
Analysis of hepsin and hepsinSA in media (data not shown) and lysates (Figure 4.8B) 
shows a similar pattern of expression and cleavage to that previously shown in Figures 
4.4 and 4.5. As noted earlier in Figure 4.4, there are 35 and 36 kDa forms of hepsin and 
hepsinSA that are partly generated by another protease as they are present independent 
of hepsin active-site integrity. However, interestingly, when hepsinSA is co-expressed 
with KLK4, the hepsinSA bands at 35 and 36 kDa increase in signal intensity (Figure 
4.8B, WCL, lane 4) compared to when hepsin SA is transfected alone or with KLK4SA  
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Figure 4.8 KLK4 is proteolysed when co-expressed with hepsin 
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(Figure 4.8B, WCL, lanes 2 and 6). Therefore, this indicates that KLK4 was active in the 
transient transfection and that it proteolysed hepsinSA. 
 
4.2.1.7 Pericellular proteolysis of KLK4 by TMPRSS2 
To examine the proteolytic relationship of TMPRSS2 and KLK4, TMPRSS2-Myc or 
active-site mutant TMPRSS2SA-Myc were co-expressed with KLK4-V5 or active-site 
mutant KLK4SA-V5 and conditioned medium and cell lysate were examined by 
Western blot analysis under reducing conditions. 
These analyses showed that KLK4 and KLK4SA appear in media at 33 kDa (Figure 
4.9A, Media). When co-expressed with TMPRSS2, KLK4 and KLK4SA (Figure 4.9A, 
Media, lanes 3 and 5) are converted to 31 kDa KLK4 and KLK4SA forms. This MW 
shift is representative of a proteolytic event at the N-terminal of KLK4 and KLK4SA as 
the forms were detected by antibodies to the C-terminal epitope tag. Analysis of cell 
lysates indicated that cell-retained KLK4 and KLK4SA are similarly converted to lower 
MW 31 kDa forms (Figure 4.9A, WCL, lane 3and 5). These data indicate that KLK4 is 
able to be cleaved by TMPRSS2. 
Analysis for the presence of TMPRSS2 and TMPRSS2SA in media (data not shown) 
and lysates (Figure 4.9B) shows a very similar pattern to that previously shown in Figure 
4.6. However, interestingly, when examining the multiple cleaved forms of TMPRSS2 
and TMPRSS2SA, it is evident that when co-expressed with KLK4, the 30 kDa 
TMPRSS2 and TMPRSS2SA band increases in intensity (Figure 4.9B, WCL, lane 3 and 
4). Therefore, these data indicate KLK4 was active and it proteolysed TMPRSS2 and 
TMPRSS2SA. 
 
4.2.1.8 Recombinant hepsin proteolyses recombinant pro-KLK14 and pro-
KLK4 
KLK14 and KLK4 are cleaved as a result of hepsin expression at the cell surface and it 
appears that this transmembrane protease leads to reduced levels of KLK4 present in 
media (Figures 4.5A and 4.8A). The ability of hepsin to directly cleave KLK4 and 
KLK14 was examined using purified active recombinant hepsin and zymogens of 
KLK4 and KLK14 (pro-KLK14 and pro-KLK4). The hepsin used in these assays is a  
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Figure 4.9 KLK4 is proteolysed when co-expressed with TMPRSS2 
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spontaneously active soluble form with the complete sequence minus the 
transmembrane and intracellular regions (Kirchhofer et al., 2005).  
Pro-KLK14-V5-His and pro-KLK4-V5-His, purified from Sf9 cells, were incubated 
with reducing molar ratios of recombinant hepsin. Western blot analysis was performed 
using anti-V5 antibody to detect all forms of KLK14 and KLK4 that have the C-
terminal V5 tag attached. To detect any forms of KLK14 and KLK4 lacking the C-
terminal epitope tags, an anti-KLK14 polyclonal antibody raised against a combination 
of N- and C-terminal KLK14 peptides, and two anti-KLK4 polyclonal antibodies raised 
against peptides from the mid and C-terminal of KLK4, were also used in the Western 
blot analyses. 
As shown in the Western blot analyses in Figure 4.10, at the KLK14:hepsin molar ratio 
of 1:1 cleaved KLK14 (28 kDa) is apparent as a faint band just below intact KLK14 (29 
kDa) (lane 2). This is consistent with the results shown previously (in Figure 4.5A) that 
co-expression with hepsin resulted in generation of a lower MW band of KLK14 in cell 
lysates. This may represent the removal of the pro-region of KLK14. However, as 
equimolar concentrations are required for the recombinant soluble domain hepsin to 
effect KLK14 cleavage, it is not an efficient reaction. In contrast, at ratios of 
KLK14:thermolysin of 1:0.08 and 1:0.008, KLK14 is cleaved to produce bands of 28, 26 
and 25 kDa (lanes 8 and 9). This reflects the efficient proteolytic removal of the KLK14 
pro- region or V5-His tag or both, by thermolysin, as discussed in Chapter 3. 
KLK4, on the other hand, is degraded by hepsin as indicated by the diminished signal 
for KLK4 at ratios of 1:1, 1:0.1 and 1:0.01 (KLK4:hepsin) (Figure 4.10B, lanes 2-4). 
Furthermore, there is no lower MW band detected for KLK4. This is consistent with 
the observation made in Figures 4.8A that co-expression with hepsin results in KLK4 
depletion. However, co-expression with hepsin had a more pronounced effect on 
KLK4 in the conditioned media than recombinant soluble hepsin has on recombinant 
KLK4 in this assay. In contrast, as shown previously by Ramsay (2008), thermolysin 
efficiently cleaves KLK4 to produce bands migrating at 31 and 32 kDa, reflecting 
removal of the pro-region or V5-His tag, or both (Figure 4.10B, lanes 8 and 9).  
Taken together, these data indicate that soluble hepsin does not efficiently proteolyse 
KLK14 or KLK4, and that the activity of hepsin may be enhanced by cell-surface 
localization. 
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4.2.1.9 KLK14 co-immunoprecipitates with hepsin and TMPRSS2 
Having established that co-expression with hepsin or TMPRSS2 results in cleaved 
KLK14 in cell lysates, interactions between this secreted protease and the cell surface 
proteases were examined further using immunoprecipitation approaches. 
To examine these interactions, KLK14-HA was transiently co-expressed in Cos-7 cells 
with hepsin-Flag, active-site mutant hepsinSA-Flag, TMPRSS2-Myc or active-site 
mutant TMPRSS2SA-Myc. Whole-cell lysates were subjected to immunoprecipitation 
using anti-Flag, anti-Myc or anti-HA antibodies and immunoprecipitates were examined 
by Western blot analysis under reducing conditions. 
As shown in Figure 4.11A, anti-Flag immunoprecipitations of hepsin-Flag and 
hepsinSA-Flag co-immunopurified KLK14-HA (lanes 2 and 3). Interestingly, along with 
full-length KLK14-HA, several cleaved forms of this protease also co-
immunoprecipitated with hepsin-Flag. On the other hand, only full-length KLK14-HA 
is co-immunoprecipitated with hepsinSA-Flag. These data suggest that cell associated 
hepsin cleaves KLK14. 
Figure 4.11B shows anti-Flag antibody Western blot analysis of the reverse 
immunoprecipitation of KLK14-HA using the anti-HA antibody. Consistent with the 
data in Figure 4.11A, this analysis showed that hepsin-Flag and hepsinSA-Flag co-
immunoprecipitate with KLK14-HA (Figure 4.11B, lanes 2 and 3). Interestingly, in 
addition to hepsin-flag and hepsinSA-Flag apparent at 45 kDa, complexes of >90 kDa 
were also co-immunoprecipitated with KLK14-HA. Also, as the 26 kDa serine protease 
domain of hepsin-Flag is apparent, a small amount of activated hepsin-Flag co-
immunoprecipitated with KLK14-HA (Figure 4.11B, lane 2). 
Similarly, Figure 4.12 shows that KLK14-HA co-immunopurified with anti-Myc 
immunoprecipitations of TMPRSS2-Myc and TMPRSS2SA-Myc (Figure 4.12A, lanes 2 
and 3). Several cleaved forms of KLK14-HA also co-immunoprecipitated with 
TMPRSS2-Myc and TMPRSS2SA-Myc. 
The anti-Myc Western blot analysis of the reverse immunoprecipitation is shown in 
Figure 4.12B and it can be seen that TMPRSS2-Myc and TMPRSS2SA-Myc co-
immunoprecipitated with KLK14-HA (Figure 4.12B, lanes 2 and 3). In addition to full-
length 53 kDa TMPRSS2-Myc and TMPRSS2SA-Myc, complexes of >250 kDa also co-
immunoprecipitated KLK14-HA (Figure 4.12B, lanes 2 and 3). Furthermore, similar to  
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Figure 4.11 Co-immunoprecipitation of KLK14 with hepsin from transfected Cos-7 cells 
 
the co-immunoprecipitation of hepsin shown in Figure 4.11B, this analysis in Figure 
4.12B shows that a small amount of activated TMPRSS2 co-immunoprecipitated with 
KLK14-HA as the 25 kDa TMPRSS2 serine protease domain is apparent in lane 2. 
The last five lanes of the Western blot analyses in Figures 4.11 and 4.12 also show the 
WCL input resolved under reducing (R) and non-reducing (NR) conditions. 
Interestingly, when co-expressed with hepsinSA-Flag or TMPRSS2SA-Myc, a cleaved  
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Figure 4.12 Co-immunoprecipitation of KLK14 with TMPRSS2 from transfected Cos-7 cells 
 
form of KLK14-HA is detected at 24 kDa under non-reducing conditions (Figures 
4.11A and 4.12A, lanes 8). However, it is not detected under reducing conditions 
(Figures 4.11A and 4.12A, lanes 6). Furthermore, 24 kDa KLK14-HA is not detected 
when co-expressed with hepsin-Flag or TMPRSS2-Myc (Figures 4.11A and 4.12A, lanes 
5 and 7). Taken together, this suggests that due to the lower MW and detection via the 
C-terminal HA epitope tag, N-terminal proteolysis occurred for a portion of KLK14-
HA. Moreover, as the 24 kDa form is detected under non-reducing, but not reducing 
conditions, there is at least one other proteolysed site within KLK14-HA, with the 
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cleaved fragments remaining attached by intramolecular disulphide bond. Finally, 
TMPRSS2 and Hepsin were not the proteases responsible for the generation of 24 kDa 
KLK14-HA. However, as shown in Figures 4.11A and 4.12A, lanes 7, they proteolysed 
this form further, rendering it undetectable under non-reducing conditions.  
The identity of the protease responsible for the generation of 24 kDa KLK14-HA is 
unknown. However, it is possible that it may be an auto-lytic event as active KLK14 has 
previously been shown to self-degrade by cleavage at multiple Arg residues (Borgono et 
al., 2007c). This speculation of course requires that in the transient transfections of Cos-
7 cells, cell-retained or conditioned media-secreted KLK14-HA was active, a detail not 
established in this or previous assays. 
 
4.2.1.10 KLK4 co-immunoprecipitates with hepsin and TMPRSS2 
As cell-retained KLK4 is also cleaved by hepsin and TMPRSS2, interactions between 
the secreted protease and these membrane-anchored proteases were also examined 
further using immunoprecipitation approaches. 
To examine these interactions KLK4-V5 was transiently co-expressed with hepsin-Flag, 
active-site mutant hepsinSA-Flag, TMPRSS2-Myc or active-site mutant TMPRSS2SA-
Myc. As shown in the anti-V5 Western blot analysis in Figure 4.13A, KLK4-V5 co-
immunoprecipitated with hepsin-Flag and hepsinSA-Flag from whole-cell lysates using 
the anti-Flag antibody (lanes 2 and 3). In addition, three other bands of cleaved KLK4-
V5 at ~28, 22 and 17 kDa co-immunoprecipitated with hepsin-Flag (Figure 4.13A, lane 
2), but not hepsinSA-Flag (Figure 4.13A, lane 3), suggesting that cell-retained KLK4 was 
proteolysed by hepsin. 
Figure 4.13B is an anti-Flag Western blot analysis of the reverse immunoprecipitation of 
KLK4-V5 using the anti-V5 antibody. It shows that 45 kDa full-length hepsin-Flag and 
hepsinSA-Flag as well as hepsin complexes >90 kDa also co-immunoprecipitate with 
KLK4-V5 (lanes 2 and 3). Furthermore, similar to the co-immunoprecipitation of 
hepsin with KLK14-HA (Figure 4.11B), as the 26 kDa serine protease domain of 
hepsin-Flag is apparent, a small amount of activated hepsin-Flag co-immunoprecipitated 
with KLK4-V5 (Figure 4.13B, lane 2).  
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Figure 4.13 Co-immunoprecipitation of KLK4 with hepsin from transfected Cos-7 cells 
 
The anti-V5 Western blot analysis (Figure 4.14A) also shows that KLK4-V5 is co-
immunoprecipitated with both TMPRSS2-Myc and TMPRSS2SA-Myc (lanes 2 and 3). 
In addition, this analysis shows that 17 kDa KLK4-V5 co-immunoprecipitated with 
TMPRSS2-Myc (Figure 4.14A, lane 2), but not TMPRSS2SA-Myc (Figure 4.14A, lane 
3), indicating that KLK4 is proteolysed by TMPRSS2.  
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Figure 4.14 Co-immunoprecipitation of KLK4 with TMPRSS2 from transfected Cos-7 cells 
 
In the anti-Myc Western blot analysis of the reverse immunoprecipitation (Figure 4.14B) 
it can be seen that TMPRSS2-Myc and TMPRSS2SA-Myc co-immunoprecipitated when 
KLK4-V5 was precipitated using the anti-V5 antibody (lanes 2 and 3). In addition, the 
figure shows that complexes >250 kDa containing TMPRSS2-Myc and TMPRSS2SA-
Myc also co-immunoprecipitated with KLK4-V5. Furthermore, similar to the co-
immunoprecipitation of TMPRSS2 with KLK14 shown previously in Figure 4.12B, as  
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Figure 4.15 KLK14, KLK4 and hepsin are located on the cell surface of transfected Cos-7 cells 
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the 25 kDa TMPRSS2 serine protease domain is apparent (Figure 4.14B, lane 2) a small 
amount of activated TMPRSS2-Myc co-immunoprecipitated with KLK4-V5. 
 
4.2.1.11 KLK14, KLK4 and hepsin are located on the cell surface of 
transfected Cos-7 cells  
KLK14 and KLK4 are secreted proteases. However, the observation that these 
proteases co-immunoprecipitate from cell lysate with the membrane-anchored proteases 
hepsin and TMPRSS2 suggests that KLK4 and KLK14 may have roles in the 
pericellular environment. Alternatively, it is possible that interactions seen from cell 
lysates were anomalous due to disruption of normal cell structures allowing interactions 
between KLK4 and KLK14 and cell-surface localized hepsin and TMPRSS2 during 
transit to the cell surface. To address this issue further, cell-surface biotinylation was 
used to examine the localization of KLK4 and KLK14.  
In these experiments KLK14-Myc and KLK4-V5 and were co-expressed with either 
hepsin-Flag or active-site mutant hepsinSA-Flag. Cell-surface proteins on intact cells 
were biotinylated, and labelled proteins then isolated from whole-cell lysates using 
streptavidin beads. Isolated proteins as well as cell lysates input and flow-through from 
the streptavidin capture were examined by Western blot analysis using anti-Flag, anti-
Myc and anti-V5 antibodies. Anti-GAPDH Western blot analysis was used to examine 
protein loading across lanes as well as to assess whether biotinylated fractions contained 
intracellular proteins. 
Interestingly, as shown in Figure 4.15i, KLK14 (lanes 1-3, upper image), KLK4 (lanes 6-
8, upper image) and hepsin (lanes 2-7, middle image) were detected in the biotinylated 
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cell-surface fraction when expressed alone and also when co-expressed. The anti- 
GAPDH analysis (Figure 4.15i, lower image) demonstrates this biotinylated fraction was 
isolated free of intracellular proteins. In Figures 4.15ii and 4.15iii, KLK14, KLK4 and 
hepsin were detected in both cell lysate and the flow-through fractions from the 
biotinylation. Naturally, the anti-GAPDH analyses of these blots reflect the detection of 
intracellular proteins in both the whole-lysate and the flow-through of intracellular 
proteins not captured by cell-surface biotinylation-streptavidin isolation. 
This result for hepsin is consistent with previous publications that have found it 
localized to the plasma membrane (Tsuji et al., 1991; Kazama et al., 1995; Zacharski et 
al., 1998). However, significantly, this is the first time KLK14 and KLK4 have been 
shown to be localized to the cell surface. Moreover, despite co-immunoprecipitation of 
KLK14 and KLK4 with hepsin, the cell surface localization is independent of hepsin or 
hepsin SA co-expression. 
 
4.2.1.12 Activity-based probe pull-down of KLK4, hepsin and TMPRSS2 
from the cell surface 
As the previous results indicate that KLK4 is cell-surface localized as well as secreted, to 
examine whether it is active in either situation an approach was used that captures active 
serine proteases using biotin-tagged activity-based probes (ABPs). The probes used in 
the study, biotin-EGR-CMK and biotin-FPR-CMK, are designed to capture serine 
proteases with specificity for cleavage after Arg (Williams et al., 1989), such as KLK14, 
KLK4, hepsin and TMPRSS2. The presence of a biotin moiety allows subsequent 
isolation of bound proteases using resin-bound streptavidin (Williams et al., 1989). 
 In these experiments KLK4-V5 and active-site mutated KLK4SA-V5 were co-
expressed with either hepsin-Flag or TMPRSS2-Myc. The ABPs were used to label 
active serine proteases on the surface of whole cells and in the conditioned media, and 
then they were isolated from whole-cell lysates and media using streptavidin beads. The 
isolated serine proteases were examined by Western blot analysis using anti-V5, anti-
Flag and anti-Myc antibodies, as well as fluorescence probe-conjugated streptavidin 
(Streptavidin-680) to detect all the proteases pulled down. 
As shown in the anti-V5 Western blot analyses in Figure 4.16, a small quantity of KLK4 
was pulled-down from the cell surface by biotin-EGR-CMK and biotin-FPR-CMK 
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when expressed alone (lanes 1 and 14) and also when co-expressed with TMPRSS2  
(lanes 5 and 18). However, KLK4 was not pulled-down from cells co-expressing hepsin 
(lanes 3 and 16).  
Hepsin was also pulled down, as shown in the anti-Flag Western blot analyses in Figure 
4.16. Full-length 45 kDa hepsin and 26 kDa hepsin serine protease domain were 
detected when co-expressed with KLK4 (lanes 3, 4, 16 and 17) and expressed alone 
(lane 20). Similarly, in the anti-Myc Western blot analyses in Figure 4.16, TMPRSS2 at 
53 kDa (full-length) and 25 kDa (serine protease domain) were detected when co-
expressed with KLK4 (lanes 5, 6, 18 and 19), and also when expressed alone (lanes 8 
and 21). It is interesting that the full-length forms of hepsin and TMPRSS2 have been 
isolated because the proteases isolated by ABP-streptavidin were eluted from 
streptavidin resin using a combination of reducing SDS-PAGE buffer and heat (100°C) 
and, as discussed in previous sections, reduction of the disulphide bonds allows the 
serine protease domain of active hepsin and TMPRSS2 to separate from the stem 
region. It would be expected that under these conditions of isolation and elution only 
the active serine protease domain would be detected by the C-terminal tag antibodies. 
Therefore, detection of unactivated hepsin and TMPRSS2 suggests that these proteases 
have formed dimers or oligomers with active protease and are then concurrently pulled 
down by the ABPs. 
To better detect KLK4, hepsin and TMPRSS2 by Western blot analysis, an increase in 
the number of cells subjected to the ABPs may be necessary. However, there is also 
marked variability in the detection of these proteases across the lanes. Consistent with 
this, the image of the Streptavidin-680 probed blot in Figure 4.16 shows that the 
variability is likely a product of the total amount of protease pulled down and loaded in 
each lane of the gel. In the Streptavidin blots, lanes 1 and 5 have considerably more 
protease detected by the Streptavidin-680 probe than any other lane. Likewise, lanes 17 
and 18 have considerably more protease detected.  So, it follows that these lanes 
correspond with the best detection of KLK4, hepsin and TMPRSS2 in the anti-V5, anti-
Flag and anti-Myc analyses. As it stands, this protocol and these results cannot be used 
to assess the relative efficiency of KLK4, hepsin and TMPRSS2 pull-down by each 
ABP. However, from the pull-down of the control proteases (Figure 4.16), bovine 
trypsin, recombinant soluble hepsin and recombinant KLK4, it appears that trypsin may 
have a higher affinity for biotin-EGR-CMK (lane 11) than biotin-FPR-CMK (lane 24). 
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Figure 4.16 Activity-based probe pull-down of hepsin, TMPRSS2 and KLK4 from the cell surface of transfected Cos-7 cells 
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While in contrast, hepsin and KLK4 may have marginally more affinity for biotin-FPR-
CMK (lanes 25 and 26) than biotin-EGR-CMK (lanes 12 and 13).  
In contrast to the cell surface ABP pull-down, KLK4 was not isolated from conditioned 
media by either biotin-EGR-CMK or biotin-FPR-CMK (Figure 4.17A, anti-V5 blots). 
Multiple proteases were isolated from the conditioned media, as indicated by the blots 
probed with Streptavidin-680 (Figure 4.17A). Furthermore, the anti-V5 Western blot 
analysis of the input conditioned media (Figure 4.17B) shows that KLK4 and KLK4SA 
are expressed. Indeed, Figure 4.17B is consistent with data presented earlier (in Figures 
4.8 and 4.9, respectively) that co-expression with hepsin causes a reduction in intensity 
of these bands (lanes 3 and 4), and co-expression with TMPRSS2 results in a reduction 
in MW of KLK4 and KLK4SA equivalent to ~1 kDa (lanes 10 and 11). It appears that 
processing of KLK4 by hepsin leads to degradation, while processing by TMPRSS2 
results in truncation; however the ABP data suggests that at the time point analysed no 
active KLK4 was present in the medium.  
ABP pull-down was also performed on cells co-expressing KLK14 and hepsin. Similar 
results were obtained as active KLK14 was not pulled down from the conditioned 
media (data not shown). Due to time-constraints further investigation of KLK14 was 
not undertaken. 
Nonetheless, taken together, these data indicate that active KLK4, hepsin and 
TMPRSS2 can be isolated from the cell surface of transfected Cos-7 cells. Significantly, 
this is the first time active KLK4 has been demonstrated in cell-based assays. 
 
4.2.2 Proteolytic interactions of hepsin, TMPRSS2 with MMP3 and 
MMP9 
The above data indicate that hepsin and TMPRSS2 are able to mediate cleavage of 
KLK14 and KLK4 at the cell surface. It is possible that this pericellular activity extends 
to activation or degradation of other secreted proteases. It has previously been shown 
that the TTSP matriptase activates MMP3 (Jin et al., 2006) and that MMP3 activates 
MMP9 (Ogata et al., 1992; Shapiro et al., 1995) and KLK4 (Beaufort et al., 2010). So, 
MMP3 and MMP9 were chosen as there is potential for proteolytic cascades of 
activation and regulation between these MMPs as well as KLK14 and KLK4 and the 
TTSPs hepsin and TMPRSS2. The potential for hepsin and TMPRSS2 to interact with 
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secreted matrix metalloproteinases, MMP3 and MMP9, was examined in this section 
using approaches similar to the previous section. Matriptase was also included in some 
of the following assays as it has previously been shown to activate MMP3 (Jin et al., 
2006; Milner et al., 2010).  
Figure 4.17 Activity-based probes do not pull down KLK4 from media of Cos-7 cells co-expressing hepsin or TMPRSS2 
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4.2.2.1 Pericellular proteolysis of MMP3 and MMP9 by hepsin, TMPRSS2 
and matriptase 
To examine the interaction of hepsin with MMP3 and MMP9, hepsin-Flag, TMPRSS2-
Myc and matriptase were co-expressed with MMP3 or MMP9, or both. Conditioned 
media and whole-cell lysates were examined by Western blot analysis using anti-MMP3 
and anti-MMP9 antibodies under reducing and non-reducing (not shown) conditions. 
As shown in Figures 4.18 to 4.20 of anti-MMP3 Western blot analyses, full-length 
MMP3 was detected at 57 kDa in cell lysate and conditioned medium. When MMP3 is 
co-expressed with hepsin, TMPRSS2 or matriptase, it is proteolysed to 46 and 45 kDa as 
well as several other cleaved forms including 53, 30 and 28 kDa. These cleaved forms 
were readily detected in cell lysate and to a lesser degree in conditioned media. 
Moreover, the co-expression of MMP9 does not alter the MMP3 cleavage products of 
hepsin, TMPRSS2 or matriptase. 
Interestingly, as MMP3 has been shown to activate in a stepwise manner with proteases 
first cleaving MMP3 to an intermediate form followed by self-activation by cleaving the 
remaining part of the pro- region to yield a 45 kDa mature peptide (Okada et al., 1986; 
Okada et al., 1988; Nagase et al., 1990), it is possible hepsin, TMPRSS2 and matriptase 
activate MMP3 by generating the 53 kDa intermediate which then self-activates. 
However, the 53, 46 and 45 kDa bands are also present, to a lesser degree, when MMP3 
is expressed alone. This may indicate the Cos-7 cells express a protease that is activating 
the expressed MMP3 as well.  
In the anti-MMP9 Western blot analyses in Figures 4.18 to 4.20, full-length MMP9 was 
detected at 92 kDa in both cell lysates and conditioned media. When expressed alone, 
MMP9 also has an 86 kDa band that can only be seen in cell lysates. Interestingly, when 
MMP9 is co- expressed with hepsin, TMPRSS2 or matriptase there is almost complete 
conversion of the 92 kDa form to 86 and 82 kDa forms. Again these cleaved forms are 
only seen in cell lysates. Furthermore, the co-expression of MMP3 with hepsin or 
matriptase did not alter the bands generated. Like MMP3, MMP9 also activates in a 
stepwise manner with an ~86 kDa intermediate form generated first, followed by the 
~82 kDa active form (Morodomi et al., 1992; Ogata et al., 1992). But MMP9 can also be 
activated by a single proteolysis step (Sorsa et al., 1997).  
In summary, hepsin, TMPRSS2 and matriptase proteolysed MMP3 and MMP9 to 
produce putative active forms of 45 and 82 kDa, respectively. 
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Figure 4.18 Pericellular proteolysis of MMP3 and MMP9 by hepsin 
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Figure 4.19 Pericellular proteolysis of MMP3 and MMP9 by TMPRSS2 
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Figure 4.20 Pericellular proteolysis of MMP3 and MMP9 by matriptase 
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4.2.2.2 MMP3 and MMP9 co-immunoprecipitate with hepsin and 
TMPRSS2 
As MMP3 and MMP9 are proteolysed by hepsin and TMPRSS2 at the cell surface, the 
interactions were examined further using immunoprecipitation of the transiently 
transfected proteases from cell lysates. 
MMP3 and MMP9 were transiently co-expressed in Cos-7 cells with either hepsin-Myc 
or TMPRSS2-Myc. Cell lysates were subjected to immunoprecipitation using an anti-
Myc antibody to precipitate hepsin-Myc and TMPRSS2-Myc, and anti-MMP3 or anti-
MMP9 antibodies to precipitate MMP3 and MMP9, respectively. The precipitates were 
then examined by Western blot analysis under reducing conditions using anti-MMP3, 
anti-MMP9 and anti-Myc antibodies. 
As shown in the anti-MMP3 Western blot analysis in Figure 4.21A, full-length MMP3 as 
well as 53, 45 and 46 kDa cleaved MMP3 were co-immunoprecipitated with hepsin and 
TMPRSS2.  In contrast, in the anti-MMP9 Western blot analysis (Figure 4.21B), cleaved 
MMP9, at 86 and 82 kDa, were co-immunoprecipitated with hepsin and TMPRSS2 
while full-length MMP9 at 92 kDa was not. This is consistent with results presented in 
Figures 4.18 and 4.19, where hepsin and TMPRSS2 co-expression resulted in the almost 
complete conversion of MMP9 to the 86 and 82 kDa forms. In addition, anti-MMP3 
and anti-MMP9 Western blot analysis of the flow-through fractions from the 
immunoprecipitations shows the full-length MMP9 is only present in a substantial 
amount when MMP9 is expressed alone.  
The reverse immunoprecipitation was used to confirm the interaction of MMP3 and 
MMP9 with hepsin and TMPRSS2. As shown in the anti-Myc Western blot analyses of 
the MMP3 and MMP9 immunoprecipitations in Figure 4.22, hepsin (Figure 4.22A) and 
TMPRSS2 (Figure 4.22B) are co-immunoprecipitated with MMP3 and MMP9. 
Furthermore, while hepsin and TMPRSS2 have multiple cleaved forms, full-length and 
the serine protease domain of hepsin/TMPRSS2 predominate in the co-
immunoprecipitation. 
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Figure 4.21 Co-immunoprecipitation of MMP3 and MMP9  with hepsin and TMPRSS2 from transfected Cos-7 cells 
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Figure 4.22 Co-immunoprecipitation of hepsin and TMPRSS2 with MMP3 and MMP9 from transfected Cos-7 cells 
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4.2.2.3 Gelatin zymography of MMP3 and MMP9 co-expressed with hepsin 
and TMPRSS2 in Cos-7 cells 
As hepsin and TMPRSS2 mediate cleavage of MMP3 and MMP9 generating bands 
corresponding with the known MW for the active forms of these proteases, further 
experiments were performed to examine the proteolytic activity of the generated bands. 
Zymography was used as it is a method for visualising hydrolytic enzymes and has been 
used extensively for MMPs (Vandooren et al., 2013). Gelatin zymography relies on in-
gel hydrolysis of gelatin by active protease followed by staining of the gel to show the 
areas of proteolytic activity. The hydrolysis in the gel is seen as a clear band, marking 
proteolytic activity. In the case of MMPs, the act of denaturing and renaturing the 
proteins, inherent in the zymography process, can activate pro- MMPs and intermediate 
forms by moving the inhibitory pro- region (Vandooren et al., 2013). So, these forms as 
well as MMPs that have been bound to inhibitors, and released by the denaturing 
process, will also be detected by zymography. Therefore, to distinguish which forms are 
intermediate and which forms have biologically relevant activity, a second assay should 
be used such as an activity based probe. However, due to time constraints, this 
investigation of MMP3 and MMP9 activity was not performed.  
MMP3 and MMP9 were transiently co-expressed in Cos-7 cells with hepsin-Myc or 
TMPRSS2-Myc and the ×10 concentrated conditioned media subjected to SDS-PAGE 
using gelatin-infused gels which were resolved under non-reducing conditions to 
preserve the intramolecular disulphide bonds of the MMPs, followed by gelatin 
zymography.  
As shown in Figure 4.23, there are bands on the gel representing pro-MMP3 (57 kDa) 
and the intermediate (53 kDa). However, the 45 kDa “active” MMP3 band is not 
present either when MMP3 is expressed alone or when co-expressed with hepsin or 
TMPRSS2. Moreover, no lower MW bands for MMP3 were detected on the gel. It is 
possible that the 45 kDa MMP3 band is obscured by a contaminant band that runs 
across all lanes at ~40 kDa – this contaminant band is not detected in the low intensity 
scan. On the other hand, it is possible the 45 kDa MMP3 is not in conditioned media; 
rather, it remains on the cell surface after activation. This is reflected by results shown 
previously in Figures 4.18 to 4.20 where very little cleaved MMP3 was detected in the 
media. From these results, however, it is unclear whether the 45 kDa MMP3 generated 
by hepsin and TMPRSS2 is active.  
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Figure 4.23 Gelatin zymography of MMP3 and MMP9 co-expressed with hepsin and TMPRSS2 in Cos-7 cells 
 
Interestingly, in contrast, 86 and 82 kDa bands of MMP9 generated when co-expressed 
with hepsin or TMPRSS2 are detected in the zymogram. This result is interesting as the 
previous Western blot analyses, shown in Figures 4.18 and 4.19, cleaved MMP9 was not 
detected in conditioned media. However, in the ×10 concentrated media, these bands 
representing intermediate (86 kDa) and active MMP9 (82 kDa) as well as full-length 92 
kDa MMP9 are detected on the zymogram.  
MMP9 is also detected at >250 kDa, representing MMP9 that was in complex, possibly 
with an inhibitor such as α2-macroglobulin. A large inhibitor (>180 kDa) such as this 
has a trapping mechanism which does not disable trapped the protease; rather it 
sterically hinders the protease active site to prevent substrate cleavage (Sottrup-Jensen, 
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1989; Rawlings et al., 2004). Therefore MMP9 released from this protease-inhibitor 
complex during the zymography denaturing-renaturing process may digest gelatin at this 
very high molecular weight. 
 
4.2.2.4 Recombinant hepsin and matriptase and bovine trypsin proteolyse 
MMP3 
Having established hepsin and matriptase cleave MMP3 and MMP9 in the pericellular 
environment, the interaction was examined further to see if soluble recombinant hepsin 
would activate the MMPs in conditioned media. Matriptase and bovine trypsin were 
assayed alongside because, as mentioned before, matriptase activates MMP3 (Jin et al., 
2006) and trypsin activates MMP3 and MMP9 (Nagase et al., 1990; Okada et al., 1992; 
Sorsa et al., 1997). Conditioned media from Cos-7 cells transiently expressing MMP3 or 
MMP9 were incubated with active recombinant hepsin, matriptase and bovine trypsin 
and examined by Western blot analysis under reducing and non-reducing (not shown) 
conditions using anti-MMP3 and anti- MMP9 antibodies. 
As shown in Figure 4.24, after 1 hour incubation MMP3 is proteolysed by hepsin, 
matriptase and trypsin to generate 53 kDa MMP3 (Figure 4.24A). Only hepsin generated 
potentially active 45 kDa and 46 kDa MMP3 within the first hour of incubation. 
However, all the serine proteases generated 45 and 46 kDa MMP3 within the 14 hours. 
Hepsin and matriptase also generated several lower MW forms of MMP3 in the 14 
hours. These bands were also seen in the analyses of lysates and media from the co-
expression assays (shown previously in Figures 4.18 to 4.20). 
In contrast, after 14 hours incubation, hepsin proteolyses 92 kDa MMP9 to the 82 kDa 
band, but otherwise MMP9 is relatively untouched by hepsin, matriptase or trypsin 
(Figure 4.24B). This is interesting as several publications have noted that MMP9 
activation is facilitated by the presence of cells or purified plasma membrane extract 
(Mazzieri et al., 1997; Fridman et al., 2003; Toth et al., 2003). Therefore, while MMP9 
was proteolysed at the cell surface by hepsin, TMPRSS2 and matriptase, as evidenced by 
cell lysate analyses, (Figures 4.18 to 4.20), it may not be readily proteolysed in cell-free 
media. 
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Figure 4.24 Co-incubation of recombinant hepsin, matriptase and bovine trypsin with MMP3 and MMP9 from transfected Cos-7 cells 
 
 
4.3 Discussion  
This chapter used a diverse range of approaches to explore the complexity of 
interactions occurring between secreted proteases KLK4 and KLK14, the 
transmembrane serine proteases hepsin and TMPRSS2, and to a lesser extent 
matriptase, and two matrix metalloproteinases MMP3 and MMP9. As summarized in 
Figure 4.25 the data suggest that:  
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Figure 4.25 Pericellular activity of KLK4, KLK14, hepsin and TMPRSS2 
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 Hepsin autoactivates, and hepsin and TMPRSS2 form homo-dimers or 
oligomers with other proteases or proteins 
 KLK4 and KLK14 are proteolysed by hepsin and TMPRSS2, and KLK4 
proteolyses hepsin and TMPRSS2 
 KLK4 and KLK14 co-localize with hepsin and TMPRSS2 independently of 
hepsin and TMPRSS2 activation 
 KLK14 and KLK4 are located on the cell surface in addition to being secreted 
into the medium 
 Active KLK4 is located on the cell surface 
 MMP3 and MMP9 are proteolysed by hepsin and TMPRSS2 (and matriptase) 
 MMP3 and MMP9 co-localize with hepsin and TMPRSS2 on the cell surface. 
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This is the first time cell-surface localization of KLK4 and KLK14 has been 
demonstrated. In addition, this is the first time active KLK4 has been isolated from the 
cell surface. The data in this chapter set up the premise for a proteolytic cascade at the 
plasma membrane involving TMPRSS2 or hepsin activating MMP3 and MMP9, with 
activated MMP3 in turn activating KLK4. 
 
4.3.1 KLK4 and KLK14 are proteolysed by hepsin and TMPRSS2, and 
KLK4 proteolyses hepsin and TMPRSS2  
As several members of the TTSP family autoactivate (Antalis et al., 2011), establishing 
the autoactivation status of hepsin was deemed a priority for the investigation of hepsin 
interactions with KLK14 and KLK4. The results presented in this Chapter are 
consistent with unpublished data by Qiu and colleagues (2007) and results from mouse 
hepsin studies by Vu and colleagues (1997) that human hepsin autoactivates. In 
addition, the results in this chapter indicate that TMPRSS2 autoactivates, consistent with 
a previous study by Afar and colleagues (2001).  
The data also indicate that hepsin and TMPRSS2 form high MW complexes of >90 kDa 
and >200 kDa, respectively, which suggests that they form homo-dimers or oligomers 
with other proteins. Consistent with this, hepsin and TMPRSS2 zymogens were isolated 
by ABP pull-down, suggesting that the unactivated proteases formed oligomers with 
active protease in order for this to occur. It is possible that homo-dimer formation may 
be a mechanism by which hepsin and TMPRSS2 self-activate. Certainly, they each have 
an unpaired cysteine residue in their serine protease domain of unknown significance 
(Leytus et al., 1988; Kurachi et al., 1994; Paoloni-Giacobino et al., 1997; Jacquinet et al., 
2001). It is possible these unpaired cysteines assist in dimerization and autoactivation 
through intermolecular disulphide bond formation. Investigation of autoactivation of 
matriptase has determined that a number of elements can induce and contribute to 
autoactivation including, reduced pH (Lee et al., 2007), serum sphingolipid sphingoine 
1-phosphate and suramin (Lee et al., 2005), several regions of the matriptase stem 
domain (Oberst et al., 2003b; Lee et al., 2007; Inouye et al., 2013), and the serine 
protease prostasin as a co-factor (Szabo et al., 2012; Buzza et al., 2013). It is not yet 
known whether similar factors have a role in the autoactivation of hepsin or TMPRSS2.  
As autoactivating proteases, hepsin and TMPRSS2 potentially have roles in initiating 
cellular processes. Hepsin has been ascribed roles in degradation of target proteins such 
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as laminin (Tripathi et al., 2008), and cascade participation through activation of several 
proteins including factor VII (Kazama et al., 1995; Halabian et al., 2009), matriptase 
(Camerer et al., 2010), HGF (Herter et al., 2005; Kirchhofer et al., 2005; Owen et al., 
2010), uPA (Moran et al., 2006) and macrophage-stimulating protein (Ganesan et al., 
2011). In contrast, there are few known substrates of TMPRSS2. To-date the only 
recognized proteolytic targets of TMPRSS2, other than itself, are PAR2 (Wilson et al., 
2005), respiratory virus surface proteins associated with infectivity and spread (Bottcher 
et al., 2006; Shirogane et al., 2008; Chaipan et al., 2009; Bertram et al., 2010; Bottcher-
Friebertshauser et al., 2010; Matsuyama et al., 2010; Glowacka et al., 2011; Shulla et al., 
2011; Heurich et al., 2013; Shirato et al., 2013), and possibly the epithelial sodium 
channel (ENaC) (Donaldson et al., 2002). 
The results in this chapter indicate that KLK14 and KLK4 may be substrates of hepsin 
and TMPRSS2. When co-expressed with hepsin or TMPRSS2, cleaved forms of KLK14 
and KLK4 were generated, or the levels of KLK14 and KLK4 in the conditioned media 
were reduced. Furthermore, when recombinant KLK4 and KLK14 zymogens were co-
incubated with the spontaneously active recombinant hepsin, KLK14 and KLK4 were 
proteolysed. However, the reaction was not efficient in this cell-free assay system as 
equimolar concentrations of hepsin were required to achieve KLK14 proteolysis, and 
little proteolysis was observed for either KLK14 or KLK4.  
It was interesting that in the co-expression assays, hepsin- and TMPRSS2-cleaved forms 
of KLK14 remain either at the cell surface or are internalized as these forms were only 
detected in cell lysates and not in conditioned media. Furthermore, the reduced levels of 
KLK14 detected in the media when co-expressed with TMPRSS2 may be due to 
KLK14 being cleaved close to the C-terminal epitope tag rendering it undetectable by 
the antibody to the tag. Or it could be that KLK14 is cleaved and sequestered to the cell 
surface by TMPRSS2. Overall, however, the impact of hepsin or TMPRSS2 on the 
proteolysis of KLK14 appeared to be relatively minor. This may be a reflection of the 
short transfection time in the co-expression studies, or it may be that hepsin and 
TMPRSS2 have minor roles in the regulation of KLK14.  
However, it is also likely that activation of KLK14 would be achieved by a protease with 
a preference for a Lys P1 residue. The transmembrane serine protease enteropeptidase is 
one such protease with a preference for Lys P1 (Zheng et al., 2009). Indeed, Brattsand 
and colleagues (2005) used enteropeptidase to activate recombinant KLK14. Due to 
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what was thought to be very restricted expression of enteropeptidase, it was not initially 
considered a candidate protease for endogenous activation. Enteropeptidase has been 
found repeatedly to be restricted in expression to the duodenum with expression rapidly 
tapering beyond this tissue (Zheng et al., 2009). Recently, however, enteropeptidase was 
detected in oral squamous cell carcinomas (Vilen et al., 2008), as well as during terminal 
differentiation of keratinocytes in the epidermis granular layer (Nakanishi et al., 2010). 
This is very interesting as KLK14 is located in the stratum corneum, in the outer most 
layer of the epidermis (Brattsand et al., 2005; Stefansson et al., 2006). Based on this 
information, preliminary experiments were performed to determine if co-expression of 
KLK14 and enteropeptidase resulted in KLK14 activation. Unfortunately, as anti-
enteropeptidase antibody was not specific, the results were not able to be interpreted 
and further studies are required. 
In comparison with KLK14, hepsin and TMPRSS2 co-expression had a greater impact 
on KLK4. In addition to detection of hepsin- and TMPRSS2-cleaved forms of KLK4 in 
cell lysates, TMPRSS2-cleaved KLK4 was also detected in media. Moreover, the levels 
of KLK4 in media were markedly reduced when co-expressed with hepsin. The 
interactions also differed from those with KLK14 in that KLK4 mediated cleavage in 
the stem regions of hepsin and TMPRSS2, the products of which were detected in the 
lysate. The activity of KLK4 was independent of hepsin and TMPRSS2 activity as 
KLK4 mediated hepsinSA and TMPRSS2SA cleavage as well. The significance of this 
for hepsin and TMPRSS2 function is not known but it does indicate that KLK4 was 
active in the transient transfections. This is interesting as KLK4 in conditioned media 
had no proteolytic impact on KLK14 in co-expression assays or co-incubation of 
conditioned media. This may have been because KLK4 was inactive, inhibited or had an 
alternative, preferred proteolysis target in the conditioned media. Certainly, activated 
KLK4 has been shown to form non-covalent oligomers consisting of stacked cyclic 
tetramers in solution (Debela et al., 2006a). Inactivity of KLK4 when in these 
conformations has been attributed to obstruction of the active site (Debela et al., 
2006a). Taken together it was possible to speculate that active KLK4 was located at the 
cell surface but not in the media. 
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4.3.2 KLK4 and KLK14 co-immunoprecipitate with hepsin and TMPRSS2, 
and KLK14 and active KLK4 are located on the cell surface 
As levels of KLK4 and KLK14, to a lesser extent, were reduced in conditioned media 
either through conversion to lower molecular weight forms or sequestration to the cell 
surface by hepsin and TMPRSS2, this led to investigation of the cell-surface interactions 
between KLK4 and KLK14 and the TTSPs. Immunoprecipitation was the first tool 
used to investigate these relationships and the results indicated that full-length KLK4 
and KLK14, and hepsin- or TMPRSS2-generated cleaved forms, co-
immunoprecipitated with hepsin and TMPRSS2. The co-immunoprecipitation of full-
length KLK4 and KLK14 was independent of hepsin and TMPRSS2 active site integrity 
as they also co-immunoprecipitated with hepsinSA and TMPRSS2SA.  
From these results, however, it is unclear whether the association between 
KLK14/KLK4 and hepsin/TMPRSS2 is direct or mediated by other proteins, and 
further, whether the interaction is at the cell surface or internal. Accordingly, cell-surface 
biotinylation was used to examine if KLK4 and KLK14 localized to the plasma 
membrane. These results showed that KLK14 and KLK4 were located on the cell 
surface of the transiently transfected cells, independent of hepsin or hepsinSA co-
expression. Furthermore, active KLK4 and KLK14 were not isolated from the media by 
ABPs. However, when ABPs were used against cell-surface proteins, active KLK4 was 
detected in cell lysates. Again, active KLK4 was detected independent of hepsin and 
TMPRSS2 activity. As neither active KLK4 nor active KLK14 were detected in the 
media, as discussed earlier, it is possible that KLK4 and KLK14 are inactive (not 
activated). Or perhaps active forms are inhibited in the media by oligomerization, as 
previously observed for KLK4 (Debela et al., 2006a), or by secreted inhibitors. Other 
possibilities include that active KLK4 and KLK14 are rapidly degraded, or the 
transfection period was of insufficient length to allow accumulation of a detectable 
amount of activated protease in the media. Early experiments (data not shown) included 
transfections of up to 48 hours for co-expression of KLK4 and KLK14, as well as 
KLK4 and KLK14 with hepsin or TMPRSS2. The data in these experiments did not 
indicate any activity for KLK4 or KLK14 in the conditioned media. However, ABP 
assays were not performed in these instances.  
Taken together, these data suggest a role for KLK14 and KLK4 in the pericellular 
environment. However, the mechanisms responsible for localizing secreted KLK14 and 
KLK4 at the surface are unknown. These proteases may be localized to the surface 
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upon secretion or sequestered from the medium by other cell-surface proteins. KLK14, 
KLK4, hepsin and TMPRSS2 may form part of a larger complex of proteins localized at 
the surface. Indeed, zymogen hepsin and TMPRSS2 were pulled-down in the ABP 
assays, possibly as a result of forming complexes with active proteases. It is possible the 
multi-protein complexes have a role in regulation of the activity of the individual 
components as cofactors, activators or regulation by degradation.  
 
4.3.3 Interactions of MMP3, MMP9, hepsin and TMPRSS2 
As mentioned earlier, KLK4 has a Gln as the P1 residue of its pro-region (Nelson et al., 
1999; Stephenson et al., 1999). This is unique in the KLK family, as all the other KLKs 
have Arg or Lys as the P1 residue (Yousef and Diamandis, 2001). It also makes it 
unlikely a serine protease with trypsin-like specificity will activate KLK4 (Takayama et 
al., 2001a; Matsumura et al., 2005; Yoon et al., 2007). In searching for proteases that 
activate KLK4, studies have turned to proteases outside of the serine protease family. 
So far, two proteases have been shown to activate KLK4, dipeptidyl peptidase I (DPPI), 
also known as cathepsin C (Tye et al., 2009), and MMP3 (Beaufort et al., 2010).  There is 
a potential activation cascade between an upstream protease activating MMP3 followed 
by MMP3 activating KLK4. MMP3 is able to be activated by a few serine proteases 
including matriptase and trypsin (Jin et al., 2006) and also plasmin (Ramos-DeSimone et 
al., 1999). In turn, MMP3 is able to activate MMP9 (Ogata et al., 1992; Shapiro et al., 
1995). So, the possibility of an activation cascade was examined by first looking at the 
activation of MMP3 and MMP9 by hepsin and TMPRSS2 and also by matriptase. 
The results of co-expression of MMP3 and MMP9 with hepsin, TMPRSS2 and 
matriptase were interesting. Similar to the results for KLK14 and KLK4 co-expression 
with hepsin and TMPRSS2, proteolysed MMP3 and MMP9 were detected in cell lysates. 
Moreover, bands of MWs corresponding to the active forms of MMP3 and MMP9 were 
among the cleaved forms detected in cell lysates. Interestingly, when compared to the 
double transfection of a TTSP with either MMP3 or MMP9, the triple co-transfection 
of a TTSP with both MMP3 and MMP9 conferred little to the proteolysis of MMP3 or 
MMP9. Very little cleaved MMP3 and no cleaved MMP9 were detected in the 
conditioned media. This could be because of the short transfection period of 24 hours. 
A longer transfection before processing the conditioned media may increase the 
detection of cleaved MMP9 and MMP3 in the media. However, the lack of cleaved 
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MMP3 and MMP9 in the media may also indicate a role for the activated MMPs in the 
pericellular environment.  
Gelatin zymography was used to assess whether activated MMP3 and MMP9 could be 
detected in the media. Unfortunately, it is unclear whether the 45 kDa MMP3 generated 
by hepsin and TMPRSS2 was active as the zymography did not show a band at this MW 
in the media. However, the 82 kDa MMP9 generated by hepsin and TMPRSS2 was 
detected and was active in the media. To extend this work, two approaches can be 
taken. First, MMP3 and MMP9 should be isolated from cell lysates by antibody affinity 
chromatography and then gelatin zymography performed on the isolates. Second, 
another method should be used to validate the zymography of the media and cell lysates 
as zymography has an inherent weakness. As mentioned earlier, as well as biologically 
relevant active MMP, pro-MMP and intermediate forms are also detected in the 
zymography assay. So, to distinguish which forms are intermediate and which forms 
have biologically relevant activity, a second assay should be used to confirm the data 
such as an ABP-based approach. Due to time constraints, the additional investigation of 
MMP3 and MMP9 activity was not performed.  
Co-immunoprecipitations of MMP3 and MMP9 with hepsin and TMPRSS2 from cell 
lysates reinforced the argument for a role for MMP3 and MMP9 in the pericellular 
environment through interaction with cell surface proteins. It is unknown if the 
interaction with the TTSPs is direct or mediated by a larger protein complex, as 
speculated earlier for KLK14 and KLK4. Indeed, several studies have shown MMP9 
associated with the plasma membrane by a variety of interactions including endothelial 
cell focal contacts (Partridge et al., 1997), uPA and uPAR (Mazzieri et al., 1997), CD44 
(Yu and Stamenkovic, 1999), and several integrins (Morini et al., 2000; Stefanidakis et 
al., 2004; Yang et al., 2008). It is possible that one or more of these interactions 
contributes to cell-surface association of MMP3 and MMP9 with the TTSPs. 
Plasma membrane association is thought to favour activation of MMP9 (Toth et al., 
2003). So it was interesting that MMP9 in conditioned media from transiently 
transfected cells was not proteolysed by recombinant matriptase or bovine trypsin. After 
14 hours incubation, recombinant hepsin achieved minimal MMP9 cleavage. In 
contrast, MMP3 in conditioned media was efficiently proteolysed to generate the 
putative active 45 kDa form when incubated with recombinant hepsin. Matriptase and 
trypsin also generated this 45 kDa form of MMP3, however, not as rapidly as hepsin. 
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Together, these data suggest a role for hepsin and TMPRSS2 in the pericellular 
proteolysis and activation of MMP3 and MMP9. Furthermore, the proteolysis of MMP9 
may be dependent on the plasma membrane. 
 
4.3.4 Summary 
In this chapter proteolytic interactions between the serine proteases KLK14, KLK4, 
hepsin and TMPRSS2 were examined as well as the interactions between hepsin and 
TMPRSS2 and the metalloproteinases MMP3 and MMP9. The results demonstrated 
that hepsin and TMPRSS2 interact with KLK14, KLK4, MMP3 and MMP9 in the 
pericellular environment resulting in proteolysis at the cell surface. 
This work adds to the growing body of studies that have proposed proteolytic 
interactions between KLKs and members of other protease families. As summarized in 
the hypothetical zymogen cascade in Figure 4.26, TTSPs hepsin, TMPRSS2 and 
matriptase are all potentially capable of activating MMP3 which in turn activates KLK4. 
KLK14 on the other hand is potentially activated by other members of the KLK family 
such as KLK5, or by TTSP enteropeptidase. Both KLKs, however, interact with the 
plasminogen activation system: KLK4 through activation of uPA, which in turn 
activates plasminogen to plasmin; and KLK14 though activation by plasmin. 
It is recognized that there are limitations to the overexpression approach used in this 
thesis to examining proteolytic interactions. These include that biologically irrelevant or 
non-preferred substrates may be cleaved because of the artificially high expression levels 
or because the proteases are not normally co-expressed (Overall and Blobel, 2007).  It is 
therefore necessary to validate potential interactions using cells that endogenously 
express these proteins using methods such as co-immunoprecipitation to identify 
interacting partners. There are also knockout mouse models available for several of the 
proteases examined in this study, including KLK4 (Simmer et al., 2009), hepsin (Wu et 
al., 1998) and TMPRSS2 (Kim et al., 2006). These in vivo models can be used in 
approaches such as through global characterization of substrate processing by 
identifying amino-termini modification using methods such as terminal amine isotopic 
labelling of substrates (TAILS)(Kleifeld et al., 2011). 
New proteolytic interactions in the pericellular environment are constantly emerging, 
however, there a numerous proteases whose proteolytic roles have not been determined.  
193 
 
Figure 4.26 KLK4 and KLK14 in zymogen cascades 
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The serine proteases kallikrein 14 (KLK14) (2, 3), kallikrein 4 (KLK4) (4-8), hepsin (9-
11) and TMPRSS2 (12, 13), are all overexpressed at the mRNA and/or protein level in 
prostate cancer tissues compared to normal prostate. Each of these serine proteases has 
the potential to interact in novel proteolytic cascade pathways in the dysregulated 
cancerous prostate environment and contribute to disease progression. 
One of the results of proteolytic cascades can be initiation of cell signalling via cell 
surface receptors. A system that has gained recognition as a potential contributor to the 
progression of prostate cancer is the four member family of protease activated receptors 
(PARs) designated PAR-1 to PAR-4. Cleavage and signalling through the PARs, which 
constitute a sub-family of G protein-coupled receptors (GPCRs), is achieved by trypsin-
like serine protease proteolysis of an activation peptide sequence from the extracellular 
N-terminal of the PAR. Activation of the PARs will be examined in more detail in the 
following chapter.  
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Chapter 5 Analysis of PAR activation by KLK4, 
KLK14 and hepsin  
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5.1 Introduction 
PARs are members of the GPCR super-family, a family of structurally similar proteins 
that mediate outside-in cell signalling (Macfarlane et al., 2001; Oldham and Hamm, 
2008). Intracellular signalling events initiated as a result of PAR activation are diverse 
and complex, and they contribute to myriad cellular events (as reviewed extensively in 
(Macfarlane et al., 2001; Ossovskaya and Bunnett, 2004; Coughlin, 2005; Steinhoff et al., 
2005; Soh et al., 2010; Adams et al., 2011)). The role of PARs in tumours and the 
tumour microenvironment is of particular interest as there is a growing body of 
evidence that PAR-induced Ca2+ signalling can contribute to progression of some cancer 
characteristics such as inflammation, cell proliferation, migration and invasion 
(Ossovskaya and Bunnett, 2004; Steinhoff et al., 2005; Kaufmann and Hollenberg, 2012; 
Rothmeier and Ruf, 2012). Signalling via the PARs has been characterized in a number 
of cell lines and tumour cells including breast (Even-Ram et al., 1998; D'Andrea et al., 
2001; Kamath et al., 2001; Matej et al., 2007; Su et al., 2009), non-melanoma skin cancer 
(Bocheva et al., 2009), colon (Darmoul et al., 2001; Darmoul et al., 2003; Darmoul et al., 
2004a; Darmoul et al., 2004b; Gratio et al., 2009; Gratio et al., 2010; Gratio et al., 2011), 
renal (Kaufmann et al., 2002; Zhang et al., 2013) and prostate (Chay et al., 2002; 
Greenberg et al., 2003; Cottrell et al., 2004; Tantivejkul et al., 2005; Wilson et al., 2005; 
Kaushal et al., 2006; Black et al., 2007; Mize et al., 2008; Ramsay et al., 2008a; Zhang et 
al., 2009). 
Activation of signalling via the PARs is one of the potential roles of serine proteases in 
the pericellular microenvironment. The serine proteases KLK4, KLK14, hepsin and 
matriptase are attractive targets for analysis of PAR activation due to their co-incident 
expression with PARs in several tissues. Of particular interest is that in prostate tissue 
and prostate cancer, KLK4 (Day et al., 2002; Obiezu et al., 2002; Xi et al., 2004; Dong 
et al., 2005; Obiezu et al., 2005; Klokk et al., 2007; Ramsay et al., 2008a; Seiz et al., 2010; 
Wang et al., 2010), KLK14 (Borgono et al., 2007c; Rabien et al., 2008), hepsin 
(Dhanasekaran et al., 2001; Xuan et al., 2006; Morrissey et al., 2008; Goel et al., 2011) 
and matriptase (Saleem et al., 2006) protein are expressed along with PAR1, PAR2 and 
PAR4 (D'Andrea et al., 1998; Myatt and Hill, 2005; Tantivejkul et al., 2005; Kaushal et 
al., 2006; Black et al., 2007; Ramsay et al., 2008a; Wang et al., 2008; Zhang et al., 2009; 
Mannowetz et al., 2010). Kidney is another tissue where expression of PAR1, PAR2 and 
PAR3 (Rondeau et al., 1996; D'Andrea et al., 1998; Grandaliano et al., 2000; Kaufmann 
et al., 2002; Grandaliano et al., 2003; Vesey et al., 2005; Vesey et al., 2007; Zhang et al., 
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2013) and KLK4 (Shaw and Diamandis, 2007; Seiz et al., 2010) has been noted. In 
particular, overlapping protein expression of PAR2 and KLK4 has been reported in 
human kidney proximal tubule cells (PTC) by Vesey and colleagues (2007)(and personal 
communication). Furthermore, from the results in the previous chapter, KLK4 and 
KLK14 localization to the cell surface may be facilitated by multi-protein complexes 
involving TTSPs, such as hepsin and possibly matriptase, as well as MMPs. This cell 
surface localization of the KLKs may facilitate pericellular activity including activation 
of PARs. 
As reviewed in Chapter 1, PARs can be activated by specific proteolysis of the 
extracellular N-terminal to reveal a new N-terminus known as the tethered ligand (Vu et 
al., 1991a; Ramachandran et al., 2012a). It is supposed that the PAR tethered ligand 
binds intra-molecularly to extracellular domains to effect PAR conformation change and 
intracellular C-terminal domain recruitment of G proteins and other signalling 
molecules (Vu et al., 1991a; Adams et al., 2011). One method used in this chapter for 
assessing PAR activation monitors intracellular mobilization of second messenger 
calcium (Ca2+). This exploits elements of signalling cascades triggered by Gq-coupling to 
activated PAR (Macfarlane et al., 2001; Steinhoff et al., 2005; Kaufmann and 
Hollenberg, 2012) (Figure 5.1). Proteolysis at distinct sites in the N-terminal domain can 
also disarm PARs by rendering the tethered ligand unavailable for receptor activation 
(Renesto et al., 1997; Dulon et al., 2003; Nakayama et al., 2003; Adams et al., 2011).  
As in other members of the GPCR super-family, PAR signalling is terminated by a 
range of mechanisms including phosphorylation of the intracellular C-terminal, 
recruitment of β-arrestins, subsequent uncoupling of the G-proteins and internalization 
of activated PARs (Soh et al., 2010; Adams et al., 2011). There is still a great deal to 
learn about PAR signal termination, especially for PAR3 and PAR4. However, as 
activation by proteolysis is irreversible, ultimately, the PARs are targeted for lysosomal 
degradation (Bohm et al., 1996a; Shapiro and Coughlin, 1998; Soh et al., 2010).  
PAR1, PAR2 and PAR4 can also be selectively activated by short peptides, modelled on 
the tethered ligands, known as PAR agonist peptides (AP) (Vu et al., 1991a; 
Scarborough et al., 1992; Chen et al., 1994; Lerner et al., 1996). PAR APs are useful 
tools for interpreting the function of PARs (Hollenberg and Compton, 2002; 
Ramachandran et al., 2012b) and so are used for this purpose in this chapter. PAR3 can 
also be activated by proteolysis of the N-terminal (Ishihara et al., 1997). However, PAR3 
198 
 
signalling is complicated by its possible function as a cofactor for PAR4 activation 
(Nakanishi-Matsui et al., 2000; Bah et al., 2007) as well as regulator of PAR1 through 
receptor dimerization (McLaughlin et al., 2007). Moreover, a PAR AP capable of 
initiating signalling via PAR3 has not been identified (Ishihara et al., 1997; Nakanishi-
Matsui et al., 2000). For these reasons PAR3 activation has not been included in this 
chapter. 
  
Figure 5.1 Gq-mediated calcium signalling 
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As the P1 residue of the activation site for the PARs is either an Arg (PAR1, PAR2 and 
PAR4) (Vu et al., 1991a; Nystedt et al., 1994; Nystedt et al., 1995a; Xu et al., 1998), or a 
Lys (PAR3) (Ishihara et al., 1997) residue, numerous trypsin-like serine proteases have 
been analysed for their ability to activate the PARs.  The serine proteases used in this 
chapter, KLK4, KLK14 hepsin and matriptase, are ideal candidates to investigate the 
activation of PARs as they have a preference for cleaving after Arg residues (Lin et al., 
1999c; Lee et al., 2000; Takeuchi et al., 2000; Takayama et al., 2001a; Friedrich et al., 
2002; Brattsand et al., 2005; Felber et al., 2005; Herter et al., 2005; Matsumura et al., 
2005; Debela et al., 2006a; Debela et al., 2006b; Obiezu et al., 2006; Oikonomopoulou et 
al., 2006a; Borgono et al., 2007a; Borgono et al., 2007b; Borgono et al., 2007c; 
Stefansson et al., 2008; Beliveau et al., 2009; Owen et al., 2010). They have previously 
been assessed for their ability to activate or disarm PARs by cleaving within the PAR N-
terminal. It has been found that KLK4 activates PAR1 and PAR2 but not PAR4 (Mize 
et al., 2008; Ramsay et al., 2008a; Gratio et al., 2010); KLK14 activates PAR1, PAR2 and 
PAR4 and disarms PAR1 (Oikonomopoulou et al., 2006a; Stefansson et al., 2008; Gratio 
et al., 2011; Ramachandran et al., 2012a); and matriptase selectively activates PAR2 but 
not PAR1 or PAR4 (Takeuchi et al., 2000; Seitz et al., 2007; Camerer et al., 2010). Until 
recently it had not been established whether hepsin could activate members of the PAR 
family, but recently published work confirms the finding in this chapter that hepsin does 
not activate PAR1 or PAR2 (Camerer et al., 2010). Trypsin was also used in this chapter 
as a model PAR-activating protease. Trypsin was first recognized as a PAR2 activator by 
Nystedt and colleagues (1994). The presence of a trypsin cleavage site in the PAR2 N-
terminal has allowed trypsin to be used extensively in PAR2 activation studies (Bohm et 
al., 1996b; Macfarlane et al., 2001). Trypsin also activates and disarms PAR1 (Vu et al., 
1991a; Blackhart et al., 1996; Kawabata et al., 1999; Loew et al., 2000; Nakayama et al., 
2003), and activates PAR4 (Kahn et al., 1998; Xu et al., 1998). 
The aim of this chapter was to examine KLK4, KLK14, hepsin and matriptase 
activation of PARs. As an element of this, prostate cancer-derived LNCaP cells stably 
overexpressing hepsin were generated and characterized to examine proteolytic cascades 
resulting in activation of PARs. 
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5.2 Results 
5.2.1 KLK14, matriptase and hepsin can affect signalling by either 
activating or disarming PARs 
At the beginning of this project the ability of serine proteases KLK14 and hepsin to 
activate or disarm PARs had not previously been examined. The experiments described 
here use Ca2+ flux assays, assessing changes in free [Ca2+i], to interrogate the activation 
of PAR1, PAR2 and PAR4 by active recombinant KLK14, hepsin, matriptase and 
bovine trypsin. As stated earlier in Chapter 2,  the cell lines used in these experiments 
are derived from lung myofibroblasts immortalized from PAR1 -/- mice (Darrow et al., 
1996). These cells, also lacking functional endogenous mouse PAR2 and PAR4, have 
been transfected to stably express one each of the human PARs, PAR1, PAR2 or PAR4 
(Andrade-Gordon et al., 1999). Designated PAR1-LMF, PAR2-LMF and PAR4-LMF, 
these cell lines are useful in vitro tools for examining PAR activation as Ca2+ flux 
response is elicited from each line by the respective PAR AP. Consecutive treatments of 
serine protease followed by PAR AP provide information about the ability of the 
proteases to activate the PAR.  
 
5.2.1.1 PAR1 activation 
As shown in Figure 5.2A, PAR1AP (50 μM) elicited a robust change in free [Ca2+i] in 
PAR1-LMF cells. Trypsin (10 nM) and KLK14 (150 nM) (Figure 5.2B and C) induced 
modest change in [Ca2+i] while the follow up treatment with PAR1AP (50 μM), 180 
seconds after KLK14 introduction, induced a small, brief change in [Ca2+i]. This 
indicates that 150 nM KLK14 activated a portion of the PAR1 on the LMF cell surface 
but a portion remained and was activated by PAR1AP.  
In contrast, hepsin (50 nM) and matriptase (10 nM) elicited very little change in free 
[Ca2+i] (Figures 5.2D and E). Moreover, the follow up treatment with PAR1AP (50 μM), 
180 seconds after hepsin or matriptase, elicited a strong Ca2+ flux response of 
magnitude similar to that observed for the solo PAR1AP treatment shown in Figure 
5.2A. This indicates that hepsin and matriptase neither activated nor disarmed PAR1 
under these assay conditions.  
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Figure 5.2 Serine protease-induced cytosolic calcium release in PAR1-LMF cells 
 
 
5.2.1.2 PAR2 activation 
As shown in Figures 5.3, when compared to PAR2AP (50 μM), trypsin (10 nM) induced 
robust mobilization of free [Ca2+i] in PAR2-LMF cells. The response to KLK14 (150 
nM) was modest, and negligible response was induced by hepsin (50 nM) (Figure 5.3C 
and D). On the other hand, matriptase (10 nM) induced Ca2+ flux of a similar magnitude 
to that of trypsin (Figure 5.3E). The follow up treatment with PAR2AP (50 μM) after 
trypsin, KLK14 or matriptase, induced a small, brief change in [Ca2+i]. This indicates 
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that, at these protease concentrations a portion of the PAR2 remained on the LMF cell 
surface and was activated by PAR2AP (Figure 5.3B, C and E).  
Figure 5.3 Serine protease-induced cytosolic calcium release in PAR2-LMF cells 
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In contrast, the follow up treatment with PAR2AP (50 μM) after hepsin, elicited a 
strong Ca2+ flux response (Figure 5.3D). However, the magnitude of the post-hepsin 
PAR2AP response is lower than that observed for the solo PAR2AP treatment shown 
in Figure 5.3A. This indicates that while there is negligible hepsin-induced PAR2-
mediated Ca2+ flux under these assay conditions, hepsin did render a portion of the 
PAR2 insensitive to activation by PAR2AP. 
Further to this, when hepsin and matriptase were pre-incubated with the serine protease 
inhibitor HAI-1B (1 μM) (Figures 5.3F and G), the very small change in free [Ca2+i] 
elicited by hepsin and the substantial response elicited by matriptase were largely 
abolished and the Ca2+ flux response to the PAR2AP follow-up treatment was near 
equal to that observed for the solo PAR2AP treatment (Figure 5.3A). This indicates 
HAI-1B prevented activation of PAR2 mediated Ca2+ flux by matriptase and also 
inactivation by hepsin. 
 
5.2.1.3 PAR4 activation 
PAR4 has been shown to be less sensitive than PAR1 or PAR2 to activation by AP, 
trypsin and other serine proteases (Vu et al., 1991a; Nystedt et al., 1994; Xu et al., 1998; 
Faruqi et al., 2000; de Garavilla et al., 2001; Al-Ani and Hollenberg, 2003). Therefore, to 
elicit robust Ca2+ mobilization PAR4AP was used at concentrations of 150-500 μM, and 
trypsin and matriptase were used at 50 nM in Ca2+ flux assays of PAR4-LMF cells, 
concentrations higher than used for the PAR1 and PAR2 assays. However, due to 
limited supply higher concentrations of KLK14 and hepsin were not feasible. KLK14 
and hepsin were used at 150 and 50 nM, respectively, the same as used for the PAR1- 
and PAR2-LMF Ca2+ flux assays.  
As shown in Figure 5.4A, PAR4AP (150 μM and 500 μM) induced robust Ca2+ flux 
response in the PAR4-LMF cells. PAR4AP at 500 μM was used in early Ca2+ flux assays, 
replicating methods published by Ramsay and colleagues (2008a). However, as shown in 
Figure 5.4A, 150 μM PAR4AP induced a higher Ca2+ mobilization response from the 
PAR4-LMF cells and so was used in subsequent assays. 
Trypsin (50 nM) and KLK14 also activated PAR4 (Figures 5.4B and C). Subsequent 
application of PAR4AP (500 μM) after trypsin induced little change in free [Ca2+i] 
indicating that trypsin activated most of the PAR4 on the LMF surface. In contrast, the  
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Figure 5.4 Serine protease-induced cytosolic calcium release in PAR4-LMF cells 
 
 KLK14 follow up PAR4AP (150 μM) treatment induced a brief change in [Ca2+i] of 
similar magnitude to that induced by KLK14. This indicates that KLK14 activated a 
portion of the PAR4 on the LMF cell surface but a portion remained and was activated 
by PAR4AP. In contrast to trypsin and KLK14, hepsin (50 nM) and matriptase (50 nM) 
(Figures 5.4D and E) elicited no change in free [Ca2+i]. The follow up treatment of 
PAR4AP (500 μM) after hepsin and matriptase elicited strong Ca2+ flux responses of 
magnitude similar to that observed for 500 μM PAR4AP solo treatment. Therefore, 
hepsin and matriptase neither activated nor disarmed PAR4 under these conditions. 
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5.2.1.4 Dose response 
A comparison was made between the Ca2+ flux response of PAR1-, PAR2- and PAR4-
LMF cells to increasing concentrations of hepsin and trypsin, and of PAR2-LMF cells to 
increasing matriptase concentrations. As shown in Figures 5.5, with increasing 
concentrations of protease, maximal changes in free [Ca2+i] were reached at 
concentrations of 50, 5 and 50 nM trypsin for the PAR1-, PAR2- and PAR4-LMF cells, 
respectively. Likewise, the maximum response was achieved with 6 nM matriptase for 
the PAR2-LMF cells. The half maximal response, EC50, of trypsin was calculated to be 
~3.6, 0.68 and 16 nM for PAR1-, PAR2- and PAR4-LMF cells, respectively.  
Figure 5.5 Dose-response curves for cytosolic calcium release in PAR-LMFs elicited by serine proteases 
 
This is comparable to previously published trypsin EC50 results of 3.64 nM for PAR1, 
between 0.51 and 3 nM for PAR2, and 5 nM for PAR4 (Blackhart et al., 1996; Corvera 
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et al., 1997; Glusa et al., 1997; Xu et al., 1998; Knecht et al., 2007). The EC50 for 
matriptase was ~1.1 nM, comparable to previously published 0.3- >10 nM (Takeuchi et 
al., 2000; Camerer et al., 2010). In contrast, up to 100 nM hepsin failed to elicit 
substantial change in free [Ca2+i] in the three PAR-LMF cell lines. 
 
5.2.2 PAR2 activation by KLK4 in PAR2-LMF cell lines is inhibited by 
SFTI-FCQR 
Recently an inhibitor, SFTI-FCQR, was engineered by modifying residues in SFTI, 
using substrate-guided design, to create a potent, KLK4-specific inhibitor (Swedberg et 
al., 2009). In addition, the ability of KLK4 to activate PAR2-induced Ca2+ flux has been 
previously published (Mize et al., 2008; Ramsay et al., 2008a). So, to assess the ability of 
SFTI-FCQR to inhibit KLK4 activation of PAR2, Ca2+ flux assays were used to monitor 
changes in free [Ca2+i] in response to KLK4 treatment compared to SFTI-FCQR 
inhibited KLK4. 
As shown in Figure 5.6, trypsin (10 nM), KLK4 (200 nM) and PAR2AP (50 μM) 
induced Ca2+ flux in the PAR2-LMF cells (Figure 5.6A-C). When applied alone, the 
inhibitor SFTI-FCQR did not induce Ca2+ flux (Figure 5.6D). Furthermore, pre-
incubation of trypsin with SFTI-FCQR did not inhibit PAR2 activation by trypsin 
(Figure 5.6E). On the other hand, Ca2+ flux induced by KLK4 was completely abolished 
by pre-treatment with SFTI-FCQR (Figure 5.6F and G). Moreover, the PAR2 on the 
cell surface remains functional after treatment with KLK4/SFTI-FCQR as Ca2+ flux 
was induced by follow up treatment with either PAR2AP or trypsin. These results 
indicate that SFTI-FCQR inhibited KLK4 proteolytic activation of PAR2 and did not 
inhibit trypsin activation of PAR2. 
 
5.2.3 Trypsin, but not KLK4, activates PAR2 in primary kidney PTC 
Human kidney PTC have previously been shown to express both PAR2 and KLK4 
protein (Vesey et al., 2007)(personal communication from Dr D. Vesey). Activation of 
PAR2 on these cells by trypsin and PAR2AP mediates a Ca2+ flux response (Vesey et al., 
2007; Vesey et al., 2013). As KLK4 initiates Ca2+ flux via activation of PAR2 on PAR2-
LMF and PC-3 cells (Ramsay et al., 2008a) (and Section 5.3.2), Ca2+ flux assays were 
used to assess the ability of KLK4 to activate PAR2 on human primary kidney PTC.  
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Figure 5.6 PAR2 activation by KLK4 in PAR2-LMF cell lines is inhibited by SFTI-FCQR 
 
 As shown in Figure 5.7A, only a very gradual and slight response to 300 nM KLK4 was 
observed. This concentration of KLK4 was sufficient to cause a moderate Ca2+ flux 
response in both PC-3 and PAR2-LMF cells (Ramsay et al., 2008a). Indeed, 200 nM 
KLK4 was sufficient to induce Ca2+ flux in PAR2-LMF cells as shown in Figure 5.7B. 
Small increases in Ca2+ flux response to KLK4 were observed by increasing KLK4 
treatments to 600 nM and 1.2 μM (Figures 5.7B and C). Treatment of the kidney PTC 
with PAR2AP (100 μM) induced a strong rapid response and also completely abolished 
the Ca2+ flux response to subsequent KLK4 (300 nM) treatment (Figure 5.7D). 
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Figure 5.7 PAR2 activation in primary kidney proximal tubule cells 
 
This indicates that the slight response to KLK4 can be attributed to action through 
PAR2 on the kidney PTC. In contrast to KLK4, trypsin (10 nM) induced a prompt, 
robust Ca2+ flux (Figure 5.7E). Furthermore, treatment of the kidney PTC with 
PAR2AP (100 μM) almost completely abolished the response to a subsequent trypsin 
treatment (Figure 5.7F). 
Taken together, this indicates that the PAR2 on the kidney PTC was functional, 
responding to both PAR2AP and trypsin. Moreover, the PTC response to trypsin and 
also the slight response to KLK4 can be attributed almost entirely to PAR2 activation. 
However, as KLK4 elicited very little Ca2+ flux response there may be some factor 
impeding KLK4, but not trypsin, activation of PAR2. And so, to further investigate the 
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KLK4 inhibition, active site titration using a MUGB assay was used to determine 
whether KLK4 was still active after exposure to the PTC in the Ca2+ flux assays. As the 
KLK4 was added to a cell suspension for the Ca2+ flux assay, the MUGB assay was 
conducted on the Ca2+ flux assay mix from the 300, 600 nM and 1.2 μM KLK4 
treatments, with cells and also with cell-free medium after the cells had been removed 
by centrifugation.  The MUGB assays showed that the activity of KLK4 was 
undiminished after the Ca2+ flux assay with the kidney PTC (data not shown). Neither 
the cell-free nor the cell-containing KLK4 from the Ca2+ flux assays showed any 
significant change in KLK4 activity under the MUGB assay conditions. Based on this 
result it is unlikely the limited PAR2 activation by KLK4 is due to an inhibitor either 
found on the surface of the kidney PTC or secreted into the extracellular medium. 
Further studies are required to examine this in greater detail. 
 
5.2.4 Generation and characterization of prostate cancer LNCaP cells 
stably expressing the transmembrane serine protease hepsin  
To examine the role of hepsin in proteolytic cascades resulting in activation of PAR2, 
LNCaP and PAR2-LMF cells were stably transfected with pcDNA3.1 and pEFIRES-p 
expression constructs, respectively, encoding hepsin-Flag or hepsinSA-Flag. LNCaP 
cells were chosen for this purpose because they express PAR2 (Chay et al., 2002; 
Greenberg et al., 2003; Ramsay et al., 2008a). Moreover, it has also been published that a 
change in [Ca2+i] can be elicited in LNCaP cells upon application of the PAR agonists 
trypsin, TMPRSS2 and PAR2AP (Wilson et al., 2005). The PAR2-LMF cells were 
chosen to use in conjunction with the LNCaP cells because PAR2 is the only functional 
PAR they express (Andrade-Gordon et al., 1999). This allows for discrimination of the 
cellular response mediated by PAR2 activation in the PAR2-LMF cells. 
 
5.2.4.1 Generation of LNCaP and PAR2-LMF cells stably expressing hepsin 
or catalytically inactive hepsin 
LNCaP and PAR2-LMF stable transfectants were screened for cell-surface hepsin-Flag 
and hepsinSA-Flag by flow cytometry. As shown in Figure 5.8A and B, hepsinSA-Flag 
was expressed at high levels on the cell surface of both LNCaP and PAR2-LMF cells, as 
indicated by the high mean fluorescence intensity (MFI). In contrast, very little hepsin-
Flag was detected; the MFI for the LNCaP-hepsin-Flag and PAR2-LMF-hepsin-Flag 
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were 15- and 35-fold lower than that of the LNCaP-hepsinSA-Flag and PAR2-LMF-
hepsinSA-Flag cells, respectively. Moreover, there is little difference between the MFI of 
LNCaP-hepsin-Flag and PAR2-LMF-hepsin-Flag cells and either LNCaP-hepsin-Flag or 
PAR2-LMF cells stained with secondary antibody.  
Figure 5.8 Cell-surface expression of hepsin-Flag  and hepsinSA-Flag on stably transfected LNCaP and PAR2-LMF cells 
 
 As will be described in the following sections, propagation of LNCaP-hepsin-Flag cells 
expressing high consistent levels of hepsin-Flag on the cell surface proved to be 
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problematic. For this reason, generation of PAR2-LMF cells stably expressing plasma 
membrane localized wild-type and catalytically inactive hepsin was not pursued further.  
 
5.2.4.2 Further attempts to generate LNCaP-hepsin and LNCaP-hepsinSA 
stable cell lines using FACS  
To produce homogeneous populations of stably transfected LNCaP-hepsin-Flag and 
LNCaP–hepsinSA-Flag cells, FACS was performed a minimum of two weeks following 
transfection and antibiotic selection to isolate cells with high levels of plasma membrane 
expression of hepsin-Flag and hepsinSA-Flag.  
In the first round of FACS, 480 single cells were selected for each of the LNCaP-hepsin 
and LNCaP-hepsinSA transfectants. After expansion as monoclonal populations, 40 
LNCaP-hepsinSA-Flag clones survived (8.3% of cells isolated by FACS) and were 
reanalysed by flow cytometry for cell surface expression of hepsinSA-Flag. As shown in 
Figure 5.9A, six of these clones had uniform, high levels of hepsinSA-Flag expression. 
In contrast, only one LNCaP-hepsin-Flag clone survived (0.21%). However, as shown 
in Figure 5.9B, it was apparent from the flow cytometry analysis that this clone had little 
cell surface expression of hepsin-Flag. 
A second round of FACs was performed using LNCaP-hepsin-Flag stable unsorted 
cells. In this FACs round, 960 single cells, as well as three collections of 8000 cells each, 
were collected into cell culture medium with increased FBS (20% v/v). Only five 
LNCaP-hepsin-Flag clones survived (0.52%) expansion as monoclonal populations. In 
contrast, all three polyclonal populations survived and were analysed by flow cytometry. 
However, as shown in Figure 5.10, the monoclonal and polyclonal LNCaP-hepsin-Flag 
populations had either very low or heterogeneous hepsin-Flag cell surface expression. 
This is indicated by the low MFIs and the broad or multiple peaks on the flow 
cytometry histograms. 
In an attempt to obtain clonal populations with matched hepsin-Flag and hepsinSA-Flag 
expression levels, a third and final round of FACS was performed on the LNCaP-hepsin 
cells. To increase the probability of obtaining high expressing populations from this 
round of FACS, one polyclonal (poly 2) and two monoclonal (clones 3f10 and 9d4) 
populations were pooled from the second FACS round for a high-expressing hepsin-
Flag enriched population for sorting. As there was success in expanding the polyclonal 
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populations from the second FACs round it was thought that paracrine effects might 
possibly induce higher survival for the LNCaP-hepsin-Flag cells. Therefore in the third 
FACS round in addition to 384 single cells collected, there were 288 collections of 3 
cells/well for triclonal populations, and a further three collections of 30,000 high-
expressing cells for polyclonal populations. The collection medium was of the same 
composition as the second round of FACS.  
Figure 5.9 LNCaP-hepsinSA-Flag cell clones selected by FACS display a high, homogeneous level of hepsinSA-Flag 
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Figure 5.10 LNCaP-hepsin-Flag monoclonal and polyclonal populations selected by a second round of FACS yield populations with low, heterogeneous hepsin-
Flag expression 
  
The three polyclonal populations survived expansion. However, as with the previous 
cell sorting, there was poor survival of cells expanded from single cell collections as only 
five proliferated (1.3%). There was a slightly better result for cells expanded from 3 
cells/well, as nine proliferated (3%). Figure 5.11 shows flow cytometry histogram 
analyses of hepsin-Flag cell surface expression for one of five monoclonal and two of 
the nine triclonal populations (Figure 5.11A), as well as the three polyclonal populations 
(Figure 5.11B). As with the populations of LNCaP-hepsin-Flag generated previously, 
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the new populations also had a either low or heterogeneous hepsin-Flag expression. 
Triclonal population LNCaP-hepsin 7b10 was the only population that showed 
homogeneous hepsin-Flag expression as demonstrated by the single peak on the 
histogram (Figure5.11A). However, the expression level of this population (MFI of 18) 
was still considerably lower than that of the LNCaP-hepsinSA-Flag (in Figure 5.10A). 
Figure 5.11 LNCaP-hepsin-Flag monoclonal and polyclonal populations selected by a third round of FACS yield populations with low, heterogeneous hepsin-Flag 
expression 
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Table 5.1 provides a summary of the LNCaP-hepsin-Flag and LNCaP-hepsinSA-Flag 
clone screening. Six LNCaP-hepsinSA-Flag monoclones that showed high levels of 
hepsinSA-Flag surface expression were retained for further examination. Only low-
medium level expressing LNCaP-hepsin-Flag clones were obtained and retained. 
 
Table 5.1 Summary of LNCaP clones stably expressing hepsin-Flag and 
hepsinSA-Flag. A single round of FACS was used to obtain monoclonal populations 
for LNCaP-hepsinSA-Flag. Three FACS rounds were performed for LNCaP-hepsin-
Flag to obtain monoclonal populations as well as several polyclonal and triclonal 
populations. MFI, mean fluorescence intensity;  -, clones not collected; ( ), clones saved and stored in 
liquid nitrogen (LN2). 
Table 5.1 Summary of LNCaP clones stably expressing hepsin-Flag and hepsinSA-Flag. 
  Number of Clones 
Population Construct FACS 
sorted 
Expanded Hepsin low-
medium 
expression  
(MFI >10<50) 
Hepsin high 
expression 
(MFI >50) 
Monoclonal Hepsin 1824 11 5 (5) 0 
 HepsinSA 480 40 13 (0) 17 (6) 
Polyclonal Hepsin 8 6 3 (3) 0 
 HepsinSA 2 2 - - 
Triclonal Hepsin 288 9 5 (3) 0 
 HepsinSA - - - - 
 
 
5.2.4.3 General observations of the growth characteristics of LNCaP-hepsin 
compared to LNCaP-hepsinSA cells  
During expansion of the FACS-sorted cells, LNCaP-hepsin-Flag cells were observed 
(not qualitatively) to have reduced growth rate in comparison with the LNCaP-
hepsinSA-Flag and LNCaP-vector cells. It was also observed that there was a very high 
level of senescence and cell death for the LNCaP-hepsin-Flag cells and this considerably 
reduced the number of clones that survived for screening by flow cytometry. Moreover, 
despite consistently selecting cells with high levels of expression of hepsin-Flag during 
FACS, only low to medium level expressors survived on each occasion.  
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5.2.4.4 Western blot analysis of cells stably expressing LNCaP-hepsin and 
LNCaP-hepsinSA 
To further examine hepsin-Flag and hepsinSA-Flag levels in stably expressing LNCaP 
cells, lysates from a selection were examined by Western blot analysis using both anti-
Flag and anti-hepsin antibodies. Anti-Hepsin A15 is a monoclonal antibody raised in 
hepsin -/- mice (Wu et al., 1998) to the complete extracellular region of human hepsin 
(Xuan et al., 2006). 
As shown in Figure 5.12, Western blot analysis confirmed a consistently lower level of 
expression of hepsin-Flag (Figure 5.12, lanes 3-7) compared to hepsinSA-Flag (Figure 
5.12, lanes 8-12). Full-length hepsin-Flag and hepsinSA-Flag were detected at 45 kDa. 
As the serine protease domain of activated hepsin is attached to the stem region of 
hepsin by a disulphide bond, it resolves separately from the stem region of hepsin when 
the lysates are resolved under reducing conditions. Consistent with this, very low levels 
the serine protease domain of activated hepsin-Flag were detected at 26 kDa under 
reducing conditions (Figure 5.12A, anti-Flag blot, lanes 3-7), while it was not detected 
for the catalytically inactive hepsinSA-Flag (Figure 5.12A, lanes 8-12).  
Another form of hepsin-Flag and hepsinSA-Flag was also detected at ~30 kDa under 
both reducing and non-reducing conditions. This indicates that overexpressed hepsin-
Flag and hepsinSA-Flag were proteolysed in the stem region by an alternative protease. 
It also indicates that as the 30 kDa forms of hepsin-Flag and hepsinSA-Flag were readily 
detected under non-reducing conditions, disulphide bonds were not the means by which 
the 30 kDa forms remain associated with the cell. There were also high MW complexes 
containing hepsin and hepsinSA >250 kDa detected under non-reducing conditions 
(Figure 5.12B). Interestingly, a greater proportion of hepsin-Flag than hepsinSA-Flag 
were detected in these complexes. It is possible that this is representative of activated 
hepsin in complex with other proteins such as protease inhibitors.  
Another interesting observation was that while LNCaP cells have previously been 
shown to express hepsin (Srikantan et al., 2002; Owen et al., 2010), endogenous hepsin 
was not detected in either the untransfected or vector-transfected LNCaP whole-cell 
lysate probed with anti-Hepsin antibody. However, when a range of prostate cancer-
derived cell lines were examined for endogenous hepsin expression, hepsin was detected 
in LNCaP and 22Rv1 cells, as well as to a lesser extent in DU145 and RWPE2 cells 
(Figure 5.13). In agreement with previously published results, hepsin was not detected in  
217 
 
Figure 5.12 Expression analysis of LNCaP-hepsin and LNCaP-hepsinSA clones 
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Figure 5.13 Endogenous expression of hepsin by prostate cancer cell lines 
 
PC-3 cells (Srikantan et al., 2002; Owen et al., 2010). As a control, lysate from Cos-7 
cells transiently transfected with hepsin-Flag gave a very robust signal. Moreover, the 
signal to detect hepsin in the prostate cancer lines is very low compared to the Cos-7-
hepsin-Flag control. From these results it is possible to conclude that if the previous 
blots (Figure 5.12) were scanned at a higher intensity to detect the secondary antibody 
signal it might be possible to detect endogenous hepsin with the anti-hepsin A15 
antibody. 
 
5.2.4.5 Examination of plasma membrane expression of hepsin and 
hepsinSA by cell-surface biotinylation 
To examine the relative proportion of hepsin-Flag and hepsinSA-Flag localized to the 
plasma membrane of stably expressing LNCaP cells, cell-surface biotinylation was 
conducted for one each of the LNCaP-hepsin-Flag and LNCaP-hepsinSA-Flag lines. In 
this, the proteins on the cell surface were biotinylated and then isolated from the whole-
cell lysates. Untreated whole-cell lysate was then compared to the biotinylated and 
unbiotinylated (flow-through) fractions using Western blot analysis and anti-Flag, anti-
Hepsin A15 and anti-GAPDH antibodies. The anti-GAPDH probe had a two-fold 
purpose on these analyses, to demonstrate relative protein loading in the lanes of the 
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whole-cell lysate and flow through blots, and also to demonstrate a lack of intercellular 
proteins in the cell-surface biotinylated fraction. 
As shown in Figure 5.14, 45 kDa and 30 kDa cleaved hepsin-Flag and hepsinSA-Flag 
were detected in whole-cell lysates (Figure 5.14, whole-cell lysate, lanes 3 and 4). In 
addition, the serine protease domain of hepsin-Flag was detected at low levels at 26 kDa 
(Figure 5.14, whole-cell lysate, lane 3). Interestingly, endogenous hepsin was also 
detected at 45 kDa in the whole-cell-lysate of the LNCaP untransfected and LNCaP-
vector cells by the anti-hepsin A15 antibody. The signal intensity is very low compared 
to overexpressed hepsin-Flag and hepsinSA-Flag. Nonetheless, it supports the results in 
the previous figure (Figure 5.13) that showed detection of endogenous hepsin in 
LNCaP cells.  
Figure 5.14 Examination of hepsin and hepsinSA cell-surface expression in LNCaP-hepsin and LNCaP-hepsinSA cells 
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 Examination of biotinylated fractions shows that very little hepsin-Flag was present on 
the cell surface in comparison to hepsinSA-Flag (Figure 5.14, biotinylated fraction, lanes 
3 and 4). Furthermore, as the signal intensity of the hepsin-Flag is very low, it was not 
possible to determine whether activated hepsin at 26 kDa represented a portion of the 
cell-surface hepsin-Flag. Interestingly, hepsin-Flag and hepsinSA-Flag were abundant in 
the flow-through fraction. Moreover, the serine protease domain of hepsin-Flag was 
detected in this fraction at 26 kDa. This raises the possibility that hepsin is either 
activated on the surface before internalization by an unknown mechanism, or hepsin is 
activated internally before presentation on the surface. 
Overall, these results reflect the results previously shown from the flow cytometry 
where very little hepsin-Flag was detected on the cell surface whereas in contrast 
hepsinSA-Flag appears to be abundantly displayed on the surface of the LNCaP stable 
lines.  
 
5.2.4.6 Examination of the interaction of recombinant pro-KLK4 and pro-
KLK14 with LNCaP-hepsin and LNCaP-hepsinSA cells 
It was previously shown in Chapter 4 that hepsin proteolyses KLK4, and to a lesser 
extent KLK14. It was also shown that KLK4 and KLK14 co-immunoprecipitate with 
hepsin, and furthermore, are cell-surface localized in addition to being secreted into the 
medium. As a preliminary step in the investigation of the role of hepsin in proteolytic 
cascades resulting in PAR activation, LNCaP-hepsin-Flag and LNCaP-hepsinSA-Flag 
cells were examined for their potential to interact with exogenous KLK4 and KLK14 
zymogen. To do this the zymogens were applied to the LNCaP-hepsin-Flag and 
LNCaP-hepsinSA-Flag cells for 1 hour and 18 hour timepoints. Media and whole-cell 
lysates were subjected to Western blot analysis using anti-V5 and anti-Flag antibodies as 
shown in Figures 5.15 and 5.16. 
From these analyses it can be seen that pro-KLK4-V5-His at 28 kDa is not proteolysed 
in the medium when applied to the LNCaP-hepsin-Flag, LNCaP-hepsinSA-Flag or 
LNCaP-vector cells as there is no apparent difference to the pro-KLK4-V5-His relative 
quantity or MW (Figure 5.15A). Examination of whole-cell lysates shows that a small 
amount of pro-KLK4-V5-His remained with the cells after they were washed (Figure 
5.15B). However, there is no hepsin-Flag-mediated proteolysis of pro-KLK4-V5-His. 
Moreover, the association of pro-KLK4-V5-His is not exclusive to the LNCaP-hepsin-
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Flag or LNCaP-hepsinSA-Flag cells as it is apparent from LNCaP-vector cells as well. 
Furthermore, the pro-KLK4-V5-His that remained with the cells was detected in high 
MW complexes on the non-reduced lysate analysis but again the interaction is 
independent of hepsin-Flag or hepsinSA-Flag overexpression.  
The analysis of the LNCaP-hepsin-Flag and LNCaP-hepsinSA-Flag whole-cell lysate 
(Figure 5.15C) shows that pro-KLK4-V5-His had no apparent effect on the hepsin-Flag 
and hepsinSA-Flag forms detected. As was previously shown (Figure 5.12), hepsin-SA- 
Flag and hepsin-Flag were detected at 45 kDa and 30 kDa under reducing and non-
reducing conditions. The serine protease domain of hepsin-Flag was also detected at 26 
kDa.  
In Figure 5.16 a similar result is shown for the association of pro-KLK14-V5-His with 
the LNCaP cells. Again, there was no apparent proteolysis of pro-KLK14-V5-His in the 
medium (Figure 5.16A) and there was also some proKLK14-V5-His that has remained 
stuck to the washed cells, independent of hepsin-Flag or hepsinSA-Flag expression 
(Figure 5.16B). The whole-cell lysate analysis of LNCaP-hepsin-Flag and LNCaP-
hepsinSA-Flag in Figure 5.16C is very similar to that shown in Figure 5.15C with no 
apparent effect of pro-KLK14-V5-His on either hepsin-Flag or hepsinSA-Flag. 
Overall, this result is consistent with results shown previously in Chapter 4 that 
recombinant hepsin had little proteolytic effect on recombinant KLK4-V5-His and 
KLK14-V5-His zymogens. The results in Chapter 4 showed that a near equal quantity 
of hepsin was required for proteolysis of these KLKs. So, as little hepsin-Flag localized 
on the plasma membrane of the LNCaP-hepsin-Flag cells, as shown in the cell-surface 
biotinylation in Figure 5.14, it is likely proteolysis of the exogenously applied KLKs 
would be minimal. 
 
5.3 Discussion 
In this chapter, activation of PAR1, PAR2 and PAR4, by the serine proteases KLK14, 
matriptase and hepsin was examined. Inhibition of KLK4 activation of PAR2 using the 
KLK4-specific inhibitor SFTI-FCQR was also examined in this chapter. This result was 
published as part of a body of work describing the design and efficacy of the SFTI-
FCQR (Swedberg et al., 2009). KLK4 activation of PAR2 was investigated further using 
cultures of human primary kidney PTC. In the final section of this chapter, the prostate 
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Figure 5.15 Recombinant pro-KLK4 is not proteolysed on LNCaP-hepsin cells 
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 cancer cell line LNCaP was used to generate stable hepsin- and hepsinSA-
overexpressing cell lines. The purpose of this was to produce a tool to investigate the 
participation of hepsin with other serine proteases in proteolytic cascades resulting in 
PAR activation. The key findings in this chapter were: 
 KLK14 activated Ca2+ mobilization via PAR1, PAR2 and PAR4; matriptase 
activated PAR2 but not PAR1 or PAR4; and there was negligible activation of 
PAR1, PAR2 or PAR4 by hepsin 
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Figure 5.16 Recombinant pro-KLK14 is not proteolysed on LNCaP-hepsin cells 
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 KLK4 initiates robust Ca2+ mobilization via PAR2 which was inhibited by the 
KLK4-specific inhibitor SFTI-FCQR 
 KLK4 elicited minimal PAR2 activation and Ca2+ mobilization in kidney PTC 
 Overexpression of transmembrane protease hepsin in LNCaP cells did not 
support cell growth and resulted in minimal plasma membrane localization. In 
contrast, overexpression of catalytically inactive hepsin readily localized to the 
plasma membrane. 
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5.3.1 KLK14, matriptase and hepsin can affect signalling by either 
activating or disarming PARs 
As mentioned in the Introduction, protease activation of PAR1, PAR2 and PAR4 to 
expose the tethered ligand requires limited proteolysis at an Arg residue. Furthermore, 
KLK14, matriptase and hepsin all have a preference for cleavage after an Arg P1 
residue. So, while an Arg P1 residue is preferred for substrate proteolysis by these 
enzymes, the results in this chapter show that it is not sufficient to initiate PAR-
mediated Ca2+ mobilization. This was exemplified by the variety of responses to the 
three proteases.  
As summarized in Figure 5.17, it was found that KLK14 was equally adept at activating 
PAR1-, PAR2- and PAR4-mediated Ca2+ mobilization in LMF cells. In contrast, 
matriptase specifically activated PAR2. However, the potency of KLK14 was much 
lower than that of either trypsin or matriptase because 15-fold less trypsin or matriptase 
(10 nM) than KLK14 (150 nM) was required to induce a robust Ca2+ mobilization in the 
PAR2-LMF cells. Furthermore, 3-fold less trypsin (50nM) than KLK14 (150 nM) 
resulted in robust activation of PAR4.  
As PAR activation is followed by rapid internalization of the activated receptor (Arora 
et al., 2007), follow up treatments of agonist peptide resulting in further Ca2+ 
mobilization can be attributed to unactivated PAR remaining on the cell surface. 
Consistent with this, KLK14 treatment didn’t result in complete activation of PARs on 
the surface of the LMFs as subsequent agonist peptide treatment resulted in Ca2+ 
mobilization. Similarly, follow up agonist peptide treatment of trypsin- and matriptase-
treated PAR2-LMF cells (10 nM) resulted in further Ca2+ mobilization. Moreover, the 
robust signal induced by agonist peptide post-matriptase treatment of PAR1- and 
PAR4-LMFs indicated that while matriptase treatment did not activate PAR1 or PAR4, 
they were able to be activated by synthetic agonist. In contrast, 50 nM trypsin resulted in 
complete activation of PAR4 as there was no further Ca2+ mobilization upon agonist 
peptide treatment. 
However, it is also known that cleavage of PARs other than at the activation site can 
result in their inactivation or disarming (Hollenberg and Compton, 2002; Ramachandran 
et al., 2012b). Furthermore, PARs that have been disarmed in this manner can still be 
activated by synthetic agonist peptides (Kawabata et al., 1999; Kuliopulos et al., 1999; 
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Hollenberg and Compton, 2002; Dulon et al., 2003; Nakayama et al., 2003; 
Oikonomopoulou et al., 2006a; Ramachandran and Hollenberg, 2008). As KLK14 
treatments did not result in complete internalization of the PARs, the remaining PARs 
were not cleaved or may have been proteolytically disarmed by KLK14. For example, it 
has previously been reported by Oikonomopoulou and colleagues (2006a) that PAR1 is 
preferentially disarmed by KLK14 through cleavage within the tethered ligand domain, 
rather than at the Arg residue immediately prior. They reasoned that this would render 
the tethered ligand unavailable for intramolecular docking and initiation of PAR1-
activated Ca2+ mobilization. They also showed that in the human embryonic kidney-
derived HEK293 cells, KLK14 activated PAR2 but induced negligible activation of 
PAR1. In addition, KLK14 prevented PAR1-mediated Ca2+ mobilization by rendering 
cells unresponsive to subsequent thrombin treatment (Oikonomopoulou et al., 2006a).  
 
Figure 5.17 Intracellular calcium signalling is initiated by KLK14 via PARs 
 
However, it is unresolved if this was the case in this chapter. To address this in the 
future, three consecutive treatments could be made, first KLK14, follow-up treatment 
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with trypsin followed by an AP treatment. This would assist with determination of the 
relative proportion of PARs activated/disarmed by KLK14, as disarmed PARs would 
not be activated by trypsin but would be activated by the subsequent AP treatment. 
Additionally,  a dose-response assessment of PAR activation by KLK14 would assist in 
determining if there is predominantly receptor activation at certain concentrations and 
receptor deactivation at other concentrations of KLK14. However, as Ca2+ mobilization 
in the PAR1-LMF cells was achieved in this chapter using 150 nM KLK14, it is possible 
that under some circumstances KLK14 induces PAR-1 signalling by Ca2+ mobilization. 
Unfortunately, the concentration of KLK14 used in the experiments by 
Oikonomopoulou and colleagues (2006a) was reported as units of “trypsin-like 
equivalents of activity” as opposed to molar concentration. This makes comparison with 
the molar concentration used in this chapter difficult. 
Interestingly, it appears that proteolytic disarming of PARs may also result in differential 
signalling, a process known as biased agonism. For instance, Ramachandran and 
colleagues (2011) have shown that neutrophil elastase, cathepsin-G and proteinase-3 
disarm PAR2 by cleaving at distinct sites in the N-terminal to release the tethered ligand. 
Whereas it is apparent that these disarming events prevent signalling via Gq-coupled 
Ca2+ mobilization, neutrophil elastase, but not cathepsin-G or proteinase-3, activates 
PAR2 signalling via Gi or G12/13-coupling and the ERK1/2 MAPK pathway 
(Ramachandran et al., 2011). Similarly, it would be interesting to examine whether 
disarming PAR1 with KLK14 selectively activates alternative intracellular signalling 
pathways such as the Gi or G12/13-initiated ERK1/2 MAPK pathway. Certainly, 
Oikonomopoulou and colleagues (2006a) found that in addition to abrogating thrombin 
activation of PAR1, high KLK14 concentrations curtailed activation by PAR1AP 
(Oikonomopoulou et al., 2006a). So it is possible KLK14 is activating PAR1 resulting in 
receptor internalization and may represent a novel mechanism for modulation of PAR1 
signalling by KLK14. 
In contrast to KLK14, hepsin elicited negligible Ca2+ mobilization via PAR1, PAR2 and 
PAR4 (Figure 5.17). Due to limited hepsin availability, only up to 100 nM was tested for 
dose response on the LMF cells.  However, hepsin (50 nM) did render a portion of 
PAR2 unresponsive to subsequent activation by agonist peptide. This was not seen for 
either PAR1 or PAR4. Furthermore, similar to matriptase, pre-treatment of hepsin with 
HAI-1B (1 μM) abolished the PAR2-mediated minimal Ca2+ mobilization response and 
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restored the complete response to agonist peptide. Therefore, as a portion of PAR2 was 
unresponsive to the follow up agonist peptide, it is possible that portion of PAR2 was 
activated by hepsin resulting in internalization. Moreover, as it caused minimal Ca2+ 
mobilization it is possible alternate signalling pathways were activated by Gi or G12/13-
coupling.   
Interestingly, during the course of these experiments, research was published that 
showed that in the keratinocyte cell line HaCaT, low level hepsin activation of PAR2 
could be attributed to indirect activation via a proteolytic cascade of hepsin activating 
endogenous matriptase which then activated PAR2 (Camerer et al., 2010). It is possible 
a similar cascade occurred in the PAR2-LMF cells, with hepsin activating endogenous 
matriptase, or another protease, which then activated PAR2. In this case, the low level 
of activation may reflect the relative amount of intermediate protease expressed by the 
PAR2-LMF cells. It may also reflect the rate-limited activation of the intermediate 
protease. Certainly, further work is required to determine if the role of hepsin in PAR 
activation is as an initiator of a proteolytic cascade, or if hepsin activates PARs directly 
resulting in initiation of alternate signalling pathways. 
 
5.3.2 KLK4 activates PAR2 in PAR2-LMF cells but not in human primary 
kidney cells 
Consistent with a previous report (Ramsay et al., 2008a), the results in this chapter 
showed that KLK4 activated Ca2+ mobilization via PAR2. In addition, it was shown that 
a small peptide inhibitor, SFTI-FCQR, re-engineered from SFTI using substrate-guided 
design (Swedberg et al., 2009), completely abolished KLK4 activation of PAR2 in LMF 
cells (Figure 5.17). Moreover, SFTI-FCQR did not elicit Ca2+ mobilization in the PAR2-
LMF cells when applied alone nor did it inhibit trypsin (Swedberg et al., 2009), 
demonstrating the specificity of SFTI-FCQR for KLK4 inhibition in a cell based assay.  
This specific inhibitor may have use in modulating pro-cancer effects of KLK4 activity. 
As well as inducing proliferation through PAR activation (Mize et al., 2008), these pro-
cancer effects include inducing epithelial to mesenchymal cellular transformation and 
increasing migration (Veveris-Lowe et al., 2005), and increasing proliferation and colony 
formation (Klokk et al., 2007). Recently Dong and colleagues (2013) used SFTI-FCQR 
in an in vitro ovarian cancer ascites microenvironment model to mitigate the effects of 
KLK4. They showed that SFTI-FCQR reduced the resistance to the chemotherapy drug 
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paclitaxel in ovarian cancer cell line SKOV-3 as well as reducing the formation of 
multicellular spheroids induced by overexpressed or exogenous KLK4. 
As mentioned in the Introduction and discussed in Chapter 1, KLK4 is expressed in a 
number of tissues apart from the prostate. For instance, it has also been detected at high 
levels in cancerous colon mucosa (Gratio et al., 2010) and breast cancer stroma (Mange 
et al., 2008) as well as normal liver and kidney tissue (Seiz et al., 2010). Moreover, KLK4 
has specifically been determined to be highly expressed in kidney tubule cells of the 
kidney cortex (Seiz et al., 2010). Therefore, it was surprising to observe in this chapter 
that KLK4 elicited only minimal signalling via PAR2 expressed by human primary 
kidney PTC. In particular, the cells used in this chapter have previously been shown to 
express PAR1, PAR2 and PAR3 (Vesey et al., 2005; Vesey et al., 2007). Furthermore, 
Ca2+ is mobilized in these cells in a PAR1-dependent manner in response to thrombin 
and PAR1AP (Vesey et al., 2005); and in a PAR2-dependent manner in response to 
trypsin and PAR2AP (Vesey et al., 2007; Vesey et al., 2013). They showed that both 
trypsin and PAR2AP induce rapid and robust PAR2-dependent Ca2+ mobilization 
(Vesey et al., 2007). Consistent with this, in this chapter it was observed that trypsin 
elicited robust Ca2+ mobilization in the kidney PTC. In contrast, treatment of these cells 
with KLK4 (300 nM) elicited negligible response, with a marginally increased response 
upon increasing KLK4 concentration to 1 μM. 
These results highlight contradictions that appear in the PAR activation/signalling field. 
For example, consistent with data in this chapter, Ramsay and colleagues (2008a) 
showed that KLK4 (300 nM) activates PAR2 as well as PAR1 expressed by LMF cells, 
as well as PAR2 in PC-3 cells. In contrast, recent work by Gratio and colleagues (2010) 
using the colon line HT-29, showed that Ca2+ mobilization induced by KLK4 (1 μM) 
could be attributed to PAR1 and not PAR2 activation. In addition, when examining 
KLK4 activation of ERK1/2 in prostate primary stromal cells, Wang and colleagues 
(2010) also concluded that KLK4 induced this signalling pathway by activating PAR1 
and not PAR2.  
The inconsistency in the Ca2+ mobilization results again raises the subject of biased 
agonism. The concept of biased agonism has expanded from the narrow definition of 
different ligands acting on the same GPCR to bring about different signalling responses 
as it has been found that the location of the GPCR in the plasma membrane (Zheng et 
al., 2008; Russo et al., 2009a) and formation of GPCR heterocomplexes (Gonzalez-
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Maeso and Sealfon, 2012) can also cause different signalling responses. Also 
encompassed in this is the concept that each cell-type has a unique signalling tool-kit, 
that can lead to differences in cellular responses to agonism (Kenakin, 2011).  
An example is the different intracellular signalling processes initiated via PAR1 
depending on whether it is activated by thrombin or activated protein C (APC) in 
endothelial cells (Feistritzer and Riewald, 2005; Finigan et al., 2005; McLaughlin et al., 
2005; Riewald and Ruf, 2005; Bae et al., 2007; Komarova et al., 2007; Mosnier et al., 
2007; Russo et al., 2009a; Soh and Trejo, 2011; Mosnier et al., 2012). Whereas thrombin 
activation of PAR1 results in RhoA-mediated signalling (McLaughlin et al., 2005; 
Komarova et al., 2007), activation by APC results in Rac1-mediated signalling (Finigan 
et al., 2005; Russo et al., 2009a). Furthermore, to activate PAR1, APC requires 
compartmentalization of both PAR1 and an APC co-factor, endothelial protein C 
receptor, to cholesterol-rich caveolar microdomains in the plasma membrane (Bae et al., 
2007; Russo et al., 2009a). This PAR1 caveolar-compartmentalization is not required for 
activation by thrombin (Russo et al., 2009a). The mode of signal transduction from 
APC-activated PAR1 to Rac-1 was also determined. Although PAR1 co-localizes with 
signal transduction partners β-arrestin and Gαi to the caveolar microdomains, induction 
of PAR1-Rac-1 (Russo et al., 2009a) signalling by APC is β-arrestin-dependent (Russo et 
al., 2009a) and not mediated by Gαi (Soh and Trejo, 2011). Other work investigating the 
biased agonism of thrombin- or APC-activated PAR1 suggests that N-terminal cleavage 
of PAR1 by APC reveals a novel tethered ligand differing from that revealed by 
thrombin. This novel tethered ligand elicits a different intracellular signalling response 
by PAR1 involving Akt/PI3K-mediated pathways (Mosnier et al., 2012).  
Another example of biased agonism involves comparison of PAR4 activation by 
PAR4AP in hepatocellular carcinoma and colon cancer cell lines. In hepatocellular 
carcinoma cells, HEP-3B and SK-HEP1, PAR4-mediated Ca2+ mobilization responses 
were not elicited by PAR4AP (Kaufmann et al., 2007). However, in colon cancer HT-29 
cells, PAR4AP treatment resulted in Ca2+ mobilization (Gratio et al., 2009).  
Accordingly, the low level of KLK4-induced Ca2+ mobilization observed in this chapter 
in kidney PTC may be another example of biased agonism. This could be examined 
further by seeing if KLK4 treatment of the kidney PTC activates any PAR-dependent, 
Ca2+-independent intracellular signalling pathways. The signalling toolkit of the kidney 
PTC may mean there are alternate pathways induced by KLK4 activation of PAR2. In 
232 
 
addition, it has not been established if cell surface compartmentalization of PAR2 or 
other signalling components are required for KLK4 activation of this receptor.  
Furthermore, as for epithelial cells, kidney PTC have apical basolateral polarity (Schluter 
and Margolis, 2012) and it has been shown recently that intestinal epithelial cells 
demonstrate differential signalling depending on whether PAR2 on the apical or the 
basolateral surface is activated (Lau et al., 2011). As the Ca2+-flux assays in this chapter 
were conducted with the kidney PTC in suspension, cell polarity would have been lost 
and this may have altered the cells PAR2-mediated signalling response.  
Biased agonism is one possible reason for the small Ca2+ mobilization induced in the 
kidney PTC by KLK4. However, there are other possibilities. For example, KLK4 may 
require a cell-surface cofactor to facilitate PAR2 activation. Indeed, the results shown in 
Chapter 4 suggest that hepsin and TMPRSS2 form cell-surface or intracellular 
complexes involving KLK4. The interaction of KLK4 with hepsin, TMPRSS2 or 
another surface protein may bring KLK4 into proximity with PAR2 to facilitate 
activation. There is also the possibility of an alternate or competitive substrate for 
KLK4 on the kidney PTC surface. Active-site titration of KLK4 immediately after 
exposure to the kidney PTC showed there was no irreversible inhibition of KLK4 
activity. Moreover, when KLK4 concentrations were increased from 300 nM to 600 nM 
then 1.2 μM, there was a small increase in Ca2+ mobilization. This could indicate that the 
inhibitor-like effects of a competitive substrate on the kidney PTC were being overcome 
by an excess of KLK4. Increasing the PAR2 surface concentration could also overcome 
the putative competitive substrate by out-competing for the KLK4 active-site (Mathews 
et al., 2000).  
Overall, the results for the kidney PTC raised some very interesting questions about the 
nature of the relationship between PAR2 (and PAR1) and KLK4. These results in 
context with other reports documenting PAR activation by KLK4 (Ramsay et al., 2008a; 
Gratio et al., 2010; Wang et al., 2010) suggest there is a complex relationship, possibly 
centred on cell-type differential signalling. The significance of this in normal or 
pathological states is unknown. 
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5.3.3 Generation and characterization of prostate cancer LNCaP cells 
stably expressing the transmembrane serine protease hepsin 
Ca2+ mobilization, in response to PAR activation has been demonstrated in a number of 
prostate-derived cell lines. These include, PAR1 activation on primary prostate stromal 
cells (Wang et al., 2010), thrombin-activated PAR1 on primary prostate cancer cells 
derived from bone (Chay et al., 2002), and trypsin-activated PAR2 on primary BPH 
stromal cells (Myatt and Hill, 2005). Ca2+ mobilization has also been demonstrated in 
prostate cancer-derived cell lines. This includes, PAR2 activation by trypsin IV in PC-3 
cells (Cottrell et al., 2004), TMPRSS2 in LNCaP cells (Wilson et al., 2005), trypsin in 
LNCaP cells (Mannowetz et al., 2010), and as mentioned earlier, KLK4 activation of 
PAR2 in PC-3 cells (Ramsay et al., 2008a).  
In this chapter, LNCaP cells stably expressing hepsin and catalytically inactive hepsinSA 
were generated for the purpose of studying the contribution of hepsin to proteolytic 
cascades resulting in PAR activation. As hepsin self-activates (Chapter 4, Section 4.3.1) 
(Vu et al., 1997; Qiu et al., 2007), it is possible that it is an initiator of proteolytic 
cascades. Indeed, as discussed earlier, Camerer and colleagues (2010) showed that 
hepsin indirectly activates PAR2 by activating matriptase which activates PAR2.  
However, generation of the LNCaP-hepsin stable cell lines proved to be challenging due 
to the high level of cell senescence, death associated with overexpression of this protein 
and the low and inconsistent levels of hepsin expression seen in stably transfected 
populations. In contrast, generation of the LNCaP-hepsinSA stable lines was 
comparatively straightforward. The LNCaP-hepsinSA cells had high, consistent 
hepsinSA expression levels as well as no discernible alteration to cell senescence or 
death when observed in comparison to LNCaP-vector transfected cells. From this, it 
was concluded that the difference in the ability to generate LNCaP-hepsin and LNCaP-
hepsinSA cells was due to the catalytic activity of hepsin. 
Interestingly, flow cytometry analysis indicated that very little hepsin localized to the 
surface of stably expressing LNCaP cells, in contrast with hepsinSA cells which showed 
high plasma membrane levels of the catalytically inactive version of this protease. This is 
interesting because it has been shown that in polarized epithelial cells matriptase 
activation at the basolateral surface is accompanied by rapid HAI-1 inhibition followed 
possibly by internalization and transcytosis to the apical surface for secretion (Wang et 
al., 2009). To avoid induction of cell senescence and death it may be possible that after 
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activation at the cell surface hepsin similarly requires rapid regulation by inhibitor 
binding and internalization.  
Results reported in other studies may account for the difficulties encountered in 
generating LNCaP-hepsin stable cells in this project. For example, early results from 
Srikantan and colleagues (2002) showed that of three prostate cancer-derived cell lines, 
PC-3, LNCaP and DU145, neither PC-3 nor DU145 express hepsin. This study went on 
to show that hepsin overexpression in PC-3 and LNCaP cells led to reduced monolayer 
growth. Further examination of the hepsin overexpressing PC-3 cells showed there was 
~75% inhibition of proliferation when compared to vector transfected cells. The hepsin 
overexpressing PC-3 cells also had reduced anchorage-independent growth as 
demonstrated by soft agar colony formation assays. The cell cycle distribution of the 
hepsin PC-3 cells compared to vector transfected cells showed that the hepsin PC-3 
cells had increased levels of cells in cell-cycle arrest at G2 (checkpoint) phase. This 
means fewer cells proceeding to M (mitosis) phase and as a consequence, reduced 
proliferation. In addition, the hepsin PC-3 cells had a higher proportion of apoptotic 
cells and decreased migration in Matrigel compared to the vector controls.  
Another study also reported reduced monolayer proliferation and soft agar colony 
formation when hepsin was transfected into the liver adenocarcinoma cell line SK-
HEP-1 (Chen et al., 2006). To confirm that hepsin was proteolytically active, expressing 
cells were assayed using factor VII as a substrate. This group further demonstrated that 
when active-site mutated hepsin was transfected, the growth and proliferation inhibition 
effects were abolished. 
Reduced monolayer proliferation and soft agar colony formation has also been shown in 
ovarian cancer BG-1 (Nakamura et al., 2006) and endometrial adenocarcinoma Ishikawa 
cells (Nakamura et al., 2008) overexpressing hepsin. Further examination of the hepsin 
BG-1 cells showed hepsin-induced increased expression and activation of the p53 
tumour suppressor protein and also p53-dependent apoptosis via activation of caspase-
3, -6 and -7 (Nakamura et al., 2006). The hepsin Ishikawa cells were also shown to have 
increased p53 expression as well as increased expression of cell-cycle regulating protein 
14-3-3σ, which is transcriptionally regulated by p53 (Nakamura et al., 2008). Cell cycle 
analysis showed increased numbers of cells in the G2-M phase as well as increased 
apoptotic cells when compared to vector transfected cells. Increased apoptosis was also 
attributed to the p53-dependent activation of caspase-3. Additionally, these cells showed 
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reduced migration and invasion in Matrigel invasion assays. As a tumourigenesis model, 
when hepsin overexpressing BG-1 and Ishikawa cells were injected subcutaneously into 
nude mice, both showed reduced tumour growth when compared to untransfected cells 
(Nakamura et al., 2006; Nakamura et al., 2008).  
Furthermore, in a recent study using doxycycline-inducible hepsin overexpression in 
PC-3 and HEK293 cells, Wittig-Blaich and colleagues (2011) demonstrated a 
doxycycline-dose-dependent loss of both cell viability and adhesion and also increased 
cell death in anchorage-dependent growth assays. This loss of viability was not seen in 
anchorage-independent growth. Moreover, viability and adhesion of the doxycycline-
induced-hepsin PC-3 cells in anchorage-dependent growth could be recovered by 
plating cells on extracellular matrix (ECM) laid down by the immortalized non-
malignant prostate cell line RWPE1 but not on ECM laid down by prostate cancer bone 
metastasis-derived PC-3 cells.  
In contrast to the above studies, several others have shown that hepsin overexpression 
either has no effect on cell growth and invasive capability or, in fact, promotes growth 
and invasion either in vitro or in vivo. For example, in contrast to results shown by 
Srikantan and colleagues (2002), stable hepsin-expressing LNCaP cells, designated 
LNCaP-34, generated by Moran and colleagues (2006), showed no change to in vitro cell 
proliferation and invasion (Li et al., 2009). Serine protease activity of hepsin expressed 
by the LNCaP-34 cells was confirmed by proteolytic activation of pro-uPA, pro-HGF 
and pro-macrophage-stimulating protein, as was the abrogation of protease activity with 
inhibitor KD1 (Moran et al., 2006; Li et al., 2009; Ganesan et al., 2011; Ganesan et al., 
2012). The cells also had increased migration on Laminin-332 (Tripathi et al., 2008). 
Moreover, when implanted orthotopically in the prostate of SCID/bg mice, LNCaP-34 
cells showed increased tumour size, increased invasion in the mouse prostate as well as 
lymph node metastasis.(Li et al., 2009). These differences in the effects of hepsin 
expression in LNCaP cells between research laboratories could be due to differences 
culture conditions or passage number. Both of these factors have been shown to effect 
cell phenotype and performance in assays for a number of cell lines including LNCaP 
cells (Hughes et al., 2007). 
In further work with LNCaP cells by Yemelyanov and colleagues (2007), they showed 
re-expression of glucocorticoid receptor (GR) in LNCaP cells that have lost endogenous 
expression and subsequent treatment of the cells with glucocorticoids inhibited 
236 
 
proliferation in monolayers and blocked anchorage-independent growth of the LNCaP 
cells. In an examination of changes to protein expression, induced by GR activation 
with glucocorticoids, it was shown that activation of the GR leads to, among other 
effects, normalized hepsin (decreased) and increased expression of the serine protease 
inhibitor maspin. In another example, in an ovarian cancer model, SKOV3 cells 
overexpressing hepsin injected subcutaneously in the left flank of nude mice showed 
increased tumour size compared to untransfected SKOV3 cells, this increase in size was 
ablated by the mutation of the hepsin catalytic site (Miao et al., 2008).  
Suppression of endogenously expressed hepsin either by RNA silencing or with activity 
blocking antibodies has been another method used to examine the effects of hepsin on 
cancer progression. Indeed, down-regulation of endogenous hepsin by specific siRNA 
significantly reduced the in vitro proliferation and invasion of breast cancer MDA-MB-
231 and HER18 cell lines compared to non-specific siRNA (Xing et al., 2011). This is 
consistent with earlier work by Torres-Rosado and colleagues (1993) which found that 
the hepatocellular carcinoma cell lines HepG2 and PLC/PRF/5 underwent growth 
arrest when hepsin antisense oligonucleotides or anti-hepsin antibodies were applied to 
the cells. In contrast, in work done by Xuan and colleagues (2006) they concluded that 
inhibiting hepsin proteolytic activity with hepsin neutralising antibodies had no effect on 
LNCaP, DU145 or CAOV-3 cell proliferation in vitro. However, in Matrigel invasion 
assays, they concluded that both DU145 and CAOV-3 were inhibited by the anti-hepsin 
antibodies. However, this study has an omission that may confound the results. They 
have not mentioned in the publication if they have tested for hepsin expression in the 
DU145 cells they used. DU145 cells used by two other groups have been shown to not 
express hepsin mRNA (Srikantan et al., 2002; Owen et al., 2010). Both LNCaP and 
CAOV-3, however, have been shown to express hepsin (Srikantan et al., 2002; 
Nakamura et al., 2006; Owen et al., 2010). 
Hepsin overexpression and suppression are useful tools to examine hepsin contribution 
to cancer progression and cell function. However, these approaches are also exposing 
contradictions yet to be resolved. The increased cell senescence observed in this chapter 
in response to hepsin overexpression is not unique, and certainly, growth cycle arrest 
induced by hepsin is a possible mechanism facilitating this. However, there are 
contrasting reports indicating that hepsin overexpression does not alter cell growth. 
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Unfortunately due to the extended process undertaken to generate the LNCaP-hepsin 
cells, time constraints precluded PAR activation studies using these cells. 
 
5.3.4 Summary 
In conclusion, in this chapter KLK14 activated Ca2+ mobilization via PAR1, PAR2 and 
PAR4. However, it is not an efficient PAR activator in comparison to trypsin or 
matriptase as relatively high KLK14 concentrations induce modest activation. In 
contrast, hepsin elicited negligible Ca2+ mobilization via the PARs. However, it is 
possible hepsin induces alternate intracellular signalling pathways.  
It was also shown that while KLK4 activates PAR2-mediated signalling in PAR2-LMFs 
and prostate cancer-derived PC-3 cells (Ramsay et al., 2008a), in this chapter KLK4 did 
not activate PAR2-mediated Ca2+ mobilization in human kidney PTC. It is possible this 
is due to biased agonism, with KLK4 activating alternative signalling pathways in these 
cells. Or it is possible KLK4 has an alternative proteolytic target in these cells. Each 
possibility is equally intriguing.  
Also in this chapter, stable but rare populations of LNCaP hepsin cells were able to be 
generated. However, the data indicate that there are stark differences in cellular effects 
between overexpression of hepsin and catalytically inactive hepsinSA in LNCaP cells. 
The contrast between the achieved cell-surface expression level of hepsin and of 
catalytic mutant hepsinSA, as well as the contrast in the observed growth rates, cell 
death and senescence warrant further attention. There is also an avenue to explore 
hepsin cellular localization and possible internalization, as well as hepsin binding 
partners in this overexpression model. Furthermore, these generated cell lines can be 
used to examine whether hepsin expression facilitates or impedes PAR activation by 
different proteases including KLK4, KLK14 and matriptase. 
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Chapter 6 General Discussion  
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6.1 Key observations 
This thesis has examined the proteolytic and cell-surface interactions of secreted serine 
proteases KLK4 and KLK14 with transmembrane serine proteases hepsin and 
TMPRSS2. This thesis also examined the interactions of hepsin, TMPRSS2 and 
matriptase with the secreted matrix metalloproteinases MMP3 and MMP9. A key 
observation in this thesis is that the KLKs and TTSPs interact at the cell surface, as do 
the TTSPs and MMPs, potentially forming multi-protein complexes. These cell-surface 
interactions potentially facilitate activation of the MMPs and KLK4. They also may 
facilitate activation of cell-surface signalling molecules such as PARs through the 
localization of the secreted proteases. Cell-surface localization of these proteases may 
also have direct and indirect effects on induction of HGFR signalling through KLK 
activation or degradation of the HGFR ligand HGF, and also through degradation of 
HAI-1 by KLK14. Figure 6.1 proposes a model for the interactions of these proteases 
in the pericellular environment, and this model will be discussed in greater detail in the 
following sections. This final Chapter highlights the implications of the findings and 
details strategies to develop further the results from this study. 
A key aspect of this study was the generation of recombinant KLK14 zymogen in Sf9 
cells. It was determined that it was an N-glycosylated protein when generated by these 
cells. However, KLK14 also demonstrated cell-type differential N-glycosylation as it was 
not N-glycosylated when generated in Cos-7 cells in this study or when generated in 
Pichia pastoris by another group (Borgono et al., 2003).  
This study also examined the proteolytic interactions of KLK14 with pro-HGF, and 
with HAI-1A and HAI-1B. It was observed that KLK14 activates pro-HGF over a 
discrete concentration range, in contrast to KLK4 which primarily degrades this factor. 
It was also observed that KLK14 degrades HAI-1A and HAI-1B, while hepsin forms 
stable complexes with HAI-1A and degrades HAI-1B. 
Proteolytic and cell-surface interactions of KLK14 and KLK4 with transmembrane 
proteases hepsin and TMPRSS2 were also examined. A critical finding was that human 
hepsin autoactivates, as previously determined for mouse hepsin (Vu et al., 1997) and 
suggested by unpublished data (Qiu et al., 2007). It was also determined that hepsin and 
autoactivating TMPRSS2 (Afar et al., 2001) proteolyse KLK14; however, there was a 
greater level of proteolysis of KLK4 by these proteases. Also, while these KLKs are 
secreted proteases, for the most part minimal evidence of their proteolysis by hepsin 
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and TMPRSS2 was detected in the conditioned media as the cleaved forms of KLK4 
and KLK14 were primarily observed in cell lysates. Furthermore, while KLK4 and 
KLK14 were located on the cell surface, independently of hepsin and TMPRSS2, they 
also co-localized with these transmembrane proteases. In addition, active KLK4 and 
KLK14 were not isolated from conditioned media. However, active KLK4 was isolated 
from the cell surface, again, independently of hepsin and TMPRSS2. 
Figure 6.1 Model for the pericellular proteolytic activity of hepsin, TMPRSS2,  KLK4, KLK14, MMP3 and MMP9 
 
This study also examined the proteolytic and cell-surface interactions of hepsin and 
TMPRSS2 with the secreted proteases MMP3 and MMP9. Similar to the finding for 
KLK4 and KLK14, while MMP3 and MMP9 were proteolysed by hepsin and 
TMPRSS2, the cleaved products were observed primarily in cell lysates. Moreover, 
MMP3 and MMP9 co-localized with hepsin and TMPRSS2.  
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Focusing on the potential role of hepsin in facilitating cell-surface localization of KLK4 
and KLK14 and other proteases, it was also determined in this study that stable 
overexpression of hepsin in LNCaP cells resulted in minimal plasma membrane 
localization. This was in contrast to catalytically inactive hepsin which readily localized 
to the plasma membrane. 
KLK14- and hepsin-induced Ca2+ mobilization via PAR1, PAR2 and PAR4 were also 
examined in this study. It was determined that KLK14 activated Ca2+ mobilization via 
PAR1, PAR2 and PAR4 whereas hepsin elicited negligible Ca2+ mobilization via these 
receptors. In addition, following on from previous studies showing that KLK4 is able to 
activate PAR2 in several cell lines (Mize et al., 2008; Ramsay et al., 2008a), it was 
determined that Ca2+ mobilization elicited via this receptor could be abolished by the 
KLK4-specific inhibitor STFI-FCQR. Interestingly, this study also showed that KLK4 
activation of Ca2+ mobilization via PAR2 is potentially cell type-dependent, as in human 
primary kidney cells it induced minimal Ca2+ mobilization via this receptor. 
 
6.2 The potential contribution of KLK14 and KLK4 to the 
HGF-HGFR signalling cascade in prostate cancer  
There are conflicting consequences of KLK14 overexpression in different pathologies 
which suggest tissue-specific tumour-suppressive or tumour-progressive roles (Borgono 
et al., 2007c; Lopez-Otin and Matrisian, 2007). For instance, KLK14 has increased 
serum levels in prostate cancer (Borgono et al., 2003; Borgono et al., 2007c) and there is 
a correlation between increased KLK14 mRNA expression and late stage prostate cancer 
(Yousef et al., 2003b). Rabien and colleagues (2008) also demonstrated that increased 
KLK14 expression correlates with decreased progression-free survival. Similarly, 
KLK14 has increased expression in breast cancer (Fritzsche et al., 2006), with increased 
mRNA correlating with poor prognosis (Yousef et al., 2002). And recently, KLK14 was 
found present in colon cancer adenocarcinoma but not in normal epithelial cells (Gratio 
et al., 2011; Chung et al., 2012). Conversely, while KLK14 is also overexpressed in 
ovarian cancer (Borgono et al., 2003), increased KLK14 expression in early stage ovarian 
cancer has been correlated with favourable prognosis (Yousef et al., 2003a).  
The method by which KLK14 potentially facilitates these states is unknown. However, 
tumour suppression may be facilitated by KLK14 generation of angiostatic fragments 
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from degradation of plasminogen (Borgono et al., 2007c; Rajapakse and Takahashi, 
2007). In contrast, tumour progression may be mediated by HGF activation and HAI-1 
degradation. 
Similar to KLK14, HGF and HGFR are overexpressed in prostate cancer (Kurimoto et 
al., 1998; Zhu and Humphrey, 2000) and there is increased activated HGF in the serum 
of patients with untreated prostate cancer compared to those with benign prostate 
disease (Hashem and Essam, 2005; Yasuda et al., 2009). HGF expression is also 
androgen-regulated (Yu et al., 2013). Furthermore, irregular receptor signalling due to 
HGFR and HGF overexpression has an established role in tumourigenesis (Trusolino et 
al., 2010; Gherardi et al., 2012) and has been associated with the progression of prostate 
cancer (Humphrey et al., 1995; Nakashiro et al., 2000; Knudsen et al., 2002; Nakashiro 
et al., 2003; Knudsen and Edlund, 2004; Hashem and Essam, 2005; Yasuda et al., 2009). 
However, activation of HGF is a rate limiting step in HGF-induced HGFR signalling 
(Kataoka and Kawaguchi, 2010). Therefore, as KLK14 activates HGF, increased 
KLK14 expression in prostate cancer may in turn lead to increased HGFR signalling 
(Figure 6.1). 
In contrast to KLK14, KLK4 degrades HGF (Figure 6.1) and so potentially negatively 
regulates HGF-HGFR signalling. This is significant for prostate cancer progression as 
the abundant HGF expression in the tumour microenvironment is accompanied by an 
initial increase in KLK4 expression in the early stages of prostate cancer, followed by 
decreased KLK4 expression in the late stages (Seiz et al., 2010). So in this capacity, 
KLK4 may function as a tumour suppressor in the early stages of prostate cancer with 
this function lost progressively as KLK4 expression declines. 
While HGF activation is potentially a direct method of KLK14 contributing to HGFR 
signalling, KLK14 may also contribute indirectly through degradation of HAI-1 (Figure 
6.1). This degradation may increase the availability of HGF-activating proteases 
including HGFA, matriptase and hepsin. For instance, active, but not inactive, HGFA 
binds to HAI-1 on the cell surface (Kataoka et al., 2000). In so doing, HAI-1 acts as 
reservoir for active HGFA, as when the HAI-1 and HGFA complex is shed from the 
cell surface it dissociates, freeing proteolytically active HGFA (Kataoka et al., 2000). 
Similarly, matriptase activity in conditioned media is increased by membrane-type-1 
matrix metalloproteinase (MT1-MMP)-mediated shedding of HAI-1 from the cell 
surface (Domoto et al., 2012). Furthermore, shed HAI-1 has been identified in several 
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MW forms suggesting that there are multiple points amenable to cleavage (Shimomura 
et al., 1999) and MT1-MMP is one protease able to generate multiple truncated forms of 
HAI-1 (Domoto et al., 2012). It is possible KLK14 also acts in this capacity, facilitating 
release of HAI-1 bound proteases through degradation. One step to explore this further 
would be to determine if KLK14 degrades HAI-1 when it is in complex with another 
protease such as hepsin or matriptase. As this study used soluble HAI-1, further analysis 
of KLK14 degradation of HAI-1 could be achieved by determining if it degrades cell-
surface HAI-1.  
It has been shown that suppression of HAI-1 leads to a more aggressive phenotype in 
prostate cancer-derived cells in vitro (Sanders et al., 2007). Similarly, HAI-1 suppression 
enhances the migratory, proliferative and invasive capabilities of breast cancer-derived 
cells (Parr and Jiang, 2006). It has also been shown in an in vivo model that when HAI-1 
was suppressed in pancreatic cancer-derived cells injected into mouse tail veins, 
pulmonary metastasis was promoted (Fukushima et al., 2011). Moreover, in this study, 
co-injection of recombinant KD1 (the truncated form of HAI-1 featuring the first 
Kunitz domain) abrogated metastasis of these cells. Furthermore, HAI-1 expression is 
androgen-regulated in prostate cells with reduced androgen correlating with decreased 
HAI-1(Knudsen et al., 2005), and in patients with castration-resistant prostate cancer, 
PSA progression-free rate is worse for patients without HAI-1 expression than those 
positive for HAI-1 (Yasuda et al., 2013). Therefore, as increased KLK14 mRNA 
expression has been correlated with aggressive forms of prostate and breast cancer 
(Yousef et al., 2002; Yousef et al., 2003b; Fritzsche et al., 2006), it is possible that 
degradation of HAI-1 by KLK14 may lead the more aggressive in vivo phenotype.  
Certainly, in pancreatic cancer and lung cancer-derived cells suppression of HAI-1 led to 
decreased E-cadherin expression and also induced EMT (Cheng et al., 2009; Fukushima 
et al., 2011), a change in cells that can facilitate migration and invasion (Lawrence et al., 
2007). This EMT was mitigated by simultaneous knockdown of HAI-1 and matriptase 
or TMPRSS4, another member of the TTSP family. This suggests that the induction of 
E-cadherin expression and subsequent EMT was mediated in part by proteolytic activity 
(Cheng et al., 2009). The connection of HAI-1 to E-cadherin has also been noted by 
Oberst and colleagues (2001) who found that HAI-1 and matriptase expression in breast 
cancer-derived cells positively correlate with E-cadherin expression, and negatively 
correlate with invasive capability. Additionally, in endometrial cancer and pancreatic 
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cancer-derived cells, overexpression of HAI-1 induced increased E-cadherin expression 
(Cheng et al., 2009; Nakamura et al., 2011) and also restored epithelial cell morphology, 
a mesenchymal-epithelial transition (Cheng et al., 2009). 
Interestingly, studies in our laboratory found that overexpression of KLK4 in prostate-
cancer derived cells induced decreased E-cadherin expression as well as increased EMT 
and migration (Veveris-Lowe et al., 2005). The mechanism by which these changes were 
induced has not been established nor has the potential for KLK14 to induce similar 
phenotypic changes been examined. It is possible that involvement of KLK4 in the 
HGF-HGFR activation cascade through either HGF degradation or HGFA activation 
(Mukai et al., 2008) leads to modulation of E-cadherin expression. Certainly, truncated 
HGF, consisting of the amino terminus and the first kringle domain, also initiates 
signalling via the HGFR, decreasing E-cadherin expression and inducing EMT in 
prostate epithelium-derived cells (Pavone et al., 2011). While this truncated form of 
HGF is attributed to splice variation (Kataoka et al., 2003), it is possible that KLK4 
proteolysis of HGF may generate similar fragments capable of initiating HGFR 
signalling pathways leading to decreased E-cadherin expression. 
Study of the interaction of KLK14 and KLK4 with HGF, and KLK14 with HAI-1 
isoforms, was conducted using N-glycosylated recombinant KLK14 and KLK4 
generated in insect cells. As N-glycosylation can affect the catalytic activity of proteases 
(Skropeta, 2009), it is necessary to determine if these KLKs are endogenously N-
glycosylated and whether it has an effect on inhibition by HAI-1 or activation of HGF 
(or PAR activation). Moreover, it would be interesting to determine if there are tissue- 
or disease-specific differences in KLK14 N-glycosylation potentially modulating 
specificity for proteolytic targets. 
There are several experiments that could be used to address these issues. For example, 
after identifying the N-glycosylation acceptor residues in KLK14 and KLK4 using 
methods outline in the discussion of Chapter 3, recombinant proteases generated with 
the N-glycosylation sites mutated could be used to determine if N-glycosylation impacts 
KLK14 activation, or KLK4 degradation, of HGF. Similarly, KLK14 degradation of 
HAI-1 could be assessed plus or minus N-glycosylation. To address endogenous N-
glycosylation, tissue-specific assessments could be made of KLK14 and KLK4 isolated 
from different tissue types. For instance, prostate-derived KLK14 could be compared to 
skin-derived forms using enzyme de-glycosylation and gel mobility shift assays. 
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Alternatively, N-glycosylation status could be assessed using lectin-antibody sandwich 
(enzyme-linked immunosorbent assay) ELISA. 
 
6.3 Implications of cell-surface interactions of hepsin and 
TMPRSS2 with secreted proteases KLK4, KLK14, MMP3 
and MMP9 
One of the most interesting results in this thesis was that the secreted proteases KLK4 
and KLK14 localized to, and active KLK4 was isolated from, the cell surface. In 
addition, it was interesting that these proteases co-localized with hepsin and TMPRSS2, 
and in turn that hepsin and TMPRSS2 co-localized with MMP3 and MMP9. As 
summarized in the model in Figure 6.1, these results set up the premise that these 
proteases co-localize in functional complexes facilitating activation of MMP3 and 
MMP9 and potentially KLK4 and KLK14.  
These complexes may also facilitate activation of cell-surface receptors and other 
proteases, as well as degradative activity in the pericellular environment. For instance, as 
KLK4 was isolated from the cell surface but not from conditioned media it is possible 
these complexes may facilitate activation of KLK4 at the cell surface potentially through 
co-localization of MMP3. Furthermore, cell-surface localization of KLK4 may facilitate 
activation of PAR1 and PAR2. Similarly, pericellular activity of KLK14 may also be 
facilitated by cell-surface localization, enhancing activation of PAR family members as 
well as degradation of transmembrane HAI-1A and HAI-1B. 
The results also showed that while KLK4 and KLK14 co-immunoprecipitate with 
hepsin and TMPRSS2, the KLKs also localize to the cell surface independently of the 
TTSPs. This suggests a pericellular role for the proteolytic activity of these KLKs. 
However, it is unknown if they localize to the surface directly upon secretion or if they 
are taken up from the extracellular environment post secretion by a cell-surface cofactor 
or receptor. It is also unknown if the activity of these KLKs is directed out into the 
pericellular environment, for example degradation or activation of proteins in the 
prostatic fluid in the prostate lumen, or if the activity of these proteases is directed at 
cell-surface proteolytic events. 
Cell-surface localization has been determined to be a critical factor in the activity of a 
number of other secreted proteases. For instance, in the coagulation cascade, tissue 
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factor (TF) is crucial for the cell-surface localization, stabilization and enhanced activity 
of factor VIIa (FVIIa), and subsequent binding and activation of factor Xa (FXa) 
(Spronk et al., 2003) (Vadivel and Bajaj, 2012). Similarly, in the plasminogen activation 
system, uPA is localized to the cell surface by its cognate receptor uPAR (Ragno, 2006), 
and plasminogen is localized by several different types of cell-surface receptors (Godier 
and Hunt, 2013). However, in each instance in addition to C-terminal protease domains, 
the coagulation factors, plasminogen and the plasminogen activation proteases have 
non-proteolytic N-terminal domains that facilitate binding to their respective cell-
surface receptors (Ragno, 2006; Godier and Hunt, 2013). In contrast, KLK4 and 
KLK14 have no such domains as they consist of a single serine protease domain. 
Binding of these KLKs to the cell surface is likely mediated by other surface localized 
proteins, however, apart from the protease active site there are no recognized motifs in 
the KLK protease domain that suggest possible binding partners or sites.  
Interestingly, recent work by Rolland and colleagues (2014) to develop a protein-protein 
interactome map has revealed the cell-surface protein TYRO3 protein tyrosine kinase as 
a potential binding partner for KLK4. This receptor tyrosine kinase is from a family of 
three kinases whose expression is known to give cancer cells advantages through 
survival, chemoresistance and motility (Graham et al., 2014). TYRO3 and its cognate 
ligand growth arrest-specific 6 (GAS6) have also been linked to the proliferative state of 
prostate cancer cells in primary tumour (Taichman et al., 2013). Nonetheless, the nature 
of the interaction between KLK4 and TYRO has yet to be determined. To date it is the 
only KLK family member to have been associated with a transmembrane/cell-surface 
binding partner. 
While this thesis is the first report of cell-surface localization of KLK4 and KLK14, 
MMP3 and MMP9 have previously been reported to be associated with the cell surface 
through interaction with a variety of binding partners (Murphy and Nagase, 2011). 
Mostly, the cell-surface binding of these MMPs has been attributed to interactions of 
their hemopexin domain. MMP9 in particular has been associated with a number of cell-
surface proteins including, β1, β2 and β5 integrins (Stefanidakis et al., 2003; Bjorklund et 
al., 2004; Redondo-Munoz et al., 2010), CD44 (Yu and Stamenkovic, 1999; Desai et al., 
2009), and low density lipoprotein-related protein (LRP) 1 and 2 (Van den Steen et al., 
2006). In contrast, MMP3 has so far only been associated with cell-surface collagen I 
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(Murphy and Nagase, 2011). Certainly, one or more of these MMP binding partners may 
facilitate co-localization with the TTSPs hepsin, TMPRSS2 and matriptase. 
The immediacy of the interactions between the proteases could also be assessed using 
methods such as bioluminescence resonance energy transfer (BRET). For instance, one 
protease generated as Renilla-tagged and another as yellow fluorescent protein (YFP)-
tagged are co-transfected. BRET is then observed if the proteases are in close proximity 
and the resonant energy from the Renilla luciferase is transferred to YFP, exciting it and 
resulting in emission.  
It is important to note that the over-expression of KLKs, TTSPs and the MMPs 
described in this thesis may create artificial interactions between the proteases due to 
alteration to cellular trafficking, cell-surface localization and protease activity. It is 
therefore necessary to corroborate the findings by examining the interactions of the 
endogenous proteins. It is also necessary to determine whether cell-surface localization 
of KLK14 and KLK4 is replicated by endogenous proteins.  
In the first instance, methods used in this thesis, such as cell-surface biotinylation and 
activity-based probes, could be used on prostate cancer-derived cells to identify cell- 
surface-localized and active proteases. The interactions between these KLKs and the 
TTSPs on the cell surface could also be examined further using co-immunoprecipitation 
studies. Moreover, as KLK14 and KLK4 localized to the cell surface independently of 
hepsin or TMPRSS2, co-immunoprecipitation could also be used in conjunction with 
two-dimensional electrophoresis followed by MS/MS analysis to identify other proteins 
associated with the protease complexes.  
As a feature of prostate cancer development from the prostate epithelium is loss of cell 
polarity, as the disease develops immunohistochemistry (IHC) of prostate tissue could 
also be used to examine if there are any global changes to localization of the TTSPs in 
relation to the KLKs. 
 
6.4 The potential for cell-surface localization of KLKs to effect 
PAR activation 
To date activation of PAR family members by KLK4 and KLK14 has been reported 
without consideration of potential cell-surface cofactors assisting with localization, 
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activation and activity of the KLKs. This is potentially an important aspect of KLK4 
and KLK14 activation of PARs because when compared to trypsin activation of PAR1, 
PAR2 or PAR4, or matriptase activation of PAR2, 4- to 30-fold higher concentrations 
of these KLKs are require to effect significant Ca2+ mobilization via these receptors.  
From the earliest days of PAR1 research, activation by thrombin has been 
acknowledged as facilitated by the hirudin-like domain of PAR1, facilitating thrombin 
binding and more potent thrombin action (Vu et al., 1991b; Nakanishi-Matsui et al., 
2000). However, the hirudin-like domain is unnecessary for PAR1 activation by all 
proteases as an extensive number of proteases lacking hirudin domain-binding capacity 
activate PAR1 in vitro (Adams et al., 2011). Furthermore, PAR2 and PAR4 lack the 
hirudin-like domain, yet they are also activated by proteases with and without hirudin 
domain-binding capacity (Adams et al., 2011). For instance, in addition to activating 
PAR1, thrombin also activates PAR4 (Kahn et al., 1998; Xu et al., 1998). However, the 
potency of thrombin is 50-fold less than for PAR1, with higher concentrations required 
to elicit a Ca2+ mobilization response from PAR4 (Kahn et al., 1998; Xu et al., 1998). 
More potent PAR4 activation by thrombin is enabled through the formation of 
heterodimers with PAR1, with PAR1 acting as a co-factor to localize thrombin (Leger et 
al., 2006; Arachiche et al., 2013).  
Similarly, it has been determined that cell-surface proteins can act as cofactors 
facilitating PAR activation. For instance, serine protease FVIIa alone will not activate 
PAR signalling, however, when in complex with TF, FVIIa activates PAR1 and PAR2 
(Camerer et al., 2000). In addition, although FXa alone is a weak activator of PAR1, 
PAR2 and PAR4, when associated with the TF-FVIIa complex, FXa demonstrates 
potent activation of PAR1 and PAR2 (Camerer et al., 2000; Riewald and Ruf, 2001; 
Camerer et al., 2002). Another example of facilitated PAR activation is endothelial 
protein C receptor (EPCR) which binds protein C. This facilitates both protein C 
activation and activation of PAR1 and PAR2 by the bound activated protein C (Riewald 
et al., 2002; Kaneider et al., 2007; Julovi et al., 2011).  
Therefore, it is possible that cell-surface proteins may facilitate KLK4 and KLK14 
activation of PARs through localization of these KLKs to the surface (Figure 6.1). This 
is the first study to determine that KLK14 and active KLK4 localize to the cell surface. 
The generation of LNCaP cells overexpressing hepsin was an attempt to ascertain 
whether hepsin facilitates localization and activation of KLK4 and KLK14 and in turn 
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facilitating PAR activation by these KLKs. Indeed, matriptase activation of PAR2 has 
been shown to be facilitated by hepsin though activation of matriptase (Camerer et al., 
2010). However, the transient co-transfection and cell-surface biotinylation experiments 
performed indicate that while KLK4 and KLK14 co-immunoprecipitate with hepsin, 
these KLKs localize to the cell surface independently of hepsin. Moreover, hepsin does 
not activate KLK4. Rather, it potentially degrades KLK4. However, it remains to be 
determined whether KLK14 is activated by hepsin (or TMPRSS2), for while activated 
KLK14 was not detected in the conditioned media of cells, the activity of cell-surface-
retained KLK14 has not been examined yet. 
One of the most interesting aspects of PAR activation examined in this chapter was that 
in human primary kidney-derived proximal tubule cells, KLK4 elicited minimal Ca2+ 
mobilization. This was in contrast to LMF cells in which KLK4 readily activated PAR2, 
as observed here and previously (Ramsay et al., 2008a), and prostate cancer-derived PC-
3 cells in which KLK4 also activated PAR2 (Ramsay et al., 2008a). Certainly it is 
possible that KLK4 requires a cell-surface cofactor or binding partner to facilitate 
activation of PAR2 and that this factor is absent in these kidney-derived cells.  
On the other hand, PAR2 may not be the primary substrate of KLK4 in the kidney. To 
explore this further, a comparative proteomics approach, such as stable isotope labelling 
by amino acids in cell culture (SILAC) (Ong et al., 2002), could be taken to identify 
KLK4 substrates. In this method, one population of kidney PTC would be grown in 
normal medium. The other population would be grown in culture medium lacking a 
standard amino acid, but supplemented with an isotopically labelled form of that amino 
acid. Incorporation of the labelled amino acid into newly synthesized proteins would 
allow the proteins from KLK4-treated kidney PTC to be distinguished from untreated 
cells in mass spectrometry analysis. This would allow identification of KLK4-cleaved 
proteins by increased abundance of the released portion in the extracellular medium. 
Similarly, this technique to identify KLK4-cleaved proteins could be applied to 
membrane and membrane-bound proteins (Liang et al., 2006). 
However, it is also interesting to note that while KLK4 has been detected by 
immunohistochemistry in kidney tubular cells of the renal cortex (Seiz et al., 2010)(and 
personal communication from Dr D. Vesey), and by ELISA in kidney tissue (Shaw and 
Diamandis, 2007) and urine (Obiezu et al., 2005; Shaw and Diamandis, 2007), in 
contrast, mRNA expression studies have not detected KLK4 transcript in kidney tissue 
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(Nelson et al., 1999; Harvey et al., 2000; Shaw and Diamandis, 2007). The significance 
of this is unknown but this situation is not unique to the kidney as KLK4 has also been 
detected by ELISA in several other tissues, including the liver and heart, while the 
mRNA transcript has not been detected (Shaw and Diamandis, 2007).  
One possible reason for this anomaly in the kidney tissue may be that these epithelial 
cells in the kidney proximal tubule may not be the primary source of KLK4. Rather, the 
presence of KLK4 in these cells may be accounted for by their function in protein 
resorption from the ultrafiltrate through endocytosis (Christensen et al., 2012). This is a 
process, mediated by LRP2 and other cell-surface proteins, to clear significant amounts 
of protein from the tubular fluid to prevent toxic effects in distal regions of the 
nephron, and also to recycle proteins through lysosomal degradation and basolateral 
secretion of recovered amino acids (Christensen et al., 2012). Indeed, endocytosis of a 
number of proteins including proteases uPA and plasminogen, and also the sex 
hormone carrier protein SHBG are mediated by LRP2 (Christensen et al., 2012). It is 
possible that the immunohistochemical and ELISA analyses (Shaw and Diamandis, 
2007; Seiz et al., 2010) detected endocytosed KLK4 in the kidney proximal tubule cells. 
Certainly, this possibility could be examined further using two approaches. First, 
examine whether kidney PTC endocytoses KLK4 by applying green fluorescent protein 
(GFP)-tagged KLK4 and monitoring uptake by fluorescence microscopy. Second, 
uptake can also be examined by subcellular fractionation followed by Western blot 
analysis to determine which cellular compartments KLK4 is directed to. 
Regardless, KLK4 interaction with kidney PTC requires further examination for four 
reasons. First, to determine if alternate signalling pathways are activated by biased 
agonism of PAR2 by KLK4. Second, to determine if there is an alternative competitive 
substrate for KLK4 in this tissue. Third, to determine if cell-surface cofactors or 
binding partners facilitate KLK4 activation of PAR2. Finally, to clarify the origin of 
KLK4 in these cells. 
 
6.5 The autocrine and paracrine HGF and PAR activation by 
KLK14 in prostate cancer  
Homeostasis in the adult prostate is marked by minimal proliferation and low cell death, 
and this state appears largely due to separation of the epithelial compartment from the 
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stromal compartment cells through maintenance of prostate architecture (Cunha et al., 
2006). Changes in local interactions between nascent epithelial cancer cells and the 
stromal compartment cells potentially occur through a breach of the basal lamina 
(Barron and Rowley, 2012). This change promotes a form of damage response by the 
stroma termed the reactive stroma. It is typified by peri-tumoural stromal cells with 
fibroblastic and myofibroblastic phenotypes (Figure 6.2), increased capillary density, and 
increased expression of repair-associated growth factors (Cunha et al., 2006; Barron and 
Rowley, 2012). While the precise mechanisms of stromal activation are not clearly 
understood, it begins at the earliest stages of PIN, evolves as cancer progresses and 
stimulates the epithelial cancer cells (Cunha et al., 2006; Barron and Rowley, 2012). 
Figure 6.2 Interaction of epithelial cell-derived KLK14 with stromal cell-derived PARs and HGF in prostate cancer 
 
KLK14 may be a factor that participates in the cancer epithelial cell-reactive stroma 
cross-talk. The loss of normal prostate architecture and epithelial cell polarity in cancer 
may allow epithelial cell-secreted proteases such as KLK14 (Petraki et al., 2006; Rabien 
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et al., 2008) to enter the stromal compartment (Figure 6.2). In so doing, KLK14 may 
participate in a double paracrine loop through activation of smooth muscle- and 
myofibroblast-derived HGF (Humphrey et al., 1995; Nakashiro et al., 2003), and 
activated HGF in turn may stimulate the cancer epithelial cell-expressed HGFR 
(Nakashiro et al., 2000; Nakashiro et al., 2003) leading to the inherent mitogenic effects. 
Furthermore, there is potential for autocrine activation as both HGF and HGFR are 
expressed in some cancer foci (Nakashiro et al., 2003). 
Similarly, KLK14 activation of PAR1 and PAR2 may have elements of autocrine and 
paracrine activation. In normal tissue these PARs are expressed by the prostate epithelial 
cells, with increased levels in primary cancer (Zhang et al., 2009; Mannowetz et al., 2010) 
which is opportune for activation by KLK14.  Epithelial cell-derived KLK14 entering 
the stromal compartment may also activate PAR1, which has increased expression in the 
prostate cancer-associated myofibroblasts (Black et al., 2007; Zhang et al., 2009), and 
PAR2, which also has increased expression in stromal compartment cells (Mannowetz et 
al., 2010) (Figure 6.2). 
 
6.6 KLK14 as a potential therapeutic target in prostate cancer 
With aberrant expression in prostate cancer  and association with aggressive disease 
(Yousef et al., 2003b; Borgono et al., 2007c; Rabien et al., 2008) KLK14 has potential to 
be a prognostic indicator for patients at higher risk of cancer recurrence after radical 
prostatectomy (Rabien et al., 2008). In addition, if endogenous KLK14 is differently N-
glycosylated when expressed by prostate cancer cells it may also have clinical application 
in diagnosis of patients. For instance, KLK6 is differentially glycosylated when derived 
from ovarian cancer cells or the central nervous system (Kuzmanov et al., 2009). For 
this reason, serum level of this aberrantly glycosylated KLK has potential use as an early 
diagnosis biomarker for ovarian cancer. 
In addition to the potential for KLK14 to be a diagnostic or prognostic marker, the 
association with aggressive disease suggests a significant role in prostate cancer. The 
results in this thesis suggest that the effects of KLK14 may be mediated by activation of 
HGF-HGFR signalling or degradation of inhibitors HAI-1A and HAI-1B. In clinical 
trials multi-target HGFR inhibitors have proven to be particularly effective against 
primary and metastatic tumours in patients with castration-resistant prostate cancer 
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(Gherardi et al., 2012). These inhibitors target the HGFR signalling pathway as well as 
associated pathways that may “rescue” signalling downstream of the primary HGFR 
inhibitor.  
KLK14 may also mediate its effects in prostate cancer progression through activation of 
PAR1, PAR2 and PAR4. Similar to HGFR signalling, targeting PARs has therapeutic 
potential. Antagonists for PAR1, PAR2 and PAR4 have been developed, with 
development of PAR1 antagonists most advanced and some recent significant progress 
in PAR2 antagonists (Adams et al., 2011). However, the focus of the PAR1 antagonist 
clinical trials has been largely cardiovascular ailments.  
An alternative approach is to target KLK14 with a selective protease inhibitor. For 
instance, as discussed earlier, the KLK4-selective inhibitor SFTI-FCQR was developed 
in our laboratory (Swedberg et al., 2009) and the results in this thesis show that it is an 
effective inhibitor of PAR2 activation by KLK4. SFTI-FCQR has potential as a cancer 
therapeutic as it was also recently shown to reverse KLK4-induced resistance in ovarian 
cancer cells to the chemotherapy drug paclitaxel (Dong et al., 2013). The precise 
mechanism of the reversal is unknown, it is likely that blocking KLK4 proteolytic 
activity with SFTI-FCQR prevented cleavage of a KLK4-specific substrate in the 
ovarian cancer cells as a similar, though lesser, effect was seen when the protease 
inhibitor aprotinin was used (Dong et al., 2013). While a KLK14-specific inhibitor has 
not been published yet, there have been preliminary developments in that area (Borgono 
et al., 2007c). If developed, it may also have clinical application when used in 
conjunction with multi-target HGFR inhibitors. 
 
6.7 Summary 
In summary, this thesis successfully identified novel proteolytic and cell-surface 
interactions between KLK4 and KLK14, and hepsin and TMPRSS2, as well as 
interactions between hepsin and TMPRSS2, and MMP3 and MMP9. These results 
provide a framework to further explore KLK4 and KLK14 activation of cell-surface 
proteins such as PARs in the context of cell-surface localization of these KLKs. The 
work in this thesis also proposes a novel method for KLK14 to promote prostate 
cancer progression through the activation of the mitogen HGF, and also through the 
degradation of a key inhibitor of HGF activating proteases, HAI-1. As HGFR signalling 
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is a key factor in progression of many types of cancer, this represents an interesting and 
exciting new avenue to examine the potential role of KLK14 in pathological processes. 
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